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Reward and anti-reward are two key processes mediating occasional and long-term 
consumption of alcohol. Traditionally, neurons were thought to be the exclusive 
mediators of reward and anti-reward. However, emerging evidence has highlighted the 
importance of the neuroimmune system, specifically, an innate immune receptor (Toll-
like receptor 4) in mediating these phenomena. Toll-like receptor 4 (TLR4) is a pattern 
recognition receptor that detects conserved molecular epitopes expressed on 
pathogens, danger molecules and drugs of abuse. In response to alcohol the 
downstream signalling pathways of TLR4 (MyD88 and TRIF pathways) are activated. 
This culminates in the expression of classical pro-inflammatory cytokines and type-one 
interferons respectively. These immune molecules act via multiple pathways to 
influence neuronal activity thereby altering alcohol-related behaviour. No study has 
currently examined the relative contribution of each signalling pathway to alcohol-
induced reward and anti-reward behaviours. Therefore, the aim of this thesis was to 
investigate the role of the TLR4-TRIF pathway in mediating acute alcohol-induced 
reward; reward priming following acute alcohol exposure; and long-term alcohol-
induced reward and anti-reward behaviours in mice. The studies presented herein 
demonstrate pharmacologically attenuating TLR4-TRIF signalling via (+)-Naltrexone; 
reduces behavioural markers of acute alcohol-induced reward such as conditioned 
place preference and two-bottle choice – an effect dependent on the time-of-day; 
prevents acute alcohol-induced sensitisation during adolescence and some but not all 
markers of reward-like behaviour later in life; and lastly, did not alter behavioural 
indices of reward and anti-reward behaviour following long-term alcohol consumption. 
Collectively, the results highlight the importance of the TLR4-TRIF pathway in 
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Chapter 1: Literature Review  
1.1 Introduction 
The consumption of alcoholic beverages has, and continues to be, an integral activity 
engaged in by members of both ancient and modern societies. Traditionally, alcoholic 
beverages were consumed primarily as a celebratory activity during large social 
gatherings (Boyle et al., 2013). However, the modernisation of fermentation and 
distillation processes, has enabled the widespread manufacturing of these beverages. 
Consequently, the way individuals, think, approach and consume alcohol has 
changed. While the tradition of consuming alcoholic beverages during celebrations 
continues, the recreational consumption of alcohol (primarily for its euphoric 
properties) has grown considerably. For example, 70 per cent of surveyed American 
adults report consuming alcohol within the past year, with a further 56 per cent 
reporting moderate to low monthly consumption (National Institute on Alcohol Abuse 
and Alcoholism (NIAAA), 2017). Higher and more frequent use is problematic and 
increasingly prevalent not only among adults, but also among adolescents. 
Approximately 27, 37 and 13 per cent of adults (18+ years old), college students (18 – 
22 years old) and adolescents (12 – 20 years old) engage in monthly binge drinking 
respectively (SAMHSA, 2016) (in the United States of America binge drinking is 
defined as achieving a blood ethanol content of 0.08g/dL in 2 h – equivalent to 4 and 
5 drinks for women and men, respectively) (NIAAA, 2004). 
 
Every society that consumes alcohol demonstrates large health, social and economic 
costs attributable to its use (both occasional and excessive) (World Health 
Organisation, 2014). This problem is exacerbated as public policy largely ignores these 
problems owing to engrained cultural attitudes towards alcohol – particularly in western 
countries. This is concerning given the health costs associated with alcohol use are 
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extremely, and unnecessarily high. For example, the consumption of alcohol results in 
3.3 million deaths annually, and consistently ranks within the top five risk factors for 
disease, disability and death worldwide (World Health Organisation, 2014). It is 
therefore unsurprising that the consumption of alcohol is causally associated with 
approximately 200 diseases, of which neuropsychiatric disorders account for the 
largest proportion of diseases. Within neuropsychiatric disorders, addiction and 
depression are the most frequently diagnosed disorder attributable to alcohol use 
(World Health Organisation, 2014). Given the large neuroanatomical overlap between 
these two disorders, it highlights that alcohol selectively modifies the brain’s limbic 
system – a region governing mood, emotion, learning and memory (Oscar-Berman & 
Marinković, 2007). 
 
However, discerning the detrimental effects of alcohol on the brain’s limbic system in 
clinical and preclinical research is complex as the term “alcoholic beverages” 
encompasses a broad range of solutions including beer, wine and spirits; and 
uncommon forms of alcohol such as moonshine and homemade spirits. These 
beverages contain hundreds to thousands of unique chemical entities (Buglass, 2015) 
– some of which have both beneficial and detrimental effects on the body (see for 
example, IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 
2010; Brown et al., 2009). Interestingly, the detrimental and psychoactive properties of 
alcoholic beverages are often attributed to a single molecule: ethanol (ethyl alcohol, 
CH3CH2OH). Ethanol is a small, polar, hydrophilic molecule, the concentration of which 
fluctuates substantially among alcoholic beverages (Ferreira & Willoughby, 2008). For 
example, beer typically contains 3 to 7 per cent ethanol while spirits are often greater 
than 50 per cent (Buglass, 2015). The chemical properties of ethanol facilitate its fast 
absorption and preferential displacement to areas where water quantity is high 
(Ferreira & Willoughby, 2008) – for example the blood and brain. Given its high 
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concentration and preferential movement to areas most affected by the consumption 
of alcoholic beverages (the brain), ethanol has become the main focus of preclinical 
research assessing the effects of alcoholic beverages on the body.  
 
Ethanol’s action upon the brain, and more specifically the mesocorticolimbic system 
are complex and are unlike any other drug of abuse such as cocaine or opioids 
(Harrison, 2007; Nestler, 2005). Ethanol interacts with numerous neurotransmitter, 
neurotrophic and neuropeptide systems to generate complex behaviours including, 
anhedonia (reduced ability to feel pleasure), anxiety, dependence, motor impairment, 
pain and reward (Costardi et al., 2015; Tabakoff & Hoffman, 2013). Many of these 
behaviours are beyond the scope of this thesis. Please refer to Neupane, (2016) and 
Egli et al., (2012) for examples of reviews summarising ethanol-induced depression 
and pain respectively. Rather, this thesis will focus on the effects of ethanol on reward 
and anti-reward behaviours.  
 
1.2 Liking, wanting and reward 
The initial, occasional and long-term consumption of alcohol are driven in part by the 
rewarding properties of ethanol (herein referred to as alcohol). Alcohol-induced reward 
is comprised of two psychological phenomenon; “liking” and “wanting” (Berridge & 
Robinson, 2016; Robinson & Robinson, 2013). “Liking” is the pleasurable impact of 
alcohol consumption. Specifically, it is the hedonic sensation an individual feels upon 
consuming alcohol and other sweet compounds such as sucrose or saccharin. It is 
important to note that “liking” can be influenced by taste and thirst under specific 
circumstances (Berridge & Robinson, 2016). Historically “liking” behaviour was 
assessed in rodents by examining affective facial reactions following the consumption 
of alcohol or sucrose (Berridge & Grill, 1983). However, “liking” (hedonic) behaviour is 
more frequently inferred by using short two-bottle choice paradigms in which rodents 
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have access to two bottles – one contains water and the other a palatable/rewarding 
or aversive solution (Willner et al., 1987). By contrast, longer testing sessions are used 
to infer both “liking” and “wanting” behaviour (Tabakoff & Hoffman, 2000). 
 
“Wanting” or incentive salience is the motivation or desire (expectation based on 
memory) to obtain rewarding stimuli (Berridge & Robinson, 2016). It is the attachment 
of significance or value to an object or cue that is associated with the rewarding 
compound. “Wanting” behaviour is typically assessed using conditioning paradigms 
such as conditioned place preference. In brevity, conditioned place preference pairs a 
distinct environmental cue with a potentially rewarding stimulus, and another 
environmental cue with a vehicle control. Over repeated sessions, the animal learns to 
associate the discrete environmental cue with the desired rewarding effect. On the last 
day of testing, mice have access to both the drug- and vehicle-paired environments 
with the amount of time spent in the drug-paired chamber (seeking behaviour) an 
inference of “wanting” behaviour (Tzschentke, 2007; 1998). 
 
“Liking” and “wanting” are essential for generating reward. Under homeostatic 
conditions, brain regions governing “liking” and “wanting” are activated by natural 
rewards such as food, water and sex (Berridge & Robinson, 2016). Alcohol, like all 
other drugs of abuse, acts upon, and hijacks these brain regions. Importantly, drugs of 
abuse activate these pathways to a greater extent than natural rewards and are 
consequently preferred (Wise, 2004).  
 
However, “liking” and “wanting” are neurobiologically distinct and initially occur 
independent from one another. Typically, the “liking” regions are activated first followed 
by the “wanting” regions. Consequently, the initial consumption of alcohol is governed 
predominately by “liking” component of reward, however the “wanting” pathways are 
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additionally activated overtime – alcohol sensitises the “wanting” pathway while 
inducing tolerance to the “liking” pathway. Therefore, the individual shifts away from 
consuming alcohol because they “like” it to a state where they “want” and need it 
(Berridge & Robinson, 2016). This transition underlies the shift from impulsive to 
compulsive use and is a key component of addiction and dependence (Berridge & 
Robinson, 2016; Koob & Le Moal, 2001).  
 
1.3 Addiction and dependence 
It is important to highlight that drug addiction is clinically and neurobiologically distinct 
from an initial drug taking experience. While these two events share similar 
neurobiological substrates, addiction is a complex, relapsing disorder resulting from 
numerous neuroadaptations due to prolonged drug exposure (Koob & Le Moal, 1997). 
These adaptions are complex, persist beyond acute withdrawal and are thought to 
involve environmental, psychological (stress, learning and conditioning) and genetic 
(predisposition to drug taking) elements (Koob & Volkow, 2009). Furthermore, in 
humans most drug users do not become addicted with a similar scenario observed in 
animals. Stable drug intake can be observed within animals without indications of 
addiction even in paradigms designed to recapitulate addictive scenarios (limited 
access, operant self-administration). This reflects the complex aetiology of drug 
addiction (Koob & Le Moal, 1997).  
 
The Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV) recognizes 
drug dependence and substance abuse disorders as a chronic disorder which is 
characterized by an impaired control over taking, and an increased craving for, drugs 
of abuse; a withdrawal syndrome upon cessation; tolerance - with a larger dose 
required to achieve the desired psychological effect; a disproportionate time seeking 
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and consuming the drug and persistence of drug-use despite negative consequences 
(American Psychiatric Association, 2013; World Health Organization, 1993).  
 
From a psychological standpoint, drug addiction is thought to reflect a shift from 
impulsive to compulsive behaviour (Koob & Le Moal, 1997). Impulsive consumption is 
thought to be driven primarily by the “liking” component of reward (Berridge & 
Robinson, 2016). After repeated intake, the individual becomes tolerant to the “liking” 
component of alcohol due to pharmacokinetic and pharmacodynamic adaptions to 
alcohol. For example, alcohol dehydrogenase and aldehyde dehydrogenase, enzymes 
responsible for metabolism of alcohol and acetaldehyde (a metabolite of alcohol) 
respectively, are upregulated, thus increasing the rate of alcohol’s catabolism - 
decreasing blood alcohol concentration (Tabakoff et al., 1986; Misra et al., 1971). 
Furthermore, the activity of receptors interacting with alcohol for example, the µ opioid 
receptor, are reduced owing to internalisation processes and a reduction in the 
expression of signalling proteins. This is designed to limit the effects of alcohol on the 
brain (He & Whistler, 2011; Gianoulakis, 2001). Over time, the “wanting” component 
of reward is slowly engaged which assists in the transition to compulsive behaviour 
(Berridge & Robinson, 2016; Koob & Le Moal, 1997). The “wanting” component of 
reward typically arises in the absence of alcohol, and can under periods of addiction, 
manifest as anxiety, stress and anhedonia. To alleviate these adverse sensations, 
alcohol is sought after and consumed. Thus, the shift from impulsivity to compulsivity 
reflects a change in motivation state from positive to negative reinforcement (Koob & 
Le Moal, 2001; 1997).  
 
1.3.1 Opponent-process theory in addiction 
Several theories have been applied to explain the psychological and biological 
mechanisms underlying the change from impulsive to compulsive behaviour observed 
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during addiction. And, although many theories account for some aspects of drug 
addiction, they cannot in their entirety account for the disorder as a whole. Therefore, 
while I acknowledge the presence and importance of other theories, for example, 
associative-learning disorder (Di Chiara, 1999), I have chosen to predominately 
examine and apply one leading theory of addiction (opponent process theory). 
However, aspects of incentive-sensitisation will additionally be incorporated (Robinson 
& Berridge, 2001). 
 
The opponent-process theory (Solomon & Corbit, 1974) is particularly relevant to drug 
addiction. Opponent-process theory states, hedonic, affective or emotional states are 
automatically opposed by CNS mechanisms, which reduce the intensity of these 
states, both pleasant and aversive to maintain homeostasis. In brief, the theory 
consists of two processes termed A and B. A-process consists of the initial positive or 
negative hedonic response to a stimulus. The magnitude of response correlates with 
the quality and duration of the stimuli and can, overtime exhibit tolerance. B-process 
occurs after the A-process has finished, is sluggish in onset, is slow to build up and 
decay, and is opposite in response to A. However, if the stimulus is consistently 
repeated, A-process becomes weaker, and the B-process becomes stronger and long 
lasting (allostasis) (Koob & Le Moal, 1997).  
 
In the context of addiction, alcohol produces an initial “liking” experience (euphoria) 
(and “wanting” to some extent), which serves as a positive reinforcer (A-process). 
However, the user subsequently experiences negative hedonic affect (anhedonia and 
dysphoria, first encountered during a “hangover”), which acts a negative reinforcer (B-
process) (Solomon & Corbit, 1974). Koob & Le Moal, (1997) furthered this concept by 
theorizing as occasional drug use transitions into a compulsive habit, this homeostatic 
process becomes dysregulated and breaks. The initial “liking”, euphoric sensation 
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begins to weaken (tolerance), and the negative hedonic experiences associated with 
anhedonia, anxiety and “wanting” occur more rapidly, are enduring, more intense and 
fail to return to base line, creating a new allostatic state. Consequently, the body must 
actively compensate for the dysregulation of the reward pathway by creating a new-
set point that is now below the original reward value (allostatic point). Collectively, 
these processes alter the overall drug taking experience. What was once considered 
rewarding to take, is now taken in an attempt to return to a baseline state. Continual 
resetting contributes to the pathology of addiction (Koob & Le Moal, 2001; 1997). 
 
Two key cellular processes are hypothesised to underlie allostasis in alcohol addiction; 
within and between-system adaptations (Koob & Le Moal, 1997). In the presence of 
constant alcohol exposure, a within-system adaption refers to the brain’s attempt to 
neutralise the drug’s effect by altering the primary responding circuitry that is producing 
desired effects (“liking” and “wanting”). In the context of alcohol addiction, a within-
system adaption is hypothesised to include cellular changes within the mesolimbic 
pathway (primary responding circuit). A within-system adaption contributes to drug 
tolerance. The individual must therefore consume higher doses with increased drug 
taking frequency to achieve the same desired effect. However, the persistence of the 
within-system adaptions in the absence of a drug may contribute to anhedonia, anxiety 
and “wanting”. By contrast, a between-system adaption is a different cellular system, 
which has opposing effects to the primary response element. A between-system 
adaptation is aimed to limit the reward by inducing a stressful or dysphoric response 
(anti-reward). In the absence of alcohol, the system still persists, exacerbating the 
“wanting” of alcohol and stressful and dysphoric sensations (Koob & Le Moal, 1997). 
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1.4 Neurobiological basis of reward, anti-reward and dependence 
Alcohol-induced reward and anti-reward are created and sustained by multiple brain 
regions. Specifically, the mesolimbic pathway mediates the “liking” and “wanting” 
components of alcohol-induced reward. Therefore, this pathway governs the initial, 
occasional and long-term (chronic) use of alcohol. As previously mentioned, acute 
alcohol activates this pathway generating reward. However, as alcohol use becomes 
more frequent, neuroplastic events within the mesolimbic pathway and brain regions 
governing stress and pain pathways (amygdala, bed nucleus of the stria terminalis and 
locus coeruleus) occur to limit the effects of alcohol. A by-product of these 
consequences, is the creation of anti-reward – a sensation characterised by 
anhedonia, stress and anxiety (Fein & Cardenas, 2015; Seo & Sinha, 2015; Koob & 
Le Moal, 2001). Importantly, the effects of alcohol on the reward and anti-reward 
pathways are influenced by many variables including the duration of exposure, route 
of administration, the time of day and the age of the individual (for example, Chatterjee 
et al., 2014; Alaux-Cantin et al., 2013; Veeraiah et al., 2012; Spanagel et al., 2004). 
The effects of duration of exposure on reward and anti-reward will be discussed in 
depth in the proceeding sections. The effects of time-of-day and age will be discussed 
as preludes to chapters 3 and 5 respectively. 
 
1.4.1 Reward following acute alcohol exposure 
Dopaminergic neurons projecting from the ventral tegmental area (VTA) to the nucleus 
accumbens are a key cellular mechanism underlying the “wanting” component of 
alcohol-induced reward (Di Chiara & Imperato, 1988; Imperato & Di Chiara, 1986). In 
response to natural rewards such as food, water and sex, the action potential 
frequency of these cells is increased causing a subsequent elevation in extracellular 
dopamine within the nucleus accumbens (Wise, 2013; 2006; Olsen, 2011; Kelley & 
Berridge, 2002; Melis & Argiolas, 1995). The rise in extracellular dopamine functions 
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as a learning mechanism, conferring motivational importance to specific stimuli (the 
“wanting” component of reward) (Wise, 2004). As such, an individual will “want” to seek 
out these rewarding stimuli. All drugs of abuse converge and act upon this pathway. 
While each drug differs in the biological mechanism, they all dose-dependently 
increase the concentration of extracellular dopamine in the nucleus accumbens 
(Imperato & Di Chiara, 1986). Importantly, the amount of dopamine release is typically 
greater following exposure to a drug of abuse than that of natural stimuli (Wise, 2004). 
Consequently, alcohol, and other drugs of abuse are imbued with a higher motivational 
value (Nestler, 2005; Wise, 2004). 
 
In regards to alcohol’s effect on this pathway, research has demonstrated 
microinjection of alcohol into the VTA but not the nucleus accumbens dose-
dependently increases accumbal dopamine (Di Chiara & Imperato, 1988; Imperato & 
Di Chiara, 1986). This idea is further supported as research has shown the enhanced 
dopamine release is not due to the inhibition of dopamine’s re-uptake in the nucleus 
accumbens (Yim & Gonzalez, 2000). This suggests alcohol specifically targets the 
soma (cell body) that reside in the VTA and not the terminals of dopaminergic neurons 
in the nucleus accumbens. Further, pharmacological or genetic inhibition of dopamine 
D1, D2 or D3 receptors and siRNA knockdown of D2 in the nucleus accumbens alters 
alcohol-induced conditioned place preference and 24 h intake of alcohol  - key indices 
of “wanting” behaviour (Sciascia et al., 2013; Bahi & Dreyer, 2012; García-Tornadú et 
al., 2010; Hamlin et al., 2007; Boyce-Rustay, 2003; Liu & Weiss, 2002; Cunningham 
et al., 2000; Risinger et al., 2000; Dyr et al., 1993). Additionally, inhibition of tyrosine 
hydroxylase, the rate-limiting enzyme in dopamine synthesis, significantly reduces 
alcohol intake (Myers & Veale, 1968). Collectively, these results suggest alcohol acts 
upon the cell body of VTA dopaminergic neurons to increase the extracellular release 
of dopamine within the nucleus accumbens. Dopamine’s effects are subsequently 
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transduced by D1 and D2 receptors primarily by medium spiny neurons (Jeanes et al., 
2014) to generate alcohol-“wanting” behaviour. 
 
There are multiple mechanisms underlying alcohol-induced firing of dopaminergic 
neurons. Of particular importance are voltage-gated potassium channels (BK 
channels) and GABAA receptors (Martin, 2010; Harris et al., 2008; Brodie et al., 2007a; 
Chester & Cunningham, 2002). Alcohol modulates the lipid microenvironment 
surrounding BK channels enhancing its activity in the soma but not dendrites of 
dopaminergic cells (Yuan et al., 2008; Crowley et al., 2005). Increasing activation of 
this channel reduces the inward potassium current preventing the after-
hyperpolarisation following action potentials (Brodie et al., 2007b; Martin, 2004). This 
increases action potential frequency and dopamine release (Brodie et al., 1999). 
Alcohol additionally acts as a functional agonist on GABAA receptors expressed by 
medium spiny interneurons (GABAergic interneurons) in the VTA (Harris, 1999). As 
such the sensitivity towards GABA is increased, leading to an influx of chlorine ions; 
and decreasing the excitability of these cells (Wallner et al., 2014; Sundstrom-Poromaa 
et al., 2002;). The loss of inhibitory function by medium spiny interneurons decreases 
GABA release on to dopaminergic neurons (Patton et al., 2016; Davies, 2003). 
Therefore, dopaminergic cells exhibit a spike in activity; increasing dopamine release 
in the nucleus accumbens (Kalivas et al., 1990). GABAA receptors are expressed on 
dopaminergic neurons as well. However, the subunit composition of these receptors 
differs to those expressed by medium spiny interneurons resulting in different 
molecular and electrophysiological properties. Consequently, dopaminergic neurons 
are less sensitive to the agonistic interaction induced by alcohol (Davies, 2003). 
 
While emphasis has been placed upon dopamine as the key mediator of alcohol-
induced “wanting” behaviour, there are additional neurotransmitter systems which 
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influence this response. For example, serotonergic and cholinergic pathways in the 
VTA and nucleus accumbens regulate the activity of medium spiny neurons and can 
cause dopamine-dependent and independent effects which influence alcohol “wanting” 
behaviour in rodents (Ding et al.,2015; Liu et al., 2013; Rodd et al., 2010). However, a 
complete discussion of these effects are beyond the scope of this thesis, please refer 
to Bell et al., (2013) for a comprehensive summary. 
 
Dopamine mediates the “wanting” but not “liking” component of alcohol reward 
(Berridge & Robinson, 2016). “Liking” occurs in discrete regions within the nucleus 
accumbens, ventral palladium and the prefrontal cortex. Interestingly, these nuclei act 
in concerted manner, with stimulation of one area activating another, amplifying the 
“liking” signal (Berridge & Kringelbach, 2015). On a molecular level, current evidence 
suggests “liking” is mediated by the endogenous opioid system (Berridge & Robinson, 
2016). Alcohol increases the extracellular concentration of endorphins and 
enkephalins and potentiates endorphin receptor binding in the nucleus accumbens 
(Jarjour et al., 2009; Méndez et al., 2001; Olive et al., 2001; Anwer & Soliman, 1995). 
Antagonising opioid receptors or delivering µ opioid receptor antisense 
oligonucleotides in the nucleus accumbens inhibits voluntary alcohol consumption  
(Pastor & Aragón, 2008; Lasek et al., 2007; Becker et al., 2002). Further, 
administration of an opioid receptor antagonist, (-)-Naltrexone, but not selective 
removal of dopaminergic terminals in the nucleus accumbens blocked alcohol intake 
in the same rodents – suggesting that “liking” is a dopamine-independent (Koistinen et 
al., 2001). However, opioid receptor antagonists attenuate alcohol-induced dopamine 
release suggesting a complex interaction between the “liking” and “wanting” systems 
(Benjamin et al., 1993; Devine et al., 1993). Endocannabinoids and orexins are 
additionally implicated in “liking” behaviour (Ho & Berridge, 2013; Mahler et al., 2007). 
However, their precise function remains to be fully elucidated. 
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1.4.2 Reward sensitisation following acute alcohol exposure 
Acute (repeated) exposure followed by a period of significant deprivation can result in 
sensitisation of the reward pathway, an effect particularly apparent during periods of 
neurodevelopment such as adolescence. Following alcohol exposure, there are 
alterations in the gene expression of endocannabinoid, opioid and dopamine D1 and 
D2 receptors within the brain (for example, McClintick et al., 2016). These are key 
mediators underlying the molecular basis of “liking’ and “wanting”. Thus, re-exposure 
to alcohol or other drugs of abuse (cross-sensitisation) induces a higher “liking” and 
“wanting” response. Interestingly, alcohol exposure during adolescence results in a 
persistent rise in the expression of these receptors – an effect which can last through 
adulthood (Alaux-Cantin et al., 2013; Hargreaves et al., 2009; Pascual et al., 2009). 
By contrast, alcohol consumption in adults often results in transient increases in the 
activity of these systems; reinforcing the concept of ontological-dependent sensitivities 
towards drugs of abuse (see Spear & Swartzwelder, 2014 for review). 
 
1.4.3 Reward following chronic alcohol exposure 
As alcohol use becomes more frequent, the brain attempts to counteract the rewarding 
effects of alcohol. As such the same brain regions and molecular processes mediating 
reward undergo within-system adaptions to limit the effect of alcohol. Long-term 
exposure to alcohol increases brain reward threshold. This is attributable to decreased 
activity of dopaminergic neurons in the VTA (Weiss et al., 1996; Diana et al., 1993; 
Shen & Chiodo, 1993) and a reduction in the amount of extracellular dopamine 
released in the nucleus accumbens (Weiss et al., 1996). Consequently, larger and 
more frequent doses of alcohol are required to achieve the same rewarding effect.  In 
the absence of alcohol, a state of anhedonia occurs. Therefore, alcohol is again 
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consumed to alleviate these adverse sensations and assisting the “wanting” 
mechanism.  
 
There are multiple mechanisms underscoring alcohol-induced dopamine deficits. For 
example, hyperactive L-type calcium channels hyperpolarise dopaminergic neurons; 
reducing the frequency of action potentials and in turn dopamine release (Rossetti et 
al., 1999). Further, the expression of tyrosine hydroxylase is decreased and the 
expression of dopamine receptors and transporters are increased (Chatterjee et al., 
2014; Sari et al., 2006; Djouma, 2002; Lograno et al., 1993). This suggests a reduction 
in dopamine synthesis and an increase in dopamine reuptake from the synapse (Weiss 
& Porrino, 2002; Rothblat et al., 2001). Importantly, the mechanisms underlying 
dopamine deficits can persist for prolonged periods, increasingly the susceptibility of 
relapse (Berridge & Robinson, 2016). 
 
Prolonged alcohol use additionally lessens the “liking” component of alcohol 
(pharmacodynamic tolerance). For example, chronic alcohol exposure reduces the 
expression of µ and d opioid receptors and increases the uncoupling of opioid 
receptors from Gi class of G proteins, their signal transducers, within the nucleus 
accumbens, cortex and hippocampus – mitigating the effects of alcohol reward (He & 
Whistler, 2011; Saland et al., 2004; Chen & Lawrence, 2000). Further, the down-
regulation of endogenous cannabinoids and their receptors increases GABA signalling 
in the nucleus accumbens and VTA (Talani & Lovinger, 2015; Melis & Pistis, 2012; 
González et al., 2002; Basavarajappa & Hungund, 1999; Basavarajappa et al., 1998). 
It is hypothesised that increased GABA signalling may further inhibit endorphin or 
dopaminergic responding neurons; limiting the “liking” and “wanting” component of 
reward. Given the effects of pharmacodynamic tolerance (the down-regulation of 
opioid and cannabinoid receptors) higher concentrations of alcohol are required to 
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induce “liking”. This effect is exacerbated owing to pharmacokinetic tolerance 
(increased rate of alcohol metabolism) further reducing the circulating concentration of 
alcohol – increasing the amount required to achieve the desired pharmacodynamic 
effects (Tabakoff et al., 1986; Misra et al., 1971). 
 
Collectively, within-system adaptions to the nucleus accumbens and VTA create a 
state of heightened “wanting” at the expense of “liking”; altering the rewarding 
properties of alcohol. These effects are primarily attributable to a reduction in 
dopaminergic and opioidergic signalling within this pathway (Diana et al., 1996). 
Therefore, an alcohol-dependent individual is in a state where they are constantly 
chasing the original hedonic sensation felt by alcohol however, they are unable to 
achieve it (Berridge & Robinson, 2016). 
 
1.4.4 Anti-reward following chronic alcohol exposure 
Prolonged alcohol use also results in the recruitment of anti-reward pathways. Anti-
reward is based on a concept that brain systems are in place to limit reward triggered 
by excessive activity within the reward pathway (B-process) (Koob & Le Moal, 2001). 
Several anatomical sites mediate the anti-rewarding properties of alcohol such as the 
hypothalamic-pituitary-adrenal (HPA)-axis, locus coeruleus, the extended amygdala 
(BNST, central nucleus of the amygdala (CeA) and the nucleus accumbens (Koob & 
Volkow, 2009). It is important to highlight that these brain regions are also involved in 
arousal, stress, fear, anxiety and the emotional component of pain (Koob & Le Moal, 
2001). 
 
Activation of the brain’s anti-reward pathway has been hypothesized to overcome the 
chronic presence of alcohol and restore homeostasis. However, in the absence of 
alcohol, these systems remain active and are hypothesised to produce aversive, 
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anhedonic, dysphoric and stress-like behaviour (Koob & Le Moal, 2001). For example, 
corticotrophin-releasing factor (CRF) and neuropeptide Y (NPY) are key stress and 
anti-stress neuropeptides (respectively) of the brain stress system and the HPA axis 
(Shekhar et al., 2005). In the absence of alcohol, the expression and release of NPY 
and CRF in the amygdala are decreased and increased respectively. The subsequent 
binding of these molecules to their cognate receptors (CRFR1 – 2 and NYPR1 – 5) 
and activation of intracellular signalling pathways are thought to contribute to the 
anxiety and anhedonia experienced by alcohol-dependent subjects (Gilpin, 2012; 
Sommer et al., 2008; Funk et al., 2006; Primeaux et al., 2006; Roy & Pandey, 2002; 
Zorrilla et al., 2001 Pich et al., 1995). In support of this, mice deficient in CRF-1 
receptors or antagonism of CRF-1 or -2 receptors decreases alcohol withdrawal 
behaviour (Pastor et al., 2011; Huang et al., 2010; Lowery et al., 2010; Wills et al., 
2010; Funk & Koob, 2007; Overstreet et al., 2004) and increasing NPY or genetic 
knock out of NPY receptor 1 and 2 receptors decrease and increase withdrawal-
induced anxiety in mice, respectively (Gilpin, 2012; Cippitelli et al., 2011; Bhisikar et 
al., 2009). 
 
Brain regions involved in anti-reward may also govern aspects of reward following 
chronic exposure to alcohol. Particular emphasis has been placed upon dopaminergic 
neurons extend from the nucleus accumbens and BNST to the CeA. Similar to alcohol 
exposure in the nucleus accumbens, alcohol increases dopamine release in the CeA 
which assists in mediating long-term motivational behaviours towards alcohol (Koob & 
Volkow, 2009). However, this behaviour is additionally mediated by opioid, 
neuropeptide Y and GABAergic systems as antagonising either of these systems in 
the nucleus accumbens, BNST or CeA can reduce alcohol self-administration (Pleil et 
al., 2015; Marinelli et al., 2010; Hyytiä & Koob, 1995). 
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In summary, the initial consumption of alcohol is driven by a complex interaction of 
“liking” and “wanting” generating alcohol-induced reward. Repeated cycles of alcohol 
consumption followed by periods of abstinence, results in neuroplastic events 
recruiting the anti-reward pathway and altering the reward pathway. Collectively, these 
processes reduce the ability to feel the “liking” component of reward, promote the 
“wanting” of alcohol and induce feelings of anxiety and anhedonia. This triggers the 
loss of control over intake associated with dependence (Koob & Le Moal, 2001). 
 
Importantly, many of the mechanistic- and system-based schemas driving the initial 
consumption of alcohol and dependence were developed in a model devoid of the 
neuroimmune system. Nevertheless, it is apparent that these theories have served, 
and continue to serve, as foundational intellectual stepping-stones upon which modern 
reward and dependence research has been based. Therefore, to progress in our 
understanding of the mechanisms underpinning initial alcohol consumption and 
dependence, we need to integrate the emerging importance of the neuroimmune 
system with the current established models of initial consumption and dependence. 
 
1.5 The Neuroimmune system 
The neuroimmune system is an incredibly intricate and diverse system comprised of 
endogenous and exogenous immune functioning cells and their associated signalling 
molecules and receptors within the central nervous system (Pacheco et al., 2012). 
These cells and their immune components are crucial for maintaining homeostasis in 
the brain and spinal cord (Ousman & Kubes, 2012). Following detection of injury or 
infection, these cells facilitate the removal and elimination of pathogens and initiate 
and propagate repair processes (Ransohoff & Brown, 2012; Bailey et al., 2006). As 
will be alluded to, alcohol manipulates the neuroimmune system creating a state of 
persistent immune activation.  
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1.5.1 Cells of the neuroimmune system 
Almost all cells within the brain and spinal cord are part of the neuroimmune system. 
However, the degree to which these cells participate varies substantially (Waisman et 
al., 2015; Tian et al., 2012). Therefore, this thesis will focus upon three key cell types: 
neurons, microglia and astrocytes. Together these cells form the tetrapartite synapse 
an important communication bridge connecting immune cells, neurons and behaviour 
(Dityatev & Rusakov, 2011; De Leo et al., 2006). 
 
1.5.1.1 Neurons 
Neurons were traditionally considered the basic functional unit of the central nervous 
system. These cells transmit and integrate sensory information in the form of electrical 
impulses modified by neurotransmitters, neuropeptides and neurotrophic factors to 
generate cognition and behaviour. From an immunological perspective, neurons were 
traditionally viewed as bystanders during and proceeding an immune response (Galea 
et al., 2007). However, it is now recognized that neurons express a broad array of 
immune molecules and receptors (see for example Leow-Dyke et al., 2012; Gosselin 
et al., 2005; Viviani et al., 2003) and can perpetuate an inflammatory response via 
neurogeneic neuroinflammation (peripheral nerve fibres release neuropeptides to 
trigger a localised inflammatory response) (Xanthos & Sandkühler, 2013) or by 
modulating neighbouring immune cells via paracrine signalling involving 
neurotransmitters and cytokines (Becher et al., 2016; Lee, 2013). 
 
1.5.1.2 Microglia 
Microglia are macrophage-like cells constituting approximately 10 per cent of the 
cellular population in the central nervous system (Ransohoff & Brown, 2012). These 
cells colonise the brain during early embryonic development where they migrate to 
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their final destination and begin to self-renew (Kierdorf et al., 2013; Ginhoux et al., 
2010). During development, the activity and activation state of microglia varies 
substantially, reflecting the individual timing of each brain regions development 
(Hanisch, 2013; Schwarz & Bilbo, 2012). As brain development continues from early 
embryogenesis to adulthood, microglia phagocytise cellular debris and apoptotic cells, 
assist in cellular differentiation and synaptic migration, elimination and guidance (Choi 
et al., 2017; Neher et al., 2011; Stellwagen & Malenka, 2006; Bishop et al., 2004). In 
addition to their role in development, microglia constantly survey their 
microenvironment by extending and retracting their philophodia searching for 
perturbations in homeostasis (Nimmerjahn et al., 2005). Further, microglia are in 
intimate contact with synapses and can clear metabolic waste, modulate synaptic 
pruning, provide trophic support and regulate basal synaptic transmission (Ribeiro 
Xavier et al., 2015; Pascual et al., 2012; Paolicelli et al., 2011; Ragozzino et al., 2006; 
Takahashi et al., 2005).  
 
1.5.1.3 Astrocytes 
Astrocytes are the most abundant cell type within the central nervous system 
(Oberheim et al., 2006). These cells are derived from a specific population of neural 
progenitor cells and typically emerge towards the end of embryonic development (Tien 
et al., 2012; Bushong et al., 2004). Astrocytes do not reach functional maturity until the 
end of adolescence mimicking the slow development of neurons (Bushong et al., 
2004). Astrocytes were traditionally classified as supportive, trophic cells owing to their 
physical proximity to neurons (one astrocyte can contact up to 100,000 and 1,000,000 
synapses in the rodent and human brain respectively (Halassa et al., 2007; Bushong 
et al., 2002; Ogata & Kosaka, 2002)). However, these cells also express a broad array 
of neurotransmitters, trophic factors and their cognate receptors. Consequently, 
astrocytes actively participate in neuronal function and development. For example, 
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they regulate synaptic plasticity, synaptogenesis, synaptic scaling and the regulation 
of ion and glutamate concentrations within the synapse (Hu et al., 2007; 
Christopherson et al., 2005; Duan et al., 1999; Berbel & Innocenti, 1988). Astrocytes 
are also in contact with endothelial cells lining the blood brain barrier and can regulate 
it’s opening and closing (Takano et al., 2005; Kacem et al., 1998).  
 
Microglia and astrocytes (glial cells) are considered the primary immunocompetent 
cells within the central nervous system (Rivest, 2009; Carpentier et al., 2004). These 
cells survey their surrounds searching for tissue injury or infection (Ousman & Kubes, 
2012; Nimmerjahn et al., 2005). Key to immune surveillance are intercellular and 
membrane-bound pattern recognition receptors including Nucleotide oligomerisation 
domain-like (NOD), Retinoic acid-inducible gene 1-like (RIG) and Toll-like receptors 
(TLR) (Kigerl et al., 2014; Carpentier et al., 2008). These receptors recognise 
conserved molecular epitopes expressed by dead and stressed host cells (danger-
associated molecular patterns (DAMPs)) and exogenous bacteria, viruses and yeasts 
(pathogen-associated molecular patterns (PAMPs)) (Takeuchi & Akira, 2010). Binding 
of PAMPs and DAMPs to pattern recognition receptors initiates an inflammatory 
response from microglia and astrocytes (for example, Suh et al., 2009; Sterka et al., 
2005; Olson & Miller, 2004). Immunological activation of these cells changes their 
morphology, rate of proliferation and gene expression. Morphologically, glial cells 
change from a ramified (resting) to an amoeboid (activated) state. This is characterised 
by a retraction of their processes and a rounding of cell body (Ransohoff & Brown, 
2012; Sofroniew & Vinters, 2009). In addition, these cells increase the transcription, 
translation and release of immune mediators including cytokines and proteases (for 
example, Gorina et al., 2010; Olson & Miller, 2004). Immune mediators aim to eliminate 
the pathogen and enhance repair. However, prolonged immune activation is 
detrimental to the surrounding microenvironment as high levels of inflammatory 
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mediators can; distract glia and neurons from performing their housekeeping functions; 
degrade the myelin sheath; and induce cell death (Chien et al., 2016; Chatterjee et al., 
2013; Sheng et al., 2003).  
 
As the immune response resolves, glia change their phenotypes to one more 
conducive to repair with increased expression of anti-inflammatory mediators such as 
interleukin-10 (IL-10) and transforming growth factor β (TGFβ) (Norden et al., 2015; 
Cherry et al., 2014; Hashioka et al., 2013; Vincent et al., 1997). Once the immune 
event is resolved, glia can return to basal behaviour or remain in a sensitised, primed 
state (Bilbo, 2009). The precise mechanism underlying the switch to either a basal or 
primed state remains disputed. Primed glia appear morphologically active in the 
absence of an immune stimuli but these cells do not overproduce immune mediators 
basally (Bilbo, 2009). However, epigenetic processes may have occurred facilitating 
an increase in immune-related gene transcription but not translation. This ensures a 
faster, stronger response upon re-exposure to an immune stimulus.  
 
With respect to the inflammatory response, important differences exist between glial 
cells. For example, microglia are more sensitive and react faster to alterations in the 
central nervous system as they have a higher expression level of pattern recognition 
receptors and produce more inflammatory mediators basally (Tian et al., 2012). 
Astrocytes are thought to be slower to activate and exhibit more control over their 
activation (Jack et al., 2005; Lee et al., 1993). Furthermore, the expression of pattern 
recognition receptors and signal transduction pathways differ between these cells 
(Jack et al., 2005; Hua & Lee, 2000). For example, astrocytes, like neurons do not 
possess all the different intracellular signalling pathways for Toll-like receptors (Okun 
et al., 2011). Therefore, activation of this class of receptors on these cells may result 
in a different signalling outcome than is classically appreciated. 
 22 
 
It is important to note glial cells are not the only cells within the central nervous system 
capable of mounting an immune response. Neurons, endothelial cells, 
oligodendrocytes, and infiltrating monocytes and T cells are all capable of mounting an 
immune response to some degree. However, the discussion of these cells is beyond 
the scope of this thesis. Please refer to Grace et al., (2014) for a recent review 
discussing the immunological capabilities of these cells.  
 
1.5.2 Immune mediators of the neuroimmune system 
The ability of the neuroimmune system to detect and respond appropriately to PAMPs 
and DAMPs is dependent on a repertoire of immunological receptors, signalling 
molecules and transcription factors (Kigerl et al., 2014). These factors act in a 
concerted manner to restore the system back to homeostasis as quickly and efficiently 
as possible. Discussion of all types of immune mediators and the peripheral 
immunology is beyond the scope of this thesis and only those pertinent to alcohol, 
reward and anti-reward will be discussed. An overview of the immune mediators will 
be provided with specific focus on the central nervous system.  
 
1.5.2.1 Immune signalling molecules and their function within the central 
nervous system 
Cytokines 
Cytokines are a diverse class of signalling proteins involved in multiple cellular 
processes such as immune surveillance, induction of inflammation, cell adhesion, 
phagocytosis and cell death (Becher et al., 2016). Cytokines belong to one of five 
families based on structural homology. They include: chemokines, colony-stimulating 
factors, interleukins (IL), interferons (IFN), transforming growth factors (TGF) and 
tumour-necrosis factor (TNF) superfamily. Within each family, cytokines are typically 
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classified as either pro- or anti-inflammatory (Dinarello, 2007). However, this is a 
drastic oversimplification as the function of cytokines is dependent upon the inducing 
signal and the responding cell type. Thus, what is considered pro-inflammatory for one 
cell type may be anti-inflammatory for another (Shachar & Karin, 2013). Cytokines 
have high affinity for their corresponding receptors. Therefore, only small 
concentrations of cytokines are required to exert a large biological effect. 
Consequently, there are several mechanisms in place to limit the effect of these 
molecules including decoy receptors and regional differences in receptors and 
intracellular signalling protein expression (Kim, 2010). 
 
All cells of the neuroimmune system express cytokines and their receptors. The 
response to cytokines is cell specific and often results in non-immunological effects. 
For example, binding of tumour necrosis factor α (TNFα) to its receptor on microglia or 
neurons results in the production of reactive oxygen species and endocytosis of 
GABAA and AMPA receptors respectively (Olmos & Lladó, 2014; Stellwagen, 2005; 
Dopp et al., 2002). Further, IL-1β activates MAPKs and CREB in hippocampal neurons 
to alter synaptic function, but activates NFκB in astrocytes to alter synaptic function 
and induce the release of inflammatory mediators (Srinivasan, 2004). 
 
Chemokines 
Chemokines are a class of cytokines characterised by the presence of three to four 
conserved cysteine residues. They can be further subdivided based on the N-terminal 
cysteine’s position creating C-X-C, C-C, CX3C and xCL1 families (Groves & Jiang, 
2016). Microglia are the main source of chemokines in the central nervous system with 
the highest expression of chemokine receptors detected on astrocytes and neurons 
(Banisadr et al., 2005b). Chemokines signal through G protein-coupled receptors to 
activate signalling pathways causing a broad array of cellular effects (Groves & Jiang, 
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2016). The key feature of chemokines is their role in chemotaxis. However, these 
molecules also play important roles in the initiation of haematopoiesis, adaptive 
immune responses and immune surveillance (Turner et al., 2014). Outside of their 
immunological role, chemokines influence neurotransmission and neuroplasticity. For 
example, application of CCL2 (MCP-1), increases the firing of dopaminergic neurons 
via closure of background potassium channels which in turn increases circling 
behaviour in rodents (Guyon et al., 2009). 
 
Danger associated molecular patterns (DAMPS) 
Endogenous danger signals are a diverse array of molecules and proteins 
predominately released from damaged or dying cells (Bianchi, 2006). However, these 
molecules are also secreted under normal, basal conditions (Reina et al., 2012). They 
range from purine metabolites such as adenosine triphosphate (ATP); DNA and RNA; 
protein chaperones (heat shock proteins) and chromatin binding proteins (high mobility 
box group 1) (Gadani et al., 2015). In addition to their traditional roles, for example, 
increasing the stability of proteins or DNA, these molecules act as signalling factors 
indicating to the central and peripheral immune system that homeostasis has been 
altered ( Yang et al., 2015; Osmanov et al., 2013). This in turn initiates an inflammatory 
response.  
 
1.5.2.2 Immune transcription factors 
Nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) 
The NFκB family is comprised of five related transcription factors (p50, p52, RelA 
(p65), c-Rel and RelB) which share a N-terminal DNA binding/dimerisation domain 
termed the Rel homology domain (S. Ghosh et al., 1998). The Rel homology domain 
enables the homo- or heterodimerisation of NFκB transcription factors and facilitates 
DNA binding to promoter, enhancer or repressor regions within the genome (Bonizzi 
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& Karin, 2004). The homodimers of RelA, c-Rel and RelB are considered activators 
facilitating transcription via their C-terminal transcriptional activation domain. By 
contrast, p50 and p52 lack this domain and thus function as repressors unless bound 
to RelA, c-Rel or RelB (Chen & Ghosh, 1999; Chen et al., 1998; Ghosh et al., 1995; 
Mercurio et al., 1993; Toledano et al., 1993). 
 
Under basal conditions, NFκB is sequestered in the cytoplasm by inhibitor of kappa 
beta (IκB) proteins (Bonizzi & Karin, 2004). Upon activation by immunological and non-
immunological signals (such as a burst of action potentials), NFκB is translocated to 
the nucleus inducing or repressing the expression of inflammatory-related genes 
including cytokines, proteases and adhesion molecules (Lawrence, 2009). 
Interestingly the activation of NFκB in neuronal cells can regulate synaptic plasticity, 
neurite outgrowth and the expression of neurotransmitters, neuropeptide or 
neurotrophic factors and their receptors (Yirmiya & Goshen, 2011). Persistent 
activation of NFκB resulting from ongoing inflammation can induce epigenetic 
processes that modify the folding of DNA and the remodelling of histones - facilitating 
either activation or repression of NFκB–targeted genes (Vento-Tormo et al., 2014; 
Gazzar et al., 2007). 
 
Activator protein-1 (AP-1) 
AP-1 represents a functional heteromer consisting of proteins belonging to the Fos, 
Jun, Maf and ATF families in the central nervous system (Karin et al., 1997). AP-1 
contains two functional domains, a leucine zipper and a basic region that govern the 
protein dimerization and the DNA binding respectively (Chinenov & Kerppola, 2001). 
AP-1 is induced by a variety of immunological and non-immunological stimuli resulting 
in its translocation from the cytoplasm to the nucleus where it binds to specific regions 
of DNA regulating the expression of genes pertaining to a range of cellular process (for 
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example, Casals-Casas et al., 2009; Cavigelli et al., 1995; Abraham et al., 1991). All 
cells of the neuroimmune system express AP-1, with c-Jun/Fos the most commonly 
expressed heteromer (Shaulian & Karin, 2002). However, the composition of these 
heteromers varies according to cell type (Herdegen & Waetzig, 2001). Consequently, 
AP-1 has diverse roles including the regulation of immune-related processes, synaptic 
plasticity and cellular differentiation (Herdegen & Waetzig, 2001). 
 
1.5.2.3 Immune receptors 
Pattern recognition receptors 
Within the central nervous system, one mechanism by which the neuroimmune system 
detects PAMPs and DAMPs is through pattern recognition receptors (Kigerl et al., 
2014). Pattern recognition receptors include: C-type lectin receptors, RNA helicases, 
NOD-like receptors, RIG-I-like receptors and TLRs (Carpentier et al., 2008; Takeuchi 
& Akira, 2010). Each pattern recognition receptor recognises unique motifs expressed 
by bacteria, viruses, fungi and host cells, initiating intracellular signalling cascades 
culminating in the induction of inflammatory-related genes (Takeuchi & Akira, 2010). 
These receptors are considered the first line of defence against foreign entities and 
can subsequently act to recruit more specialised immunological cells (Takeuchi & 
Akira, 2010). In addition to the detection of pathogens and danger signals, it is 
becoming increasingly apparent that a specific class of pattern recognition receptors 
(TLRs) can detect and initiate inflammatory responses towards drugs of abuse such 
as opioids, cocaine, and amphetamines and alcohol (Bachtell et al., 2015). 
 
Toll-like receptors 
Toll-like receptors are a family of pattern recognition receptors that are expressed 
throughout cells of the neuroimmune system. Toll-like receptors belong to the 
Toll/interleukin-1 receptor superfamily, and are a type 1 integral membrane 
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glycoprotein (Akira & Takeda, 2004). These receptors consist of three key domains: 
N-terminal (extracellular or extra-endosomal), transmembrane and C-terminal 
(intracellular or intra-endosomal) domains (O’Neill & Bowie, 2007). The N-terminal 
domain consists of 16 – 28 leucine-rich repeats that form a horseshoe-like structure 
(Bell et al., 2003). It is hypothesised that the concave surface created by the leucine-
rich repeats are directly involved in the recognition of pathogens. The C-terminal 
domain (the Toll/IL-1R (TIR) domain) binds adapter molecules regulating signal 
transduction (Botos et al., 2011). For signal transduction to occur, monomeric TLRs 
must dimerise. Most TLRs exist as homodimers. However, TLR2 can exist as 
heterodimers with TLR1, 4, 6 and 10 (Oosting et al., 2014; Fernandez-Lizarbe et al., 
2013; Jin et al., 2007; Kang et al., 2009).  
 
Following dimerization, adapter proteins are recruited to the TIR domain and are 
phosphorylated to induce their activation. TIR domain-containing adaptor protein 
(TIRAP) and TLR adaptor molecule (TRAM) are the main adapter proteins that bind to 
the TIR domain. These proteins subsequently recruit the myeloid differentiation 
primary response protein 88 (MyD88) and the TIR-domain-containing adapter-inducing 
interferon-β (TRIF) proteins respectively (Akira & Takeda, 2004; Beutler & Rietschel, 
2003). Activation of TIRAP-MyD88 or TRAM-TRIF results in divergent signalling 
outcomes. For example, activation of the MyD88 pathway results in the 
phosphorylation of mitogen-associated protein kinases (MAPKs) p38, c-Jun, STAT 
and JNK, the formation and activation of AP-1, and early phase of NFκB (Sakai et al., 
2017; Horng et al., 2002; Fitzgerald et al., 2001; Burns et al., 1998). This results in the 
transcription of genes relating to classical pro-inflammatory cytokines such as IL-1β, 
TNFα, and CCL2 and reactive oxygen-inducing enzymes such as COX-2 and iNOS 
(Sakai et al., 2017; Fitzgerald et al., 2001). In contrast, signalling via the TRAM-TRIF 
pathway results in the downstream activation of interferon response factor (IRF) 3 and 
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7, which in turn regulate the expression of CCL5 and type-1 interferons such as 
interferon-β (Sakai et al., 2017; Fitzgerald et al., 2003; Kawai et al., 2001).  The TRAM-
TRIF pathway additionally results in the late phase activation of NFκB that transcribes 
anti-inflammatory genes such as IL-10 (Fitzgerald et al., 2003). Collectively, these 
inflammatory mediators facilitate the removal of the inflammatory stimuli and initiate 
wound healing. TLR4 is the only TLR that engages both signalling pathways; TLRs 1, 
2, 5, 6, 7, 8, 9 and 10 signal via MyD88 where as TLR3 signals via TRIF (Akira & 
Takeda, 2004). 
 
1.5.2.4 Investigating TLR4 signalling in the CNS 
TLR4 is unique among TLRs as it signals through both MyD88 and TRIF pathways, 
can reside on the cell surface or within endosomes and is widely expressed throughout 
the central nervous system (Buchanan et al., 2010; Kielian, 2006). Under basal 
conditions, TLR4 is predominately expressed on microglia, with low levels of 
expression detected on neurons and astrocytes (Bsibsi et al., 2002). It is unclear 
however, if astrocytes and neurons express MyD88, TRIF and other downstream 
signalling molecules necessary for signal transduction as studies conflict in regards to 
reporting the expression of these proteins (Okun et al., 2010; Rolls et al., 2007). 
Further, the expression of TLR4’s co-receptors differ between neuroimmune cells. For 
example, neurons and glia express a combination of MD1, MD2 and CD14. Unlike 
neurons, MD-1 in neuroimmune cells is bound to exclusively to its co-receptor RP105 
and not TLR4 (Okun et al., 2011; Divanovic et al., 2005). Therefore, the precise 
function of TLR4 may differ to those expressed on microglia. Lastly, while neurons and 
astrocytes are capable of inducing prototypical cytokines used as markers of MyD88 
and TRIF activation, it is presently thought that these cells may not express proteins 
pertinent to the TLR4 pathway. Therefore it is unclear whether these cytokines are 
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produced due to TLR4 activation or whether another immune pathway caused their 
expression (Okun et al., 2011; Préhaud et al., 2005). 
 
Within the central nervous system, TLR4 plays an important part in host immunity but 
also has crucial non-immunological roles such as the regulation of cellular 
development, differentiation and migration of neuronal precursor cells (Okun, 2014; 
Buchanan et al., 2010). However, discerning the molecular and behavioural 
consequences of TLR4 is difficult. For example, genetic knockout of TLR4 can result 
in compensatory mechanisms such as an upregulation of TLR2: confounding any 
conclusions (Okun et al., 2010; Rolls et al., 2007). Further, traditional pharmacological 
agonists and antagonists such as lipopolysaccharide (LPS), a cell wall component of 
gram negative bacteria, and LPS:RS, LPS from Rhodobacter sphaeroides, 
respectively, cannot cross the blood brain barrier thereby limiting the study of TLR4 
respectively (Banks & Robinson, 2010). In spite of this, a large number of studies still 
infer central TLR4 activation via peripheral administration of LPS. At present there are 
three pharmacological antagonists which readily cross the blood brain barrier to inhibit 
TLR4: TAK242, T5432126 and (+)-Naltrexone.  
 
TAK 242 blocks the interaction between TLR4 and its adapter proteins TIRAP and 
TRAM stopping the activation of the MyD88 and TRIF pathways (Matsunaga et al., 
2011). By preventing this interaction, TAK242 inhibits the activation NFκB and IRF3 
and subsequent release of inflammatory cytokines (Li et al., 2006). However, while this 
drug has provided insight into TLR4’s function (Wang et al., 2013), clinical trials using 
this drug for the treatment of sepsis have failed (Rice et al., 2010). T5342126 inhibits 
the interaction between TLR4 and MD2 preventing the subsequent rise in LPS-induced 
IL-6, IL-8, TNFα and Akt-1. Unfortunately, the relatively fast metabolism limits the 
efficacy of this drug (Chavez et al., 2011). (+)-Naltrexone is an enantiomer of the µ 
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opioid receptor antagonist (-)-Naltrexone. Both isomers are TLR4 antagonists, 
however, the spatial rotation of a hydroxyl and amine group prevents the (+)-isomer 
from binding to µ opioid receptors (Selfridge et al., 2014; 2015). Interestingly, (+)-
Naltrexone is currently thought to be a biased TLR4-antagonist preferentially 
attenuating the TRIF pathway. In BV2 cells, a microglia-like cell line, (+)-Naltrexone 
reduced LPS-induced NO and IFNβ production an effect attributable to a decrease in 
IRF3. This drug did not attenuate IL-1β production, NFκB, p38 or JNK (Wang et al., 
2016). In vivo, this drug prevented LPS induced changes to microglial morphology and 
can reverse chronic constriction injury-induced pain and cocaine and opioid self-
administration (Northcutt et al., 2015; Hutchinson et al., 2012; 2008;). The precise 
mechanism of (+)-Naltrexone’s biased antagonism remains to be fully elucidated. 
There are no specific MyD88 pharmacological inhibitors that can readily cross the 
blood brain barrier.  
 
Studies using (+)-Naltrexone have revealed an interesting interaction between TLR4 
and modern pharmaceuticals. Opioid receptor agonists and antagonists potentiate and 
inhibit TLR4 signalling (Hutchinson et al., 2010a; 2010b). This highlights that TLR4 
serendipitously interacts with a third class of molecular patterns, xenobiotic-associated 
molecular patterns (XAMPs) (Hutchinson et al., 2011; Buchanan et al., 2010). XAMPs 
represent a broad range of pharmaceuticals such as opioids, cocaine, 
methamphetamines and alcohol. These pharmaceuticals share one common 
characteristic: they are all drugs of abuse.  
 
Interestingly, TLR4 is not activated by other n-chain alcohols including methanol, 
propanol or butanol nor ethanol’s short-lived metabolites acetate or acetaldehyde 
(Blanco et al., 2005; Jacobsen unpublished). However, n-chain alcohols have immune 
altering capabilities with the degree of immunomodulation relating to the length of the 
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hydrocarbon backbone (Carigan et al., 2013). All n-chain alcohols (aside from 
methanol) dysregulate the peripheral immune system with attenuated cytokine 
production and immune-related transcription factor translocation (Carignan et al. 2013; 
Hoyt et al. 2013). By contrast methanol and ethyl-glucuronide, a minor, long-lasting 
metabolite of ethanol, augment the release of inflammatory cytokines and increase the 
expression and activity of immune related transcription factors (Lewis et al., 2013; 
Desy et al. 2010). Whether n-chain alcohols or ethanol’s minor metabolites alter the 
neuroimmune system remain to be determined.  
 
1.6 Parallels between an immune response to a lipopolysaccharide and 
alcohol within the central nervous system 
Within the central nervous system, an alcohol-induced TLR4 signal closely resembles 
that of an LPS-induced TLR4 signal. The extent to which TLR4 is engaged following 
LPS or alcohol exposure however is dependent upon: age, anatomical location (central 
vs. peripheral), concentration, cell type, extracellular protein co-factors and duration of 
exposure (Doremus-Fitzwater et al., 2015; Pascual-Lucas et al., 2014; Alfonso-
Loeches et al., 2010; Mandrekar et al., 2009). The consequences of alcohol- and LPS-
induced TLR4 signalling on the neuroimmune system may be broken down into 
morphological and functional changes, the effects on receptors and signal transduction 
pathways and immune-related molecules. 
 
1.6.1 Morphological and functional changes 
1.6.1.1 Acute exposure to alcohol or LPS 
Microglia 
Exposure to alcohol or LPS activates microglia in a time- and dose-dependent manner 
in vitro and in vivo. For example, a single dose of LPS alters the morphology of 
microglia from ramified to amoeboid, and increases the expression of microglial 
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markers Iba-1 and CD11b in vivo. Functional markers of microglia activation such as 
ED-1, a phagocytic marker, are additionally increased (Hoogland et al., 2015). The 
response to LPS is rapid, occurring three hours post exposure and persists for up to a 
week (Hoogland et al., 2015). On the contrary, four doses of alcohol are required to 
change microglia from a ramified to amoeboid state and increase cellular expression 
of Iba-1 and CD11b in vivo (Marshall et al., 2013; McClain et al., 2011). However, 
functional markers are unaffected (Marshall et al., 2013). Despite the lack of change 
in functional markers when using histological approaches, in vitro experiments suggest 
acute alcohol (and LPS) increase the phagocytic abilities of microglia (Fernandez-
Lizarbe et al., 2009). Collectively, this suggests alcohol exposure results in a similar 
immune response to a classical immunogen.  
 
Astrocytes  
Akin to microglia, astrocytes are activated by acute exposure to LPS or alcohol. Both 
compounds increase the expression of GFAP, an astrocyte marker, and alter their 
morphology to a more amoeboid-like shape. Unlike microglia, the response towards 
LPS or alcohol is not rapid, typically beginning approximately 12 h post exposure 
(Pascual-Lucas et al., 2014; Blanco et al., 2005). LPS and alcohol transiently interfere 
with the ability of astrocytes to perform housekeeping functions such as maintaining 
glutamate homeostasis (Ayers-Ringler et al., 2016; Tilleux & Hermans, 2007). 
Collectively, alcohol, like LPS, alters the phenotype of astrocytes to one that is 
immunologically more reactive at the expense of basal, homeostatic functions. 
 
Neurons 
Research has primarily focused on the susceptibility of neurons towards the neurotoxic 
effects of LPS and alcohol, with few studies considering whether these cells alter their 
phenotype to one more in line with to an immune response. 
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In general, acute exposure to LPS results in cell death. Interestingly, cell death occurs 
in a regional specific manner with the dopaminergic cells innervating the substantia 
nigra, particularly sensitive to the immune consequences of LPS (Zhou et al., 2012; 
Jeong et al., 2010). By contrast, neurons in the hippocampus or cortex are more robust 
and are unaffected by a single exposure to systemic LPS (Kim et al., 2000). This effect 
has been attributed to the number of glial cells within these brain regions; the 
substantia nigra and cortex exhibit the highest and lowest number respectively 
(Lehnardt et al., 2003). Notably, dopaminergic cells that survive LPS exposure exhibit 
transient alterations to their functionality. For example, tyrosine hydroxylase 
expression and dopamine re-uptake are reduced (Kim et al., 2000). In contrast, an 
acute dose of alcohol does not result in neurodegeneration in vivo. In vitro, co-culture 
of neurons with glial cells results in neuronal cell death following 24 h of alcohol 
exposure (Fernandez-Lizarbe et al., 2009). However, caution must be used when 
interpreting in vitro results, as the concentration of alcohol employed typically exceeds 
that found in vivo and LPS does not enter the brain. Therefore, unlike exposure to LPS, 
acute alcohol does not result in high levels of cell death and long-term alterations to 
cellular functionality. This suggest the immune altering effects of acute alcohol to 
neurons is low.  
 
1.6.1.2 Chronic exposure to alcohol or LPS 
Microglia 
Chronic exposure to LPS or alcohol results in exaggerated and prolonged activation of 
microglia. Chronic administration of these compounds intensifies Iba-1, CD11b and 
CD68 staining, causes a retention of an amoeboid morphology in the absence of the 
compound and produces irregular cell shapes and sizes (Hoogland et al., 2015; 
Pascual et al., 2011). Activation markers such as ED-1 are persistently elevated 
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following chronic LPS exposure (Hoogland et al., 2015). However, it is unclear whether 
this marker is altered following chronic alcohol exposure. Chronic LPS exposure 
results in widespread changes to glial morphology throughout the brain. By contrast 
the response to alcohol is area specific. For example, chronic alcohol administration 
alters microglial staining in the hippocampus, ventral tegmental area, cingulate cortex 
and midbrain but not the amygdala (He & Crews, 2008). Just like acute exposure, 
chronic exposure to alcohol shifts microglia to an inflammatory phenotype. This 
phenotype is long-lasting and persists in the absence of the drug (McClain et al., 2011). 
 
Astrocytes 
Chronic administration of LPS and alcohol results in long-term alterations to astrocyte 
morphology such as increased GFAP expression and a retraction of their processes 
creating an amoeboid-like shape (Adermark, 2015; Bull et al., 2015; Hauss-
Wegrzyniak et al., 1998; Ortiz et al., 1995). These effects persist for prolonged periods 
(days – weeks) before returning to baseline (Adermark, 2015; Zamanian et al., 2012). 
Chronic stimulation with either LPS or alcohol inhibits the ability of these cells to 
perform housekeeping functions such as maintaining glutamate homeostasis and 
synaptogenesis; and can result in astrocyte cell death (Ayers-Ringler et al., 2016; Shen 
et al., 2016; Bull et al., 2015; Sharma et al., 2015). Therefore, chronic exposure 
induces immunological activation of astrocytes an effect that persists even after the 
initial stimulus is removed. 
 
Neurons 
Chronic administration of LPS or alcohol results in high levels of neurodegeneration 
(Alfonso-Loeches et al., 2013; 2010). The prefrontal cortex is particularly sensitive to 
the effects of chronic LPS and alcohol, exhibiting the greatest loss in cell number 
(Vetreno et al. 2015; de Pablos et al., 2006; Fan et al., 2005). Furthermore, chronic 
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immune stimulation of neurons, whether by LPS or alcohol alters the functional 
properties of these cells. For example, chronic administration of LPS or alcohol alters 
membrane resistance, action potential threshold, slows the frequency of action 
potentials (Bajo et al., 2014; Hellstrom et al., 2005), increases the aggregation of poly-
ubquitinated proteins, down-regulates the autophagy pathway  (Pla et al., 2016; 2014) 
and reduces the myelination of neurons (Alfonso-Loeches et al., 2010; Hellstrom et al., 
2005).  
 
1.6.1.3 Priming following exposure to alcohol or LPS 
Following administration of LPS or alcohol, microglia often do not return to their basal 
state. Rather, these cells can remain in a ‘primed’ state of partial activation (Bilbo, 
2009). For example, administration of alcohol during adolescence leads to long-lasting 
increases in microglial Iba-1 or CD11b expression and alters microglia morphologically 
to a more amoeboid shape in adulthood (Cruz et al., 2017; Norden & Godbout, 2013; 
McClain et al., 2011). It is hypothesised that these cells do not exhibit basal increases 
in immune mediators and receptors. Subsequent immunological activation whether by 
the original or new stimuli (cross-sensitisation) results in an exaggerated inflammatory 
response. There is some evidence to suggest astrocytes may also exist in a primed 
state (Hennessy et al., 2015; Norden & Godbout, 2013). However, it is unclear whether 
this process is due to ageing or can occur at any ontological period. It is presently 
unclear whether neurons exhibit a priming effect following exposure to LPS or alcohol. 
 
1.6.2 Receptor signalling and alterations to signal transduction pathways 
1.6.2.1 Acute exposure to alcohol or LPS 
Receptors 
Acute LPS and alcohol facilitate the translocation of TLR4 and TLR2 in to lipid rafts 
within the plasma membrane (Fernandez-Lizarbe et al., 2013). In brief, lipid rafts are 
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sub-domains of the plasma membrane and serve as signalling platforms enabling the 
co-localisation of specific proteins expediting their interaction to increase signalling 
transduction (Katagiri et al., 2001). Following stimulation with LPS or alcohol, TLR4 
and TLR2 are rapidly translocated to caveloae-enriched lipid rafts, promoting the 
recruitment of downstream adaptor molecules onto the cytoplasmic side of these 
microdomains. The raft is subsequently endocytosed and trafficked to the endoplasmic 
reticulum, golgi and the nucleus in astrocytes and microglia where downstream 
signalling molecules can exert their biological function (Pascual-Lucas et al., 2014; 
Fernandez-Lizarbe et al., 2013). Thus, acute stimulation of LPS or alcohol results in a 
rapid decrease in the surface expression of TLR4 owing to its internalisation. 
Interestingly, higher concentrations of alcohol but not LPS are known to disrupt the 
lipid membrane resulting in a loss of lipid rafts (Fernandez-Lizarbe et al., 2013). LPS 
and alcohol’s effect on TLR4 signalling have been characterised using astrocytes and 
microglial cells both in vitro and in vivo (Pascual-Lucas et al., 2014; Fernandez-Lizarbe 
et al., 2013). However, the effect of alcohol or LPS on neuronal TLR4 is presently 
unknown. 
 
At the gene-level, acute administration of alcohol increases the mRNA expression of 
multiple TLRs including TLR2, 3, 4 and 7 (Crews et al., 2017). These experiments have 
been conducted in brain homogenates. Therefore, the cell type underlying the gene 
elevations is unknown. By contrast, studies have shown LPS causes an increase and 
decrease in the expression of TLRs mRNA in astrocytes and microglia respectively 
(Marinelli et al., 2015). 
 
Signalling pathway 
LPS and alcohol trigger the translocation, recruitment and phosphorylation of early 
TLR4 signalling molecules MyD88, TRAF-6 and IRAK from the plasma membrane to 
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TLR4-rich lipid rafts within microglia and astrocytes (Fernandez-Lizarbe et al., 2013; 
Blanco et al., 2008). Recruitment of these signalling molecules occurs rapidly (within 
10 mins) and is short-lived – resolving within an hour. Following internalisation and 
activation of adaptor molecules, alcohol and LPS induce the phosphorylation of Fos 
and MAPKs: ERK, p38 and JNK. The phosphorylation of these proteins peak at 30 
mins and decline 3 to 24 h post exposure (Fernandez-Lizarbe et al., 2013; Blanco et 
al., 2008). In contrast, mixed hippocampal cells isolated from mice demonstrated no 
increase in JNK, ERK or p38 when stimulated with 50mM alcohol for 30 min (Wu et 
al., 2012) suggesting this response may be specific to some but not all cells of the 
neuroimmune system.  
 
The hallmark of TLR4-MyD88 signalling is the downstream activation of NFκB and AP-
1.  Alcohol and LPS induce the phosphorylation and translocation of the p65 subunit 
of NFκB to the nucleus in microglia and astrocytes (Fernandez-Lizarbe et al., 2009; 
Blanco et al., 2005). Further, the DNA binding activity of NFκB is increased following 
alcohol and LPS exposure indicating activated gene transcription (Crews et al., 2006; 
Heese et al., 1998). Microglia or astrocytes isolated from mice deficient in TLR4 or 
inhibiting TLR4 activation via antibodies or siRNA inhibits the recruitment of adapter 
proteins, activation of intracellular signalling pathways and the translocation of 
transcription factors to the nucleus (Fernandez-Lizarbe et al., 2013; Alfonso-Loeches 
et al., 2010; Blanco et al., 2005). 
 
In addition to the MyD88 dependent pathway, alcohol and LPS activate the TRIF 
pathway in microglia (Regen et al., 2011). This process is not well characterised in vivo 
however. Alcohol and LPS significantly increase the formation and phosphorylation of 
IRF-3 dimers approximately 3 h post exposure. This coincides with increases in STAT-
1 protein and Ifnb and Ip10 mRNA levels (Lawrimore et al., 2017; Fernandez-Lizarbe 
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et al., 2013; Tarassishin et al., 2011; Kozela et al., 2010; Qin et al., 2005). It is presently 
unclear why the onset of TRIF signalling is slower than that of MyD88; whether late 
phase NFκB is activated; and the cell or signalling location of TRIF following alcohol 
and LPS exposure in microglia. 
 
It is important to note that the temporal dynamics of the response towards alcohol and 
LPS is unique to each cell type; with microglia and astrocytes exhibiting differences in 
terms of the expression and activation kinetics of MAPKs (Norden et al., 2015; 
Fernandez-Lizarbe et al., 2009; Blanco et al., 2005) with microglia exhibiting faster and 
more robust induction of MAPKs compared to astrocytes. Furthermore, the recruitment 
of TLR4’s signalling molecules is significantly lower for alcohol than LPS (Fernandez-
Lizarbe et al., 2009; Blanco et al., 2008) and therefore, the overall systems response 
towards the two stimuli will differ. This furthers the idea that activating a receptor with 
different ligands is not going to give an identical response. The molecular response is 
dependent upon the binding affinity and binding site of the ligand. These variables 
influence the conformation of the receptor, impacting which signalling proteins are 
recruited and the subsequent biological outcome.  
 
1.6.2.2 Chronic exposure to alcohol or LPS 
Unlike the acute effects of alcohol or LPS, long-term exposure to these compounds 
results in pharmacodynamic alterations influencing receptor-mediated signalling 
events in neuroimmune cells. This in turn impacts molecular and behavioural outcomes 




Chronic administration of LPS (greater than two doses or 18 h of exposure) reduces 
or does not alter surface expression of TLR4 (Cuschieri et al., 2006; Nomura et al., 
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2000). There are however, notable reductions of TLR4 dimers in lipid rafts suggesting 
the ability to induce transduction is impaired. Chronic administration of alcohol 
increases the expression of TLR4 mRNA and protein on astrocytes, microglia and 
neurons (Vetreno & Crews, 2012). Interestingly, unlike previous studies demonstrating 
the highest level of TLR4 expression on microglia (Bsibsi et al., 2004), in this study the 
highest expression of TLR4 was found in neurons rather than glia. It is presently 
unclear whether the signal transduction properties of TLR4 is altered following chronic 
alcohol exposure.  
 
Signalling pathway 
LPS tolerance is a phenomenon in which chronic administration of LPS results in a 
diminished immune response. Interestingly, the tolerance induced by LPS results in 
heterologous desensitisation toward related inflammatory stimuli such as TNFα but not 
IFNβ. This indicates that LPS tolerance predominately modifies the MyD88 but not 
TRIF pathways. While LPS tolerance has been demonstrated in microglia following 
chronic LPS administration (Chu et al., 2016), the underlying mechanisms are 
unknown. In the periphery however, the effects of LPS tolerance are well 
characterised. Given that microglia are hypothesised to be of myeloid-origin (Ginhoux 
et al., 2010), it is possible that some of the mechanisms underlying peripheral LPS-
tolerance are conserved in this cell type. In the periphery, there are multiple 
mechanisms underlying LPS tolerance including; reduced TLR4-MyD88 interaction (as 
inferred by immunoprecipitation), decreased IRAK, p38, ERK1/2 and JNK expression 
and upregulation of negative regulatory proteins such as IRAK-M (see Seeley & 
Ghosh, 2017 for review). Tolerance is also associated with changes in the subunit 
composition of NFκB: the expression of the p65-p50 heteromer is decreased and the 
p50 homodimer, a transcriptional repressor, expression is increased. Further, histone 
modification, nucleosome remodelling, miRNA binding to promoter regions and DNA 
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methylation are also modified repressing the transcription of inflammatory-related 
genes (Chen et al., 2009; Gazzar et al., 2007). 
 
The effects of chronic alcohol administration on TLR4s downstream signalling pathway 
are not well characterised. Chronic administration of alcohol increases the expression 
of MyD88, MAPKs and NFκB and alters epigenetic processes in vivo (Montesinos et 
al., 2016; Pascual et al., 2011). This suggests a lack of TLR4 tolerance towards alcohol 
(Alfonso-Loeches et al., 2010). No study has conclusively demonstrated that the TRIF 
pathway is activated following chronic alcohol exposure in vivo. However, preliminary 
in vitro evidence indicates 24 h of alcohol exposure increases IRF3 expression in 
microglia- and neuronal- like cells (Lawrimore et al., 2017). Future studies are required 
to fully characterise the MyD88 or TRIF response to chronic alcohol. This is of 
particular importance as TLR4 acting compounds can potentially exhibit preferential 
augmentation or attenuation MyD88 or TRIF pathways (biased ligands) (Wang et al., 
2016). 
 
1.6.2.3 Priming following alcohol or LPS 
Receptors 
The effects of alcohol-induced priming on TLR4 expression have predominately been 
characterised in studies assessing the effects of adolescent binge drinking and later 
life behaviours. Adolescent alcohol exposure results in a persistent upregulation of 
TLR4, TLR3, TLR2 and RAGE mRNA through adulthood (Vetreno & Crews, 2012). 
Similarly, morphine, another XAMP and TLR4 agonist, induces the persistent 
upregulation of microglial TLR4 mRNA in the nucleus accumbens (Schwarz & Bilbo, 
2013). In contrast, a persistent upregulation of TLR4 mRNA or protein is not observed 
following LPS  exposure (Cardoso et al., 2015). Interestingly, in studies designed to 
examine the long-term effects of sepsis, LPS results in prolonged increases in TLR4’s, 
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endogenous agonist HMGB1, within the central nervous system (Chavan et al., 2012). 
This indicates while LPS may not directly increase TLR4 expression, there is an 
ongoing sensitisation event which may alter immune activation. 
 
Signalling pathway 
At present, no study has examined whether acute exposure to alcohol or LPS during 
adolescence or adulthood results in a persistent upregulation of TLR4 signalling 
pathway proteins (MyD88 or TRIF) later in life. 
 
1.6.3 Expression of immune proteins 
1.6.3.1 Acute exposure to alcohol or LPS 
The cytokine response following LPS and alcohol exposure is dependent upon cell-
type, duration of exposure and the age of the animal. In vitro acute LPS increases IL-
6, IL-1β, TNFα, CCL2 and IL-10 but not TGFβ protein expression from microglial cells. 
The increase occurs within 2 h, and persists for, 2 and 12 h (Norden et al., 2015). By 
contrast, astrocytes exhibit a decreased and slower inflammatory response towards 
LPS (12 – 24 h post exposure), with elevations in TNFα, CCL2 and TGFβ but not IL-
6, IL-1β or IL-10 (Norden et al., 2015). Further in vitro experiments demonstrate that 
acute alcohol increases Il1b, Il6 and Ip10 mRNA from astrocytes and microglia 
(Pascual-Lucas et al., 2014; Boyadjieva & Sarkar, 2010). It is unclear whether the 
expression of other cytokines differ following alcohol exposure in astrocytes or 
microglia. Again, caution must be used when interpreting in vitro results, as alcohol 
concentrations typically exceed those in an in vivo setting, and as a result potentially 
exacerbate an alcohol mediated TLR4 signal.  
 
In vivo, a single dose of LPS increases the protein and mRNA levels of pro-
inflammatory cytokines and type one interferons (Püntener et al., 2012; Qin et al., 
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2008). A single dose of alcohol increases the mRNA, but not protein of classical pro-
inflammatory, interferon and anti-inflammatory products (Qin et al., 2008). In addition, 
the expression profile differs from LPS. For example, a single dose of LPS increased 
the mRNA expression of Il1b, Il10, Ccl2, Tnfa, Cox-2 and gp91phox and the protein 
expression of IL-1β, CCL2 and TNFα in the brain. By contrast, a single dose of alcohol 
increased the mRNA of Tnfa, Ccl2 and Cox-2 but not Il1b, Il10 or gp91phox. Further, the 
protein concentration of IL-1β, TNFα or CCL2 was unaltered (Qin et al., 2008). Four 
doses of alcohol is sufficient to induce protein change indicating the immunological 
stimulatory effects of alcohol are not as pronounced compared to LPS (Qin et al., 
2008). Furthermore, acute administration of LPS increases the expression of IFNβ 
from neurons (Lynch et al., 2004; Gahring et al., 1996). However, conjecture remains 
whether these cells produce IFNβ from a traditional manner given these cells are 
thought to lack certain TLR4 signalling pathway proteins (Okun et al., 2011). It is further 
unclear whether acute alcohol alters cytokine production from neurons.  
 
Interestingly, the age of the mouse also influences the neuroimmune response towards 
alcohol and LPS. For example, acute LPS and alcohol induces a reduced IL-6, CCL2 
and TNFα response in adolescent mice compared to adults (Doremus-Fitzwater et al., 
2015; Kane et al., 2013) suggesting that adolescent mice are some-what protected 
against the effects of LPS and alcohol compared to adult mice. 
 
1.6.3.2 Chronic exposure to alcohol or LPS 
Owing to the effects of endotoxin tolerance, chronic exposure to LPS reduces the 
expression of classical pro-inflammatory molecules but not type 1 interferons (Gazzar 
et al., 2007). By contrast, chronic administration of alcohol increases the mRNA and 
protein of pro-inflammatory and type-1 interferon’s, with a reduction in anti-
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inflammatory proteins (Pascual et al., 2015). However, it is unclear whether the 
inflammatory response differs between cell types.  
 
1.6.3.3 Priming following alcohol or LPS exposure 
The priming effect of LPS and alcohol differs. Acute but not chronic LPS induces a 
priming response. For example, postnatal administration of LPS leads to persistent 
upregulation of cytokines in the hippocampus of mice - an effect that persists until 
adulthood (Musaelyan et al., 2014). Furthermore, a single dose of LPS caused a 
persistent elevation in TNFα for ten months (Qin et al., 2007). However, acute alcohol 
does not induce a priming response. For example, four days of alcohol exposure did 
not result in a persistent upregulation of IL-6 or TNFα protein in the hippocampus or 
entohiroinal cortex of adult mice (Marshall et al., 2013). Similarly, an adolescent 
alcohol binge did not result in long-lasting cytokine increases at the protein level (Zhao 
et al., 2013; McClain et al., 2011). Despite an absence of inflammatory cytokines, 
HMGB1 remains persistently elevated in adulthood following chronic alcohol exposure 
during adolescence suggesting a degree of immune-sensitisation (Montesinos et al., 
2016; 2015). The differences between LPS and alcohol may be due to the nature of 
the inflammatory response. Acute alcohol reflects a low transient rise in immune 
mediators. By contrast, chronic alcohol increases the expression and release of 
immune mediators similar to an acute LPS-induced immune response. The severity of 
the immune response cannot be readily overcome with anti-inflammatory feedback 
mechanisms, resulting in long lasting (priming) changes to inflammatory gene 
transcription. However, chronic LPS alerts an immunological safety threshold. 
Regulatory mechanisms are activated in an attempt to limit inflammation and 




Overall, acute and chronic alcohol and acute but not chronic LPS induce TLR4 
signalling resulting in an increase in inflammatory-related transcription factors and 
molecules. While both stimuli initiate and perpetuate an inflammatory response as 
indicated in the aforementioned section (Table 1), there are crucial differences 
between the two that lead to fundamentally different behavioural effects. For example: 
1. The initial immune response towards LPS is significantly greater compared to 
alcohol. A single dose of LPS results in a profound upregulation and release of 
inflammatory mediators within the central nervous system. By contrast a single 
dose of alcohol results in a moderate increase in mRNA of some but not all 
immune genes. Importantly, protein level is not increased following a single 
dose of alcohol. This suggests alcohol is not as strong an immunogen as LPS; 
rather alcohol creates a sub-inflammatory response (Qin et al., 2008). 
2. Acute administration of LPS results in cellular and molecular changes 
throughout most brain regions (Qin et al., 2007). Acute alcohol, results in cellular 
and molecular changes within discreet brain regions associated with reward and 
anti-reward (He & Crews, 2008). 
3. Chronic administration of LPS results in tolerance (Gazzar et al., 2007). Owing 
to the comparatively lower level of immune system engagement, it is unlikely 
alcohol has crossed the immunological threshold for inducing tolerance.  
4. Unlike LPS, additional TLRs may be involved in the response towards alcohol 
such as TLR2 and TLR7 (Coleman et al., 2017; Pascual et al., 2015). 
5. While both LPS and alcohol promote the clustering of TLR4 on lipid rafts 
(Fernandez-lizarbe et al., 2009) the mechanism underlying alcohol-induced 
TLR4 signalling is vastly different. LPS directly interacts with LPS-binding 
protein, CD14 and MD2 to transduce a signal via TLR4 (Kim & Kim, 2017; 
Beutler & Rietschel, 2003). Like LPS, alcohol-induced TLR4 activation requires 
co-receptors CD14 and MD2. However the precise mechanism remains unclear 
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(Alfonso-Loeches et al., 2010). We have hypothesised that alcohol induces 
reactive oxygen species (owing to local metabolism) or alters the osmotic stress 
place on neuroimmune cells (Yu et al., 2015; Tsung et al., 2007). This in turn 
causes the release of DAMPs such as HMGB1, a TLR4 agonist thereby 
initiating an immune response. Alcohol additionally, induces a “leaky gut” 
resulting in the translocation of bacterial, viral and fungal proteins and lipids 
from the gut to blood and the liver. Activation of resident and circulating 
peripheral immune cells by these proteins are hypothesised to activate the 
neuroimmune system (see Crews & Vetreno, 2015 for review).  
6. Unlike alcohol, LPS does not readily cross the blood brain barrier. LPS-TLR4 
binding occurs in the periphery which subsequently activates the neuroimmune 
system by circulating cytokines crossing the blood brain barrier 
(circumventricular organs); active transport of cytokines across the brain 
endothelium; activation of peripheral nerve fibres such as the vagal nerve, which 
transmit cytokine signals to specific brain regions; activation of endothelial cells 
and peripheral macrophages with the cerebral vasculature to produce 
inflammatory mediators within the brain; or migration of peripheral immune cells 
into the brain by extravasation (Quan & Banks, 2007) or by the brain’s lymphatic 
system (Louveau et al., 2015).  
 
Exposure to LPS results in much higher levels of inflammatory mediators and 
generates a state of neuroinflammation. Neuroinflammation has profound effects on 
both human and animal behaviours. For example, the high levels of inflammatory 
mediators observed during pathological neurodegenerative disease states such as 
Alzheimer’s and Parkinson’s disease cause neuronal cell death, which in turn directly 
affects an individual’s memory, language, and mood (McGeer & McGeer, 2010; 
Rogers et al., 2007). However, an alcohol-induced immune response is relatively 
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smaller and occurs in discrete neuroanatomical areas compared to that of a LPS-
induced immune response. As such, it has been hypothesized that the immune 
response is acting in a manner similar to neurotransmission (central immune 




Table 1 Summary neuroimmune responses towards alcohol and LPS 
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1.7 What do these immune mediators do? 
The parallels listed above focus primarily upon the traditional immunological role of 
TLR4, its transcription factors and signalling molecules. In addition to this role, it is 
becoming increasingly apparent that immune molecules act as neuromodulators 
capable of modifying the electrophysiological properties of neurons, the release of 
neurotransmitters and neuropeptides which under specific circumstances can alter 
behaviour (Miller et al., 2013; Parsadaniantz & Rostène, 2008; Rostène et al., 2007). 
Prolonged exposure to immune mediators results in transcriptional and epigenetic 
processes altering the expression of genes related to neurotransmitters and receptors. 
This reinforces or diminishes synaptic activity, thus modulating plasticity and further 
modifies neuronal behaviour. 
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The proceeding sections focus primarily on how immune mediators can alter the 
behaviour of neurons. It is important to note, neurons can additionally modulate the 
activity of glial cells and their immune responses. However, this area is beyond the 
scope of this thesis, please refer to Neumann, (2001) for review.  
 
1.7.1 Acute exposure to immune molecules 
Acute exposure to alcohol results in an increase in immune-related molecules such as 
cytokines, and reactive oxygen creating enzymes (Fernandez-Lizarbe et al., 2009; Qin 
et al., 2008; Blanco et al., 2005). Emerging data suggests these immune molecules; 
specifically cytokines, exhibit characteristics similar to neurotransmitters (Miller et al., 
2013; Rostène et al., 2007). For example, they are located in nerve-terminal vesicles, 
are often co-localised to phenotypically defined neurons such as dopaminergic or 
cholinergic neurons, are released following membrane depolarisation and can bind to 
post-synaptic receptors activating intracellular signalling pathways and membrane 
depolarisation (Knapp et al., 2011; Guyon et al., 2009; Banisadr et al., 2005b; de Jong, 
2005).  
 
1.7.1.1 Cytokines and neuromodulation 
The neuromodulatory properties of cytokines are becoming increasingly appreciated. 
Particular emphasis has been placed on CCL2, a chemokine, with well characterised 
neuronal function. For example, CCL2 and its receptor CCR2 are expressed by glia 
and neurons respectively (Banisadr et al., 2005b; Oh et al., 1999; Hayashi et al., 1995). 
In particular, CCR2 co-localises to dopaminergic and cholinergic neurons within the 
substantia nigra and VTA (Banisadr et al., 2005b; 2005a). Application of CCL2 into the 
substantia nigra closes K+ channels in dopaminergic neurons increasing their 
membrane resistance. This leads to increased frequency of pacemaker and burst 
action potentials potentiating dopamine release and in turn increases circling 
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behaviour in rodents (Guyon et al., 2009). CCL2 additionally acts via T-type Ca2+ and 
Na+ channels in neurons in the cortex, hippocampus, hypothalamus and 
mesencephalon (Belkouch et al., 2011; You et al., 2010; Gosselin et al., 2005; van 
Gassen et al., 2005). However, the behavioural and functional consequences of these 
interactions remain to be fully elucidated.  
 
Interestingly, CCL2 expression is increased following alcohol exposure – an effect 
dependent on TLR4 (Pascual et al., 2015; Qin et al., 2008). Further, mice deficient in 
CCR2 exhibit reduced alcohol intake (Blednov et al., 2005). Given the importance of 
dopamine in alcohol reward, it is likely that a lack of CCL2 signal in CCR2-/- mice 
reduces extracellular dopamine, alcohol-induced reward and consequently the intake 
of alcohol is attenuated. 
 
The neuromodulatory properties of the TNF superfamily are crucial for the generation 
of anti-reward behaviour. For example, administration of TNFα into central amygdala 
(CeA) increased the amplitude but not frequency of miniature excitatory postsynaptic 
currents (mEPSCs) and decreased the threshold for triggering action potentials without 
altering membrane properties of CeA neurons – an effect mediated by glutamate and 
PI3K (Ming et al., 2013). This resulted in the release of GABA and CRF (an anti-reward 
peptide) from presynaptic neurons. Attenuating microglial activation using minocycline 
attenuated the effects of TNFα on CeA neurons suggesting microglia are involved in 
mediating this process (Ming et al., 2013; Knapp et al., 2011).  
 
TNFα is increased in the brain following chronic alcohol exposure and remains 
elevated once the drug has been cleared (Qin et al. 2008). Given CRFs pivotal role in 
mediating anti-reward behaviours such as anxiety, alcohol-induced TNFα signalling 
could potentiate its release in the CeA further exacerbating the symptoms of anti-
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reward (Chen et al., 2013; Knapp et al., 2011). Further, the increased TNFα-induced 
GABAergic tone may contribute to anhedonia as this process could potentially reduce 
CeA dopaminergic neurotransmission – a key component of chronic alcohol intake. 
 
Aside from cytokines, glial derived neurotrophic factor (GDNF) is gaining increasing 
importance in coupling the effects of glia and neurons following alcohol exposure (Ron 
& Barak, 2016; Lin et al., 1993). GDNF and its receptor are highly expressed in the 
VTA and nucleus accumbens respectively (Glazner et al., 1998). This protein regulates 
the survival and maintenance of dopaminergic neurons and is involved in learning, 
memory, synaptic plasticity, all key variables influencing the “wanting” component of 
reward (Ghitza et al., 2010). Infusion of GDNF into the VTA increases the spontaneous 
activity of dopaminergic neurons increasing the concentration of extracellular 
dopamine in the nucleus accumbens via an ERK1/2 dependent process (Wang et al., 
2010). Administration of GDNF during alcohol withdrawal, a period characterised by 
dopamine deficiency, normalises the level of extracellular dopamine potentially 
attenuating relapses to alcohol drinking (Barak et al., 2014; 2011) Crucially, ibudilast, 
a microglial specific anti-inflammatory agent increases GDNF expression (Mizuno et 
al., 2004) which may assist in this drugs ability to reduce alcohol drinking (Bell et al., 
2015) and the self-administration of, and relapse to cocaine and methamphetamines 
(Poland et al., 2016; Snider et al., 2012; Beardsley et al., 2010).  
 
1.7.2 Chronic exposure to immune molecules 
Chronic exposure to alcohol results in higher levels of inflammatory mediators that 
persist even in the absence of the alcohol (Pascual et al., 2016; 2015). Prolonged 
exposure to immune-related molecules results in long-term adaptions on a cellular, 
epigenomic and genomic level (Hennessy & McKernan, 2016; Carson et al., 2014; 
Hellstrom et al., 2005).  
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1.7.2.1 Cellular changes 
Neuroimaging studies in rodents and humans consistently demonstrate a reduction in 
white matter content; myelinated neurons; and the astrocyte expression marker GFAP 
following prolonged alcohol exposure (Vetreno et al., 2015; Alfonso-Loeches et al., 
2013; 2012; 2010; Blanco et al., 2005; Korbo, 1999). The loss of myelin, neurons and 
astrocytes is attributable to the persistent expression of inflammatory molecules and 
reactive oxygen species which activate caspases (cell death proteins) and reduced the 
expression of myelin synthesising enzymes (Alfonso-Loeches et al., 2013; Fernandez-
Lizarbe et al., 2009). These losses, which are particularly evident in the frontal cortex, 
striatum and hippocampus, have functional consequences (Nixon, 2006; Crews et al., 
2004). For example, mice exposed to long-term alcohol exhibit impairments in tasks 
assessing memory and cognitive function as well as increases in anxiety-like and 
reward-seeking behaviours. This effect is mitigated by genetic knock out of immune 
receptors (Alfonso-Loeches et al., 2012; 2010; Pascual et al., 2011). This suggests 
that the loss of neurons, myelin and support from astrocytes reduces neuroplasticity; 
creating a brain more hardwired towards obtaining reward and generating anti-reward. 
 
Glial cells are crucial to the homeostatic functioning of neurons (Kettenmann et al., 
1996). Chronic alcohol exposure alters the phenotype of these cells, causing them to 
neglect many of their normal housekeeping functions such as maintaining glutamate 
homeostasis and clearance of metabolic waste (Ayers-Ringler et al., 2016; Pla et al., 
2014; Spanagel & Rosenwasser, 2005). Under basal conditions astrocytes regulate 
the clearance of extracellular glutamate through GLAST (EAAT1) and GLT-1 (EAAT2) 
astrocyte-specific glutamate transporters (Rothstein et al., 1996). These transporters 
co-transport Na+, which in turn activates neuronal Na+/K+ - ATPase pump, reducing 
neuronal excitability via clearance of K+ from the extracellular space (Kanai & Hediger, 
1992; Storck et al., 1992). Following acute alcohol exposure, the expression of GLAST 
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and GLT-1 is increased in organotypic cortical cell cultures to remove excessive 
glutamate induced by alcohol (Adermark & Bowers, 2016). Chronic consumption, 
however, decreases the expression of these transporters, causing the concentration 
of extracellular glutamate to rise. Increased extracellular glutamate causes 
excitotoxicity and neurodegeneration (Sattler & Tymianski, 2001). Restoring GLAST 
and GLT-1 function in the nucleus accumbens decreases glutamate concentration and 
prevents withdrawal-induced drinking and seizures (Hakami et al., 2017). 
 
1.7.2.2 Transcription factor changes 
NFκB   
NFκB has primarily been characterised in terms of its ability to transcribe genes 
pertaining to an immune response. It is therefore unsurprising that this transcription 
factor contributes to alcohol-induced neurodegeneration (Pascual et al., 2011; 
Fernandez-Lizarbe et al., 2009; Blanco et al., 2008). However, NFκB has many other 
roles beyond the immune system such as its expression within neurons and the 
regulation of synaptic function, plasticity and expression of neurotransmitters and their 
receptors (Nennig & Schank, 2017; Yirmiya & Goshen, 2011). NFκB binding sites have 
been found in the promoter region of β-endorphin, opioid, neuropeptide Y and 
glutamate receptor genes (Chiechio et al., 2006; Karalis, 2004; Kraus et al., 2003; 
Richter et al., 2002; Musso et al., 1997). Given that chronic alcohol increases the 
expression and activity of NFκB, this may increase transcription (or repression) of 
opioid- and neuropeptide Y-related genes (Nennig & Schank, 2017), which in turn, 
alters the “liking” component of alcohol reward and anxiety behaviour respectively. 
 
NFκB transcription factor activity in neurons is additionally required for memory 
formation and consolidation – important processes generating the “wanting” 
component of reward. For example, the activity of Iκβ (a regulator of NFκB activity) in 
 54 
neurons and microglia modifies hippocampal long-term potentiation during associative 
learning (Kyrargyri et al., 2014). Further, NFκB is required for spine formation and 
synaptogenesis –important processes underlying plasticity and memory formation. 
While data on alcohol is lacking, studies examining cocaine have shown attenuating 
NFκB reduced cocaine-induced reward; an effect which coincided with the decreased 
cocaine-induced formation of dendritic spines in the nucleus accumbens (Russo et al., 
2009). This indicates the ability of the mouse to form associative memories was 
reduced.  
 
cAMP response element binding protein (CREB) 
CREB is a key transcription factor expressed in brain regions associated with reward 
and addiction (Olson, 2005; Pandey et al., 2003; 2001; Misra et al., 2001). CREB 
regulates genes involved with vesicle transport, synaptic transmission, cell 
growth/differentiation, cell adhesion/motility, cellular stress and the immune response. 
Given the breadth of processes regulated by CREB, it is unsurprising, that this 
transcription factor is involved in alcohol-induced plasticity, memory and learning –  
necessary processes to create addiction (McClung & Nestler, 2007).  Importantly, this 
transcription factor is activated by TLR4 (Avni et al., 2010; Park et al., 2005) and 
alcohol (Wand et al., 2001; Pandey et al., 1999). Both promote its activation and 
translocation to the nucleus (Park et al., 2005; Hsu et al., 2004; Wand et al., 2001). 
Activation of CREB limits the rewarding, and reinforces the anti-rewarding, effects of 
alcohol (McPherson & Lawrence, 2007). For example, CREB decreases the 
expression of reward-related proteins such as dopamine D1 and D2 receptors on 
medium spiny neurons; and increases the expression of anti-reward related proteins 
such as CRF (McPherson & Lawrence, 2007; Nestler, 2005).  
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1.7.2.3 Epigenetic modifications 
Epigenetics is an emerging field in addiction research. It is principally concerned with 
modifications to the structure of chromatin that can repress or enhance transcription 
factor binding. There are numerous types of epigenetic modifications that occur in 
mammalian cells such as DNA methylation and histone modifications (Bernstein et al., 
2007). Importantly, chronic exposure to immune molecules and alcohol can induce 
long-term changes to the function and behaviour of neurons by altering their 
epigenome specifically around genes mediating reward and anti-reward (Pandey et 
al., 2008a).  
 
Methylation modifications to DNA can regulate the transcription of genes. Typically, 
DNA methylation occurs via DNA methyltransferases (DNMT), an enzyme which adds 
a methyl group to cytosine flanked by a guanine molecule (CpG dinucleotides). These 
CpG nucleotides are largely found in promoter regions and can interfere with 
transcription by blocking transcription factor binding. Methylation additionally recruits 
histone deacetylase complexes (HDACs) to assist in the remodelling of chromatin that 
further regulates transcription factor binding  (see Bernstein et al., 2007 for review).  
 
Hypermethylation of genes associated with synaptic plasticity and neurotransmission 
such as opioid, dopamine and GABA receptors have been identified following alcohol 
exposure (Xu et al., 2017; Zhang & Gelernter, 2016; Barbier et al., 2015). This effect 
may be attributable to immune-molecules as they are known to regulate the 
methylation process. For example, LPS stimulation alters CpG methylation and 
decreases the expression of DNMT and HDACs potentially restricting synaptic 
plasticity (Shen et al., 2016). 
 
 56 
Another form of epigenetic modifications involves chromatin modification. Chromatin 
is a form of packaged and condensed DNA. It consists of DNA wound around histone 
proteins. Post-translational modification to the histone proteins via acetylation or 
methylation can cause chromatin to be remodelled forming a more or less condensed 
state respectively. This in turn facilitates or restricts access of transcription factors, 
enhancer or repressor proteins to promoter regions. Acetylation and methylation of 
histones are controlled by histone acetyltransferase (HAT) and HDACs respectively. 
Acetylation generates an open, transcriptionally active state, while removal of the 
acetyl group closes chromatin, repressing transcription (see Li, 2002 for review).  
 
Importantly, immune molecules and alcohol exposure modifies the state of chromatin 
particularly around genes relating to neuronal differentiation and synaptic plasticity. 
For example, alcohol exposure inhibits HDAC activity, induces the acetylation of 
histone H3 and H4, and increases the expression of CREB-binding protein, a histone 
acetyltransferase within the amygdala (Moonat et al., 2013; Pandey et al., 2008b). 
These alterations cause chromatin remodelling to a less condensed state facilitating 
the binding of CREB and CBP. CREB-CBP increases the expression of neuropeptide 
Y, prodynorphin, BDNF and Arc in the amygdala (Sakharkar et al., 2014; Legastelois 
et al., 2013; You et al., 2013). This leads to an increase in dendritic spine density (a 
marker of plasticity) and a reduction in anxiety-like and drinking behaviours (Moonat et 
al., 2013). In contrast, chronic alcohol exposure induces tolerance to alcohol and 
normalises molecular signatures of the epigenome. Upon withdrawal, HDAC activity is 
increased, histones are deaceylated and condense, CREB-CBP activity is reduced as 
is the expression of NPY and BDNF (Moonat et al. 2013; Roy & Pandey 2002). This in 
turn decreases dendritic spine density (reduces plasticity) increasing anxiety-like and 
drinking behaviours (Berkel & Pandey, 2017). Additionally, inhibiting HDAC activity 
 57 
prevents GABA hyposensitivity of dopaminergic neuronal firing in the ventral tegmental 
area that typically accompanies chronic alcohol exposure (Berkel & Pandey, 2017).  
 
CREB and CBP are downstream products of the TLR4 signalling pathway. Activation 
of TLR4 results in the phosphorylation of CREB and CBP (Wen et al., 2010). CREB 
then competes for CBP, a cofactor required for NFκB signalling. Therefore, chronic 
alcohol exposure may decrease CREB, and cause CBP to bind preferentially to NFκB. 
This may create a state of heightened inflammation as transcription of inflammatory 
molecules is potentially increased (Wen et al., 2010). The increased inflammatory 
response would increase HDAC activity reducing plasticity and decreasing genes 
important to reward such as tyrosine hydroxylase, and enkaphalins. However, HDACs 
reciprocally influence glial inflammatory response. For example, LPS-activated 
microglia exhibit decreased histone acetylation activity (Correa et al., 2011) and HDAC 
inhibitors impair NFκB dependent synthesis of IκBα and reduce the DNA binding of 
p65, c-FOS, c-Jun and FRA2. This in turn limits inflammation as indicated by a 
downregulation in IL-1β and COX-2 (Faraco et al., 2009). 
 
1.8 Linking TLR4 to the neurobiological basis of reward and anti-reward 
Alcohol exposure induces an inflammatory response from astrocytes, microglia and 
neurons. The preceding sections have highlighted how inflammatory mediators alter 
behaviour by switching the phenotype of astrocytes, inducing epigenetic remodelling 
and transcription factor activity surrounding genes relating to reward and anti-reward 
processes, and can under some circumstances induce neurodegeneration. 
Collectively, these processes assist in creating and maintaining reward and anti-
reward behaviours. However, there is limited evidence directly implicating alcohol-
induced TLR4 signalling in creating and altering the neurobiological processes 
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underlying reward and anti-reward. Thus, the following sections are designed to 
highlight potential links between alcohol, TLR4, reward and anti-reward. 
 
1.8.1 TLR4-Dopamine 
Preliminary evidence suggests there is an interaction between dopamine, the key 
molecule mediating the “wanting” component of reward and alcohol-induced TLR4 
signalling. For example, alcohol-induced TLR4 signalling in VTA dopaminergic 
neurons induces the expression of tyrosine hydroxylase, the rate-limiting enzyme in 
dopamine synthesis via protein kinase C (PKC) and CREB (Aurelian et al., 2016). 
However, microdialysis studies are needed to confirm whether this translates to 
increased dopamine release within the nucleus accumbens. Associative evidence 
demonstrates that attenuating TLR4 via (+)-Naloxone reduces morphine and cocaine-
induced dopamine release (Northcutt et al., 2015; Hutchinson et al., 2012). Importantly, 
these drugs of abuse activate TLR4, thereby furthering the link between TLR4 
activation and dopamine signalling. 
 
Studies examining the direct effects of TLR4 on the dopaminergic system following 
chronic alcohol are lacking. A study using LPS to mimic the high levels of inflammatory 
mediators observed during chronic alcohol administration demonstrated a reduction in 
alcohol-induced VTA dopaminergic neuron firing seven to ten days post exposure 
(Blednov et al., 2011a). This paradoxically coincided with elevated alcohol intake and 
reduced alcohol conditioned taste aversion (an inverse marker of “likability”). It was 
hypothesised that the high level of inflammatory mediators reduced basal 
dopaminergic neurotransmission thus contributing to the anhedonia (anti-reward). 
Therefore, upon re-exposure to alcohol mice exhibited potentiated intake to reduce the 
anhedonic sensations and restore dopamine levels (Blednov et al., 2011a). Thus 
alcohol-induced TLR4 signalling may mediate both acute and chronic effects of alcohol 
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on the dopaminergic system. Again however, given the discrepancies between an 
immune response to LPS and alcohol this finding must be interpreted with caution.  
 
1.8.2 TLR4-GABAA 
GABA is a major inhibitory neurotransmitter system within the central nervous system 
and contributes to both reward and anti-reward behaviours associated with alcohol use 
(Harris et al., 2008; Davies, 2003). Of particular importance is GABAAα2, a subunit of 
GABA receptors that is strongly expressed in reward and anti-reward regions such as 
the nucleus accumbens, amygdala, BNST and hypothalamus (Davies, 2003). Genetic 
association studies repeatedly demonstrate an association between GABAAα2 and the 
behavioural consequences of alcohol use such as dependence (Soyka et al., 2008; 
Edenberg et al., 2004). Furthermore, mice with impaired GABAAα2 function 
demonstrate reduced alcohol intake and preference (Blednov et al., 2013). 
Interestingly, siRNA knock down of GABAAα2 in the CeA but not ventral pallidum 
decreases the expression of TLR4 and reduces binge-like alcohol drinking (June et al., 
2015; Liu et al., 2011). Electrophysiological evidence further supports a link between 
alcohol, GABAAα2 and the TLR4 signalling pathway. However, the results are far from 
uniform. For example, alcohol-induced TLR4 signalling alters inhibitory post-synaptic 
currents in GABAergic cells but does not influence baseline GABA release or excitatory 
post-synaptic potentials (Yan, 2015; Bajo et al., 2014). (+)-Naloxone, a TLR4-TRIF 
antagonist, blocks early low-dose alcohol-induced potentiation of GABAergic 
transmission (Bajo et al., 2014). However, other studies using CeA slices from TLR4-/- 
mice have cast doubts upon these findings with no alterations in GABA activity 
compared to wildtype mice (Harris et al., 2017). Therefore, authors have postulated 
that CD14 or IL-1β may be responsible for alterations in GABA signalling and not TLR4 
itself (Harris et al., 2017). Crucially, CD14 mediates acute alcohol- or LPS-induced 
excitatory postsynaptic potentials from GABAergic cells and deletion of IL-1β’s 
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negative regulator IL-1Rn alters basal phasic and tonic GABAergic transmission and 
alcohol-induced facilitation of phasic GABAergic transmission. Administration of IL-
1Ra reverses and restores alterations in GABA signalling (Bajo et al., 2015a; 2015b; 
2014; Wang et al., 2000). Collectively the results suggest TLR4, its co-receptors and 
downstream signalling pathways modulate GABAergic signalling within the CeA. This 
modulation may cause increased disinhibition of dopaminergic or CRF-expressing 
neurons further increasing the release of reward and anti-reward-related 
neurotransmitters and neuropeptides respectively (June et al., 2015; Liu et al., 2011). 
This in turn would modulate the behavioural effects of reward, anxiety and anhedonia 
in mice.  
 
1.8.3 TLR4-NMDA 
Alcohol has differential effects on glutamate reflecting acute or chronic exposure. For 
example, acute alcohol exposure reduces glutamatergic signalling in the nucleus 
accumbens and other limbic regions (Möykkynen & Korpi, 2012). However, withdrawal 
from alcohol results in a hyperglutamatergic state owing to the constant suppression 
during alcohol exposure (Piña-Crespo et al., 2014). This in turn is implicated in alcohol-
induced excitotoxicity and seizures in the absence of alcohol (Piña-Crespo et al., 2014) 
(however, recent findings cast doubts on this hypothesis (Collins and Neafsey, 2016)). 
Importantly, TLR4 and glutamate are linked. For example, TLR4-/- mice do not exhibit 
increased expression of GluR1, NR1 or GluR1/NR1 heteromers following adolescent 
alcohol consumption – an effect which coincided with alterations in reward and anxiety-
behaviour in adulthood (Montesinos et al., 2016). While studies linking alcohol-TLR4-
NMDA and behaviour are lacking, experiments examining kainate-induced seizures 
can be used to infer interactions between TLR4 and NMDA. Similar to chronic alcohol, 
inflammatory molecules are elevated during a seizure. Under these conditions, IL-1β 
and HMGB1 (TLR4 signalling molecule and agonist respectively) reduce NMDA-
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induced outward current via p38, a MAPK, and enhance NMDA Ca2+ influx – 
collectively increasing neuronal excitability that initiates and propagates seizures 
(Carmignoto, 2014; Maroso et al., 2011; Viviani et al., 2003). Given that withdrawal 
from alcohol results in high levels of IL-1β and HMGB1 (Pascual et al., 2015; Whitman 
et al., 2013; Qin et al., 2008), these TLR4 signalling molecules could potentiate 
alcohol-induced NMDA currents following withdrawal from chronic alcohol 
consumption. This may, in turn, contribute to alcohol-induced excitotoxicity and 
seizures (Maroso et al., 2011). 
 
1.8.4 TLR4-epigenetic modifications 
The adverse effects following chronic alcohol consumption result from long-term 
epigenetic changes to genes governing plasticity and inflammation in brain regions 
involving reward, stress and learning (Moonat et al. 2013; Roy & Pandey, 2002). The 
epigenetic modifications typically involve chromatin remodelling owing to histone 
modifications. TLR4 regulates many alcohol-induced epigenetic processes including 
the expression of histone acetyl-transferase and the acetylation of histone H3 and H4 
in the medial prefrontal cortex - an effect that coincided with increased anxiety- and 
reward-like behaviour in mice (Pascual et al., 2011). Interestingly, adolescent alcohol 
exposure increased acetylation of histone H3 and H4 and decreased methylation of 
H3 (Kyzar et al., 2016; Montesinos et al. 2016). This promoted long-term alterations in 
the expression of BDNF, its receptor TrκB and transcription factors FosB, ΔFosB and 
Cd5k – all of which are implicated in addiction-related plasticity (McClung & Nestler, 
2007). This coincided with alterations in glutamatergic and dopaminergic signalling in 
the nucleus accumbens, prefrontal cortex and striatum, which may underlie the 
predisposition of these mice to seek rewarding stimuli and exhibit increased anxiety 
behaviour later in life (Montesinos et al., 2016). Importantly, mice deficient in TLR4 are 
protected against these effects. Thus, alcohol-induced TLR4 signalling can induce 
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epigenetic modifications to histones, thereby modulating the expression of reward and 
plasticity related genes which influences alcohol-related behaviour.  
 
1.8.5 TLR4-CREB 
Neural plasticity is required for the development of alcohol addiction. Of pivotal 
importance to addiction-related plasticity is CREB. Alcohol-induced activation of TLR4 
increases CREB in the prefrontal cortex and nucleus accumbens (Aurelian et al., 2016; 
Montesinos et al., 2016). This alcohol-induced TLR4-CREB signalling has been 
implicated in both the rewarding and anti-rewarding effects of alcohol by inducing 
alterations to BDNF and glutamatergic pathways (Aurelian et al., 2016; Montesinos et 
al., 2016). Further, TLR4s downstream signalling molecules such as interferon activate 
CREB to limit inflammation (Liu et al., 2004) which has the potential to limit reward-
related neuroimmune signalling. 
 
1.8.6 TLR4-neurodegeneration 
Long-term exposure to alcohol results in demyelination, synaptic loss, and a reduction 
in white matter. These processes are mediated by glial cells and alcohol-induced 
excitotoxicity. Chronic exposure to alcohol increases the expression and release of 
inflammatory mediators and changes microglia and astrocytes to an immunologically 
active state via TLR4 (Alfonso-Loeches et al., 2010; Blanco et al., 2005). For example, 
alcohol-induced TLR4 signalling increases COX-2 and iNOS, which subsequently 
elevate reactive oxygen species. Reactive oxygen species activate the caspase 
pathway within neurons culminating in apoptosis and neurodegeneration (Alfonso-
Loeches et al., 2012; 2010). The inflammatory response additionally causes 
dysregulation of the autophagy pathway causing the accumulation of ubquitinated 
proteins that cannot be removed owing to an inability to form specific phagosomes. 
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The build-up of these proteins additionally activates apoptotic pathways inducing 
neurodegeneration (Pla et al., 2016; 2014).  
 
The alcohol-induced TLR4-inflammatory response has also been linked to the down-
regulation of proteins involved in the synthesis of myelin and the alteration in the 
composition of myelin sheaths collectively causing myelin aberrations (Montesinos et 
al., 2015; Pascual et al., 2014; Alfonso-Loeches et al., 2010). These alterations 
coincide with decreased performance in behavioural tests assessing cognitive 
function, memory, learning and reward processing. Importantly, alcohol does not 
activate glia or the neuroimmune system in TLR4-/- mice (Montesinos et al., 2015; 
Pascual et al., 2011; Alfonso-Loeches et al., 2010). These mice are therefore protected 
against neurodegeneration and demyelination and exhibit improved performance in 
behavioural tests compared to wildtype mice. Neurodegeneration and demyelination 
create a brain that is less plastic. The reduced plasticity may assist in the retention of 
anxiety and reward-sensitivity following chronic alcohol exposure as mice can no 
longer interpret and adapt to new stimuli and are thus solely focused on obtaining 
alcohol. 
 
1.9 Integrating TLR4 into reward and anti-reward behaviour 
The preceding sections have highlighted that alcohol activates TLR4 signalling, 
inducing an inflammatory response. Acute exposure results in a transient, sub-
inflammatory rise in TLR4’s immune mediators. These immune molecules can act as 
neuromodulators, altering the function of neurons and the behavioural response 
towards alcohol. Prolonged access to alcohol, induces a robust increase in TLR4’s 
immune mediators and can influence alcohol-related behaviour by inducing epigenetic 
modifications to neuroplasticity and neurotransmitter-related genes, increase 
activation of immune and plasticity associated transcription factors, cause neuronal 
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dysregulation via alterations in myelin and distract astrocytes from maintaining 
glutamate homeostasis. Collectively, these processes highlight the pivotal importance 
of alcohol-induced TLR4 signalling in the neurobiological basis of reward and anti-
reward.  From a behavioural perspective however, we are only beginning to appreciate 
the translational importance of TLR4 in mediating the effects of alcohol-induced reward 
and anti-reward.  
  
1.9.1 TLR4-induced alcohol reward behaviour 
1.9.1.1 Acute 
Acute reward behaviour is typically assessed using a variety of experimental 
approaches. The most commonly used are conditioned place preference and alcohol 
two-bottle choice which primarily assess the “wanting” and the “liking” component of 
alcohol-induced reward respectively. Longer two-bottle choice tests can also examine 
the “wanting” component of alcohol reward to some degree. 
  
The past five years has seen an influx of manuscripts assessing the role of alcohol-
induced TLR4 signalling on acute reward behaviour. However, there is a lack of 
consensus surrounding the role of TLR4 in the behavioural manifestation of “liking” 
and “wanting”. This is likely attributable to different behavioural models, background 
strains of mice, inappropriate statistical analysis and method of investigating TLR4 
(genetic knockout or pharmacological antagonists). Studies have shown that: 
1. Genetic knockout of TLR4s co-receptor, CD14 reduces the preference but not 
intake of alcohol during a 24 h two-bottle choice test compared to wildtype mice. 
However, there was no difference between CD14-/- and wildtype mice during a 
2 h two-bottle choice test (Blednov et al., 2017; 2011b).  
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2. Mice deficient in TLR4-NFκB signalling (C3/HeJ mice) demonstrate reduced 
intake and preference for alcohol during a 24 h and 3 h two-bottle choice test 
compared to genetically similar mice (C3H/HeOuJ) (Mayfield et al., 2016). 
3. TLR2-/- mice display reduced 24 h and 2 h intake and preference for alcohol. 
Further these mice also display enhanced quinine intake compared to wildtype 
mice indicating a potentially altered olfactory or gustatory sense (Blednov et al., 
2017). 
4. MyD88-/- mice consume less alcohol during a 2 h but not 24 h test compared to 
wildtype mice. Further, male but not female MyD88-/- mice exhibit reduced 
saccharin preference compared to wildtype mice indicating an alteration to the 
“liking” component of reward (Blednov et al., 2017).  
5. 24 h and 2 h alcohol and saccharin intake and preference are similar in wildtype 
(C57BL/6J) and TLR4-/- (C57BL/6J background) mice (Montesinos et al., 2016; 
Pascual et al., 2011). Further, wildtype (Balb/c) and TLR4-/- (Balb/c background) 
mice exhibit similar 8 h saccharin and quinine intake and preference but 
reduced 8 h alcohol preference (see appendix).  
6. Pharmacological inhibition of TLR4 via (+)-Naloxone (30 or 60mg/kg) reduced 
alcohol intake during a 24 h but not 2 h alcohol preference test (Harris et al., 
2017).  
 
Collectively, the results from voluntary drinking paradigms, suggest CD14, TLR2 and 
MyD88 are involved in the acute preference and intake of alcohol indicating these 
receptors and signalling pathways are crucial to the “liking” and to some extent the 
“wanting” component of alcohol-reward. However, the role of TLR4 is ambiguous with 
studies demonstrating either a reduction or no effect on alcohol intake (potentially 
indicating compensatory mechanisms). This suggests TLR4 may modify aspects of the 
“liking” component of reward. However, no study has examined TLR4’s role in the 
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“wanting” component of reward (using conditioned paradigms) or demonstrated a link 
between alcohol, TLR4 and the mechanisms underlying “liking” component of reward 
such as the µ opioid receptor or endocannabinoids. Consequently, additional studies 
are required to clarify TLR4’s, MyD88’s and TRIF’s role in the molecular underpinnings 




The TLR4-signalling and the mesolimbic reward pathway are primed/sensitised 
following alcohol exposure. Upon re-exposure to alcohol or other drugs of abuse, the 
expression of immune mediators and reward-related molecules (dopamine and opioid 
peptides) is exacerbated inducing a heightened state of reward. This effect is 
particularly apparent in adolescents that consume high levels of alcohol (binge 
drinking). Binge drinking during adolescence primes the reward and TLR4-related 
pathways to over-respond in adulthood (see Chapter 4). Consequently, these 
individuals are extremely susceptible to “liking” and “wanting” alcohol later in life.  
 
There are limited studies examining the effects of TLR4-induced signalling on 
mediating this reward-priming effect from a behavioural perspective. Associative 
studies have shown adolescent alcohol exposure potentiates Tlr4 mRNA expression 
in brain regions associated with the “wanting” component of reward in adult. However, 
the reward-related effects of this are presently unknown. Montesinos et al., (2016) 
however, demonstrated alcohol exposure during adolescence potentiated the 
“wanting” of cocaine in adulthood, an effect absent in TLR4-/- mice. In addition, TLR4-
/- mice are protected against adolescent alcohol-induced anxiety and attenuated 
cognitive performances in adulthood. These author’s hypothesised this effect was 
mediated by alterations in a TLR4-NMDA interaction within the prefrontal cortex. 
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Interestingly, adolescent but not adult morphine (a TLR4 agonist) pre-exposure 
increased the expression of Tlr4 mRNA and TLR4+ CD11b+ cells (microglia) in the 
nucleus accumbens, an effect that coincided with a potentiation of morphine 
conditioned place preference later in life (Schwarz & Bilbo, 2013). Attenuating 
microglia activation decreased the rise in Tlr4 mRNA and decreased morphine-
induced conditioned place preference (Schwarz & Bilbo, 2013). Collectively, these 
studies imply that activation of TLR4 signalling during adolescence can create a 
priming effect that potentiates drug “wanting” behaviour later in life. However, studies 
using TLR4-/- mice are inherently confounded owing to the pivotal role of TLR4 in 
neurodevelopment (Okun et al., 2011; Chapter 4). Thus, no study has determined 
whether transiently attenuating TLR4 (thereby allowing normal development to 
continue) during alcohol exposure in adolescence can prevent priming and the 
potentiation of alcohol “liking”, “wanting” or anti-reward behaviour later in life. Further 
no study has considered which TLR4 signalling pathway mediates priming, or how 
TLR4 priming alters the neuronal system.  
 
1.9.1.3 Chronic 
Long-term alcohol intake desensitises the reward pathway, shifting the balance of 
alcohol-induced reward from a predominately “like” to a “want” driven phenomena 
(Berridge & Robinson, 2016). Studies examining the long-term consequences of 
alcohol typically use a model termed ‘chronic intermittent access’ to induce 
dependence. In brief, mice receive alcohol vapour or are exposed to a bottle containing 
alcohol on alternating days. On intervening days, mice receive water. This exposure 
model lasts for a minimum of two to six weeks. Mice are then tested for alcohol 
preference using two-bottle choice. At this stage, most researchers assume their mice 
are dependent and consequently describe this test as a measure of “wanting” 
behaviour. As previously mentioned, animals can exhibit stable drug intake without 
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exhibiting signs of addiction and dependence. Further, these do not test for alterations 
in the “liking” response (assessed via saccharine preference test following chronic 
alcohol consumption). Thus, these studies are somewhat limited in their conclusion 
and consequently, caution must be used when interpreting any effects (or lack thereof) 
attributable to TLR4 on reward behaviour following chronic exposure. 
 
In spite of these caveats, studies have demonstrated, chronic alcohol exposure 
increases the expression of TLR4 and its downstream transcription factors and 
signalling molecules in key brain regions associated with reward such as the ventral 
tegmental area (for example, June et al., 2015; Vetreno et al., 2013). Consequently, a 
large body of evidence has focused on understanding the role of TLR4 in chronic 
alcohol-reward behaviour. Again, there is a lack of consensus surrounding the role of 
TLR4 in the behavioural manifestation of “liking” and “wanting” following chronic 
alcohol intake. For example: 
1. Transcriptome profiling revealed an over-representation of the TLR4 signalling 
pathways following chronic alcohol exposure in brain regions associated with 
reward in mice (Mayfield et al., 2016).  
2. A long-term intermittent access model of alcohol exposure determined TLR2-/-, 
TLR4-/- and wildtype (C57BL/6J) mice exhibit similar levels of intake and 
preference for alcohol (Blednov et al., 2017; Pascual et al., 2011). 
3. TLR4-/- mice retain conditioned taste aversion following chronic access to 
alcohol (indicating a potential reduction of alcohol “liking”) (Pascual et al., 2011). 
4. Pharmacological inhibition of TLR4 via T5432126 significantly reduced alcohol 
intake and preference following chronic intermittent access and alcohol vapour 
exposure – an effect which additionally reduced microglia reactivity in the 
amygdala (Bajo et al., 2016).  
 69 
5. (+)-Naloxone attenuated alcohol intake following chronic intermittent access 
(Harris et al., 2017). 
6. siRNA knock down of TLR4 in the VTA and CeA but not the ventral palladium 
decreased operant self-administration of alcohol (June et al., 2015; Liu et al., 
2011). 
 
Collectively, these studies highlight that pharmacological blockade but not genetic 
knockout of TLR4 influences the “wanting” component of reward following long-term 
administration of alcohol. However, the involvement of TLR4s on the “liking” 
component of reward, the relative influence of either the MyD88 or TRIF pathway in 
“wanting” or “liking” and a link between alcohol-TLR4 and wanting/liking remains to be 
elucidated.  
 
1.9.2 TLR4-induced alcohol anti-reward behaviour  
In addition to tolerance and desensitisation of the reward pathway following long-term 
alcohol use, the anti-reward pathway is recruited in order to restore homeostasis to the 
brain. Chronic alcohol exposure increases the expression of TLR4-related immune 
mediators in brain regions governing anti-reward (Knapp et al. 2016; Crews et al., 
2013). Behaviourally, alcohol-induced TLR4 signalling increases anxiety-like 
behaviour as assessed by the elevated plus maze, open field maze and the light-dark 
box. Further, these changes were associated with alterations in epigenetic processes 
including down regulation of histone acetyltransferase and acetylation of histone H3 
and H4 and an upregulation of NFκB (Pascual et al., 2011). Importantly, TLR4-/- mice 
were protected against alcohol-induced anxiety and epigenetic modifications (Pascual 




Another variable influencing anti-reward is reduced plasticity following chronic alcohol 
exposure. TLR4-/- mice are protected against short and impairment in long-term 
memory, conditioned aversion and reversal learning behaviour following chronic 
alcohol exposure (Pascual et al., 2011). These behaviours rely on the ability to form 
new memories and engage higher order functions that are dependent upon synaptic 
plasticity and epigenetic processes.  
 
The engagement of anti-reward behaviour is dependent upon repeated cycles of 
alcohol drinking. However, given that antagonising TLR4 by pharmacological and 
genetic means reduces alcohol consumption it is difficult to gauge whether behaviours 
exhibited by these mice are simply due to a reduction in alcohol intake and thus anti-
reward processes are less engaged, or whether TLR4 is actually crucial for the anti-
reward process independent of alcohol intake. Additionally, these studies, do not 
explore which TLR4 signalling pathway is involved in anti-reward behaviour nor do they 
provide a link between TLR4 and neuronal drivers of anti-reward behaviour.  
 
1.9.3 Summary  
The introductory chapter of this thesis aimed to highlight TLR4’s pivotal role in the 
molecular causes and the behavioural translation of reward and anti-reward behaviour. 
However, there are numerous limitations and gaps in the current field that prevent 
researchers to conclusively discern TLR4’s role in alcohol-induced reward and anti-
reward behaviours. For example: 
1. Which TLR4 signalling pathway, MyD88 or TRIF is activated following acute 
and chronic alcohol exposure? And do they remain primed following adolescent 
alcohol use? 
2. Are these signalling pathways of equal importance to reward and anti-reward 
behaviour? 
 71 
3. Is the TLR4 pathway (MyD88 or TRIF) involved in the “wanting” component of 
alcohol reward following acute and chronic exposure? And are they involved 
with the sensitisation of the “wanting” component of reward following adolescent 
alcohol use? 
4. Is the TLR4 pathway (MyD88 or TRIF) involved in the “liking” component of 
alcohol reward following chronic alcohol exposure? And are they involved with 
the sensitisation of the “liking” component of reward following adolescent 
alcohol use? 
5. Does the TLR4 pathway mediate neuronal and neuroimmune priming following 
alcohol exposure? 
6. How does alcohol-induced TLR4 signalling influence traditional neuronal 
mediators of reward and anti-reward? 
 
These questions predominately focus on discerning which TLR4 signalling pathway is 
responsible for reward and anti-reward behaviour. As such, the overarching aim of this 
thesis project was to identify whether both TLR4 signalling pathways (MyD88 and 
TRIF) were active during and following acute and chronic alcohol exposure and to 
determine the effects of attenuating the TLR4-TRIF pathway on reward and anti-
reward behaviour. Specifically, chapters 2 and 3 explore the interaction between 
circadian rhythm, TLR4 and reward following acute alcohol exposure. These studies 
test whether the efficacy of (+)-Naltrexone, a potential TLR4-TRIF biased antagonist, 
on acute alcohol drinking (“liking”) and seeking (“wanting”) behaviour is dependent on 
light-cycle. Chapters 4 and 5 examine the effects of TLR4 on adolescent alcohol-
induced priming/sensitisation and later life reward and anti-reward behaviours. These 
experiments demonstrate that administration of (+)-Naltrexone before or after 
adolescent alcohol exposure prevents alcohol drinking (“liking”) but not seeking 
(“wanting”) behaviour in adulthood. Chapters 6 and 7 examined (+)-Naltrexone’s effect 
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on reward and anti-reward behaviours following chronic alcohol use. These studies 
determined (+)-Naltrexone had limited efficacy in modifying reward or anxiety-like 
behaviour following long-term alcohol use. The precise experimental questions, aims 
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Chapter 2: Circadian rhythms, reward and TLR4 
2.1 Circadian rhythm 
The earth’s daily rotation creates periods of light and darkness imbuing a diurnal 
rhythm upon life. Therefore, to maximise host fitness, organisms ranging from simple 
bacteria to complex mammals, oscillate their behaviour, biochemistry and physiology 
to meet the specific demands of that time-of-day (Lowrey & Takahashi, 2004; Harmer 
et al., 2001). This oscillatory pattern of expression is termed circadian rhythm. The 
circadian rhythm is an entrainable 24-hour rhythm that responds to external cues 
(zeitgiebers, ZT) including food, water, light, drugs of abuse (including alcohol) and 
immune responses (Hutko et al., 2008; Marpegán et al., 2005; Spanagel et al., 2005; 
Gauvin et al., 1997; Stephan & Zucker 1972).  However, the circadian rhythm can 
persist in the absence of zeitgiebers, suggesting inherent biological mechanisms 
underlie the daily rhythm in physiology (Partch et al., 2014; Dardente & Cermakian, 
2007).  
 
2.2 How is circadian rhythm controlled? 
Within organisms, the circadian rhythm is organised in a hierarchical manner 
consisting of a system level (cell extrinsic) and molecular level (cell intrinsic) oscillators 
(Reppert & Weaver, 2002). The suprachiasmatic nuclei (SCN) within the hypothalamus 
is the main brain region involved in the regulation of circadian rhythm at the system 
level (Reppert & Weaver, 2002). The SCN consists of approximately 10,000 – 20,000 
neurons which function in a concerted manner generating a rhythmic network whose 
activity oscillates around a 24 h period (Mohawk & Takahashi, 2011; Abrahamson & 
Moore, 2001; Welsh et al., 1995). The SCN receives retinal input, entraining neurons 
to light cues and consequently linking the external world to the internal environment 
(Abrahamson & Moore, 2001). Brain regions isolated from the SCN often cease to 
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exhibit the circadian rhythm. Hence, these regions receive sympathetic and 
parasympathetic input to entrain and regulate a 24 h rhythm. For example, SCN 
innervates the adrenals to release glucocorticoids supressing and de-repressing the 
immune system at different times of the day (Chung et al., 2011; Abe et al.,  1979) and 
sympathetic innervation to the liver results in daily rhythms in insulin and plasma 
glucose (Yamamoto et al.,  1987).  
 
Cells can also oscillate independently from SCN input suggesting intrinsic molecular 
mechanisms generate a 24 h rhythm. Cellular rhythm is created by a regulatory 
feedback loop consisting of interconnected transcription factors and kinases that are 
expressed in a repetitive and predictable manner forming the cellular clock. The 
cellular clock consists of two activator (CLOCK and BMAL1) and two repressor 
proteins (PER and CRY). In brevity, the cellular clock begins when CLOCK and BMAL1 
dimerise and bind to enhancer boxes (E-box; DNA response elements) in the promoter 
region of CRY and PER, initiating their transcription. PER and CRY accumulate, 
dimerise and supress the transcription of CLOCK and BMAL1. The subsequent decline 
in CLOCK and BMAL1 decreases the transcription of PER and CRY. Therefore, the 
decreased expression of the repressor proteins enables the transcription of the 
activator proteins again (see Partch et al., (2014) for review). This cycle occurs over a 
24 h period and in doing so imparts a repetitive rhythm (a time-of-day effect) on the 
mammalian transcriptome – with 2 to 10 per cent of all genes being regulated by this 
process (Miller et al., 2007; Akhtar et al., 2002; Duffield et al., 2002). 
 
2.3 Rhythmic oscillations in reward  
2.3.1 Circadian rhythms in reward pathways 
The nucleus accumbens and ventral tegmental area (VTA) are innervated by, and 
express key components of the intrinsic and extrinsic clock. For example, the SCN 
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innervates the VTA via glutamatergic afferents from the medial prefrontal cortex 
regulating diurnal reward behaviour (Baltazar et al., 2014; Baltazar et al., 2013); and 
dopamine transporter, dopamine D1 and D2 receptors, monoamine oxidase and 
tyrosine hydroxylase – key proteins regulating dopamine synthesis and the “wanting” 
component of reward, contain BMAL1 and CLOCK binding sites in their promoter 
regions (Hampp et al., 2008; Sleipness et al., 2008; Sleipness et al., 2007; McClung 
et al., 2005; Akhisaroglu et al., 2005). This suggests the circadian clock controls 
aspects of dopaminergic activity including neurotransmitter synthesis, release, 
degradation and postsynaptic actions. No study has determined whether the µ opioid 
receptor or any of its endogenous agonists (associated with the “liking” component of 
reward) are under the control of clock proteins in the nucleus accumbens or VTA. 
However, aspects of the µ opioid receptor signalling pathway exhibit time-of-day 
effects (Pačesová et al., 2015). This suggests either cell extrinsic or intrinsic 
mechanisms may additionally influence the mediators underlying the “liking” 
component of reward. 
 
The preceding section highlighted that elements of the reward pathway are influenced 
by circadian rhythm. These findings translate to time-of-day differences in the activity 
of the reward pathway. Under basal conditions c-FOS (a marker of neuronal activation) 
peaks and nadirs within the nucleus accumbens, prefrontal cortex and VTA midway 
through the active (dark) phase and the inactive (light) phase in rodents respectively 
(Baltazar et al., 2013). This daily fluctuation occurs within dopaminergic and non-
dopaminergic cells. However, particular emphasis has been placed on dopaminergic 
fluctuations. For example, the expression of tyrosine hydroxylase, monoamine oxidase 
and extracellular concentration of dopamine, its metabolites, and the rate of clearance 
are elevated during the active and diminished during the inactive phases (Baltazar et 
al., 2013; Webb et al., 2009; Paulson & Robinson, 1994). However, the firing rate of 
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VTA dopaminergic neurons does not differ between active and inactive phases 
indicating that the time-of-day differences are due to the synthesis, release and binding 
of dopamine and not the electrophysiological properties of the neurons themselves 
(Luo & Aston-Jones, 2009; Luo et al., 2008; Miller et al., 1983). Interestingly, non-TH 
glutamatic acid decarboxylase expressing neurons (GABAergic) in the VTA exhibit 
increased firing during the dark cycle (Luo & Aston-Jones, 2009). Little research has 
examined the time-of-day dependent effects on opioidergic cells. Morphine- (a µ opioid 
receptor agonist) induced c-FOS expression does not fluctuate according to time-of-
day in the SCN. However, its downstream signalling molecules ERK1/2 and GSK3β 
exhibit a daily rhythm in their expression (Pačesová et al., 2015).Therefore, while 
overall neuronal activity does not differ, specific parts of the opioid receptor signalling 
pathway may be more sensitive or tolerant reflecting the time-of-day. This suggests 
there may be specific times at which an individual is more sensitive or averse to 
rewarding stimuli. 
 
Collectively, the reward pathway in rodents exhibits peaks and troughs in activity 
during the active and inactive phases respectively. From an evolutionary perspective 
having a heightened reward pathway during the active phase is beneficial allowing an 
individual to better discriminate between rewarding and aversive stimuli, thus enabling 
motivational value to be assigned to objects pertinent for survival such as food, water 
and sex. This same mechanism however, may now exacerbate the rewarding 
properties conferred by drugs of abuse, such as alcohol. 
 
2.3.2 Behavioural consequences of circadian rhythm in reward mechanisms 
Given the diurnal variation in the expression of dopamine, it suggests that there are 
times at which individuals are uniquely sensitive towards drugs of abuse. In rodents, 
the self-administration of cocaine, opioids, barbiturates and phencyclidine typically 
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peaks during the active period (dark) and nadirs during the mid-to-late inactive period 
(light) (Perreau-Lenz et al., 2012; Lynch et al., 2008; Baird & Gauvin, 2000; Gauvin et 
al., 1997; Lukas et al., 1984; Deneau et al., 1969). Further, self-administered electrical 
brain stimulation of reward pathways peaks during the active phase (Terman & 
Terman, 1975; Terman & Terman, 1970). This technique is independent of metabolism 
suggesting that time-of-day effects in reward behaviour are not simply due to altered 
pharmacodynamics. However, these time-of-day results are far from uniform. For 
example, cocaine-induced conditioned place preference is greatest early in the 
inactive (light) phase and the lowest during active (dark) phase (Kurtuncu et al., 2004; 
Abarca et al., 2002). This suggests that time-of-day effects are dependent on the type 
of drug and the behavioural measure assessed. 
 
Like most drugs of abuse, alcohol intake peaks during active phase and nadirs during 
the inactive phase (Gauvin et al., 1997). However, supporting experiments to eliminate 
the confounding variables such as thirst, taste and aversion have not been performed. 
Therefore, it is unclear whether the time-of-day dependent effects are due solely to 
alcohol’s rewarding properties (“liking” and “wanting”). Associative evidence suggests 
saccharin (an innate inducer of the “liking” component of reward) intake peaks during 
the dark phase (Perreau-Lenz et al., 2009) – indicating that the time-of-day effects 
observed with alcohol may also be due to rhythmic fluctuation in “liking”. No study has 
examined the “wanting” component of alcohol reward with respect to the time-of-day.  
 
Aside from reward as a driver of alcohol intake, thirst and energy demand must also 
be considered. The circadian clock entrains to, and is entrained by food and water 
intake (see Eckel-Mahan & Sassone-Corsi, (2013) for review). When food and water 
is freely available, rodents usually eat and drink during the active (dark) phase. This 
effect is entrained by light cues and is thus mediated by the SCN and hypothalamus. 
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The hypothalamus subsequently interacts with peripheral organs such as the liver and 
pancreas to regulate metabolism via the release of hormones such as leptin and 
ghrelin (Waddington Lamont et al., 2007). If food availability is restricted, the activity of 
these organs shift to coincide with food intake (Mistlberger & Antle, 2011). Therefore, 
studies assessing alcohol intake must consider whether the effects of a treatment 
aimed at attenuating alcohol intake is related to alterations in thirst, hunger or reward.  
 
Collectively, the behavioural outcomes following acute drug exposure are dependent 
on time-of-day. In contrast, the long-term use of drugs are not dependent on time-of-
day rather, they alter the expression of CLOCK, BMAL1, PER and CRY (Prosser et 
al., 2014; Glass et al., 2012; Melendez et al., 2011; Chen et al., 2004; Tornatzky & 
Miczek, 1999). Therefore, long-term alcohol or drug use functions as a zeitgieber 
entraining the circadian rhythm to when alcohol is usually consumed (Stowie et al., 
2015; Brager et al., 2010). However, unlike other zeitgiebers that are predictable, for 
example, light, alcohol intake during periods of addiction is unpredictable and unstable 
(American Psychiatric Association, 2013; Koob & Le Moal, 1997). This in turn 
dysregulates numerous neurobiological processes which are dependent upon 
rhythmic oscillations and can lead to immune dysfunction and heightened levels of 
circulating stress hormones (Voigt et al., 2013).   
 
2.4 Rhythmic oscillations in the immune system 
2.4.1 Peripheral immune system 
In addition to the effects on the reward pathway, the activity of the immune system is 
dependent on time-of-day (Bass & Lazar, 2016). These oscillations are driven by 
sympathetic and parasympathetic effects from the SCN (for example, glucocorticoid 
release) and the molecular clock mechanisms that regulate the; movement of innate 
and adaptive immune cells; expression of pattern recognition receptors and their 
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signalling pathways; transcription and translation of cytokines and complement 
proteins; and specific immune activities (for example, phagocytosis) (Guerrero-Vargas 
et al., 2014; Gibbs et al., 2012; Silver et al., 2012; Spengler & Kuropatwinski, 2012; 
Barriga et al., 2001). The time-of-day dependent effects are regulated primarily at the 
transcription-translation stage. For example, BMAL1-CLOCK bind to E-boxes in the 
promoters of chemokine genes such as CCL2 and CCL8 (Nguyen et al., 2013); 
CLOCK can directly interact with the p65 subunit of NFκB enhancing its activity 
(Spengler & Kuropatwinski, 2012); REV-ERBs, a negative regulator of the molecular 
clock, mediates the recruitment of nuclear receptor co-repressor and histone 
deacetylase to promoter regions, down regulating gene expression (Lam et al., 2013); 
and glucocorticoid receptor binds to NFκB and AP-1 repressing their activities 
(Dickmeis et al., 2013; Coutinho & Chapman, 2011). These regulatory processes act 
in a concerted manner, temporally gating specific parts of the immune response to 
distinct times of the day. For example, the highest number of leukocytes peaks at ZT5 
and the expression of TLR9 nadirs at ZT6 (Gibbs et al., 2012; Scheiermann et al., 
2012; Silver et al., 2012). These regulatory processes limit various aspects of the 
immune system to specific times of the day to prevent synchrony thereby  decreasing 
the likelihood of inducing a “cytokine storm” such as those seen during sepsis (Curtis 
et al., 2014).  
 
Given daily oscillation in immune processes, the degree of immune response and the 
subsequent susceptibility to immune challenges, such as LPS-induced septic shock, 
vary according to time-of-day (Shackelford & Feigin 1973; Halberg et al., 1960). It is 
important to note that while each particular aspect of the immune system peaks and 
nadirs at different circadian phases, in general the immune system and the subsequent 
lethality induced by LPS can be partitioned into two phases (Curtis et al., 2014). As 
rodents’ transitions to their active period (ZT9 – ZT15), a phase in which the risk of 
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infection or injury is the greatest, the immune system is in a state of heightened 
sensitivity with increased number of immune cells and inflammatory cytokines and 
enzymes. As the individual transitions to the inactive, rest stage (ZT21 –ZT3) where 
the likelihood of infection and injury is lessened, there is a reduction in inflammatory 
related processes and an increase in the expression anti-inflammatory and repair 
molecules (see Curtis et al., (2014) for review).  
 
Like drugs of abuse, immune activation can modulate circadian oscillations. For 
example, LPS can disrupt the phase, period and amplitude of the molecular clock 
shifting the phase of optimal immune response, and can disrupt interaction between 
cellular clock components and immune-related transcription factors; limiting the anti-
inflammatory actions of clock proteins (for example; Wang et al., 2016; Okada et al., 
2008). Consequently, it is hypothesised that there would be a state of heightened 
inflammation irrespective of time of day. 
  
2.4.2 Neuroimmune system 
The circadian oscillation in immune function has primarily been characterised in the 
periphery. However, almost all cells of the neuroimmune system are influenced by cell 
extrinsic clocks and express the molecular machinery necessary for the cell intrinsic 
clocks (Fonken et al., 2015; Prolo, 2005). Consequently, neuroimmune cells exhibit 
circadian rhythms in vivo and in vitro. For example, the protein and mRNA expression 
of GLAST (an astrocyte-specific glutamate transporter) peaks during the middle of the 
active phase and nadirs at the beginning of the inactive phase (an effect which is 
regulated alcohol intake) (Spanagel et al., 2004); the expression of GFAP exhibits 
rhythmic oscillations in the SCN with astrocytes appearing more star-shaped during 
the active phase compared to the inactive phase (ViaIle & Servière, 1993); and SCN 
astrocytes increase secretion of ATP (a DAMP) in the latter half of the active cycle 
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compared to the inactive cycle (Womac et al., 2009). Further, microglia display 
rhythmic fluctuations in basal inflammatory gene expression (IL-1β, TNFα and IL-6) 
with the magnitude of an immune response towards LPS and subsequent behavioural 
changes dependent on the light cycle - with the greatest effect observed during the 
inactive phase (Fonken et al., 2015). Interestingly, ex vivo microglia isolated from older 
rats exhibit a flattened circadian-dependent expression in cytokine levels and 
diminished circadian rhythms compared to young rats (Fonken et al., 2016). However, 
caution must be used when examining ex vivo microglia as they no longer receive the 




While the activity of the neuroimmune cells fluctuates according to time-of-day, it is 
unclear whether an immune response, specifically, a TLR4-based immune response 
is dependent on circadian rhythm. Fonken et al., (2015) demonstrated LPS induces a 
potentiated immune response during the inactive period (ZT6) compared to the active 
period (ZT16) with increases in IL-1β, IL-6 and TNFα, and decreased IL-10 protein and 
mRNA. No other study has examined a TLR4-based immune response in the central 
nervous system. Rather, most studies have examined the time-of-day effects of TLR4 
in the periphery. For example, Keller et al., (2009) demonstrated that 8 per cent of the 
macrophage transcriptome oscillates throughout the day with genes involved in the 
regulation and expression of TLR4 and its downstream signalling pathways (MyD88 
and TRIF) varying substantially. In general, the expression of the TLR4 signalling 
pathway was greater during the beginning of the active (night) compared to the inactive 
phase.  Further research supports these findings as LPS-induced production of 
inflammatory cytokines such as IL-6, IL-12, CCL2 and CCL5 from macrophages and 
recruitment of leukocytes is greater at the beginning of the active (ZT12) compared to 
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inactive phase (ZT0) (Gibbs et al., 2012). The potentiated immune response during the 
active period was attributed to the increased interaction between NFκB and CLOCK 
during the active phase. Collectively, the results from the periphery contrast those in 
the central nervous system with exaggerated levels of TLR4-induced cytokines during 
the active phase compared to the inactive phase. Further studies are needed to 
determine whether there are time-of-day differences between the MyD88 and TRIF 
pathways in the periphery and the brain. 
 
2.5 Study 1 aims and hypothesis 
Given the expression of reward and TLR4 pathway both exhibit time-of-day dependent 
effects, and that TLR4 activation potentially alters acute reward behaviour, it raises the 
possibility that an alcohol-induced TLR4 signal exhibits a greater influence on the 
reward pathway reflecting the time-of-day. Consequently, drugs targeting the TLR4 
pathway may be more or less effective at attenuating reward processing during specific 
times of the day. Therefore, the aims of this study were to determine: 
1. whether the “liking” and “wanting” components of alcohol reward vary according 
to the time-of-day; 
2. whether the TLR4 signalling and reward pathway exhibits peaks and nadirs in 
expression which reflect the time-of-day; 
a. whether the TRIF or MyD88 pathway exhibit time-of-day effects; and 
3. whether the efficacy of a TLR4-TRIF antagonist on attenuating the “liking” and 
“wanting” component of alcohol reward is dependent on the time of day. 
 
Given that a large body of work demonstrates the expression of peripheral TLR4 and 
molecular mediators of reward is greatest during the active phase, it was hypothesised 
that attenuating TLR4 during this phase would have the greatest effect on reward-like 
behaviour in mice. 
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Circadian rhythm affects drug-induced reward behaviour and the innate immune 
system. Peaks in reward-associated behaviour and immune responses typically occur 
during the active (dark) phase of rodents. While the role of the immune system, 
specifically, Toll-like receptor 4 (TLR4, an innate immune receptor) in drug-induced 
reward is becoming increasingly appreciated, it is unclear whether its effects vary 
according to light-cycle. Therefore, the aim of this study was to characterise the effects 
of the phase of the light-cycle and the state of the innate immune system on alcohol 
reward behaviour and subsequently determine whether the efficacy of targeting the 
immune component of drug reward depends upon the light-cycle. 
 
This study demonstrates that mice exhibit greater alcohol-induced conditioned place 
preference and alcohol two-bottle choice preference during the dark cycle. This effect 
overlapped with elevations in reward-, thirst- and immune-related genes. 
Administration of (+)-Naltrexone, a biased TLR4 antagonist, reduced immune-related 
gene expression and alcohol preference with its effects most pronounced during the 
dark cycle. However, (+)-Naltrexone, like other TLR4 antagonists exhibited off-target 
side effects, with a significant reduction in overall saccharin intake – an effect likely 
attributable to a reduction in tyrosine hydroxylase (Th) mRNA expression levels. 
Collectively, the study highlights a link between a time-of-day dependent influence of 
TLR4 on natural and alcohol reward-like behaviour in mice. 
 




Alcohol is the most widely consumed drug globally (WHO, 2015). The initial 
consumption of alcohol is characterised by its rewarding, hedonic properties. These 
properties assist in the development of repetitive/habitual use, which can lead to 
misuse, loss of control of intake, and addiction (Koob & Le Moal, 2001). The rewarding 
properties of alcohol are attributable to its actions on the brain’s mesolimbic system 
(Imperato & Di Chiara, 1986). Specifically, dopaminergic neurons projecting from the 
ventral tegmental area (VTA) to the nucleus accumbens (NAcc) are thought to mediate 
reward and attach salience (Koob & Volkow, 2009; Wise, 2004). Alcohol activates 
these neurons via multiple pathways for example, alcohol; causes the release of 
GABA, or directly activates the GABAA receptors in VTA; increases opioid peptides in 
the VTA and NAcc; and alters glutamate signalling which innervates the NAcc’s 
dopaminergic projections (see Nestler, (2005) for review). Collectively, these 
processes control dopaminergic neurotransmission thereby influencing reward, 
specifically, the likability of, and the motivation to consume alcohol (Robinson et al., 
2013). 
 
The extent to which alcohol initially activates the mesolimbic system is dependent upon 
the time-of-day (circadian rhythm, and associated diurnal or nocturnal behaviours). 
Within mammals, circadian rhythm is generated and maintained, at a circuit level via, 
the suprachiasmatic nucleus (SCN), and on a cellular level, by a feedback loop 
involving a group of transcription factors (Reppert & Weaver, 2002). The SCN functions 
as the master regulator, linking the external (via the retinal-hypothalamic tract) and 
internal environments (Moore & Lenn, 1972; Stephan & Zucker, 1972). Consequently, 
the SCN sends neural and endocrine signals to regulate the function of organs and 
cells according to the time-of-day (for example Moore & Eichler, 1972). However, most 
cells can generate their own rhythm via an auto-regulatory feedback loop involving 
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transcription factors. These transcription factors include two activator (CLOCK and 
BMAL1) and two repressor proteins (PER and CRY). In brevity, the cellular clock 
begins when CLOCK and BMAL1 dimerise and bind to enhancer box (E-box; DNA 
response elements) in the promoter region of CRY and PER, initiating their 
transcription. PER and CRY accumulate, dimerise and suppress the transcription of 
CLOCK and BMAL1. The subsequent decline in CLOCK and BMAL1 decreases the 
transcription of PER and CRY. This rhythmic interaction generates the cellular 
circadian rhythm over a 24 h period (Partch et al., 2014; Dardente & Cermakian, 2007), 
which is estimated to influence approximately 2 – 10 per cent of the mammalian 
transcriptome (Miller et al., 2007; Akhtar et al., 2002; Duffield et al., 2002). 
 
The circadian influence on the reward pathway varies according to brain region and 
cell type. In the NAcc, dopaminergic and non-dopaminergic cell activity peaks during 
the active (dark) phase of rodents (Baltazar et al., 2013). This is attributable to transient 
elevations in transcription and translation of genes pertinent to the function of the 
mesolimbic system, such as tyrosine hydroxylase and the dopamine transporter 
(Chung et al., 2014; Ferris et al., 2014). Behaviourally, this manifests as a heightened 
sensitivity towards rewarding experiences to alcohol and other drugs of abuse during 
the active phase and a lower sensitivity during the inactive phase. For example, alcohol 
intake, alcohol preference and self-intracranial electrical stimulation of the reward 
pathway are greatest during the active (dark) phase relative to the inactive (light) phase 
(Perreau-Lenz et al., 2012; Gauvin et al., 1997; Terman & Terman, 1975). However, 
each drug of abuse appears to be unique, as cocaine-induced conditioned place 
preference is greatest during the light cycle (Kurtuncu et al., 2004).  
 
Alcohol-induced reward-like behaviours are additionally influenced by the 
neuroimmune system (Crews et al., 2017; Lacagnina et al., 2016; Cui et al., 2014). 
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Particular emphasis has been placed on Toll-like receptor 4 (TLR4), a pattern 
recognition receptor as a key mediator of reward induced by alcohol and other drugs 
of abuse (Bachtell et al., 2015). Activation of TLR4 results in the induction of two 
signalling pathways (MyD88 or TRIF) that culminates in the expression of classical 
pro-inflammatory cytokines or type-one interferons respectively (Akira & Takeda, 
2004). Alcohol and other drugs of abuse activate TLR4 (either directly or indirectly) 
resulting in the induction of inflammatory mediators (Fernandez-Lizarbe et al., 2013; 
2009). It is hypothesised that inflammatory mediators act on neighbouring neurons 
within the mesolimbic system (tetrapartite synapse), culminating in altered neuronal 
function and potentially influencing the presentation of reward-like behaviours 
(Lacagnina et al., 2016; Jacobsen et al., 2014). 
 
Translationally, the effects of TLR4 on alcohol reward-like behaviour are mixed with 
studies demonstrating either attenuation or no effect on alcohol intake and preference 
(Harris et al., 2017; Aurelian et al., 2016; Bajo et al., 2016; June et al., 2015; Liu et al., 
2011; Pascual et al., 2011). These discrepancies are likely due to methodological 
differences between the studies including brain region examined and method of 
drinking. Interestingly, despite TLR4 being implicated in alcohol drinking behaviour, 
few studies have considered which TLR4-signaling pathway (MyD88 or TRIF) is driving 
the alterations in reward behaviour (Blednov et al., 2017; Harris et al., 2017), and they 
have not considered the time-of-day associated rhythmicity of TLR4 expression and 
the subsequent impact this may have on behaviour. 
 
Similar to the cellular and molecular components of the mesolimbic system, the 
expression of the TLR4-signaling pathway oscillates according to the time-of-day 
(Bass and Lazar, 2016). In the periphery, peak expression of TLR4-related signalling 
and inflammatory molecules are observed at the onset of their active (dark, nocturnal) 
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phase and nadirs at the beginning of the inactive (light, diurnal) phase (Keller et al., 
2009). Within the brain however, the opposite response is observed. Isolated 
hippocampal microglial cells exhibit peak TLR4-related gene expression during the 
light phase compared to the dark phase (Fonken et al., 2015). However, it is unclear 
whether the MyD88 or TRIF pathway fluctuates according to circadian rhythm within 
the brain and periphery and whether these signalling pathways are involved in alcohol-
induced reward-like behaviour. Therefore, this study sought to determine whether light 
cycle (dark vs light) differences exist in the expression of MyD88, TRIF and their 
downstream signalling molecules in naïve mice and mice following alcohol exposure. 
This study also investigated whether the efficacy of a biased TLR4 antagonist on 
attenuating reward-like behaviour is dependent on the light-cycle. The results 
presented suggest that the preference for rewarding and aversive compounds peaks 
and nadirs during the dark cycle with reward-, thirst-, hunger-, and immune-related 
genes following a similar pattern. We demonstrate that attenuating TLR4 via (+)-
Naltrexone reduces alcohol drinking and conditioned place preference (key indicators 
of reward) with the degree of attenuation greater during the dark cycle. However, we 
found that (+)-Naltrexone additionally reduces saccharin preference. These effects 
coincide with a reduction in Tlr4 and Ifnb and Th mRNA in the nucleus accumbens. 
Collectively these results suggest TLR4 may play a role in dopamine synthesis and 




Male (8 – 10-week-old) Balb/c mice, obtained from the University of Adelaide 
Laboratory Animal Services (Adelaide, SA, Australia) were used for the following 
experiments. Mice were housed in light/dark (12:12 hours) and temperature controlled 
rooms (23±3°C) with food and water available ad libitum. The light cycle began at 7am 
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(ZT0) and concluded at 7pm (ZT12). Following seven days of acclimatisation, mice 
were handled by the experimenter for five days prior to experimentation. Mice were 
weighed daily throughout the handling and experimental periods. All animal care and 
experiments complied with the principles of the Australian Code of Practice for the care 
and use of animals for scientific purposes and were approved by the University of 
Adelaide’s Animal Ethics Committee. 
 
3.3.2 Drugs 
Saccharin and quinine were purchased from Sigma Aldrich (St Louis, MO, USA). 
Ethanol (99.5%) (herein referred to as alcohol) was purchased from Chemsupply 
(Gliman, SA, Australia). Oral gavages of alcohol were dosed at 1.5g/kg and 3.2g/kg 
(25 per cent v/v) for conditioned place preference and molecular studies respectively. 
Saline oral gavages were volume-matched. The dose of alcohol used in conditioned 
place preference was based upon the effective dose 50 from an unpublished 
conditioned place preference dose response curve. 3.2g/kg was derived from the 
mean 2 h intake of alcohol from mice on the first day of drinking in the dark tests.  
 
(+)-Naltrexone, a TLR4-TRIF antagonist was synthesised and kindly supplied by Dr 
Kenner Rice (Chemical Biology Research Branch, National Institute on Drug Abuse 
and National Institute of Alcohol Abuse and Alcoholism, Bethesda, MD, USA). (+)-
Naltrexone was administered via intraperitoneal injections with doses ranging from 1 
to 75 mg/kg (dose volume 10 ml/kg). Saline intraperitoneal injections were volume-
matched. 
 
3.3.3 Rationale of behavioural tests 
This study implemented a range of paradigms to assess alcohol reward. Specifically, 
this study was designed to assess two components of reward, likability and seeking 
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behaviour (motivation to obtain alcohol “wanting”). The likability of alcohol was 
assessed using the two-bottle choice paradigm. Despite its relative coarseness in 
obtaining accurate drinking information, the two-bottle choice test can inform 
researchers about the general avidity of alcohol (Tabakoff & Hoffman, 2000). For 
example, the consumption of low concentration alcohol is largely driven by taste. By 
contrast, the consumption of alcohol at higher concentrations are attributable to its 
actions on the mesolimbic pathway, as increasing the concentration of alcohol imparts 
an increasingly bitter and aversive taste (Spanagel, 2000; Tabakoff & Hoffman, 2000). 
Consequently, when testing the likability of alcohol, a range of concentrations must be 
assessed.  
 
The two-bottle choice test is limited in its assessment of the motivational properties of 
alcohol (Tabakoff & Hoffman, 2000). To infer this component of alcohol, conditioned 
place preference was utilised. Conditioned place preference is a paradigm in which 
mice learn to associate alcohol in one particular environment. If alcohol is hedonic 
(reinforcing), the mouse will choose to spend more time in that environment over 
another when given free access to both. By contrast, if the mouse finds alcohol 
aversive, it will spend less time in the environment. Thus, the motivation to seek alcohol 
is illustrated by the time spent in the paired environment in the absence of receiving 
alcohol (Bardo & Bevins, 2000).  
 
To control for taste, and basal hedonic tone, the preference for quinine and saccharin 
were assessed. Quinine, a bitter compound is thought to reflect the higher 
concentrations of alcohol while saccharin, a sweet compound is thought to reflect the 
lower concentrations of alcohol. Additionally, saccharin is innately reinforcing, thus if 
mice exhibit deficits in basal hedonic behaviour, this will become evident during the 
test.  
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3.3.4 Experimental design 
Testing began at ZT2 and ZT14 for mice undergoing tests during the light (inactive) 
and dark (active) phase respectively (figure 1). The behavioural experiments ranged 
from 2 – 24 h. For studies evaluating (+)-Naltrexone (and saline), mice were injected 
30 min prior to undergoing behavioural testing (ZT1:30 and ZT13:30 for light and dark 
phases respectively) (figure 1). 
 
3.3.5 Alcohol drinking tests 
Three alcohol-drinking paradigms were used for the following experiments: 24 h and 8 
h two-bottle choice and drinking in the dark. 
 
3.3.5.1 Alcohol two-bottle choice 
Alcohol drinking and preference was assessed using an 8 or 24 h two-bottle choice 
paradigm. Following 14 days of acclimatisation and handling, mice were placed into 
individual cages. After a further week of acclimatisation, mice were presented with two 
bottles containing water 2 h after the beginning of the light or dark cycle (ZT2 or ZT14 
respectively) for 8 or 24 h. Two bottles of water were initially presented to mice in order 
to control for novelty-induced drinking. For the 8 h test, the bottles were removed at 
ZT10 or ZT22, weighed and replaced with a single bottle of water randomised to either 
the left or right side of the cage for the remaining 16 h. For the 24 h two-bottle choice 
test, after the test period had elapsed the bottles were removed, weighed and replaced 
with two new bottles.  
 
Following five days of drinking water from two bottles, mice were offered one bottle 
containing water and the other 3, 6, 9, 12, 15, 18, 21 or 42 per cent of alcohol (v/v). 
The concentration and bottle position was randomised daily to prevent the immediate 
acquisition of alcohol drinking and side preferences respectively. After 8 h bottles were 
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removed weighed and replaced by a water bottle randomly allocated to either side of 
the cage lid. For mice in the longer test, the bottles were replaced with two new bottles 
(one containing alcohol the other water) after 24 h. 
 
The amount of alcohol consumed was determined by the difference in bottle weights 
before and after drinking sessions. This enabled the calculation of the amount of 
alcohol consumed per kilogram bodyweight (grams/kilogram) and the preference ratio 
(alcohol intake ÷ (total water + alcohol intake)) for each mouse and averaged for each 
group per concentration of alcohol. An empty cage with two bottles was used to 
determine the rate of evaporation and spillage. The rate of evaporation was subtracted 
from the final weight of test bottles. 
 
3.3.5.2 Saccharin and quinine two-bottle choice 
Mice were also tested using the same 8 h paradigm above for saccharin (1, 15, 30, 45 
and 60 mM) and quinine (0.001, 0.01, 0.1, 1 and 5 mM) preference. However, instead 
of the bottle of alcohol, mice received a bottle of saccharin or quinine and a bottle of 
water. 
 
For studies evaluating the dose of (+)-Naltrexone, the protocol for the 8 h two-bottle 
choice protocol was followed. However, the concentration of the alcohol, saccharin 
and quinine were fixed at 12 per cent, 15 mM, 0.1 mM respectively. 
 
3.3.5.3 Drinking in the dark (alcohol and saccharin) 
Drinking in the dark, a limited access alcohol intake test was additionally used. 
Following two weeks of acclimatisation and handling, mice were individually housed. 
After one week of further acclimatisation, the single bottle of water was replaced with 
a bottle of 20 per cent (v/v) alcohol 2 h into the beginning of the light or dark cycle (ZT2 
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and ZT14). After 2 h, the bottle of alcohol was removed weighed and replaced with a 
bottle of water. This was repeated for the following two days. On the fourth day, mice 
were offered the bottle for 4 h. 
 
Mice were additionally tested for saccharin (15 mM) consumption using a 2 h limited 
access paradigm as outlined above. However, this test was not repeated for 4 
consecutive days.  
 
3.3.6 Conditioned place preference 




The conditioning apparatus consisted of two conditioning chambers (10.9 (length) x 
9.3 (width) x 35 (height) cm) separated by a neutral chamber (16.6 x 4.8 x 35 cm). The 
neutral chamber contained black walls with grey flooring. The conditioning chambers 
differed in tactile and visual cues. The flooring of the conditioning chambers were either 
black plexiglass perforated holes (5 mm apart) or black plexiglass grids (5 mm apart). 
The walls of each chamber were white or black. The combination of wall colour to floor 
texture was randomised for each cohort to prevent any inherent biases mice have for 
a specific texture x colour combination.  
 
During conditioning, a sliding partition restricted access to only one chamber. 
Movement and time spent in each chamber was recorded using Logitech Quickcam 




Day 1: Pretest. Mice were placed into the neutral chamber and allowed to explore all 
three chambers for 30 min.  
 
Day 2 to 9: Conditioning. Mice received an oral gavage of alcohol (1.5 g/kg) and placed 
within their conditioning chamber for 30 min on days 1, 3, 5 and 7. On days 2, 4, 6 and 
8, mice received an oral gavage of saline and placed within the unconditioned chamber 
for 30 min. Mice received a total of four conditioning sessions with each drug (alcohol 
or saline). 
 
Day 10: Test. Mice received an oral gavage of saline, were placed into the neutral 
chamber and allowed to explore all three chambers for 30 min.  
 
To infer whether the conditioning was successful, the time spent in the conditioned 
chamber during the post-test was subtracted from the time spent in the conditioned 
chamber during the pre-test. 
 
3.3.7 Blood alcohol concentration assay 
Serum alcohol concentration was measured using a commercial kit (ADH-NAD 
Reagent Multiple Test Vial; Sigma-Aldrich) and performed as per the manufacturer 
instructions. In brief, it estimates alcohol induced reduction of nicotinamide adenine 
dinucleotide (NAD+) to NADH in the presence of alcohol dehydrogenase. The reaction 
is observed by recording the absorbance of 340 nM by the solution. For two-bottle 
choice tests blood was acquired immediately after behavioral testing by creating a 
small incision into the tail of the mouse. To determine blood alcohol concentration 
following conditioned place preference, a separate cohort of mice underwent the 
conditioned place preference procedure. However, 30 minutes after the last alcohol 
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conditioning session tail blood was collected. Blood was subsequently collected and 
spun down (1500g) at 4oC for 10 mins, thereby separating serum from the residual 
pellet. 
 
3.3.8 Molecular analysis 
3.3.8.1 Gavage model 
The dose and duration of alcohol administered for the molecular studies were designed 
to model the drinking in the dark tests. 3.2g/kg was derived from the mean 2 h intake 
of alcohol from all cohorts of mice on the first day of drinking in the dark tests. 
 
In brief, mice were injected for four consecutive days with either (+)-Naltrexone or 
saline followed by a gavage of alcohol or saline 30 min later. The injections of (+)-
Naltrexone or saline commenced at either ZT1 or ZT13. The gavages of alcohol 




3.3.9 RNA Isolation and qPCR 
Brain regions were isolated by placing the brain into an acrylic matrix (Able Scientific, 
Canning Vale, WA, AUS) and subsequently cutting them into 1 to 2 mm thick sections. 
The nucleus accumbens and the hypothalamus was subsequently microdissected 
using micropunches (Kai Medical, Seki City, Japan) and submerged in RNAlater® ICE 
(ThermoFisher Scientific, Waltham, MA, USA) prior to performing RNA isolation. RNA 
was isolated using Maxwell® 16 LEV simply RNA Tissue Kit (Promega, Madison, WI, 
USA) as per manufacturer instructions. RNA was quantified using spectrophotometric 
analysis, with the quality of RNA verified by the OD260/280 ratio. 900 ng of RNA was 
reverse transcribed into cDNA using iScriptTM cDNA reverse transcription kit (BioRad, 
Hercules, CA, USA) as per manufacturer instructions. 
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Gene expression was assessed using iTaqTM Universal SYBR® Green Supermix (as 
per manufacturer instructions). Real time PCR was performed using the CFX96 
TouchTM Real-Time PCR Detection System (BioRad). All primers were synthesised by 
Integrated DNA Technologies Pte. Ltd. (Baulkham Hills, NSW, Australia) with their 
sequences outlined in the supplementary material (Table 1).  
 
The relative difference in expression level of each of the genes of interest were 
normalised to the CT of GAPDH for both the test and control sample. The ΔCT of the 
test sample was normalised to the ΔCT a control sample (equal amount of cDNA from 
all samples), and then expressed as a ratio (2-ΔΔCT).  
 
3.3.10 Statistical analysis 
Experiment 1: The effect of light-cycle on the intake and preference for alcohol, 
saccharin and quinine was analysed using a two-way ANOVA with Tukey post hoc 
(figure 2). The effect of light-cycle on conditioned place preference and relative 
conditioned place preference was analysed using a two-way ANOVA with Tukey post 
hoc and a paired two-tail t-test respectively (figure 3). 
Experiment 2: The effect of light-cycle on hunger-, reward-, thirst- and TLR4-related 
gene expression was analysed using a paired two-tail t-test (figures 4 and 5). 
Experiment 3: The effects of light-cycle and the dose of (+)-Naltrexone on alcohol, 
saccharin and quinine intake and preference was analysed using two-way ANOVA with 
Tukey post hoc (figure 6). The effects of light-cycle and (+)-Naltrexone on the intake 
and preference for varying concentrations of alcohol, saccharin and quinine was 
analysed using a three-way ANOVA with Tukey post hoc (figure 7). The effects of light-
cycle and (+)-Naltrexone on conditioned place preference and relative conditioned 
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place preference was assessed using three-way ANOVA with Tukey post hoc and two-
way ANOVA with Tukey post hoc respectively (figure 8 and s5). 
Experiment 4: The effect of light-cycle and (+)-Naltrexone on hunger-, reward-, thirst- 
and TLR4-related gene expression was analysed using a two-way ANOVA with 
Bonferonni post hoc (figures 9 and 10). 
 
All summary values presented as mean ± standard error of mean (SEM). p-values ≤ 




Figure 1 Experimental timeline. All behavioural testing began 2 h into the light or 
dark phase. Conditioned place preference occurred between ZT2 to ZT3 and ZT14 to 
ZT15 for mice in the light or dark phase respectively. Drinking in the dark (days 1 – 3) 
occurred between ZT2 to ZT4 and ZT14 to ZT16 for the light and dark cohorts 
respectively. On the final day of testing, the test concluded at ZT6 and ZT18 for the 
light and dark cohorts respectively.  
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3.4 Results 
3.4.1 Experiment 1: Are there light-cycle differences in reward-like behaviour? 
To determine whether alcohol reward-like behaviour was dependent on light-cycle, 
mice underwent the two-bottle choice paradigm for 8 h during the light (ZT2 – ZT10) 
or dark cycle (ZT14 – ZT22) (figure 2a – b). A two-way ANOVA determined a significant 
effect of light-cycle on alcohol intake and preference (effect of light-cycle, F(1, 9) = 5.21, 
p =0.048 and F(1, 9) = 9.16, p =0.014, respectively). Post hoc analysis determined that 
mice exposed to alcohol during the dark cycle exhibited significantly greater intake and 
preference for alcohol compared to those in the light cycle at 21 and 42 per cent.  
 
To determine whether the light-cycle dependent effect on alcohol intake and 
preference was due to an increased reward or decreased aversion, the preference for 
two compounds: saccharin, a sweet-tasting and rewarding compound; and quinine, a 
bitter-tasting and aversive compound, was assessed (figures 2c – f). Similar to alcohol, 
saccharin intake and preference was dependent on light-cycle (effect of light-cycle, F(1, 
9) = 15.53, p = 0.0034 and F(1, 9) = 8.32, p = 0.015, respectively) with mice in the dark 
cycle exhibiting potentiated intake and preference compared to the light cycle at 30 
and 60mM (post hoc analysis). However, the behavioural response to quinine was 
inconsistent. There was a significant effect of light-cycle for intake and the preference 
ratio (intake ratio) (effect of light-cycle, F(1, 9) = 4.72, p = 0.052 and F(1, 9) = 20.31, p = 
0.0009, respectively). Overall, mice in the dark cycle exhibited greater intake but a 
reduced intake ratio for quinine. For all preceding tests the concentration of the solution 
(alcohol, saccharin or quinine) was a significant variable.  The statistical values can be 
found in the supplementary material. 
 
The light-cycle dependent effects observed in the alcohol, saccharin and quinine 
drinking tests may be attributable to thirst rather than reward. Indeed, a light-cycle 
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dependent effect was found for water intake, with mice in the dark cycle exhibiting 
greater intake (supplementary material, figure s1, p = 0.0057). Thus, to control for this 
confounding variable, conditioned place preference, a reward/memory paradigm which 
is independent of thirst was used (figure 3a – b). The change in conditioned-chamber 
time was significantly affected by conditioning drug (effect of drug, F(1, 9) = 50.45, p = 
0.004). However, there was no effect of light-cycle or an interactive effect (effect of 
light-cycle, F(1, 9) = 2.41, p =0.17; and interaction, F(1, 9) = 0.95, p = 0.37, respectively). 
However, if the relative change in conditioned place preference is considered (alcohol 
chamber time – saline chamber time), a significant light-cycle effect emerges. Mice in 
dark cycle exhibited a greater change in conditioned preference than those in the light 
cycle (effect of light-cycle, t= 2.17 df = 16, p = 0.047). Therefore, for the remaining 
experiments, relative conditioned chamber time was evaluated. 
 
3.4.2 Experiment 2: Are there light-cycle differences in the molecular basis of 
reward-like behaviour? 
The light-cycle dependent variations in preference and intake are potentially explained 
by the circadian oscillations in reward-, hunger- and thirst-related genes. Thus, the 
expression of these genes in the nucleus accumbens and hypothalamus was 
compared between light (ZT2) and dark (ZT14) cycles (figure 4a – b). A two-tail t-test 
determined significant light-dark cycle differences in the expression of: Drd2, Oprm1, 
Avp and Ghrl (effect of light-cycle, t = 1.77 df = 4, p = 0.11 and t = 3.96 df = 4, p = 
0.0033; t = 3.18 df = 4, p = 0.0097 and t = 3.67 df = 4, p = 0.021, respectively). This 
effect was not ubiquitous among reward- and hunger-related genes, as light-cycle had 
no effect on the expression of Drd1, Th, Lepr and Rxfp1 (effect of light-cycle, t = 1.77 
df = 9, p = 0.11; t = 1.00 df = 4, p = 0.071; t = 2.45 df = 4, p = 0.69 and t = 0.65 df = 4, 
p = 0.55, respectively).  
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Given the emerging role of the neuroimmune system in the manifestation of reward-
like behaviour, the expression of the TLR4-signaling pathway was additionally 
assessed (figures 5a – b). Light cycle significantly influenced the expression of Tlr4 
mRNA in the nucleus accumbens but not hypothalamus (effect of light-cycle, t = 3.9 df 
= 4, p = 0.019; and t = 2.97 df = 4, p = 0.069, respectively). By contrast, the expression 
of Ccl2 and Ifnb mRNA was significantly influenced by light-cycle in the nucleus 
accumbens (effect of light-cycle, t = 2.27 df = 4, p = 0.05; and t = 2.49 df = 4, p = 0.047, 
respectively) and hypothalamus (effect of light-cycle, t = 2.57 df = 4, p = 0.049 and t = 
2.85 df = 4, p = 0.049, respectively). The effect of light-cycle was more pronounced in 
the hypothalamus with Md2, Trif and Il1b exhibiting light-cycle dependent effects as 
well (effect of light-cycle, t = 6.76 df = 4, p = 0.0025; t = 6.18 df = 4, p = 0.0035 and t = 
4.0 df = 4, p = 0.043 respectively). No differences were observed in either the nucleus 
accumbens or hypothalamus for Cd14, Myd88, Il10, or Hmgb1 mRNA (see 
supplementary material for results of the statistical analysis).  
 
3.4.3 Experiment 3: Does the efficacy of (+)-Naltrexone on attenuating the 
reward-like behaviour depend on the light-cycle? 
Since light-cycle differences were observed in reward-like behaviour and TLR4-related 
gene expression, questions arose as to whether TLR4 was causatively involved in 
these effects, and if it was, were these events mediated by the TRIF- or MyD88-
dependent pathway and would the efficacy of a TLR4-based intervention be dependent 
upon light-cycle. Given the expression of Ifnb mRNA was elevated in the nucleus 
accumbens and hypothalamus, it was hypothesised that the TRIF-pathway may be 
mediating these effects. Thus, (+)-Naltrexone, a biased TLR4-TRIF antagonist, was 
used in the following experiments. Interestingly, there was not an effect of (+)-
Naltrexone on serum alcohol concentration following 2, 8 or 24 h two-bottle choice 
paradigms (effect of pretreatment, F(1, 5)  = 0.070, p = 0.80, F(1, 5)  = 1.59, p = 0.24 and 
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F(1, 5)  = 3.76, p = 0.088 respectively) (figure 4s a – c). However, post hoc analysis 
determined a significant difference in serum alcohol concentration between saline and 
(+)-Naltrexone treated mice during the dark cycle in the 8 but not 2 or 24 h tests. 
Further, there was a significant effect of (+)-Naltrexone on serum alcohol concentration 
following conditioned place preference (effect of pretreatment, F(1, 5)  = 29.93, p < 
0.0001). Again, post hoc analysis determined there was a significant difference 
between (+)-Naltrexone and saline mice during the dark cycle. Therefore, caution must 
be used when interpreting these studies as (+)-Naltrexone may modify alcohol 
metabolism following a bolus gavage.  
 
For the following experiments characterising the light-cycle effects on the behavioural 
pharmacology of (+)-Naltrexone, a significant effect of light-cycle was observed for 
alcohol, saccharin and quinine intake and preference (figure 6a – f). Like earlier 
experiments, mice in the dark cycle exhibited significantly greater intake and 
preference for alcohol and saccharin (supplementary data).   
 
Overall, there was a significant effect of (+)-Naltrexone’s dose on the intake and 
preference for 12 per cent alcohol (effect of dose, F(6, 48) = 15.72, p < 0.0001 and F(6, 
48) = 7.57, p < 0.0001, respectively) (figure 6a and b) with a significant interactive effect 
observed for alcohol intake but not preference (interaction, F(6, 48) = 4.98, p = 0.0005 
and F(6, 48) = 0.63, p = 0.70, respectively). Post hoc analysis determined that mice in 
the dark cycle exhibited a significant reduction in intake and preference from 45 – 75 
mg/kg doses of (+)-Naltrexone relative to saline. In comparison, mice in the light cycle 
exhibited a reduction in preference but not intake at doses of 60 – 75 mg/kg.  
 
The preference but not intake of saccharin was significantly modified by (+)-
Naltrexone’s dose (effect of dose, F(6, 48) = 3.82, p = 0.0034 and F(6, 48) = 0.56, p = 0.76 
 169 
respectively) (figure 6c – d). Further, both intake and preference demonstrated 
interactive effects between (+)-Naltrexone and light-cycle (interaction, F(6, 48) = 2.01, p 
= 0.024 and F(6, 48) = 3.65 p < 0.0046, respectively). Post hoc analysis further 
demonstrated a significant reduction in saccharin preference in the light-cycle between 
30 and 75 mg/kg dose of (+)-Naltrexone - an effect absent in the dark cycle. By 
contrast, quinine intake but not the intake ratio was significantly affected by (+)-
Naltrexone (effect of dose, F(6, 48) = 3.05, p = 0.013 and F(6, 48) = 0.79, p = 0.58, 
respectively). There were no interactive effects for intake or the intake ratio (interaction, 
F(6, 48) = 1.7, p = 0.15 and F(6, 48) = 1.2, p = 0.28, respectively). Collectively, the results 
suggest (+)-Naltrexone attenuates the intake and preference of alcohol. However, this 
action of (+)-Naltrexone may be due to non-specific effects as saccharin and quinine 
intake were significantly perturbed as well.  
 
To further the findings of light-cycle-dependent effects of (+)-Naltrexone on alcohol 
intake and preference, 60 mg/kg dose of (+)-Naltrexone was administered to mice and 
their preference for differing concentrations of alcohol was examined. These tests are 
important, given different mechanisms are thought to govern the responses to low and 
high doses of alcohol (Kiefer, 1995). 
  
Light-cycle and concentration were found to be significant variables influencing 
preference and intake for alcohol, saccharin and quinine (p < 0.05) (see supplementary 
data). There was a significant effect of pretreatment on the intake and preference for 
alcohol (effect of pretreatment, F(1, 344) = 4.95, p = 0.027 and F(1, 344) = 13.58, p = 
0.00027) (figure 7a – b). No interactive effects were found for intake or preference. 
However, post hoc analysis determined (+)-Naltrexone significantly reduced alcohol 
preference at 12, 21 and 42 per cent alcohol compared to saline. There were no post 
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hoc differences between (+)-Naltrexone and saline during the light phase for intake or 
preference of alcohol.  
 
There was a main effect of pretreatment on saccharin intake but not preference (effect 
of pretreatment, F(1, 220) = 8.95, p = 0.0031 and F(1, 220) = 0.25, p = 0.62, respectively) 
(figure 7c – d). A significant interactive effect was observed for saccharin intake (light-
cycle x treatment, F(4, 220) = 9.11, p = 0.0026). However, this effect was not observed 
for saccharin preference (F(1, 220) = 1.37, p = 0.24). Further, there were no post hoc 
differences between the groups for intake or preference. By contrast, quinine intake 
and the intake ratio were unaffected by pretreatment (effect of pretreatment, F(1, 220) = 
4.315, p = 0.09 and F(1, 220) = 2.01, p = 0.16, respectively) (figure 7e – f). There were 
no interactive effects or post hoc differences for quinine intake and the intake ratio.  
 
To provide further evidence indicating TLR4-TRIF involvement in reward/reinforcing 
behaviour, conditioned place preference was assessed (figure 8). Pretreatment 
significantly modified relative alcohol-induced conditioned place preference (effect of 
pretreatment, F(1, 7) = 20.52, p = 0.0027). Post hoc analysis determined (+)-Naltrexone 
significantly decreased relative alcohol-induced conditioned place preference time 
compared saline during the dark only. There was no effect of light-cycle, nor an 
interaction between light-cycle and pretreatment (effect of light-cycle, F(1, 7) = 0.0011, 
p = 0.92; and interaction, F(1, 7) = 1.62, p = 0.24).  
 
(+)-Naltrexone was additionally screened against a 24 h two-bottle choice and drinking 
in the dark paradigm. Both paradigms found a significant effect of (+)-Naltrexone with 
post hoc analysis demonstrating a significant effect of (+)-Naltrexone on alcohol intake 
during the dark but not light cycle. See supplementary materials for figures and precise 
statistical information. 
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3.4.4 Experiment 4: Does the efficacy of (+)-Naltrexone on attenuating the TLR4 
pathway depend on the light-cycle? 
qPCR was used to identify potential mechanisms underpinning the behavioural 
changes induced by alcohol and (+)-Naltrexone. There were significant effects of light-
cycle, pretreatment ((+)-Naltrexone vs. saline) and drug (alcohol vs. saline) for Tlr4 
and Ifnb mRNA expression in the nucleus accumbens (Tlr4, effect of light cycle, F(1, 16) 
= 11.79, p = 0.0034; pretreatment, F(1, 16) = 7, p = 0.022; and drug, F(1, 16) = 6.49, p = 
0.021) (Ifnb light-cycle, F(1, 16) = 9.09 p = 0.0083; pretreatment, F(1, 16) = 8.26, p = 0.010; 
and drug, F(1, 16) = 13.69, p = 0.0019). Within the hypothalamus only Ifnb exhibited a 
significant effect of light-cycle (F(1, 16) = 8.92, p = 0.0087), pretreatment (F(1, 16) = 13.63, 
p = 0.020) and drug (F(1, 16) = 9.54, p = 0.007). Tlr4 expression was significantly 
influenced by light-cycle (F(1, 16) = 9.45, p = 0.0073), drug (F(1, 16) = 20.14, p = 0.004) 
but not pretreatment (F(1, 16) = 3.71, p = 0.072). Post hoc analysis furthered these 
findings as (+)-Naltrexone attenuated alcohol-induced increases in Tlr4 and Ifnb 
mRNA expression in the dark but not light cycle.  
 
Interestingly, (+)-Naltrexone did not affect the expression of Trif in the nucleus 
accumbens or hypothalamus (NAcc, effect of light-cycle, F(1, 16) = 0.71, p = 0.41; 
pretreatment, F(1, 16) = 4.46, p = 0.053;  and drug, F(1, 16) = 0.71, p = 0.41) (hypo light-
cycle, F(1, 16) = 23.23, p = 0.0002; pretreatment, F(1, 16) = 3.21, p = 0.092; and drug, F(1, 
16) = 1.36, p = 0.26). All remaining TLR4-related genes did not exhibit a significant 
effect of all three variables (statistical information are available in the supplementary 
material, see figures s5 – 6).  
 
Interestingly, while there was an effect of pretreatment on the expression of Lepr (F(1, 
16) = 6.44, p = 0.022) and Rxfp1 mRNA (F(1, 16) = 6.01, p = 0.026) there was no effect 
of drug nor light-cycle (see supplementary). However, there was a significant effect of 
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light-cycle (F(1, 16) = 13.15 p = 0.0023), pretreatment (F(1, 16) = 17.76, p = 0.0007) but 
not drug (F(1, 16) = 2.38, p = 0.14) on the expression of Th mRNA (figure 10). Post hoc 
analysis determined a (+)-Naltrexone significantly reduced alcohol-potentiated Th 





Figure 2 Circadian timing affects the intake and preference of alcohol (a - b) and 
saccharin (c - d) but not quinine (e - f). There was a main effect of light-cycle on the 
intake and preference for alcohol (3 – 42%) and saccharin (1 – 60mM) and the intake 
ratio of quinine (0.001 – 5mM). However, the intake of quinine was independent of light 
cycle. Post hoc analysis determined significant differences between light and dark at 
21 – 42 per cent alcohol (a), 30 – 60mM of saccharin (c) and 5mM quinine (f). All data 
was analysed using a two-way ANOVA with Tukey post hoc. Summary values 
represented as mean±SEM; n=10, *p < 0.05; **p < 0.01, *** p < 0.001. 
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Figure 3 Circadian timing alters the relative preference for an alcohol-induced 
conditioned place preference. Light-cycle did not alter alcohol-induced conditioned 
place preference (a). However, when the relative change in conditioned chamber time 
was assessed, there was significantly greater preference towards alcohol during the 
dark compared to the light cycle (b). All data was analysed using a two-way ANOVA 
with Tukey post hoc (a) and a paired two-tail t-test (b). Summary values represented 
as mean±SEM; n=8, *p < 0.05. 
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Figure 4. Circadian timing effects the expression of genes relating to reward (a), 
thirst and hunger (b). The expression of Drd2, Oprm1 and Ghrl were significantly 
elevated during the dark cycle compared to the light cycle. By contrast, the expression 
of Avp, was significantly elevated during the light compared to the dark cycle. The 
expression of Drd1, Th, Lepr and Rxfp1 was unaffected by light-cycle. All data was 
analysed using a paired two-tail t-test. Summary values represented as mean±SEM; 
n=3, *p < 0.05; **p < 0.01. 
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Figure 5 Circadian timing effects the expression of TLR4-related genes in the 
nucleus accumbens (a) and hypothalamus (b). The expression of Tlr4, Ccl2 and 
Ifnb was significantly greater during the dark cycle compared to the light cycle in the 
nucleus accumbens. By contrast, the hypothalamus exhibited a more pronounced 
effect of circadian timing with greater expression of Tlr4, Md2, Trif, Il1b, Ccl2 and Ifnb 
during the dark cycle compared to the light cycle. All data was analysed using a paired 
two-tail t-test. Summary values represented as mean±SEM; n=3-4, *p < 0.05. 
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Figure 6 Circadian timing influences the efficacy of (+)-Naltrexone on the intake 
and preference for alcohol (12%) (a – b), saccharin (30 mM) (c – d) and quinine 
(0.1 mM) (e – f). (+)-Naltrexone decreased the intake and preference for alcohol with 
a greater effect observed during the dark cycle compared to the light cycle as inferred 
by post hoc differences. (+)-Naltrexone did not affect the intake of saccharin, however, 
the drug significantly decreased the preference for saccharin between 30 - 75mgkg 
and 75mg/kg in the light and dark cycles respectively. The response to quinine was 
the opposite, with (+)-Naltrexone altering intake but not intake ratio. All data was 
analysed using a two-way ANOVA with Tukey post hoc. Summary values represented 
as mean±SEM; n=8-10, *p < 0.05, **p < 0.01, ***p <0.001, ****p <0.0001 compared to 




Figure 7 Circadian timing influences the efficacy of (+)-Naltrexone (60 mg/kg) on 
decreasing the intake and preference for alcohol (a – b) and saccharin (c – d) but 
not quinine (e – f). There was a main effect of pretreatment on the intake (a) and 
preference (b) for alcohol (3 – 42%) with (+)-Naltrexone exhibiting a greater effect 
during the dark cycle (post hoc analysis). Similarly, there was a main effect of 
pretreatment on intake (c) but not preference (d) for saccharin (1 – 60mM). 
Pretreatment had no effect on quinine intake (e) or intake ratio (f) (0.001 – 10mM). All 
data was analysed using a three-way ANOVA with Tukey post hoc Summary values 
represented as mean±SEM; n=10. 
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Figure 8 Circadian timing influences efficacy of (+)-Naltrexone on relative 
change in conditioned chamber time. There was a significant effect of pretreatment 
on alcohol-induced conditioned place preference time with mice in the dark cycle 
exhibiting a significant reduction between saline and (+)-Naltrexone in conditioned 
place preference time. All data was analysed using a two-way ANOVA with Tukey post 






















































Figure 9 Circadian timing influences efficacy of (+)-Naltrexone on decreasing the 
mRNA expression of the TLR4-signaling pathway. There was a significant effect of 
pretreatment on the expression of Tlr4 and Ifnb in the nucleus accumbens and Ifnb in 
the hypothalamus. Post hoc analyses determined differences between the groups 
were observed in the dark cycle only. All data was analysed using a two-way ANOVA 
with Bonferonni post hoc. Summary values represented as mean±SEM; n=3, *p < 0.05, 
**p < 0.01. 
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Figure 10 Circadian timing influences the efficacy of (+)-Naltrexone on 
decreasing the mRNA expression of tyrosine hydroxylase. (+)-Naltrexone 
significantly reduced the expression of Th with its greatest effect observed during the 
dark cycle. All data was analysed using a two-way ANOVA with Bonferonni post hoc. 





The current study demonstrates that the intake and preference for alcohol, saccharin 
and quinine fluctuate according to the time-of-day. The preference for alcohol and 
saccharin peaked during the dark phase, while quinine preference was greatest during 
the light phase. This effect coincided with elevations in reward-, thirst- and immune-
related genes. This study further highlighted that the efficacy of (+)-Naltrexone, a 
biased TLR4 antagonist, on attenuating alcohol-induced immune signalling and 
alcohol preference is dependent on the light-cycle, with the greatest effect again 
observed in the dark cycle. However, (+)-Naltrexone additionally reduced saccharin 
intake and preference. These effects are potentially attributable to (+)-Naltrexone’s 
down regulation of Th mRNA. Given T5342126, a TLR4-MD2 disruptor, additionally 
attenuates alcohol and saccharin intake (Bajo et al., 2016), the studies collectively 
indicate a pivotal link between TLR4 and natural reward-like behaviours. 
 
The effects of the circadian influence on reward and drug seeking behaviour have 
recently received renewed interest (see Parekh et al., 2015; Perreau-Lenz & Spanagel, 
2015; Webb et al., 2015 for review). Earlier studies indicated rodents have a higher 
preference and intake of alcohol during the dark cycle (Gauvin et al., 1997). 
Interestingly, the time of heightened sensitivity towards drugs of abuse appears to be 
unique to each class, as cocaine exhibits its greatest rewarding effects during the day 
(Kurtuncu et al., 2004). Results presented in this study reinforce the importance of the 
light-cycle with respect to alcohol reward-like behaviour. Despite higher water intake 
during the dark cycle, mice in the dark cycle exhibited greater preference and intake 
of alcohol compared to those in the light cycle. These findings were furthered as mice 
exhibited relatively higher conditioned place preference towards alcohol during the 
dark cycle compared to the light. The increased intake and preference for alcohol 
however, are potentially attributable to either an increase in the rewarding- or a 
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decrease in the aversive properties of alcohol. To control for this possibility, the intake 
of saccharin; a sweet non-calorific, non-alcoholic rewarding solution, and quinine; an 
aversive, bitter solution, was measured. Mice displayed light-cycle-dependent 
differences in saccharin intake and preference, with the greatest preference observed 
during the dark cycle. By contrast, the lowest intake ratio for quinine was during the 
dark cycle. As mice in the dark cycle exhibited enhanced and reduced preference 
towards saccharin and quinine, respectively. It is difficult to determine whether the 
increased preference of alcohol was due to increased reward or reduced aversion. 
Further, one cannot rule out the possibility of alcohol as an energy source acting as a 
motivator for increases in preference and intake. 
 
Previous studies have identified circadian differences in nucleus accumbens and 
ventral tegmental area (key reward-related regions) in terms of gene and protein 
expression and the activity of dopaminergic- and non-dopaminergic neurons (Hampp 
et al., 2008; Sleipness et al., 2008; Sleipness et al., 2007). Our results are in 
accordance with these findings; the expression of dopamine and opioid receptors and 
tyrosine hydroxylase mRNA in the nucleus accumbens was increased during the dark 
cycle. The elevated levels of reward-related genes (if translated into protein) may 
enhance an individual’s sensitivity towards alcohol (Mendez & Morales-Mulia, 2008; 
Gianoulakis, 2001). In addition, we observed light-cycle dependent expression in 
genes related to thirst and hunger in the hypothalamus. The fluctuations in vasopressin 
and leptin mRNA may additionally drive the intake of alcohol (Pickering et al., 2007; 
Wurst et al., 2007). The day-night differences in reward-related gene expression are 
attributable to multiple circuit-level and molecular mechanisms. For example, the SCN 
innervates the reward pathway via glutamatergic afferents from the medial prefrontal 
cortex regulating reward behaviour (Baltazar et al., 2014; Baltazar et al., 2013); and 
dopamine transporter, dopamine D1 and D2 receptors, monoamine oxidase and 
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tyrosine hydroxylase – key proteins regulating dopamine synthesis and reward, 
contain BMAL1 and CLOCK binding sites in their promoter regions (Webb et al., 2009; 
Hampp et al., 2008; Sleipness et al., 2008; Sleipness et al., 2007; McClung et al., 2005; 
Akhisaroglu et al., 2005). This suggests the circadian clock controls aspects of 
dopaminergic activity including neurotransmitter synthesis, release, degradation and 
postsynaptic actions. No study has determined whether the µ opioid receptor or any of 
its endogenous agonists (associated with the “liking” component of reward) are under 
the control of clock proteins in the nucleus accumbens or VTA. 
 
Given the emerging role of the immune system in reward-like behaviour, the 
expression of the TLR4 pathway was additionally examined. Interestingly, a light-cycle 
dependent effect was observed for some, but not all TLR4-related genes in the nucleus 
accumbens and hypothalamus. Both these regions exhibited increases in Tlr4, Ifnb 
and Ccl2 mRNA during the dark cycle. However, the hypothalamus reported additional 
light-dark differences in Md2, Trif and Il1b expression. These findings are in contrast 
to Fonken et al., (2015) who observed that isolated microglia exhibit peaks in 
inflammatory gene expression during the light cycle. There are however, numerous 
differences in terms of study design between the present study and Fonken et al., 
(2015), which may explain these differences (genes and cells examined, in vivo vs ex 
vivo tissue and methods of analysis). The present findings are similar to studies 
examining circadian influence on peripheral immune cells. For example, peripheral 
macrophages exhibit an increase in TLR4-related mRNA during the dark (active) cycle 
(Keller et al., 2009). Nevertheless, these data point to regional specific circadian 
control of brain innate immune reactivity. Like the reward-related gene expression, the 
oscillations in TLR4-related gene expression are driven by sympathetic and 
parasympathetic effects from the SCN and the molecular clock mechanisms. For 
example, BMAL1-CLOCK binds to E-boxes in the promoters of chemokine genes 
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(Nguyen et al., 2013); CLOCK can directly interact with p65 subunit of NFκB enhancing 
its activity (Spengler & Kuropatwinski, 2012); and glucocorticoid receptors bind to 
NFκB and AP-1 repressing their activities (Dickmeis et al., 2013; Coutinho & Chapman 
2011). These regulatory processes act in a concerted manner, temporally gating 
specific parts of the immune response to distinct times of the day. 
 
The role of TLR4 in regulating cocaine- and opioid-induced reward is well established 
(Northcutt et al., 2015; Hutchinson et al., 2012). However, for TLR4’s impact on alcohol 
pharmacodynamics, there are conflicting evidence with studies demonstrating either 
no effect or a reduction in alcohol drinking and reward-like behaviour (Blednov et al., 
2017; Harris et al., 2017; Aurelian et al., 2016; Bajo et al., 2016; June et al., 2015; Liu 
et al., 2011; Pascual et al., 2011). The differential results are likely attributable to 
differences in brain regions examined, models of alcohol exposure and species 
examined. However, only two of the preceding studies have considered whether the 
differences (or lack thereof) are attributable to activation of different TLR4-signaling 
pathways (TRIF or MyD88) (Blednov et al., 2017; Harris et al., 2017). Given the light-
cycle differences in the expression of Ifnb mRNA, and previous work establishing a 
causal relationship between interferon signalling and excessive alcohol use (Duncan 
et al., 2016; Manzardo et al., 2016; Johnson et al., 2015), (+)-Naltrexone, a biased 
TLR4-TRIF antagonist was used to explore the role of TLR4-TRIF signalling on light-
cycle dependent differences in alcohol drinking and reward behaviour.  
 
(+)-Naltrexone significantly attenuated alcohol intake and preference across a range 
of doses, alcohol concentrations and testing times. However, the response was mixed. 
While there were significant effects regarding the dose of (+)-Naltrexone on intake and 
preference, post hoc analysis determined the differences were most pronounced 
during the dark cycle. Similarly, the reduction in relative alcohol-induced conditioned 
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place preference by (+)-Naltrexone was only statistically significant during the dark 
cycle. These two paradigms would infer that (+)-Naltrexone attenuates alcohol-induced 
reward-like behaviour with the greatest effect during the dark cycle. However, the 
results are confounded. (+)-Naltrexone significantly modified saccharin (but not 
quinine) intake and preference. Therefore, (+)-Naltrexone may act as an antagonist 
towards all rewarding compounds, rather than one specific to alcohol. While this finding 
contrasts Northcutt et al., (2015), they are congruent with the actions of other 
pharmacological TLR4 antagonists such as T5342126 (Bajo et al., 2016). Hence, there 
appears to be a critical circadian-TLR4 signalling involvement in the rewarding 
properties of multiple diverse agents.  
 
The findings presented in this manuscript add to the growing body of evidence aimed 
at elucidating the precise function of each of the TLR4-signaling pathways in alcohol-
reward behaviour. Interestingly, our findings largely contrast those by Harris et al., 
(2017) who demonstrated a lack of effect of (+)-Naloxone, a chemically-related 
compound and TLR4-TRIF antagonist, on alcohol drinking behaviour in naïve mice. 
However, Harris et al., (2017) observed a significant effect of (+)-Naloxone in 
paradigms designed to mimic excessive drinking. This would suggest TLR4-TRIF is 
involved in the chronic but not acute effects of alcohol. In addition to the TRIF pathway, 
TLR4 signals via MyD88 raising the possibility that the acute effects of alcohol are 
mediated by this pathway as well. Recent evidence has shown naïve MyD88-/- mice 
exhibit potentiated alcohol intake compared to wildtype mice (Blednov et al., 2017). On 
the surface, this may suggest MyD88 is a negative regulator of alcohol-reward 
behaviour. However, MyD88-/- mice also display reduced saccharin intake (Blednov et 
al., 2017) and opioid-induced reward (Hutchinson et al., 2012), suggesting that MyD88-
/- mice may find alcohol less rewarding than wildtype mice and therefore must consume 
greater quantities to achieve the same pharmacological effect. Collectively, these 
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studies and ours highlights the growing appreciation that the individual TLR4-signalling 
pathways play a unique role in alcohol reward. 
 
To identify potential mechanisms underlying (+)-Naltrexone’s ability to attenuate 
alcohol-reward like behaviour, genes relating to reward and the immune system within 
the nucleus accumbens and hypothalamus were examined. Alcohol increased the 
expression of genes related to the TLR4 pathway. Specifically, a rise in Tlr4, Cd14, 
Md2, Trif, Myd88, Ccl2, Hmgb1 and Ifnb mRNA expression was observed. This 
indicates an acute moderate dose of alcohol upregulates markers of the MyD88 and 
the TRIF pathway. Only Tlr4 and Ifnb, however, reported additional light-cycle and 
pretreatment effects. There was a significant decrease in the expression of Tlr4 and 
Ifnb mRNA following (+)-Naltrexone. However, like the behavioural tests, only 
significant post hoc differences were found in the dark cycle. Again, highlighting that 
the largest effect of (+)-Naltrexone occurred during the dark cycle. The dark cycle effect 
may be due to a floor effect. That is, because TLR4 expression is relatively lower during 
the light cycle, an antagonist may be unable to reduce the signalling and expression 
further. By contrast, when the expression is comparatively higher (during the dark 
cycle), the antagonist now appears to exert an effect. This extends to conclusions 
about TLR4s involvement in reward-like behaviour. During the light cycle, TLR4 
expression was low and therefore, TLR4 may exert a smaller effect on reward 
behaviour compared to during the dark when its expression was the highest. 
 
No genes associated with hunger or thirst were significantly altered by alcohol in the 
hypothalamus. By contrast, alcohol significantly potentiated the expression of Oprm1 
and Th mRNA in the nucleus accumbens. These genes are pivotally involved in the 
manifestation of reward-like behaviour (Alves et al., 2015; Charbogne et al., 2014; 
Webb et al., 2009). However, only the expression of Th mRNA was significantly altered 
 188 
by light-cycle and pretreatment – suggesting a link between TLR4 and tyrosine 
hydroxylase (TH) (figure 10). This study is not the first to highlight a potential link 
between TLR4 and TH as Aurelian et al., (2016) determined TLR4 activation induces 
the expression of TH in VTA dopaminergic neurons via a PKA/pCREB signal. Work 
from the present study builds upon this connection suggesting that either IFNβ or CCL2 
may underlie this link given both inflammatory mediators demonstrated a significant 
effect of pretreatment. Interestingly, all three inflammatory mediators (IFNβ, CCL2 and 
TLR4) can signal through PKA and CREB (Akira &Takeda, 2004), leading to altered 
transcription of Th mRNA. Importantly the downregulation of Th mRNA following (+)-
Naltrexone potentially explains the broad effects (decreased saccharin preference) 
observed with TLR4 antagonists. Tyrosine hydroxylase is the rate limiting enzyme of 
catecholamine synthesis, catalysing the conversion of tyrosine to L-DOPA, a precursor 
molecule for dopamine (see Daubner et al., (2011) for review). Consequently, reducing 
its transcription using (+)-Naltrexone may reduce basal dopamine level. Thus, mice 
experience reduced rewarding sensations upon consuming saccharin and alcohol. 
Collectively, the results highlight the importance of TLR4 in regulating basal dopamine 
synthesis and implicates the TLR4 system in the rewarding properties of multiple 
diverse agents. 
 
In summary, the results highlighted above suggest the preference for rewarding and 
aversive stimuli peak and nadir during the dark cycle respectively. This effect coincides 
with elevations in genes relating to dopaminergic and opioidergic transmission and the 
TLR4-signalling pathway. Attenuating the TRIF component of the TLR4-signalling 
pathway significantly reduced alcohol preference, with a greater effect during the dark 
cycle. Saccharin preference was additionally reduced by TLR4 blockade– an effect 
potentially attributable to a reduction in Th mRNA. Given that antagonism of TLR4 
reduced alcohol- and saccharin preference and tyrosine hydroxylase mRNA, TLR4 
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may play a role in the dopamine synthesis and natural reward-like behaviour. Further 
research is required to establish how these preclinical studies translate to the human 
condition, and whether future pharmacological targeting of neuroimmune systems 
generally (Ray et al., 2017) or TLR4 specifically, may need to be timed specifically to 
a light cycle. Moreover, these data point to a significant impact on the brain of time-of-
day on long term impact of alcohol exposure. 
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3.8 Supplementary material 
 
Table 1 Primer sequence used in qPCR 
Gene Forward Primer 5’ – 3’ Reverse Primer 5’ – 3’ 
Ccl2 – 
Chemokine (C-
C motif) ligand 
2 
ACACTGGTTCCTGACTCCTCT ACCTGAGGACTGATGGTGGT 















Drd2 –  
Dopamine 



















Hmgb1 –  
High mobility 




Ifnb –  
Interferon beta 
1, fibroblast  
TGGGAGATGTCCTCAACTGC CCAGGCGTAGCTGTTGTACT 











Il10 –  












Gene Forward Primer 5’ – 3’ Reverse Primer 5’ – 3’ 









Oprm1 –  
Opioid receptor, 
mu 1, transcript 





















molecule 1  
AACCTCCACATCCCCTGTTTT GCCCTGGCATGGATAACCA 
Th –Tyrosine 






3.8.1 Statistics for in-text figures 
 
Figure 2 Circadian timing affects the intake and preference of alcohol (a - b), 
saccharin (c - d) but not quinine (e - f) and the conditioned preference towards 
alcohol (g – h). All data analysed using a two-way ANOVA with Tukey post hoc. 
 
(a) Alcohol intake 
Effect of concentration, F(8, 72) = 68.34, p <0.0001 
Effect of light-cycle, F(1, 9) = 5.21, p =0.048 
Interaction: concentration x light-cycle, F(8, 72) = 2.02, p =0.056 
 
(b) Alcohol preference 
Effect of concentration, F(8, 72) = 2.2, p = 0.037 
Effect of light-cycle, F(1, 9) = 9.16, p = 0.014 
Interaction: concentration x light-cycle, F(8, 72) = 0.30, p = 0.96 
 
(c) Saccharin intake 
Effect of concentration, F(4, 36) = 18.94, p < 0.0001 
Effect of light-cycle, F(1, 9) = 15.53, p = 0.0034 
Interaction: concentration x light-cycle, F(4, 36) = 2.98, p = 0.0318 
 
(d) Saccharin preference 
Effect of concentration, F(4, 36) = 1.74, p = 0.16 
Effect of light-cycle, F(1, 9) = 8.32, p = 0.015 
Interaction: concentration x light-cycle, F(4, 36) = 0.40, p = 0.81 
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(e) Quinine intake 
Effect of concentration, F(4, 36) = 180.4, p < 0.0001 
Effect of light-cycle, F(1, 9) = 12.09, p = 0.0052 
Interaction: concentration x light-cycle, F(4, 36) = 6.14, p = 0.0005 
 
(f) Quinine preference 
Effect of concentration, F(4, 36) = 2.94, p = 0.031 
Effect of light-cycle, F(1, 9) = 20.31, p = 0.0009 
Interaction: concentration x light-cycle, F(4, 36) = 0.35, p = 0.84 
 
Figure 5 Circadian timing affects the expression of genes relating to reward (a), 
thirst and hunger (b) and the TLR4 pathway (c – d). All data analysed using a two-
way ANOVA with Tukey post hoc. 
 
(c) Nucleus accumbens 
Effect of light cycle, Cd14, t = 0.67 df = 4, p = 0.54 
Effect of light cycle, Md2, t = 0.22 df =4, p = 0.84 
Effect of light cycle, Myd88, t = 1.37 df = 4, p = 0.24 
Effect of light cycle, Trif, t =1.62 df = 4, p = 0.18  
Effect of light cycle, Il1b, t = 0.12 df = 4, p = 0.90 
Effect of light cycle, Il10, t = 0.89 df=4, p = 0.42 
Effect of light cycle, Hmgb1, t = 0.033 df = 4, p = 0.98 
 
(d) Hypothalamus 
Effect of light cycle, Cd14, t = 1.31 df = 4, p = 0.26 
Effect of light cycle, Myd88, t = 0.52 df = 4, p = 0.63 
Effect of light cycle, Ccl2, t = 1.16 df = 4, p = 0.33 
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Effect of light cycle, Il10, t = 1.78 df = 4, p = 0.68 
Effect of light cycle, Hmgb1, t = 1.6 df = 4, p = 0.24 
 
Figure 6 Circadian timing influences the efficacy of (+)-Naltrexone on decreasing 
the intake and preference for alcohol (a – b) and saccharin (c – d) but not quinine 
(e – f). All data analysed using a two-way ANOVA with Tukey post hoc. 
 
(a) Alcohol intake 
Effect of dose of (+)-Naltrexone, F(6, 48) = 15.72, p < 0.0001 
Effect of light-cycle, F(1, 8) = 15.12, p = 0.0046 
Interaction: dose of (+)-Naltrexone x light-cycle, F(6, 48) = 4.99, p = 0.0005 
 
(b) Alcohol preference 
Effect of concentration, F(6, 48) = 7.57, p < 0.0001 
Effect of light-cycle, F(1, 8) = 40.85, p = 0.0002 
Interaction: dose of (+)-Naltrexone x light-cycle, F(6, 48) = 0.64, p = 0.70 
 
(c) Saccharin intake 
Effect of dose of (+)-Naltrexone, F(6, 48) = 2.56, p = 0.076 
Effect of light-cycle, F(1, 8) = 64.85, p < 0.0001 
Interaction: dose of (+)-Naltrexone x light-cycle, F(6, 48) = 0.86, p = 0.53 
 
(d) Saccharin preference 
Effect of dose of (+)-Naltrexone, F(6, 48) = 3.82, p = 0.0034 
Effect of light-cycle, F(1, 8) = 39.16, p = 0.0002 
Interaction: dose of (+)-Naltrexone x light-cycle, F(6, 48) = 2.68, p = 0.024 
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(e) Quinine intake 
Effect of dose of (+)-Naltrexone, F(6, 48) = 3.05, p = 0.013 
Effect of light-cycle, F(1, 8) = 11.09, p = 0.010 
Interaction: dose of (+)-Naltrexone x light-cycle, F(6, 48) = 1.67, p = 0.15 
 
(f) Quinine preference 
Effect of dose of (+)-Naltrexone, F(6, 48) = 0.79, p = 0.58 
Effect of light-cycle, F(1, 8) = 1.08, p = 0.33 
Interaction: dose of (+)-Naltrexone x light-cycle, F(6, 48) = 1.29, p = 0.28 
 
Figure 7 Circadian timing influences the efficacy of (+)-Naltrexone (60 mg/kg) on 
decreasing and the intake and preference for alcohol (a – b) and saccharin (c – 
d) but not quinine (e – f) and the conditioned preference for alcohol (g – h). All 
data analysed using a three-way ANOVA with Tukey post hoc. 
 
(a) Alcohol intake 
Effect of concentration, F(7, 320)  = 61.53, p < 0.0001 
Effect of light-cycle, F(1, 320) = 4.12, p = 0.043 
Effect of pretreatment, F(1, 320) = 4.95, p = 0.026 
Interaction: concentration x light-cycle, F(7, 320) = 3.05, p = 0.0040 
Interaction: concentration x pretreatment, F(7, 320) = 0.60, p = 0.76 
Interaction: light-cycle x pretreatment, F(1, 320) = 2.33, p = 0.13 
Interaction: concentration x light-cycle x pretreatment, F(7, 320) = 2.82, p = 0.0073 
 
(b) Alcohol preference 
Effect of concentration, F(7, 320)  = 3.72, p = 0.0007 
Effect of light-cycle, F(1, 320) = 311.2, p < 0.0001 
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Effect of pretreatment, F(1, 320) = 25.68, p < 0.0001 
Interaction: concentration x light-cycle, F(7, 320) = 2.52, p = 0.016 
Interaction: concentration x pretreatment, F(7, 320) = 2.31, p = 0.026 
Interaction: light-cycle x pretreatment, F(1, 320) = 11.17, p = 0.0009 
Interaction: concentration x light-cycle x pretreatment, F(7, 320) = 0.79, p =0.60 
 
(c) Saccharin intake 
Effect of concentration, F(4, 220) = 97.07, p < 0.0001 
Effect of light-cycle, F(1, 220) = 75.11, p < 0.0001 
Effect of pretreatment, F(1, 220) = 8.95, p = 0.0031 
Interaction: concentration x light-cycle, F(4, 220) = 12.39, p < 0.0001 
Interaction: concentration x pretreatment, F(4, 220) = 1.43, p = 0.23 
Interaction: light-cycle x pretreatment, F(1, 220) = 9.11, p = 0.0028 
Interaction: concentration x light-cycle x pretreatment, F(4, 220) = 1.83, p = 0.13 
 
(d) Saccharin preference 
Effect of concentration, F(4, 220) = 0.85, p = 0.49 
Effect of light-cycle, F(1, 220) = 31.38, p < 0.0001 
Effect of pretreatment, F(1, 220) = 0.25, p = 0.62 
Interaction: concentration x light-cycle, F(4, 220) = 0.68, p = 0.61 
Interaction: concentration x pretreatment, F(4, 220) = 0.24, p = 0.92 
Interaction: light-cycle x pretreatment, F(1, 220) = 1.37, p = 0.24 
Interaction: concentration x light-cycle x pretreatment, F(4, 220) = 0.27, p = 0.89 
 
(e) Quinine intake 
Effect of concentration, F(4, 220) = 45.38, p < 0.0001 
Effect of light-cycle, F(1, 220) = 0.016, p = 0.90 
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Effect of pretreatment, F(1, 220) = 4.32, p = 0.039 
Interaction: concentration x light-cycle, F(4, 220) = 0.38, p = 0.83 
Interaction: concentration x pretreatment, F(4, 220) = 4.27, p = 0.0024 
Interaction: light-cycle x pretreatment, F(1, 220) = 0.018, p = 0.89 
Interaction: concentration x light-cycle x pretreatment, F(4, 220) = 0.062, p = 0.99 
 
(f) Quinine preference 
Effect of concentration, F(4, 220) = 4.39, p = 0.0020 
Effect of light-cycle, F(1, 220) = 0.0058, p = 0.94 
Effect of pretreatment, F(1, 220) = 2.02, p = 0.16 
Interaction: concentration x light-cycle, F(4, 220) = 2.49, p = 0.0443 
Interaction: concentration x pretreatment, F(4, 220) = 0.89, p = 0.47 
Interaction: light-cycle x pretreatment, F(1, 220) = 14, p = 0.0002 
Interaction: concentration x light-cycle x pretreatment, F(4, 220) = 0.51, p = 0.73 
 
Figure 8 Circadian timing influences efficacy of (+)-Naltrexone on relative 
change in conditioned chamber time. All data analysed using a two-way ANOVA 
with Tukey post hoc. 
 
Relative conditioned place preference 
Effect of pretreatment, F(1, 7) = 20.52, p = 0.0027 
Effect of light-cycle, F(1, 7) = 0.0011, p = 0.92 





3.8.2 Supplementary figures 
 
 
Figure s1 Circadian timing affects the intake of water. Mice in the dark cycle 
consumed significantly more water compared to mice in the light cycle. All data was 
analysed using a paired two-tail t-test. Summary values represented mean±SEM; 














































Figure s2 Circadian timing and the dose of (+)-Naltrexone significantly modify 
water intake. Mice receiving (+)-Naltrexone in the dark cycle consumed significantly 
more water compared to mice in the light cycle. All data was analysed using a two-way 
ANOVA with Tukey post hoc. Summary values represented as mean±SEM; n=9, *p < 
0.05 compared to saline (dark); # p < 0.05 compared to saline (light). 
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Figure s3 The efficacy of (+)-Naltrexone (60 mg/kg) on decreasing 24 h intake 
and preference (a –b) of alcohol (20%), 2-4 h intake of alcohol (c) and saccharin 
(15mM) (d) is greatest during the dark cycle. All data was analysed using a three-
way ANOVA with Tukey HSD post hoc (a – c) and a two-way ANOVA with Tukey post 
hoc (d). There was a significant effect of pretreatment on the intake and preference of 
alcohol during the 24 h two-bottle choice tests. Similarly, the drinking in the dark and 
2 h saccharin access tests exhibited a significant effect of pretreatment. Post hoc 
analysis determined (+)-Naltrexone significantly attenuated intake compared to saline 
during the dark but not light cycle in both paradigms. Summary values represented as 
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Figure s4 Serum alcohol concentration from saline and (+)-Naltrexone-treated 
mice (60 mg/kg) following 2 h (a), 8 h (b) and 24 h (c) alcohol drinking tests and 
conditioned place preference (d). All data was analysed using a two-way ANOVA 
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Figure s5. Circadian timing influences efficacy of (+)-Naltrexone (60 mg/kg) on 
change in conditioned chamber time. All data was analysed using a three-way 
ANOVA with Tukey post hoc (a – d). Summary values represented as mean±SEM; 



















































Figure s6 Effect of alcohol, saline (I.G), (+)-Naltrexone (60 mg/kg) on the 
expression of TLR4 and reward-related genes in the Nucleus Accumbens. All 
data was analysed using a two-way ANOVA with Bonferonni post hoc. Summary 






































































































































































































































































































































































































































































































































































































































































































































































Figure s7 Effect of alcohol, saline and (+)-Naltrexone (60 mg/kg) on the 
expression of TLR4 and hunger/thirst-related genes in the hypothalamus. All data 
was analysed using a two-way ANOVA with Bonferonni post hoc. Summary values 
represented as mean±SEM; n=3, *p < 0.05; **p < 0.01. 
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3.8.3 Supplementary material statistics  
 
Figure s1. Light-cycle dependent water intake. 
Paired two-tail t-test 
 
Effect of light cycle, t=2.83 df=96, p = 0.0057 
 
Figure s2 Circadian timing and the dose of (+)-Naltrexone significantly modify 
water intake. All data analysed using a two-way ANOVA with Tukey post hoc. 
 
Effect of dose of (+)-Naltrexone, F(6, 48) = 12.01, p < 0.0001 
Effect of light-cycle, F(1, 8) = 99.62, p < 0.0001 
Interaction: dose x light-cycle, F(6, 48) = 5.72, p = 0.0002 
 
Figure s3 Circadian timing influences the efficacy of (+)-Naltrexone on 
decreasing 24 h intake and preference (a –b) of alcohol, 2-4 h intake of alcohol 
(c) and saccharin (d). All data analysed using a two-way three-way ANOVA with 
Tukey post hoc (a – c) and two-way ANOVA with Tukey post hoc (d). 
 
(a) 24 h intake 
Effect of concentration, F(7, 288) = 69.58, p < 0.0001 
Effect of light-cycle, F(1, 288) = 78.51, p < 0.0001 
Effect of pretreatment, F(1, 288)  = 3.66, p = 0.050 
Interaction: concentration x light-cycle, F(7, 288 = 14.53, p <0.0001 
Interaction: concentration x pretreatment, F(7, 288 = 1.82, p = 0.071 
Interaction: light-cycle x pretreatment, F(1, 288)  = 0.089, p = 0.77 
Interaction: concentration x light-cycle x pretreatment, F(7, 288 = 1.13, p = 0.34 
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(b) 24 h preference 
Effect of concentration, F(7, 288)  = 1.37, p = 0.22 
Effect of light-cycle, F(1, 288)  = 356.1, p < 0.0001 
Effect of pretreatment, F(1, 288)  = 29.93, p < 0.0001 
Interaction: concentration x light-cycle, F(7, 288)  = 1.25, p = 0.27 
Interaction: concentration x pretreatment, F(7, 288) = 0.55, p = 0.79 
Interaction: light-cycle x pretreatment, F(1, 288)  = 4.60, p = 0.033 
Interaction: concentration x light-cycle x pretreatment, F(7, 288)  = 1.13, p = 0.35 
 
(c) 2 – 4 h limited access to alcohol  
Effect of day of testing, F(3, 144) = 11.77, p < 0.0001 
Effect of light-cycle, F(1, 144) = 97.97, p < 0.0001 
Effect of pretreatment, F(1, 144)  = 11.19, p = 0.0011 
Interaction: day of testing x light-cycle, F(3, 144) = 2.77, p = 0.044 
Interaction: day of testing x treatment, F(3, 144) = 2.29, p = 0.08 
Interaction: light-cycle x pretreatment, F(1, 144)  = 2.23, p = 0.14 
Interaction: day of testing x light-cycle x pretreatment, F(3, 144) = 1.39, p = 0.25 
 
 (d) 2 h saccharin intake  
Effect of light-cycle, F(1, 9) = 68.31, p < 0.0001 
Effect of treatment, F(1, 9) = 21.31, p  = 0.0013 
Interaction: light-cycle x treatment, F(1, 9) = 5.34, p = 0.046 
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Figure s4 Serum ethanol concentration following 2 h (a), 8 h (b) and 24 h (c) 
alcohol drinking tests and conditioned place preference (d). Summary values 
represented as mean±SEM; n=6, *p < 0.05; **p < 0.01. All data analysed using a 
two-way ANOVA with Tukey post hoc. 
 
(a) 2 h  
Effect of light-cycle, F(1, 5)  = 35.06, p = 0.0004 
Effect of pretreatment,, F(1, 5)  = 0.070, p = 0.80 
Interaction (light-cycle x pretreatment), F(1, 5)  = 0.33, p = 0.58 
 
(b) 8 h  
Effect of light-cycle, F(1, 5)  = 95.86, p < 0.0001 
Effect of pretreatment,, F(1, 5)  = 1.59, p = 0.24 
Interaction (light-cycle x pretreatment), F(1, 5)  = 0.039, p = 0.85 
 
(c) 24 h  
Effect of light-cycle, F(1, 5)  = 0.42, p = 0.54 
Effect of pretreatment,, F(1, 5)  = 3.76, p = 0.088 
Interaction (light-cycle x pretreatment), F(1, 5)  = 16.27, p = 0.0038 
 
(d) Conditioned place preference 
Effect of light-cycle, F(1, 5)  = 356.1, p < 0.0001 
Effect of pretreatment,, F(1, 5)  = 29.93, p < 0.0001 
Interaction (light-cycle x pretreatment), F(1, 5)  = 29.93, p < 0.0001 
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Figure s5 Circadian timing influences efficacy of (+)-Naltrexone on change in 
conditioned chamber time. All data analysed using a two-way or three-way ANOVA 
with Tukey post hoc. 
 
Conditioned place preference 
Effect of pretreatment, F(1, 56) = 26.65, p < 0.0001 
Effect of conditioning drug, F(1, 56) = 2.15, p = 0.15 
Effect of light-cycle, F(1, 56) = 2.74, p =0.10 
Interaction: conditioning drug x pretreatment, F(1, 56)  = 14.26 p = 0.0004 
Interaction: conditioning drug x light-cycle, F(1, 56) = 0.51, p = 0.48 
Interaction: pretreatment x light-cycle, F(1, 56) = 0.51, p =0.48 
Interaction: conditioning drug x pretreatment x light-cycle, F(1, 56) = 0.954, p = 0.33 
 
Figure s6 Effect of alcohol and (+)-Naltrexone on the expression of TLR4 and 
reward-related genes in the Nucleus Accumbens. All data analysed using two-way 
ANOVA with Bonferonni post hoc. 
 
(a) Md2 light-cycle (F(1, 24) = 3.51, p = 0.08), drug (F(1, 24) = 11.3, p = 0.04), pretreatment 
(F(1, 24) = 0.133, p = 0.32). No significant interactions. 
 
(b) Cd14, light-cycle (F(1, 24) = 0.66 p = 0.43), drug (F(1, 24) = 5.4, p = 0.033), pretreatment 
(F(1, 24) = 0.92, p = 0.48). No significant interactions. 
 
(c) Myd88, light-cycle (F(1, 24) = 0.0072 p = 0.93), drug (F(1, 24) = 10.11, p = 0.0058), 
pretreatment (F(1, 24) = 2.21, p = 0.16). No significant interactions. 
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(d) Il1b, light-cycle (F(1, 24) = 0.0006 p = 0.98), drug (F(1, 24) = 0.79, p = 0.37), 
pretreatment (F(1, 24) = 0.16, p = 0.69). No significant interactions. 
 
(e) Il10, light-cycle (F(1, 24) = 0.12 p = 0.73), pretreatment (F(1, 24) = 0.027, p = 0.87), 
drug (F(1, 24) = 0.0024, p = 0.96). No significant interactions. 
 
(f) Ccl2, light-cycle (F(1, 24) = 0.433 p = 0.51), pretreatment (F(1, 24) = 0.12, p = 0.91), 
drug (F(1, 24) = 29.7, p < 0.0001). There were significant interactions between light-cycle 
and preatreatment (F(1, 24) = 10.17, p = 0.0057) light-cycle, pretreatment and drug (F(1, 
24) = 6.07, p = 0.025). No other significant interactions. 
 
(g) Hmgb1, light-cycle (F(1, 24) = 1.47 p = 0.24), pretreatment (F(1, 24) = 3.88, p = 0.066), 
drug (F(1, 24) = 8.49, p = 0.01). No significant interactions. 
 
(h) Drd1, light-cycle (F(1, 24) = 25.22 p = 0.001), pretreatment (F(1, 24) = 1.14, p = 0.30), 
drug (F(1, 24) = 3.7, p = 0.072). No significant interactions. 
 
(i) Drd2, light-cycle (F(1, 24) = 0.62 p = 0.44), pretreatment (F(1, 24) = 0.032, p = 0.86), 
drug (F(1, 24) = 4.27, p = 0.55). There was a significant interactions between drug and 
pretreatment (F(1, 24) = 05.92 p = 0.027). No other significant interactions. 
 
(j) Oprm1, light-cycle (F(1, 24) = 5.63 p = 0.031), drug (F(1, 24) = 17.78, p = 0.0007), 
pretreatment (F(1, 24) = 1.09, p = 0.31). No significant interactions. 
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Figure s7 Effect of alcohol and (+)-Naltrexone on the expression of TLR4 and 
hunger/thirst-related genes in the hypothalamus. All data analysed using two-way 
ANOVA with Bonferonni post hoc. 
 
(a) Md2, light-cycle (F(1, 24) = 2.79, p = 0.11), drug (F(1, 24) = 0.89, p = 0.36), pretreatment 
(F(1, 24) = 3.82, p = 0.069). No significant interactions. 
 
(b) Cd14, light-cycle (F(1, 24) = 0.52, p = 0.48), drug (F(1, 24) = 4.29, p = 0.055), 
pretreatment (F(1, 24) = 0.0001, p = 0.99). No significant interactions. 
 
(c) Myd88, light-cycle (F(1, 24) = 13.94, p = 0.0018), drug (F(1, 24) = 30.61, p = 0 < 0.001), 
pretreatment (F(1, 24) = 0.21, p = 0.65). No significant interactions. 
 
(d) Il1b, light-cycle (F(1, 24) = 5.59, p = 0.031), drug (F(1, 24) = 17.92, p = 0.006), 
pretreatment (F(1, 24) = 3.22, p = 0.092). No significant interactions. 
 
(e) Il10, light-cycle (F(1, 24) = 1.06, p = 0.32), drug (F(1, 24) = 5.27, p = 0.035), 
pretreatment (F(1, 24) = 0.11, p = 0.74). No significant interactions. 
 
(f) Ccl2, light-cycle (F(1, 24) = 0.22, p = 0.64), drug (F(1, 24) = 3.58, p = 0.077), 
pretreatment (F(1, 24) = 15.65, p = 0.0011). No significant interactions. 
 
(g) Hmgb1, light-cycle (F(1, 24) = 1.65, p = 0.22), drug (F(1, 24) = 8.29, p = 0.011), 
pretreatment (F(1, 24) = 2.68, p = 0.12). There was a significant interactions between 




(h) Avp, light-cycle (F(1, 24) = 4.23, p = 0.056), drug (F(1, 24) = 041, p = 0.84), pretreatment 
(F(1, 24) = 3.61, p = 0.076). No significant interactions. 
 
(i) Grhl, light-cycle (F(1, 24) = 18.36, p = 0.006), drug (F(1, 24) = 1.33, p = 0.27), 
pretreatment (F(1, 24) = 2.28, p = 0.15). No significant interactions. 
  
(j) Lepr, light-cycle (F(1, 24) = 19.38, p = 0.004), drug (F(1, 24) = 0.22, p = 0.64), 
pretreatment (F(1, 24) = 6.437, p = 0.022). No significant interactions. 
 
(k) Rxfp1, light-cycle (F(1, 24) = 36.89, p < 0.0001), drug (F(1, 24) = 11.20, p = 0.29), 







The preceding manuscript (chapter 3) highlighted the importance of TLR4’s circadian 
rhythm in the expression of the “liking” and “wanting” components of alcohol-induced 
reward (Table 3). In brief, there were significant time-of-day effects in behavioural tests 
assessing the “liking” and “wanting” components of alcohol (Figure 2 and 3) with peak 
reward behaviours observed during the dark cycle (active period). Similarly, there were 
light-cycle dependent effects in the expression of genes pertaining to both the “liking” 
and “wanting” component of reward (Drd1 and Oprm1 for example) and the TLR4 
pathway. Again, peak expression was generally observed during the dark cycle. 
Interestingly, the hypothalamus exhibited more light-cycle-dependent effects in terms 
of TLR4 pathway expression compared to the nucleus accumbens. The reason 
underlying this is remains to be fully elucidated, but may relate to the relative number 
or phenotype of neuroimmune cells within each area (Lawson et al., 1990) or that the 
SCN is located within hypothalamus and may therefore influence this area more than 
the nucleus accumbens. Genes representing the TRIF pathway (Trif and Ifnb) 
exhibited similar light-cycle dependent effects compared to genes representing the 
MyD88 pathway (Il1b, Tnfa and Ccl2) suggesting both pathways have elements which 
fluctuate according to the time-of-day. Antagonising the TLR4-TRIF pathway with (+)-
Naltrexone reduced the intake and preference of alcohol during 2 and 8 h two-bottle 
choice preference tests; indicating a potential reduction in the “liking” component of 
alcohol-reward. The effect of (+)-Naltrexone was not specific to alcohol-induced “liking” 
as saccharin (an innate like-inducing solution) intake and preference was additionally 
reduced. The decreased alcohol intake may additionally be attributable to an altered 
aversive or gustatory response as quinine intake was modified by (+)-Naltrexone. 
However, when quinine was assessed over a broader concentration range, the effect 
of (+)-Naltrexone was lost. Given quinine reflects the aversive bitter component of 
concentrated alcohol solutions, it suggests the TLR4-TRIF pathway may be involved 
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in modifying the aversive component of alcohol in addition to reducing the “liking”. The 
“wanting” component of reward, as inferred by conditioned place preference and the 
24 h two bottle choice, was significantly reduced following (+)-Naltrexone. The reduced 
“wanting” of alcohol is potentially attributable to the decreased expression of Th mRNA 
suggesting dopamine synthesis is reduced and thus, alcohol is imbued with less 
motivational significance. However, the mechanism underlying the reduced “liking” 
component remains elusive and may be attributable to acute electrophysiological 
modifications to opioidergic or cannabinoid neurons as well as decreases in gene and 
protein expression. Further experiments are therefore required to elucidate this finding. 
The effects of (+)-Naltrexone on attenuating reward-behaviour were generally more 
pronounced during the active (dark) phase (post hoc analysis) coinciding with the 
highest mRNA expression in the Tlr4 signalling pathway and reward pathway activity. 
The greater effect of (+)-Naltrexone may simply be due to the greater preference for 
alcohol and saccharin observed during the active period. Therefore, antagonising this 
behaviour when it’s at its peak may result in the largest reduction in behaviour rather 
than examining a true “circadian-dependent phenomenon”. Alternatively, the diurnal 
variation in drinking behaviour may also suggest TLR4’s influence on the reward 
pathway is more pronounced during the active phase when its expression is highest. 
Thus, attenuating the TLR4-TRIF pathway during this phase has the greatest effect on 
reducing alcohol, saccharin and quinine intake and preference. 
 
Collectively, this study highlights the importance of TLR4-TRIF in the acute actions of 
the “liking” and “wanting” components of reward and the importance of considering 
circadian timing when examining the efficacy of TLR4 antagonists. 
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Table 2 Summary of behavioural results (post hoc differences) from chapter 3 
 Effective dose(s) of (+)-Naltrexone 
Light-cycle 
Behaviour Light Dark 
Intake Preference Intake Preference 
Water intake ­ 30 mg/kg  N/A ­ 15 – 30 
mg/kg 
N/A 
2 h alcohol intake -¾ N/A ¯ 60 mg/kg N/A 
8 h alcohol two bottle 
choice  
-¾ ¯ 60 – 75 
mg/kg 
¯ 60 – 75 
mg/kg 
¯ 45 – 75 
mg/kg 
2 h saccharin intake ¾ N/A ¯ 60 mg/kg N/A 
8 h saccharin two bottle 
choice  
¾ ¯ 30 – 75 
mg/kg 
¾ ¯ 75 mg/kg 
8 h quinine two bottle 
choice  
­ 30 mg/kg ¾ ¾ ¾ 
24 h alcohol two bottle 
choice 
¾ ¾ ¾ ¯ 60 mg/kg 
Conditioned place 
preference 
N/A ¾ N/A ¯ 60 mg/kg 
N/A, not applicable; ­, increased intake/preference relative to saline; ¯ decreased 




Lawson, L. J., Perry, V. H., Dri, P., & Gordon, S., 1990. Heterogeneity in the 
distribution and morphology of microglia in the normal adult mouse brain. 
Neuroscience, 39(1), 151–170. 
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Chapter 4: Adolescence, reward priming and TLR4 
Following exposure to alcohol, the TLR4-signalling and reward pathway can remain in 
a primed or sensitised state (Vetreno & Crews, 2012; McClain et al., 2011; Pascual et 
al., 2009). This manifests as alterations in the expression of cytokines, neuroplastic 
and reward-related genes and protein (for example, Montesinos et al., 2016; Boutros 
et al., 2015; Centanni et al., 2014; Alaux-Cantin et al., 2013 Vetreno et al., 2013). 
These elevations increase the subsequent sensitivity towards alcohol causing a 
heightened “liking” and “wanting” sensation (see Doremus-Fitzwater & Spear, 2016; 
Spear, 2016 for review). Age is a key variable influencing the rate at which priming 
occurs. For example, adolescence, a period characterised by profound 
neurodevelopmental changes, are particularly sensitive to perturbations in 
immunological and neuronal homeostasis and therefore readily undergo priming 
(Spear & Swartzwelder, 2014; Bilbo & Schwarz, 2012). By contrast, in adulthood, the 
brain has reached developmental maturity and is therefore more resilient to 
perturbations, requiring higher doses or longer stimulation times before exhibiting a 
priming effect.  
 
4.1 Adolescence 
Adolescence is an evolutionary conserved period demarcating childhood from 
adulthood. In humans and rodents, adolescence begins following a surge of gonadal 
hormones, and typically occurs between 12 – 25 years and 21 – 42 postnatal days, 
respectively. However, the absolute boundaries of adolescence in both humans and 
rodents is relatively imprecise and there is little consensus regarding the definitive end 
of this period  (Adriani et al., 2004; Adriani & Laviola, 2004; Tirelli et al., 2003; Spear, 
2000; Petersen & Leffert, 1995). Both species exhibit similar neurodevelopmental 
patterns characterised by hormonal, physiological, neural and behaviour alterations. 
This confers a set of conserved behaviours evident in both species such as increased 
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peer-oriented social interactions (including bonding and aggression) (for example, 
Csikszentmihalyi et al., 2014; Primus & Kellogg, 1989) and novelty seeking/risk taking 
(for example,  Steinberg, 2010; Adriani et al., 1998). 
 
The potentiated novelty seeking behaviour is attributed to neurodevelopmental 
alterations in the limbic system predisposing adolescent’s to be overly sensitive 
towards rewarding stimuli (Doremus-Fitzwater & Spear, 2016; Spear, 2000). The 
reward-sensitive phenotype promotes goal-direct behaviour and evolutionarily would 
assist species to focus on obtaining food, water and a mate (Spear, 2011; Romer, 
2010; Steinberg, 2010). Beyond its evolutionary role, this phenotype causes 
adolescent’s to engage in positive behaviours including establishing meaningful 
friendships and pursuing education (Telzer, 2016). However, this phenotype can also 
cause misaligned, detrimental goal-seeking behaviour such as unprotected sex, 
reckless driving and alcohol abuse (Johnston et al., 2015; Hingson et al., 2009; 2003). 
This phenotype is mirrored in rodents (Alaux-Cantin et al., 2013; Vetter et al., 2007) 
and is  exacerbated as adolescent rodent’s sensitivity to aversive stimuli is attenuated 
(Vetter-O'Hagen et al., 2009; Andersen et al., 1997). Collectively, the increased reward 
and decreased aversion promotes high levels of alcohol intake with very little 
immediate consequences. This pattern of drinking (binge drinking) is particularly 
problematic to neurodevelopment as alcohol reinforces an immature brain state which 
is primed/sensitised towards alcohol (Spear & Swartzwelder, 2014).  
 
4.2 Reward development 
The increased reward sensitivity and attenuated aversion is attributable to 
developmental changes occurring in the limbic system (Crews et al., 2006). For 
example, the prefrontal cortex (PFC), amygdala, nucleus accumbens and ventral 
tegmental area undergo substantial reorganisation inferred by volumetric changes in 
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MRI scans (Uematsu et al., 2012; Ernst & Mueller, 2008; Giedd et al., 1999). The 
volume of these regions generally follows an inverted U shape across adolescence 
(Gogtay et al., 2004; Sowell et al., 1999). The volume initially increases until mid-
adolescence owing to the overproduction of axons and synapses. These are 
subsequently pruned and refined, reducing brain volume from mid to late adolescence. 
In terms of reward sensitivity, emphasis has been placed on neurodevelopmental 
alterations to the dopamine pathway. During adolescence, the number of 
dopaminergic fibres linking the prefrontal cortex to the nucleus accumbens increases 
(Naneix et al., 2012; Wahlstrom et al., 2010; Benes et al., 2000; Rosenberg & Lewis, 
1995) and inhibitory control of PFC activity by dopaminergic projections from the VTA 
increases (Tseng & O'Donnell, 2007). This indicates that as adolescence progresses 
there is greater top-down feedback from regions involved in attention, memory and 
reward processing (PFC) thereby reducing impulsivity (Gogtay et al., 2004).  
 
On a molecular level, there is conflicting evidence regarding the expression of 
dopamine’s receptors, enzymes and transporters and the activity of dopaminergic 
neurons across adolescence. For example, studies found that while the levels of 
dopamine peak during adolescence (Andersen et al., 1997; Teicher et al., 1993), there 
was an overall reduction in dopamine synthesis and turnover rates in the nucleus 
accumbens compared to adult mice (Trantham-Davidson et al., 2017; Stamford, 1989). 
Further, adolescents exhibited reductions in basal dopamine release but had a greater 
dopamine reserve compared to adults (Andersen & Gazzara, 2006; Stamford, 1989). 
It was therefore hypothesized that adolescents exhibit greater dopamine release when 
stimulated (Laviola et al., 2001). However, other groups have reported contrary 
findings with adolescent rodents exhibiting increased tyrosine hydroxylase and 
dopamine receptors in the nucleus accumbens (Naneix et al., 2012; Mathews et al., 
2009; Andersen, 2002; Tarazi & Baldessarini, 2000) and greater dopaminergic tone 
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(Andersen, 2002; Andersen et al., 1997) and dopamine turnover rates (Spear, 2000). 
The discrepancies in results are likely due to the ontological period (age), sex, the 
behaviour assessed and the molecular biology techniques used to assess expression 
levels. Despite differing findings, the conclusions drawn by these studies are the same: 
the fluctuation in dopamine may underlie the heightened sensitivity towards rewarding 
stimuli and confer greater motivational importance upon obtaining the stimuli. This in 
turn predisposes adolescent’s to engage in reward-seeking behaviour (Doremus-
Fitzwater & Spear, 2016).  
 
There is little consensus regarding the developmental progression of the endogenous 
opioid pathway in reward regions (a key mediator of the “liking” component of reward). 
The variability in results is again likely attributable to the differing brain regions, sex 
and method of assessment (Carretero et al., 2004; McDowell & Kitchen, 1987). For 
example, receptor binding studies (either autoradiography or displacement assays) 
demonstrated that the expression of µ, d and κ opioid receptors in the amygdala, 
hippocampus and nucleus accumbens peak during early adolescence (around P25) or 
in adulthood (P56) (Kapcala, 1986; Seizinger et al., 1982; Tsang et al., 1982; Ng et al., 
1984; Bloom et al., 1980; Patey et al., 1980). By contrast, immunohistochemical 
studies suggest the expression of µ opioid receptors declines from one week post-
natal onwards (Carretero et al., 2004). Importantly, the pharmacological properties of 
the receptor such as binding affinity and dissociation constant remain unchanged 
(Kornblum et al., 1987; Petrillo et al., 1987; Tavani et al., 1985). However, the 
recruitment of µ opioid receptor’s intracellular signalling pathways, as inferred by 
[35S]GTPγS binding is decreased in adolescents relative to adults, and the ratio µ 
opioid receptors binding to [35S]GTPγS is decreased in reward-related brain regions 
(Talbot et al., 2005). The increased (or similar) receptor expression but reduced 
receptor coupling suggests adolescent brains are somewhat resilient to the effects of 
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the endogenous opioids. This conclusion contrasts the wealth of behavioural studies 
demonstrating adolescent mice typically consume higher levels of saccharin compared 
to adult mice suggested an augmented “liking” component of reward (for example, 
Friemel et al., 2010; Wilmouth & Spear, 2009).  It is important to note that opioids are 
not the only mechanism underlying the reward sensitive phenotype. For example, 
cannabinoid receptors exhibit peak binding activity during adolescence, indicating an 
increased sensitivity of this system (Belue et al., 1995) and decreased receptor-
mediated tonic current of GABAA receptors during adolescence may also mediate 
reward sensitivity (Yan et al., 2010; Li et al., 2006; 2003). These processes may 
contribute to the increased saccharin intake observed during adolescence. However, 
an in-depth discussion of the neuronal processes underlying these behaviours are 
beyond the scope of this thesis. Please refer to Crews et al., (2016) and Spear, (2000) 
for reviews.  
 
Overall, the developmental effects occurring within the limbic pathway confer 
enhanced sensitivity to reward and attenuated sensitivity to aversion in adolescent’s. 
When these findings are applied to the context of alcohol use, adolescent’s will exhibit 
increased “liking” and “wanting” of alcohol with the experience of aversive taste or 
dysphoria lessened. This enables adolescents to consume high levels of alcohol (binge 
drinking) with little immediate consequences. As such binge drinking is increasingly 
prevalent among adolescents. For example, approximately 20 per cent of teenagers 
report engaging in binge drinking within the past week (Johnston et al., 2015). Like 
humans, adolescent rodents typically display greater intake and preference for alcohol 
and exhibit greater conditioned place preference and IV self-administration of alcohol 
indicating a greater “liking” and “wanting” component of reward compared to adults 
(Carrara-Nascimento et al., 2012; Maldonado et al., 2008; Truxell et al., 2007; Brunell 
& Spear, 2006; Doremus et al., 2005; Philpot et al., 2003). Further, adolescent rodents 
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are insensitive to the detrimental effects of alcohol and are protected against motor 
impairment, social impairment, anxiety, and require higher doses of alcohol to exhibit 
conditioned taste aversion and resist conditioned odour aversion towards alcohol (see 
Spear & Swartzwelder, 2014 for review).  
 
4.3 Reward priming and later life effects 
The consumption of alcohol during adolescence can have enduring consequences 
(McCambridge et al., 2011). For example, human youths that engage in binge drinking 
exhibit alterations in brain volumes, integrity of white matter tracts and distinctive 
patterns of brain engagement during cognitive tasks (Risher et al., 2015; Squeglia et 
al., 2015; Ozsoy et al., 2013; McQueeny et al., 2009; De Bellis et al., 2005). Further, 
epidemiological studies demonstrate correlations between the age of first alcohol use 
and alcohol dependence later in life suggesting that the brain is sensitised to the effects 
of alcohol (for example, Green et al., 2016; Irons et al., 2015; McCambridge et al., 
2011). These effects are mirrored in vivo (Vetreno et al., 2017; Montesinos et al., 2016; 
Swartzwelder et al., 2014; Alaux-Cantin et al., 2013)  However, establishing causation 
in humans is difficult as discerning the effects of adolescent alcohol from 
individual/genotype differences, personality traits and environmental factors such as 
socio-economic status, peer pressure and abusive/alcohol-dependent parents 
confounds findings (Stone et al., 2012; Donovan, 2004). 
 
In rodents, adolescents exposed to alcohol exhibit attenuated sensitivity towards the 
aversive components of alcohol in adulthood (Crews et al., 2016; Spear & 
Swartzwelder, 2014). For example, adolescent alcohol exposure decreases alcohol-
induced motor impairment, acute withdrawal, conditioned taste aversion, social 
inhibition, sedation time and anxiety behaviour in adulthood (for example, Mejia-Toiber 
et al., 2014; Varlinskaya et al., 2014; Matthews et al., 2008; Diaz-Granados & Graham, 
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2007). Furthermore, the increased sensitivity towards the rewarding components are 
persistently increased (Alaux-Cantin et al., 2013). Similar to humans, adolescent 
rodents exposed to alcohol increases 2 and 24 h alcohol intake and conditioned place 
preference in adulthood – indicating increased “liking” and “wanting” of alcohol (Alaux-
Cantin et al., 2013; Broadwater & Spear, 2013; Gilpin et al., 2012; Pascual et al., 2009). 
Further, these mice exhibit higher breakpoints across progressive ratios when using 
self-administration furthering the potentiated “wanting” of alcohol (Amodeo et al., 
2017). However, these findings are far from uniform with studies demonstrating the 
opposing effects (Slawecki & Betancourt, 2002). The different results are likely 
attributable to early vs late adolescence, route of alcohol exposure, and the behaviour 
examined later in life.  In addition to alterations in reward and aversion, mice exposed 
to alcohol during adolescence exhibit greater levels of impulsivity and reduced 
behavioural flexibility as inferred by altered performance in the Barnes maze (Vetreno 
& Crews, 2015). This state further perpetuates the enhanced reward sensitivity as 
these mice become solely focused on obtaining alcohol. Collectively, these changes 
underlie the “locked-in” hypothesis of adolescent alcohol exposure. It suggests 
adolescent sensitivities towards alcohol are retained into adulthood. Consequently, the 
phenotype of an adult closely resemble that of an adolescent (increased novelty 
seeking/risk taking) (Crews et al., 2016; Spear & Swartzwelder, 2014). 
 
There are shared mechanisms between adolescent and adult priming such as 
alterations to dopamine signalling (Karkhanis et al., 2015; Franklin et al., 2009; Pascual 
et al., 2009). However, there are also mechanisms unique to adolescence. Adolescent 
alcohol exposure alters the epigenetic profile of plasticity and reward related genes 
such BDNF, ARC and CREB (Sakharkar et al., 2016; Pandey et al., 2015). This 
process is likely mediated by increases in HDAC activity leading to decreased 
acetylation in the promoter regions of ARC and BDNF (Pandey et al., 2015). Altered 
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expression of BDNF and ARC is thought to alter dendritic spine density in the 
amygdala which in turn influences anxiety and drinking behaviour in adulthood 
(Trantham-Davidson et al., 2017; Pandey et al., 2015). In addition, perturbations to 
dendritic spine density is associated with altered dopaminergic signalling (Lin et al., 
2015; Goldwater et al., 2009) and may therefore potentially alter reward as well. 
Furthermore, adolescent alcohol intake increases the number of immature dendritic 
spine formation, causing long-term potentiation at lower intensities (Risher et al., 
2015). This finding mirrors those observed during neurodevelopmental disorders that 
lead to long-term memory deficits and other cognitive impairments (Penzes et al., 
2011; Chen et al., 2010). Adolescent alcohol exposure induces many other epigenetic 
processes including the expression of regulatory microRNAs and histone methylation 
(Prins et al., 2014; You et al., 2014; Pietrzykowski et al., 2008) which have the potential 
to alter reward-related processes. 
 
Further, the increased reward-sensitivity later in life may be due to alterations in the 
dopamine pathway. Following adolescent alcohol exposure, rodents exhibit increased 
baseline dopamine release in the nucleus accumbens (Philpot et al., 2009) and a 
reduction in dopamine D2 auto-receptor expression (negative regulator of dopamine) 
(Pascual et al., 2009). Upon re-exposure to alcohol in adulthood, these rodents exhibit 
decreased dopamine release despite increased activity in the nucleus accumbens (Liu 
& Crews, 2015) suggesting a state of reward deficiency and further potentiating the 
“wanting” of alcohol (Zandy et al., 2015). This effect is potentially attributable to the 
decreased feedback between the nucleus accumbens and the PFC indicating reduced 
top-down control of the reward pathway (Liu & Crews, 2015). This further suggests 
alcohol has altered the developmental pattern of the reward pathway via synaptic 
remodelling predisposing an individual to increased alcohol “wanting”. 
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In addition, the GABAergic system, the main inhibitory pathway is also altered. For 
example, adolescent alcohol exposure decreases GABAA α4 and the extrasynaptic 
GABAA d receptor mRNA in adulthood (McClintick et al., 2016; Risher et al., 2015; 
Centanni et al., 2014). This decreases basal GABAergic currents however, upon re-
exposure to alcohol, this current is potentiated. This suggest adults under basal 
circumstances exhibit less inhibition, however, upon re-exposure there is an increase 
in inhibition potentially leading to tolerance (Risher et al., 2015; Fleming et al., 2011). 
 
The examples provided above are a select handful. Alcohol affects almost all brain 
regions and neurotransmitter systems. Consequently, the effects of adolescent alcohol 
are likely to be widespread and involve almost all neurotransmitter systems within the 
brain (McClintick et al., 2016). Recent research however, has highlighted the 
importance of the neuroimmune system, specifically the innate pattern recognition 
receptor TLR4, in mediating the molecular actions of alcohol, reward and development.  
 
4.4 TLR4 and neurodevelopment 
Toll-like receptor 4 and the development of the CNS are inextricably linked. This is 
perhaps unsurprising as Toll-like receptors were first identified as a crucial regulators 
of embryogenesis in the fly (Belvin and Anderson, 1996; Nüsslein-Volhard & 
Wieschaus, 1980). Recent research has extended these findings demonstrating TLR4 
is involved in key aspects of neurodevelopment such as axonal growth and neural 
progenitor cell proliferation and development (Barak et al., 2014; Okun et al., 2011). 
Further, genetic knockout of TLR4 can severely alter the phenotype of the central 
nervous system (Okun et al., 2012). For example, TLR4-/- mice contain relatively fewer 
glia and more neurons compared to wildtype mice (Rolls et al., 2007). TLR4’s 
downstream signalling molecules, such as NFκB, are additionally crucial to neuronal 
development. For example, NFκB is involved in synaptic scaling, synaptic positioning 
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and ensures the correct expression of neurotransmitter receptors within neurons 
(Zhang & Hu, 2012).  
 
Given TLR4 is pivotally involved in development, activation of this receptor during 
periods of neurodevelopment can be detrimental. For example, high doses of LPS 
impair spatial learning and increase anxiety behaviour in adulthood an effect 
attributable to neuronal cell death and synaptic loss- particularly in cholinergic and 
serotonergic neurons (Vetreno et al., 2017; 2014). Lower doses of LPS transiently alter 
social and anxiety-like behaviour and lead to long-lasting modifications in 
electrophysiological properties of neurons (Ming et al., 2015a; 2015b) further 
highlighting the detrimental effects of immune activation during adolescence. 
 
4.5 Alcohol-induced TLR4 signalling during adolescence 
Similar to adults, alcohol exposure during adolescence initiates an immune response 
within the CNS. For example, adolescent alcohol exposure activates microglia and 
astrocytes; increases expression of innate immune receptors RAGE and TLR2, 3 and 
4, TLR agonist HMGB1, inflammatory cytokines and reactive oxygen species in the 
brain of rodents (Montesinos et al., 2016; Pascual et al. 2016; Alfonso-Loeches et al., 
2013; Vetreno & Crews, 2012; Pascual et al., 2007). It is unclear however, whether 
alcohol-induced TLR4 activation results in the activation of the MyD88 and TRIF 
pathways – an area requiring future research.  
 
It is important to note, that in general the elevations in immune responses of an 
adolescent are blunted compared to those of adults. For example, alcohol increased 
IL-6 and IκBα in the amygdala, hippocampus and hypothalamus with adults exhibiting 
a more robust response compared to adolescence – an effect which coincided with 
reduced BACs (Doremus-Fitzwater et al., 2015). Further, adolescent mice exhibited 
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blunted alcohol-induced cytokine expression compared to adults in the cortex and 
hippocampus (Doremus-Fitzwater et al., 2015; Kane et al., 2013). This finding mirrors 
the age differences in the neuroimmune response towards LPS. Adult mice exhibit 
greater expression of inflammatory mediators following LPS compared to adolescent 
mice. This effect was attributable to circulating gonadal hormones as gondectomy 
mitigated the ontological differences (Cai et al., 2016). Additional studies suggest 
CREB may additionally contribute to the ontological differences in the neuroimmune 
response. Compared to adults, CREB is upregulated in the adolescent brain 
(Pennypacker et al., 1995). Given that CREB competitively competes for CBP, a co-
factor required for NFκB signalling within the brain (Wen et al., 2010) it is hypothesised 
the NFκB activity would be decreased, dampening a potential immune response 
towards LPS and alcohol. However, the mechanisms underlying the attenuated 
neuroimmune response is an area which requires further research. Regardless, the 
limited inflammatory response is presumably designed to stop the detrimental effects 
of an over-active immune system on neurodevelopment.  
 
4.6 Alcohol-induced TLR4 priming/sensitisation 
Neuroimmune cells can enter a “primed” state following alcohol-induced immune 
activation. It is important to note, “primed” neuroimmune cells appear morphologically 
active however, they do not over produce immune mediators basally (Bilbo, 2009). 
Neuroimmune priming has been observed in the context adolescent alcohol exposure. 
For example, alcohol exposure during adolescence increased the number of amoeboid 
microglia and CD68 expression (a marker of “activated microglia”) in adulthood 
(McClain et al., 2011). Interestingly however, immune receptors such as MHCII, TLR2 
– 4, reactive oxygen-inducing enzymes, NFκB, cytokines and danger signals are 
additionally elevated in the brains of adult rodents that received alcohol during 
adolescence (Cruz et al., 2017; Montesinos et al., 2016; Vetreno & Crews, 2012; 
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McClain et al., 2011). It is presently unclear whether the MyD88 and TRIF pathways 
remain elevated or what cell type is responsible for these elevations following 
adolescent alcohol use. The results therefore suggest rather than remaining in a 
“primed” state, the neuroimmune system is continually sensitised exhibiting basal 
increases in the expression of immune mediators.  
 
The ongoing elevation in TLR4-related mediators is likely to perturb the development 
of neurons. As alluded to in chapter 1.8, TLR4 and its downstream mediators alter the 
functional, epigenetic and structural properties of neurons. These effects are also 
observed in the adult brains of rodents who received alcohol during adolescence 
(Montesinos et al., 2016; 2015). For example, adolescent alcohol exposure reduces 
markers of plasticity (ARC and BDNF), epigenetic processes (HDAC and histone 
proteins) and myelin as well as increases in markers of the TLR4 pathway and 
apoptosis in adulthood (Montesinos et al., 2016; Sakharkar et al., 2016). The reduction 
in plasticity and potentiated neuroimmune responses, reinforces an immature brain 
which is sensitive to the effects of alcohol later in life (Montesinos et al., 2016). In 
addition to the developmental effects, it has been hypothesised that subsequent 
activation of the immune system by the original or a new immunogen, will result in an 
exaggerated inflammatory response. This exaggerated response will act on 
neighbouring cells influencing their function and potentially increasing the hedonic and 
anhedonic aspects of drugs of abuse later in life.  
 
Crucially however, attenuating TLR4 protects against the enduring effects of 
adolescent alcohol exposure. Inhibiting alcohol-induced TLR4 signalling prevents the 
reduction in plasticity and epigenetic processes, decreases markers of inflammation 
and prevents adolescent alcohol-induced potentiation of reward (“wanting” and “liking”) 
and anxiety behaviour later in life (Montesinos et al., 2016; 2015). Collectively, the 
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results suggest that adolescent mice are hypo-sensitive to the immediate effects of an 
alcohol-induced immune response. However, the neuroimmune system, in particular 
the TLR4 pathway, readily undergoes sensitisation exhibiting long-term increases in 
basal expression. Upon re-exposure to alcohol, the response of this pathway will 
potentially be exaggerated. This in turn contributes to molecular and behavioural 
alterations which underlie the enduring consequences of adolescent alcohol exposure 
including reward sensitisation. 
 
4.7 Study 2 aims and hypothesis 
The previous sections aimed to highlight the importance of TLR4 in mediating the 
effects of alcohol, development and reward. These sections further illustrated that 
alcohol-induced activation of TLR4 during adolescence can sensitise this pathway 
which may contribute to developing behavioural deficits associated with adolescent 
alcohol use later in life; specifically, increased reward-seeking behaviour. However, 
definitive evidence demonstrating TLR4’s involvement in this process is lacking. Thus 
far, only one study has sought to determine the role TLR4 in mediating the 
consequences of adolescent alcohol use on reward and anti-reward behaviour later in 
life. Montesinos et al., (2016) demonstrated adolescent alcohol exposure increased 
cocaine-induced conditioned place preference, 48 h alcohol two bottle choice, 
saccharin intake and time spent in the enclosed arms of the elevated plus maze. 
Collectively the results suggest adolescent alcohol exposure potentiated the “liking” 
and “wanting” components of reward and increased “anti-reward” later in life 
(Montesinos et al., 2016). These behaviours coincided with increased inflammatory 
mediators, HDAC expression and acetylation of histones. The behavioural and 
molecular alterations induced by adolescent alcohol exposure were all absent in TLR4-
/- mice. This suggests TLR4 is crucial in mediating alcohol-induced epigenetic 
remodelling and sensitisation which leads to potentiated “wanting”, “liking” and anti-
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reward later in life. However, given TLR regulates neurodevelopmental processes, the 
results above are inherently confounded. For example, TLR4-/- mice contain higher 
levels of neurons and comparatively fewer glia compared to wildtype mice (Okun et 
al., 2012; Rolls et al., 2007). Consequently, the reduced immune response observed 
by Montesinos et al., (2016) may simply be due to a reduction in the number of primary 
immune cell in the CNS. Further, TLR4 is involved in the regulation of neurogenesis, 
neurite/axonal growth and neuronal differentiation and survival suggesting that TLRs 
may influence cognition (Okun et al., 2011). Therefore, the precise role of TLR4 in the 
effects of alcohol, reward sensitisation and adolescence can only be studied using 
conditional knockouts or a pharmacological antagonist. Further, these studies failed to 
differentiate or discuss differences between the MyD88 and TRIF pathway in mediating 
these effects and they used chronic, high doses of alcohol which do not accurately 
follow human drinking behaviour. Therefore, the aims of this study were to determine:  
1. whether a more relevant model of adolescent alcohol exposure; 
a. modifies the “liking” and “wanting” components of alcohol reward and 
alcohol-induced anti-reward later in life; 
b. modifies the expression of TLR4- and reward-related pathways later in 
life; 
i. and whether it preferentially modifies the TRIF or MyD88 pathway;  
2. whether attenuating the TLR4-TRIF either before or after adolescent alcohol 
exposure;  
a. modifies alcohol-induced alterations to the “liking” and “wanting” 
components of reward and anti-reward later in life; and 
b. modifies alcohol-induced alterations to the TLR4- and reward pathway 
later in life. 
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Given that adolescent alcohol exposure modifies the reward pathway and the 
neuroimmune system, we hypothesised that inhibiting the TLR4-signalling pathway 
before or after adolescent alcohol exposure would reduce, but not completely reverse 
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Adolescents frequently engage in risky behaviours such as binge drinking. Binge 
drinking, in turn, perturbs neurodevelopment reinforcing reward seeking behaviour in 
adulthood. Current animal models are limited in their portrayal of this behaviour and in 
their assessment of the neuroimmune systems involvement, specifically the role of 
Toll-like receptor 4 (TLR4). Therefore, the aims of this project were to develop a more 
relevant animal model of adolescent alcohol exposure and to characterise its effects 
on TLR4 signalling and alcohol-related behaviours later life. Balb/c mice received a 
short (P22 – P25) alcohol binge during in early adolescence, and underwent tests to 
investigate anxiety (elevated plus maze), alcohol seeking (conditioned place 
preference) and drinking behaviour (drinking in the dark) in adulthood. Four doses of 
alcohol during adolescence increased alcohol-induced conditioned place preference 
and alcohol intake in adulthood. However, this model did not affect basal elevated plus 
maze performance. Subsequent analysis of nucleus accumbal mRNA, revealed 
increased expression of TLR4-related mRNAs in mice who received alcohol during 
adolescence. To further elucidate the role of TLR4, (+)-Naltrexone, a biased TLR4 
antagonist was administered 30 mins before or after the adolescent binge paradigm. 
When tested in adulthood, (+)-Naltrexone treated mice exhibited reduced alcohol 
intake however, alcohol seeking and anxiety behaviour was unaltered. This study 
highlights that even a small amount of alcohol, when given during a critical 
neurodevelopmental period, can potentiate alcohol-related behaviours and TLR4 
activation later in life. Interestingly, attenuation of TLR4 before or after adolescent 
alcohol exposure reduced alcohol intake but not seeking behaviour in adulthood. 
Keywords: Toll-like receptor 4, TRIF, alcohol, development, neurodevelopment, 
adolescent, GABA  
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5.2 Introduction 
Adolescence is a unique neurodevelopmental period characterized by an increased 
sensitivity towards rewarding stimuli and an attenuated sensitivity to aversive stimuli 
(Spear, 2011). This phenotype causes adolescents to engage in risk-taking behaviors 
such as unprotected sex, reckless driving and binge drinking (Johnston et al., 2015; 
Hingson et al., 2009; 2003). Binge drinking in turn profoundly perturbs 
neurodevelopment causing a retention of adolescent-like phenotypes such as reward-
sensitivity in adulthood (the “locked-in” hypothesis) (Crews et al., 2016; Doremus-
Fitzwater & Spear, 2016). Consequently, individuals that consume alcohol during 
adolescence are more likely to develop problems associated with alcohol use in 
adulthood (see Spear, 2011 for review). This finding is reinforced by the link between 
age of first use and alcohol dependence later in life (DeWit et al., 2000). Crucially, 
these phenomen are readily translatable to rodents (Spear, 2011). Adolescent rodents 
exposed to alcohol exhibit potentiated alcohol-reward behaviors in adulthood as 
inferred by increased conditioned place preference, self-administration and two bottle 
choice drinking (Pandey et al., 2015; Alaux-Cantin et al., 2013; Maldonado et al., 2008; 
Rodd-Henricks et al., 2002). However, the magnitude of this potentiation is variable 
owing to differences in sex, genetic background, age and the model of adolescent 
alcohol exposure (Strong et al., 2010; Walker & Ehlers, 2009; Blizard et al., 2004; 
Siciliano & Smith, 2001). The model of alcohol exposure is a particularly important 
variable. To reach high blood alcohol concentrations (BACs) researchers often use 
methods that bypass the natural route of administration (for example Gass et al., 2014; 
Gilpin et al., 2012). This in turn, influences the molecular and behavioral responses 
towards alcohol (Osterndorff-Kahanek et al., 2015; 2013; Gilpin et al., 2012) and 
consequently, it is unclear how much these models reflect the human condition (Ward 
et al., 2014). 
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Despite different exposure methodologies rodent studies have identified multiple 
mechanisms underlying adolescent alcohol-induced reward sensitivities in adulthood 
with particular emphasis placed upon the molecular and cellular alterations within the 
nucleus accumbens and amygdala (Spear & Swartzwelder, 2014). For example, 
adolescent alcohol exposure reduces the expression of plasticity-related genes 
(BDNF, ARC and CREB), negative regulators of dopaminergic function (dopamine D2 
receptor and GABA receptors) and alters dopaminergic firing and tone in adulthood 
(Sakharkar et al., 2016; Philpot et al., 2009; Pascual et al., 2009; Pietrzykowski et al., 
2008). These alterations enhance an individual’s sensitivity towards dopamine-
inducing experiences such as alcohol use, and reduced the ability to alter learnt 
behavior (Vetreno et al., 2015; Alaux-Cantin et al., 2013; Maldonado-Devincci et al., 
2010). 
 
Recent research has additionally highlighted the importance of the neuroimmune 
system in contributing to the adverse neurodevelopmental consequences of 
adolescent alcohol exposure (Crews et al., 2016; Montesinos et al., 2016). Particular 
emphasis has been placed on Toll-like receptor 4 (TLR4), a pattern recognition 
receptor broadly expressed throughout the central nervous system (Akira & Takeda, 
2004; Bsibsi et al., 2002). Following activation, TLR4 signals via the MyD88 or TRIF 
pathways culminating in the expression of classical pro-inflammatory cytokines and 
type 1 interferon’s respectively (see Akira & Takeda, 2004 for review). Alcohol 
indirectly activates TLR4 recruiting MyD88 and TRIF in vitro (Crews et al., 2013; 
Fernandez-Lizarbe et al., 2009). However, whether both pathways are activated in vivo 
remains to be determined. Alcohol-induced recruitment of these adapters causes a 
signaling cascade resulting in the translocation of immune-related transcription to the 
nucleus. This in turn increases the expression of inflammatory proteins from both 
microglia and astrocytes (Fernandez-Lizarbe et al., 2009; Blanco et al., 2005). 
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Importantly, TLR4-/- mice display reduced levels of cytokines, chemokines and 
inflammatory transcription factors immediately following adolescent alcohol exposure 
and later in adulthood compared to wildtype mice (Montesinos et al., 2016; Pascual et 
al., 2016; Kane et al., 2013). This coincides with reduced synaptic and myelin 
derangements, long-term aberrant synaptic remodelling, decreased histone 
acetylation at BDNF and FosB promoter regions (Montesinos et al., 2016). 
Behaviourally, TLR4-/- mice do not exhibit long-term cognitive impairments 
(Montesinos et al., 2015), display less anxiety-like and drug seeking behaviour in 
adulthood compared to wildtype following adolescent exposure (Montesinos et al., 
2016). While the precise neuroanatomical area underlying the long-term actions of 
adolescent alcohol-induced TLR4 activation remains to be determined, studies using 
morphine (another TLR4 agonist) have identified the nucleus accumbens as a key 
substrate (Schwarz et al., 2013). 
 
TLR4 is additionally pivotal to normal neurodevelopmental processes (see Okun et al., 
2011 for review), therefore, studies using TLR4-/- animals are inherently confounded. 
For example, TLR4-/- mice have higher levels of neurons and relatively fewer glia 
compared to wildtype mice (Rolls et al., 2007). Further, the use of TLR4-/- mice does 
not enable researchers to investigate the relative contribution of the MyD88 or TRIF 
pathways in the behavioral and molecular response to alcohol. Lastly, studies 
investigating the TLR4 often use excessive doses/treatments of alcohol exposure 
which may exaggerate endpoints. Therefore, the aims of this study were to determine 
whether a more relevant model of adolescent alcohol exposure alters reward-related 
behavior and mRNA and the TLR4 pathway later in life and secondly, to determine 
whether pharmacologically attenuating TLR4 prevents any alcohol-induced reward 
alterations later in life. These alterations were assessed using conditioned place 
preference, drinking in the dark and the elevated plus maze with the transcription of a 
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selection of gene targets relating to reward (dopaminergic, opioidergic, GABAergic and 
glutamatergic processes) and plasticity (BDNF and CREB) within the nucleus 




Pregnant female Balb/c mice (10 – 15 days into their gestation cycle) were obtained 
from the University of Adelaide Laboratory Animal Services, Adelaide, SA, Australia. 
Following their arrival to the animal facility, mice were housed in light/dark (12/12h, 
lights on/off at 7am/7pm respectively) and temperature (23 ± 3°C) controlled rooms. 
Food and water was available ad libitum.  
 
After the dams had given birth, their offspring developed undisturbed until postnatal 
(P) day 22 at which point they began the adolescent alcohol exposure paradigm (figure 
1a – b). The young age selected for this study was designed to reflect the age at which 
individuals are particularly sensitive to the effects of alcohol (DeWit et al., 2000). After 
the completion of the paradigm, mice were weaned and separated into single sex 
housing (P25) and were left undisturbed until P51. At beginning of adulthood (P56) 
mice began behavioural testing. Mice undergoing conditioned place preference or 
elevated plus maze remained group housed. Mice undergoing drinking in the dark were 
separated into individual cages.  
 
Adult mice were handled by the experimenter for five days prior to testing. Conditioned 
place preference and elevated plus maze occurred during the light phase of the 
mouse’s light/dark cycle. Drinking in the dark (2 – 4 h access alcohol drinking) began 
2 h into the mouse’s dark cycle. Both male and female mice were used for behavioural 
experiments. Statistical analysis determined sex was not a significant variable for 
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behavioural experiments and consequently, data from both male and female animals 
were pooled together for data analysis.  
 
All animal care and experiments complied with the principles of the Australian Code of 
Practice for the care and use of animals for scientific purposes and was approved by 
the University’s Animal Ethics Committee. 
 
5.3.2 Drugs 
Ethanol (99.5%) (herein referred to as alcohol) was purchased from Chemsupply 
(Gliman, SA, Australia). Alcohol was administered as an oral gavage (10 – 30 per cent 
v/v). The dose of alcohol ranged from 0.5g/kg to 3.5g/kg for adolescent alcohol 
exposure paradigm and 1.5g/kg for conditioned place preference. Saline oral gavages 
were volume-matched. 
 
(+)-Naltrexone, a pharmacological TLR4 antagonist was synthesised and supplied by 
Dr Kenner Rice (Chemical Biology Research Branch, National Institute on Drug Abuse 
and National Institute of Alcohol Abuse and Alcoholism, Bethesda, MD, USA). (+)-
Naltrexone was administered via intraperitoneal injections at a dose of 60mg/kg (dose 
volume 10 ml/kg). Saline intraperitoneal injections werer volume-matched. 
 
5.3.3 Adolescent alcohol exposure 
5.3.3.1 Rationale 
Consuming alcohol during adolescence can impair neurodevelopment, reinforcing an 
underdeveloped, immature brain. In adulthood, these individuals are at risk for 
developing anxiety and alcohol-drinking disorders indicating alcohol specifically alters 
the development of brain regions governing hedonia, reward, motivation and emotion 
(Doremus-Fitzwater & Spear, 2016). This phenomenon is translatable to animal 
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models with adolescent mice and rats exposed to alcohol exhibiting potentiated alcohol 
preference and anxiety later in life (for example, Sakharkar et al., 2016). However, 
generalising the magnitude of effects is difficult owing to differences in experimental 
design. For example, current rodent models by-pass the natural oral route of 
administration (Gass et al., 2014; Gilpin et al., 2012) to produce greater blood alcohol 
concentrations and are prolonged/chronic in nature (Vetreno et al., 2015). 
Consequently, the behavioural and molecular responses attributable to alcohol are 
either exaggerated, minimised or clouded (Ward et al., 2014). To circumvent these 
confounding variables, a shorter model was utilised.  
 
5.3.3.1 Adolescent exposure model 
Mice received an oral gavage of alcohol (0.5, 1.5, 2.5, 3.5g/kg) or saline (volume 
matched) for four consecutive days (P22 – 25). An hour after the last oral gavage, tail 
blood was collected and blood alcohol concentration (BAC) was quantified. Mice were 
then weaned (P25), separated into single sex cages and allowed to mature 
undisturbed until P51(Figure 1a).  
 
For studies assessing the role of TLR4 on the neurodevelopmental outcomes following 
adolescent alcohol exposure, a similar protocol was used.  However, thirty minutes 
pre- or post adolescent alcohol exposure, mice received an intraperitoneal injection of 
(+)-Naltrexone or saline (Figure 1b). The objective of using both a pre- and post-
treatment paradigm was to ascertain the mechanism by which (+)-Naltrexone works 
(pretreatment) and to determine its efficacy once the pathology has commenced (post-
treatment). Mice in this experiment received 2.2 g/kg of alcohol rather than a range of 
doses to minimise the number of rodents used in this study. The dose of alcohol was 
calculated by determining the effective dose 50 (ED50) from conditioned place 
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preference later in life (figure 3a). An hour after the last gavage of alcohol, blood was 
harvested from the tail to quantify BAC. 
 
5.3.4 Adult behavioural tests 
At the beginning of adulthood (P56) mice underwent elevated plus maze, conditioned 
place preference or drinking in the dark (P63).  
 
5.3.4.1 Conditioned place preference 
Conditioned place preference was used to infer alcohol-seeking and -rewarding 




The conditioning apparatus consisted of two conditioning chambers (10.9 (length) x 
9.3 (width) x 35 (height) cm) separated by a neutral chamber (16.6 x 4.8 x 35 cm). The 
neutral chamber contained black walls with grey flooring. The conditioning chambers 
differed in tactile and visual cues. The flooring of the conditioning chambers were either 
black plexiglass perforated holes (5mm apart) or black plexiglass grids (5mm apart). 
The walls of each chamber were white or black. The combination of floor texture and 
wall colour were altered for each cohort to prevent any inherent bias the rodents have 
for a specific texture/colour combination.  
 
During conditioning, a sliding partition restricted access to only one chamber. 
Movement and time spent in each chamber was recorded using Logitech Quickcam 





Pre-test (day 1): Mice were placed into the neutral chamber and allowed to explore all 
three chambers for 30 min.  
 
Conditioning (day 2 – 9): Mice received an oral gavage of alcohol (1.5 g/kg) and placed 
within their conditioning chamber for 30 min on days 1, 3, 5, 7. On days 2, 4, 6 and 8, 
mice received an oral gavage of saline and placed within the unconditioned chamber 
for 30 min. Mice received a total of four conditioning sessions with each drug (alcohol 
or saline). 
 
Test (Day 10): Mice received an oral gavage of saline and were placed into the neutral 
chamber and allowed to explore all three chambers for 30 min.  
 
To infer whether the conditioning was successful, the time spent in the conditioned 
chamber during the post-test was subtracted from the time spent in the conditioned 
chamber during the pre-test. 
 
5.3.4.2 Drinking in the dark 
Binge-like consumption of alcohol was assessed using the drinking in the dark 
procedure (Thiele & Navarro, 2014). At P56 mice were individually housed and 
acclimatised to their new environment for one week prior to experimentation. 2 h into 
the mouse’s dark cycle, the bottle of water was removed and replaced with a bottle of 
20 per cent (v/v) alcohol for 2 h (P63 – 65). After 2 h, the alcohol bottle was removed, 
weighed and replaced with a bottle of water. On the fourth and final day of testing 
(P66), mice received alcohol for 4 h.  
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5.3.4.3 Elevated plus maze 
To infer basal anxiety-like behaviour mice underwent the elevated plus maze (Carola 
et al., 2002). The elevated plus maze consisted of two areas characterised by high 
walls and a relatively dark environment and an open area. 
 
Apparatus 
The maze is made of black PVC and consists of four arms: two open and two closed. 
All arms were 30 cm long and 5 cm wide. The two enclosed arms had walls 25 cm 
high. The maze was elevated 1.2 m off the ground.  
 
Procedure 
Mice were moved into the behavioural testing room 30 minutes prior to testing to 
acclimatise them to a new environment. Mice were subsequently placed into the centre 
of the elevated plus maze with their head facing towards the open arm and allowed to 
explore the apparatus for five minutes. The time spent, number of exits, distance 
travelled and the number of immobile episodes was recorded using a Logitech 
Quickcam Pro 5000s and AnyMaze (Stoelting co., Wooddale, IL, USA). 
 
5.3.5 Blood alcohol concentration assay 
Serum alcohol concentration was measured using a commercial kit (ADH-NAD 
Reagent Multiple Test Vial; Sigma-Aldrich) and performed as per the manufacturer 
instructions. In brief, it estimates alcohol induced reduction of nicotinamide adenine 
dinucleotide (NAD+) to NADH in the presence of alcohol dehydrogenase. The reaction 
is observed by recording the absorbance of 340 nM by the solution. Serum alcohol 
was acquired immediately after behavioural testing or adolescent alcohol exposure. 
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5.3.6 RNA isolation, reverse transcription and quantitative PCR (qPCR) 
The nucleus accumbens region was isolated using micropunches (Kai Medical, Seki 
City, Japan) from whole brains and submerged in RNAlater® ICE (ThermoFisher 
Scientific, Waltham, MA, USA) prior to performing RNA isolation. RNA was isolated 
using Maxwell® 16 LEC simply RNA Tissue Kit (Promega, Madison, WI, USA) as per 
manufacturer instructions. RNA was quantified using spectrophotometric analysis, with 
the quality of RNA verified by the OD260/280 ratio. Isolated RNA (900ng) was reversed 
transcribed into cDNA using iScriptTM cDNA reverse transcription kit (BioRad, 
Hercules, CA, USA) as per manufacturer instructions.  
 
Gene expression was assessed using iTaqTM Universal SYBR® Green Supermix as 
per manufacturer instructions. Real time PCR was performed using the CFX96 
TouchTM Real-Time PCR Detection System (BioRad, Hercules, CA, USA). Mouse 
Bdnf, Ccl2, Cd14, Creb1, Drd1, Drd2, Gabra1, Gabra2, Gapdh, Gria1, Grin1, Hmgb1, 
Ifnb, Il1b, Il10, Md2, Myd88, Ntrk2, Oprm1, Th, Tlr4 and Trif forward and reverse 
primers were synthesised by Integrated DNA Technologies Pty. Ltd. (Baulkham Hills, 
NSW, Australia). For primer sequences refer to supplementary materials. The genes 
assessed were based upon previous studies demonstrating differences in 
dopaminergic, opioidergic, GABAergic and glutamatergic processes following 
adolescent alcohol exposure (Alaux-Cantin et al., 2013; Pascual et al., 2009). 
 
The relative difference in expression level of each of the genes of interest were 
normalised to the CT of GAPDH for both the test and control sample. The DCT of the 
test sample was normalised to the DCT of a control sample (a equal amount of cDNA 
from all the different groups), and then expressed as a ratio (2^-DDCT). 
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5.3.7 Statistical analysis 
Experiment 1: Conditioned place preference (chamber x dose), elevated plus maze 
(arm x dose) and drinking in the dark (day x dose) were analysed using a two-way 
ANOVA with repeated measures and Tukey post hoc (figures 2 – 3).  
Experiment 2: qPCR was analysed using a one-way ANOVA with Bonferonni post hoc 
(figures 4 – 5).  
Experiment 3: qPCR analysed using a two-way ANOVA with Bonferonni post hoc 
(intervention x gavage) (figures 6 – 7). 
Experiment 4: Conditioned place preference (chamber x intervention x gavage x 
order), elevated plus maze (arm x intervention x gavage x order) and drinking in the 
dark (day x intervention x gavage x order) was assessed using a four-way ANOVA with 
Tukey post hoc (figure 8 – 10). 
 
All summary values presented as mean ± standard error of mean (SEM). p-values ≤ 
0.05 were considered statistically significant.  
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Figure 1 Timelines for behavioural experiments. (a) Between postnatal days (P) 22 
and 25 adolescent mice received a gavage of alcohol (0.5 g/kg – 3.5 g/kg) or saline 
daily. On P25, mice were weaned and separated into single sex cages and left to 
develop undisturbed until adulthood. Mice were subsequently tested for anxiety-like, 
alcohol-seeking or alcohol drinking in adulthood using the elevated plus maze (on 
P56), conditioned place preference (P56 – 66) and drinking in the dark (P63 – P66) 
respectively. (b) Adolescent mice received either (+)-Naltrexone or saline 30 minutes 
before or after an oral gavage of saline or alcohol (2.2 g/kg) for four consecutive days 
(P22 – 25). Mice were left to develop undisturbed until adulthood upon which they were 
tested using the elevated plus maze, conditioned place preference or drinking in the 




5.4.1 Experiment 1: Does a short adolescent alcohol exposure model potentiate 
anxiety and alcohol-reward behaviour in adulthood? 
An important consideration when examining the effects of adolescent alcohol exposure 
on later life behaviour is the relative rise in blood alcohol following the initial alcohol 
experience. One hour after the last gavage tail blood was isolated and BAC was 
quantified. The gavage model produced a dose dependent increase in blood alcohol 
ranging from 57 to 431mg/100mL at the lowest (0.5 g/kg) and highest (3.5 g/kg) doses 
respectively (effect of dose, F(3. 32) = 319.8, p < 0.0001). The precise statistical 
information and figures can be viewed in the supplementary material (figure s1).  
 
Basal anxiety-behaviour in adulthood (P56) was assessed using the elevated plus 
maze. A two-way ANOVA determined alcohol exposure during adolescence did not 
influence the time spent, number of exits, distance travelled or immobile episodes in 
the elevated plus maze in adulthood (effect of dose; time, F(4, 36) = 1.1, p = 0.37; exits, 
F(4, 36) = 1.0, p = 0.42; distance, F(4, 36) = 1.18, p = 0.34; and immobile episodes, F(4, 36) 
= 0.57, p = 0.68, respectively) (figure 2a – d). Post hoc analysis did not reveal any 
significant differences between the treatment groups with respect to the dose of 
alcohol. However, there was a significant effect of maze arm (open or closed) with 
respect to time, number of exits, distance travelled and immobile episodes (effect of 
maze arm; time, F(1, 9) = 126.1, p < 0.0001; exits, F(1, 9) = 403.8, p < 0.0001; distance, 
F(1, 9) = 4.952, p = 0.05; and immobile episodes, F(1, 9) = 135.7, p < 0.0001, 
respectively). No interactive effects (effect of dose x maze arm) or post hoc differences 
were present for any of the variables (p > 0.05, see supplementary material for full 
statistical description). These findings suggest that four consecutive doses of alcohol 
during adolescence are insufficient to alter baseline anxiety-like behaviour in adulthood 
using this model in Balb/c mice.  
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To determine whether adolescent alcohol exposure modifies alcohol-reward behaviour 
in adulthood, adult mice underwent conditioned place preference (figure 3a). 
Irrespective of the adolescent treatment, all mice exhibited conditioned place 
preference towards alcohol (effect of conditioning chamber, F(1, 11) = 47.12, p < 0.001) 
(figure 3a). Further, there was an effect of the adolescent alcohol dose on the change 
in time alcohol-conditioned chamber time in adulthood (effect of dose, F(4, 44) = 4.36, p 
= 0.0047). The Tukey post hoc revealed significant differences between vehicle and 
0.5g/kg, 1.5g/kg, 2.5g/kg and 3.5g/kg of alcohol, with the greatest difference observed 
at 2.5g/kg. Interestingly, however was no interactive effect between the dose of alcohol 
and the conditioning chamber suggesting the differences between doses is small 
(interaction, F(4, 44) = 1.69, p = 0.17). These results highlight that a comparatively minor 
dose of alcohol during adolescence is sufficient to potentiate alcohol-seeking 
behaviour in adulthood.  
 
To verify that the adolescent alcohol model potentiates alcohol reward-behaviour in 
adulthood, mice underwent drinking in the dark, a limited access-drinking paradigm 
(figure 3b). One concentration of alcohol (2.2 g/kg) was selected for this experiment 
based from the ED50 of the conditioned place preference results in figure 3a. A two-
way ANOVA determined adolescent alcohol exposure significantly influenced alcohol 
intake in adulthood (effect of adolescent drug, F(1, 9) = 8.18, p = 0.019) (figure 3b). 
There was an additional effect of testing day (effect of day, F(3, 27) = 109.9, p < 0.001 
respectively) with post hoc analysis demonstrating significant differences between 
saline and alcohol groups on day 2 and 4. Collectively, the results indicate that four 
consecutive doses of alcohol during adolescence does not influence baseline anxiety-
like behaviour but increases the alcohol-seeking behaviour and intake in adulthood. 
Importantly, a dose-dependent effect on alcohol seeking was shown.  
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5.4.2 Experiment 2: Does adolescent alcohol exposure “sensitise” molecular 
mediators of reward and the TLR4-signalling pathway in adulthood? 
The increased alcohol seeking behaviour is potentially explained by alterations in 
reward-related genes in adulthood caused by adolescent alcohol exposure. Thus, the 
expression of genes relating to alcohol reward, seeking and synaptic plasticity in the 
nucleus accumbens were examined in adulthood prior to behavioural testing (P56) 
(figure 4). The genes assessed were based upon previous studies demonstrating 
differences in dopaminergic, opioidergic, GABAergic and glutamatergic processes 
following adolescent alcohol exposure (Alaux-Cantin et al., 2013; Pascual et al., 2009). 
A one-way ANOVA determined a significant effect of alcohol dose on the expression 
of Drd1, Th, Oprm1, Gabra1, Gabra2 and Creb1 mRNA in adulthood (effect of dose; 
Drd1, F(4, 10) = 3.74, p = 0.016; Th, F(4, 10) = 3.4, p = 0.041; Oprm1, F(4, 10) = 4.46, p = 
0.0073; Gabra1, F(4, 10) =  4.09, p = 0.011; Gabra2, F(4, 10) = 2.89, p = 0.035; and Creb1, 
F(4, 10) =  3.60, p = 0.014). This effect was not consistent however, as no alcohol-dose 
effect was observed for Drd2, Gria1, Grin1, Bdnf or Ntrk2 mRNA levels (effect of dose; 
Drd2, F(4, 10) = 2.04, p = 0.12; Gria1, F(4, 10) = 2.11, p = 0.10; Grin1, F(4, 10) = 0.52, p = 
0.71; Bdnf, F(4, 10) =  2.34, p = 0.080; and Ntrk2, F(4, 10) = 1.01, p = 0.41). Collectively, 
these data indicate that adolescent alcohol exposure significantly increased the 
expression of receptors previously associated with alcohol seeking behaviour and 
intake (Drd1, Th, Oprm1, Gabra1 and 2 and Creb1), while having no effect on genes 
related to glutamate (Gria1 and Grin1) or plasticity support (Bdnf and Ntrk2). 
 
The role of the neuroimmune system in mediating the long-term consequences of 
adolescent alcohol exposure is of increasing interest (Montesinos et al. 2016). 
Therefore, the expression of the genes pertinent to the TLR4 pathway was assessed 
(figure 5). A one-way ANOVA determined a significant effect of alcohol dose on the 
expression of Tlr4, Md2, Trif, Ccl2, Ifnb and Hmgb1 mRNA (effect of dose; Tlr4, F(4, 10) 
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= 3.42, p = 0.016; Md2, F(4, 10) =  3.25, p = 0.023; Trif, F(4, 10) = 3.90, p = 0.0090; Ccl2, 
F(4, 10) = 3.70, p = 0.012; Ifnb, F(4, 10) =  2.68, p = 0.044; and Hmgb,1 F(4, 10) = 3.63, p = 
0.014). There was no effect of alcohol dose on the expression of Cd14, Myd88, Il1b or 
Il10 mRNA (effect of dose; Cd14, F(4, 10) =  1.72, p = 0.16; Myd88, F(4, 10) = 1.026, p = 
0.40; Il1b, F(4, 10) =  1.50, p = 0.22; and Il10, F(4, 10) = 2.53, p = 0.056). Interestingly, 
adolescent alcohol exposure increased the expression of genes associated with the 
TRIF and not the MyD88 pathway in the nucleus accumbens of adult mice. This 
suggests an inherent bias of the immune system in the brains of these animals induced 
by adolescent alcohol exposure. 
 
5.4.3 Experiment 3: Does (+)-Naltrexone attenuate the long-term increases of the 
TLR4 pathway induced by adolescent-alcohol? 
Given that adolescent alcohol exposure potentiated the expression of Trif and Ifnb 
mRNA within the nucleus accumbens, the question arose as to whether the TLR4-
TRIF pathway was associative or causative in mediating alcohol seeking and intake 
behaviours observed later in life. Therefore, (+)-Naltrexone, a pharmacological biased 
antagonist of the TLR4-TRIF pathway (Wang et al., 2016) was administered either 
before or after exposure to adolescent alcohol exposure and later life behaviour and 
mRNA expression was assessed. The decision to include both pre- and post-treatment 
was to ascertain whether TLR4-TRIF pathways were involved in these behaviours and 
whether the isomer is of any benefit once the pathology has commenced. Importantly, 
(+)-Naltrexone did not influence BAC following adolescent alcohol exposure 
suggesting any alteration in behaviour was unlikely to be attributable to alterations in 
pharmacokinetics (figure s2). 
 
The ability of (+)-Naltrexone to selectively attenuate adolescent alcohol induced TLR4 
gene expression was investigated using qPCR. A two-way ANOVA determined a 
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significant effect of gavage (alcohol or saline) on Tlr4, Ifnb and Hmgb1 mRNA in the 
nucleus accumbens of mice in the pretreatment paradigm (figure 6a) (effect of gavage; 
Tlr4, F(1, 4) = 40.51, p = 0.0007; Ifnb, F(1, 4) = 2.59, p = 0.015; and Hmgb1, F(1, 4) = 8.71, 
p = 0.025). There was an additional effect of intervention (saline vs (+)-Naltrexone) for 
these genes (effect of intervention; Tlr4, F(1, 4) = 10.09, p = 0.019; Ifnb, F(1, 4) = 44.68, 
p = 0.022; and Hmgb1, F(1, 4) = 0.035, p = 0.85). There were interactive effects for Ifnb 
and Hmgb1 but not Tlr4 mRNA (interaction; Tlr4, F(1, 4) = 0.17, p = 0.68; Ifnb, F(1, 4) = 
9.28, p = 0.02; and Hmgb1, F(1, 4) = 0.073, p = 0.79). The expression of Trif was 
unaffected by intervention (F(1, 4) = 0.83, p = 0.39) or gavage (F(1, 4) = 2.25, p = 0.18). 
However, an interactive effect was observed (F(1, 4) = 19.57, p = 0.0045). 
 
A two-way ANOVA determined the expression of Trif and Ifnb was influenced by 
gavage (effect of gavage; Trif, F(1, 3) = 0.45, p = 0.52; and Ifnb, F(1, 3) = 3.04, p = 0.013) 
and intervention (effect of intervention; Trif, F(1, 3) = 17.76, p = 0.0056; and Ifnb, F(1, 3) 
= 12.90, p = 0.011) in the post-treatment paradigm (figure 6b). There was no significant 
interactions between gavage and intervention for these two genes (interaction; Trif, F(1, 
3) = 4.87, p = 0.069; and Ifnb, F(1, 3) = 0.26, p = 0.62). In contrast, to the pretreatment 
paradigm however, Tlr4 mRNA was only significantly modified by intervention (F(1, 3) = 
5.13, p = 0.040) but not gavage (F(1, 3) = 2.4, p = 0.17). There was no interaction 
between the two variables (interaction, F(1, 3) = 4.14, p = 0.08). There was no effect of 
intervention (F(1, 3) = 1.17, p = 0.31), gavage (F(1, 4) = 5.76, p = 0.05) or an interactive 
effect (F(1, 3) = 2.35, p = 0.16) on Hmgb1 expression. All remaining genes did not exhibit 
a significant effect of intervention or gavage with statistical information available in the 
supplementary material (figure s3 – 4). 
 
Interestingly, both pre- and post-treatment paradigms had a signficant effect of the 
intervention (saline vs (+)-Naltrexone) on the expression of Gabra2 mRNA (effect of 
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intervention; pretreatment, F(1, 3) = 17.84, p = 0.05; and post-treatment, F(1, 3) = 15.79, 
p = 0.048) (figure 7a and b). There was no effect of gavage on the expression of 
Gabra2 mRNA in either paradigms (effect of gavage; pretreatment, F(1, 3) = 1.63, p = 
0.33; and post-treatment, F(1, 3) = 1.96, p = 0.30). However, a significant interactive 
effect between gavage and intervention was observed for both cohorts (interaction; 
pretreatment, F(1, 3) = 349.1, p = 0.0029; and post-treatment, F(1, 3) = 24.61, p = 0.038). 
Bonferonni post hoc determined (+)-Naltrexone significantly reduced the expression of 
Gabra2 mRNA compared to saline. The expression of Th was significantly influenced 
by the intervention in the pre- but not post-treatment paradigm (effect of intervention; 
pretreatment, F(1, 3) = 117.1, p = 0.008; and post-treatment, F(1, 3) = 5.01, p =0.15). The 
expression of Th was not influenced by gavage (effect of gavage; pretreatment, F(1, 3) 
= 6.56, p =0.12; post-treatment, F(1, 3) = 3.78, p = 0.19) nor was there an interactive 
effect for the pre- and post-treatment paradigms (interaction; pretreatment, F(1, 3) = 
4.97, p = 0.15; post-treatment, F(1, 3) = 3.54, p = 0.20, respectively). There was no effect 
of intervention for any other reward pathway-related mRNA (figure s2, see 
supplementary material for full list of statistical results).  
 
5.4.4 Experiment 4: Does (+)-Naltrexone attenuate behavioural alterations in 
adulthood induced by adolescent alcohol exposure? 
To verify that (+)-Naltrexone selectively attenuated the enhanced rewarding properties 
of alcohol and did not modify basal behaviour adult mice underwent the elevated plus 
maze (figure 8a and b). There was a significant effect of arm on performance in the 
elevated plus maze (effect of arm, F(1, 144) = 39.71, p < 0.0001), with post hoc analysis 
determining all cohorts of mice spent significantly longer in the closed arm relative to 
the open arm. 
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A 4-way ANOVA determined percent of time spent in each of the arms was not 
influenced by the gavage, intervention or the order in which that intervention was 
received (pre- or post-treatment) (effect of gavage, F(1, 144) = 0.12, p = 0.73; effect of 
intervention, F(1, 144) = 0.12, p = 0.73; and effect of order F(1, 144) = 0.80, p = 0.37, 
respectively) – confirming the previous findings that this model exclusively augments 
reward behaviour. However, the multiple comparisons test determined that mice 
receiving an IP injection of saline followed by a gavage of saline (pretreatment 
paradigm) exhibited an increase in open arm time compared to all other cohorts (figure 
8a). This effect was not observed in the post-treatment paradigm. This finding is 
furthered as an interactive effect between arm and order was found (F(1, 144) = 39.87, p 
< 0.0001). Collectively, this suggests that under specific circumstances, alcohol and 
(+)-Naltrexone may modify performance in the elevated plus maze. A list of all 
interactive effects can be found in the supplementary material.  
 
The remaining markers of elevated plus maze performance (distance travelled, 
number of exits and immobile episodes) all exhibited a similar trend in their main 
effects. There was a significant effect of arm (p < 0.001) but not gavage, intervention 
or the order of the intervention (effect of gavage, intervention and order p >0.05). 
Significant interactions were observed for arm x adolescent exposure x order and arm 
x adolescent exposure x order x intervention (p < 0.05) (a complete list of statistical 
analyses can be found in the supplementary materials).  
 
(+)-Naltrexone’s ability to attenuate the rise in alcohol-reward behaviour in adulthood 
was assessed using conditioned place preference (figure 9a and b). The change in 
conditioning time was significantly modified by conditioning chamber but not gavage, 
intervention or order (effect of conditioning chamber, F(1, 144) = 56.09, p < 0.0001; effect 
of gavage, F(1, 144) = 0.16, p = 0.69; effect of intervention, F(1, 144) = 0.051, p = 0.82; and 
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effect of order F(1, 144) = 0.018, p = 0.89). Thus, while mice overall preferred the alcohol-
conditioned chamber compared to the unconditioned chamber, there was no overall 
effect of alcohol or (+)-Naltrexone on modifying alcohol-induced conditioned place 
preference. Post hoc analysis demonstrated that both control cohorts (Saline IP -> 
Saline IG and (+)-Naltrexone IP -> Saline IG) exhibited a reduced change in alcohol-
conditioned chamber time compared to Saline IP -> Alcohol IG group, supporting 
earlier findings that adolescent alcohol potentiates time spent in the alcohol-
conditioned chamber in adulthood (figure 9a). Similarly, in the post-treatment the 
Saline IG -> Saline IP cohort exhibited a reduced change in chamber time compared 
to alcohol IG -> Saline IP. This suggests despite no main effect of gavage, there was 
still a post hoc effect of adolescent alcohol exposure on later life behaviour. This is 
further supported by the significant interactive conditioning chamber x gavage (F(1, 144) 
= 4.88, p = 0.037). This indicates that adolescent alcohol exposure still potentiated 
alcohol-induced conditioned place preference under specific circumstances. For the 
remaining interactive effects refer to supplementary material. 
 
In contrast to conditioned place preference, drinking in the dark was significantly 
affected by gavage, intervention and testing day but not the order, (effect of gavage, 
F(1, 256) = 4.64, p = 0.032; effect of intervention, F(1, 256) = 82.58, p < 0.0001; effect of 
testing day, F(3, 256) = 8.81, p < 0.0001; and effect of order F(1, 256) = 0.004, p = 0.95) 
(figure 10a and b). Post hoc analysis determined: mice that received alcohol during 
adolescence exhibited potentiated alcohol intake in adulthood compared to mice that 
received saline. Furthermore, mice that received alcohol and (+)-Naltrexone in the pre- 
or post-treatment paradigms exhibited reduced intake compared to mice that received 
alcohol and saline. Interactions of intervention x gavage (F(1, 256) = 38.40, p < 0.0001), 
testing day x intervention x adolescent gavage (F(3, 256) = 2.57, p = 0.054) and order x 




Figure 2 Adolescent alcohol exposure has no effect on performance in the 
elevated plus maze in adult mice. Increasing the dose of alcohol does not influence 
the time (a), distance (b), exits (c) or immobile episodes (d) in each arm during a five-
minute test. All data was analysed using a two-way ANOVA with Tukey post hoc. 
Summary values represented as mean±SEM; n=10; between arms (open vs closed) 





Figure 3 Adolescent alcohol exposure potentiates alcohol-induced reward 
behaviours in adulthood. Adolescent alcohol exposure dose-dependently increases 
the time spent in the alcohol-conditioned chamber relative to saline (a) and alcohol 
intake (b). CS, conditioning stimuli; US, unconditioned stimuli. All data was analysed 
using a two-way ANOVA with Tukey post hoc. Summary values represented as 
mean±SEM; n=10; *p < 0.05; **p < 0.01, *** p < 0.001.  
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Figure 4 Adolescent alcohol exposure dysregulates the expression of genes 
associated with reward/reinforcement within the nucleus accumbens. Alcohol 
during adolescence increased the expression of Drd1, Th, Oprm1, Gabra1, Gabra2 
and Creb1 but did not affect the expression of Drd2, Gria1, Grin1, Bdnf or Ntrk2 mRNA 
in adulthood. All data was analysed using a one-way ANOVA with Bonferonni post hoc. 
Summary values represented as mean±SEM; n=4; *p < 0.05; **p < 0.01, *** p < 0.001. 
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Figure 5 Adolescent alcohol exposure increases the expression of TLR4-related 
genes within the nucleus accumbens. Alcohol during adolescence increased the 
expression of Tlr4, Md2, Trif, Ccl2, Ifnb and Hmgb1 but did not affect the expression 
of Cd14, Myd88, Il1b or Il10 mRNA in adulthood. All data was analysed using a one-
way ANOVA with Bonferonni post hoc. Summary values represented as mean±SEM; 
n=4; *p < 0.05; **p < 0.01, *** p < 0.001. 
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Figure 6 Antagonising TLR4 signalling either before (a) or after (b) adolescent 
alcohol exposure prevents long-term increases of Tlr4 and Ifnb mRNA in the 
nucleus accumbens of adult mice. (+)-Naltrexone selectively reduces alcohol-
induced sensitisation of Tlr4 and Ifnb mRNA in adulthood but does not alter the 
expression of MyD88-related genes. All data was analysed using a two-way ANOVA 
with Bonferonni post hoc. Summary values represented as mean±SEM; n=4, *p < 0.05; 





Figure 7 Antagonising TLR4 signalling either before (a) or after (b) adolescent 
alcohol exposure prevents long-term increases of Th and Gabra2 mRNA in the 
nucleus accumbens of adult mice. (+)-Naltrexone selectively reduces alcohol-
induced sensitisation of Gabra2 mRNA in adulthood but does not alter the expression 
of other reward/reinforcement related genes. All data was analysed using a two-way 
ANOVA with Bonferonni post hoc. Summary values represented as mean±SEM; n=4, 
*p < 0.05; **p < 0.01, *** p < 0.001. 
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Figure 8 Antagonising TLR4 signalling either before (a, c, e, g) or after (b, d, f, h) 
adolescent alcohol exposure has no effect on time spent (a and b), distance 
travelled (c and d), number of exits (e and f) or immobile episodes (g and h) in 
the elevated plus maze in adult mice. Adolescent alcohol and (+)-Naltrexone does 
not influence the time, distance, number of exits or immobile episodes (d) in each arm. 
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All data was analysed using a four-way ANOVA with Tukey post hoc. Summary values 
represented as mean±SEM; n=10, *p < 0.05; **p < 0.01. 
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Figure 9 Antagonising TLR4 signalling either before (a) or after (b) adolescent 
alcohol exposure has no effect on preference for an alcohol-conditioned 
stimulus in adult mice. (+)-Naltrexone does not influence alcohol-induced 
conditioned place preference. All data was analysed using a four-way ANOVA with 







Figure 10 Antagonising TLR4 signalling either before (a) or after (b) adolescent 
alcohol exposure decreases alcohol intake in adult mice. (+)-Naltrexone reduces 
the intake of alcohol irrespective of whether the mice received alcohol or saline during 
their adolescence. All data was analysed using a four-way ANOVA with Tukey post 
hoc. Summary values represented as mean±SEM; n=10. All post hoc differences 
presented in comparison to Saline I.P -> Alcohol I.G (a) and Alcohol I.G -> Saline I.P 
(b).  
* Saline I.P -> Saline I.G; • Naltrexone I.P -> Saline I.G; x Naltrexone I.P -> Alcohol I.G 
(a) ****p < 0.0001;  •p < 0.05; •••p < 0.001; xxp < 0.01; xxxp < 0.001; xxxxp < 0.0001 
•  Saline I.G -> Naltrexone I.P (b) *p < 0.05; **p < 0.01  
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5.5 Discussion 
Adolescence is a vulnerable stage of neurodevelopment, throughout which the brain 
undergoes substantial reorganisation and maturation. Exposure to drugs of abuse, in 
particular alcohol, can perturb normal brain development, reinforcing an immature 
brain state in both rodents and humans (Spear & Swartzwelder, 2014). As adults, these 
individuals are at risk of developing psychiatric disorders such as addiction and anxiety 
disorders (Spear & Swartzwelder, 2014). Results from our study demonstrated four 
oral gavages during early adolescence potentiated alcohol-induced conditioned place 
preference and alcohol drinking when tested in adulthood. However, performance in 
the elevated plus maze was not altered. These behavioural alterations coincided with 
elevations in the expression of genes relating to dopamine, opioid and GABA receptors 
but not other neurotransmitter or neurotropic systems in the nucleus accumbens of 
adult mice. Furthermore, the expression of genes relating to the TLR4 pathway (Tlr4, 
Md2, Trif, Ccl2, Ifnb and Hmgb1) were also increased. Administration of (+)-Naltrexone 
either before or after adolescent alcohol exposure, prevented the increase in Tlr4, Ifnb 
and Gabra2 mRNA and decreased alcohol intake later in life. However, (+)-Naltrexone 
failed to modify adolescent alcohol potentiated conditioned place preference, elevated 
plus maze performance or the increased expression of other neurotransmitter and 
neurotrophic-related genes. Collectively, the results highlight the potential importance 
of the alcohol-TLR4-IFNβ axis in mediating adolescent-induced potentiation of later life 
drinking behaviour but not alcohol-seeking or anxiety behaviour. 
 
Current models examining the effects of adolescent alcohol exposure are often limited 
in the generalisability of their effects as they use clinically irrelevant routes of 
administration (i.e. intraperitoneal, Gilpin et al., 2012); are prolonged in nature (Vetreno 
et al., 2015; Pascual, et al., 2009); or use very high doses of alcohol (Vetreno & Crews 
2012). These limitations are particularly important, as the dose of alcohol and route of 
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administration influences the response to alcohol (for example, Ward et al., 2014; 
Osterndorff-Kahanek et al., 2013). Consequently, an aim of this study was to evaluate 
the effects of a shorter model of adolescent alcohol exposure and characterise its 
behavioural and molecular outcomes. Similar to study’s using more chronic models 
(Montesinos et al., 2016; Alaux-Cantin et al., 2013; Maldonado-Devincci et al., 2010), 
our adolescent alcohol exposure model potentiated conditioned place preference and 
alcohol drinking behaviour later in life. Interestingly, peak conditioned place preference 
was not observed at the highest dose of alcohol - an effect potentially attributable to 
alcohol’s memory impairing effects at higher doses (Land, 2004). However, unlike 
chronic studies (Montesinos et al., 2016) this shorter model did not alter anxiety-like 
behaviour suggesting higher or more chronic doses of alcohol are required to engage 
brain regions governing anxiety (He & Crews, 2008). Alternatively, the lack of 
difference in anxiety behaviour may be related to the mouse strain used in the study. 
Balb/c are an anxiety-sensitive strain of mice (Carola et al., 2002; Griebel et al., 2000; 
Makino et al., 1991) potentially masking an alcohol response. 
 
To ascertain why these rodents exhibited potentiated reward-like behaviour, the 
nucleus accumbens of adolescent alcohol exposed mice was collected in adulthood 
and genes pertaining to reward were assessed. The nucleus accumbens was selected 
owing to its pivotal importance in the generation of reward. Similar to Alaux-Cantin et 
al., (2013) our study demonstrated genes pertaining to GABA and the endogenous 
opioid system were elevated in adulthood following adolescent alcohol exposure. The 
current study additionally demonstrated increases in genes relating to dopamine 
synthesis (Th) and receptors (Drd1). Tyrosine hydroxylase, dopamine and opioid 
receptors are associated with the hedonic and salient motivational properties of alcohol 
(Berridge & Robinson, 2016). Therefore, persistent elevation in these genes is likely to 
increase the sensitivity of these individuals to hedonic and motivational properties of 
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alcohol in adulthood. In contrast to Alaux-Cantin et al., (2013), mRNA from other 
neurotransmitter systems such as glutamate, were not significantly altered by 
adolescent alcohol exposure. Closer analysis demonstrates a unique expression 
pattern, which would not prove statistically significant using conventional data analysis 
that relies on a linear change (ANOVA). For example, the alcohol dose response effect 
on Grin1 expression is bell-shaped, highlighting the importance of examining a broad 
range of doses when examining adolescent alcohol exposure. Lastly, despite this 
shorter exposure model demonstrating increased expression of genes relating to 
reward, and elevated alcohol seeking and drinking later in life, it remains to be 
determined whether this result is ontologically specific or can occur irrespective of 
developmental stage. 
 
This study’s primary focus was to investigate the effects of adolescent alcohol 
exposure on the neuroimmune system. Specifically, the role of the TLR4 pathway was 
examined based on the recent studies implicating this receptor and its signalling 
pathway in alcohol-related behaviours (for example, Blednov et al., 2017; Harris et al., 
2017; Aurelian et al., 2016; Montesinos et al., 2016; Liu et al., 2011; Pascual et al., 
2011). Despite its purported importance in mediating these behaviours, no study has 
examined how alcohol modifies the gene expression of TLR4’s signalling pathways 
during crucial neurodevelopment periods such as adolescence. TLR4 has two main 
signalling pathways (the MyD88 and TRIF pathway) with their activation leading to 
increased production of classical proinflammatory cytokines (IL-1β) and type 1 
interferons, respectively (Akira & Takeda, 2004). Results from our study demonstrate 
adolescent alcohol exposure resulted in the persistent elevation of Tlr4, Md2, Trif, Ccl2, 
Ifnb and Hmgb1 mRNA in adulthood within the nucleus accumbens. Interestingly, 
alcohol exposure did not alter the expression of genes classically associated with the 
MyD88 pathway, suggesting that the long-term neuroimmune effects of alcohol may 
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have a more pronounced effect on the TRIF pathway. However, studies determining 
whether the mRNA increases translate to protein-level differences are required to 
verify these conclusions. 
 
While this study did not address the immediate effects of alcohol exposure during 
adolescence, published literature from in vitro experiments suggests acute alcohol 
activates both the MyD88 and TRIF pathways (Fernandez-Lizarbe et al., 2009). 
However, the degree of immune activation appears to be dampened compared to 
adults (Doremus-Fitzwater et al., 2015; Kane et al., 2013). While the mechanism 
underlying the limited immune response is unknown, it is hypothesised that this 
phenomenon is designed to limit neuroinflammatory responses which can perturb 
neurodevelopment (Ismail & Blaustein, 2013; Ismail et al., 2013). 
 
The rise in immune mediators has both short and long-term consequences. In the 
acute setting, the immune mediators act upon neighbouring neurons altering their 
function and behaviour (for example, Marshall et al., 2016). This in turn is hypothesised 
to potentiate hedonic and anhedonic aspects of drugs of abuse (see Lacagnina et al., 
2016 for review). For example, both TLR4 and CCL2 modify dopaminergic 
neurotransmission in the striatum (Northcutt et al., 2015; Hutchinson et al., 2012; 
Guyon et al., 2009). In addition, activation of TLR4 during adolescence has long-term 
effects on neurodevelopment (see Bilbo & Schwarz 2012, for review). For example 
alcohol-induced TLR4 signalling reduces myelination, synaptic pruning, and increases 
neuronal and astrocyte cell death and alters epigenetic processes which reinforce an 
immature adolescent brain (Montesinos et al., 2016; Montesinos et al., 2015; Pascual 
et al., 2014; Pascual et al., 2009). These events may assist in producing an 
underdeveloped, immature brain that is uniquely sensitive to the hedonic aspects of 
alcohol exposure and is more susceptible to develop addiction with chronic use. 
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In addition to the immediate and neurodevelopmental effects, this study highlighted 
that adolescent alcohol exposure can lead to persistent increases in the TLR4 related 
mRNAs. The study demonstrated mice exposed to alcohol during adolescence 
exhibited an increase in the expression of multiple inflammatory genes in adulthood 
prior to re-exposure. This is in accordance with other studies demonstrating increased 
expression of microglial activation markers ED1 and MHCII (McClain et al., 2011), 
inflammatory cytokines, chemokines and proteins (Pascual et al., 2016) and immune 
receptors (TLR4, TLR3 and RAGE) (Vetreno & Crews, 2012) in adult mice that were 
exposed to alcohol during adolescence. The effects of this persistent elevation in 
immune-related genes are yet to be fully elucidated. However, it has been 
hypothesised that subsequent activation of the immune system by the original or a new 
immunogen, will result in an exaggerated inflammatory response. This exaggerated 
response will act on neighbouring cells influencing their function; potentially increasing 
the hedonic and anhedonic aspects of drugs of abuse. Crucially, TLR4 appears to 
assist in mediating the enduring upregulation of neuroimmune-related genes. 
However, studies examining the role of TLR4 in adolescent alcohol priming often use 
knock out animals and thus the model is confounded given the pivotal role of TLR4 in 
neurodevelopment. For example, TLR4-/- mice display increased neuronal 
differentiation, higher total neuron cell counts and fewer glia compared to wildtype mice 
(Rolls et al., 2007). Given the pivotal role of glial TLR4 in mediating the molecular and 
behavioural adaptations induced by alcohol (Fernandez-Lizarbe et al., 2009), it is 
interesting to speculate whether the reduced inflammatory effects observed in these 
studies (Montesinos et al. 2016; Alfonso-Loeches et al., 2010) is simply due to the 
reduced number of glial cells or whether it is a TLR4 specific event.  
 
The current study is the first to consider the relative contribution of TLR4s signalling 
pathways on the effects of adolescent alcohol exposure. To separate out the potential 
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MyD88 and TRIF-dependent effects, (+)-Naltrexone was used. (+)-Naltrexone is a 
stereoisomer of the clinically approved (-)-Naltrexone used to treat alcohol 
dependence. Both isomers are thought to bind to the LPS-binding pocket of TLR4’s 
co-receptor MD2, however the precise binding site and mechanism remain to be fully 
elucidated (Hutchinson et al., 2010). Unlike the (-)-isomer, the (+)-isomer is devoid of 
mu opioid receptor activity. This compound has been further screened against 70 
neurotransmitter, peptide, growth factor receptors, ion channels, second messengers 
and enzymes without any additional interactive effects (Hutchinson et al., 2010). In 
vitro experiments demonstrate (+)-Naltrexone blocks LPS-induced IRF3 
phosphorylation and the production of nitric oxide, TNFα and IFNβ production in BV2 
cells. It had no effect on the phosphorylation of p65, p38, JNK or ERK1/2 or the 
expression of IL-1β in these cells (Wang et al., 2016). Collectively, these results 
suggest (+)-Naltrexone is a biased TLR4-TRIF antagonist, as it failed to attenuate 
markers classically associated with the TLR4-MyD88 pathway. In vivo studies report 
contradictory findings as (+)-Naltrexone attenuated cocaine-induced IL-1β production 
(Northcutt et al. 2015). Results from our study further reinforce the concept that (+)-
Naltrexone is a biased TLR4-TRIF antagonist as the drug decreased the expression 
of Ifnb but not Il1b or Tnfa mRNA in adult mice who received alcohol as adolescence.  
 
Attenuating the rise in interferon mRNA may assist in reducing reward-like behavior in 
adulthood. Recent research has demonstrated that interferons share structural and 
functional similarities to endorphin, an endogenous opioid (Blalock & Smith, 1981; 
Blalock & Smith, 1980). Critically, interferons can bind to µ opioid receptor causing 
endorphin-like effects (Jiang et al., 2000). Given that activation of the µ opioid receptor 
contributes to generating the hedonic sensations (or “liking” of alcohol), it is 
hypothesized that attenuating the rise in interferons may reduce the potentiated 
hedonic sensation induced by alcohol later in life. While both drinking in the dark and 
 296 
conditioned place preference require opioidergic activity (Kamdar et al., 2007; 
Middaugh & Bandy, 2000), conditioned place preference additionally requires the 
dopaminergic system (Kamdar et al., 2007; Buccafusco, 2009). This may explain why 
a difference was observed for drinking in the dark and not conditioned place 
preference. Alternatively, given alcohol seeking and drinking behaviour engages 
different brain regions, the discrepancy in behavioural outcomes may be due to 
neuroanatomical restrictions in the expression of TLR4 or its required signalling 
components. For example, if TLR4 or related genes are not expressed to high levels 
in brain regions governing conditioned place preference, it is unlikely to have a 
substantial effect in mediating this behaviour. This may assist in explaining why siRNA 
knock down of TLR4 in the CeA but not ventral pallidum attenuates alcohol-binge 
drinking behaviour (Liu et al., 2011). 
 
Interestingly, (+)-Naltrexone attenuated the expression of alcohol-induced Gabra2 and 
Th mRNA. GABA A2 and tyrosine hydroxylase are associated with the molecular and 
behavioral effects of alcohol and are particularly important to the generation of reward 
behavior (Harris et al., 2008). Importantly, previous studies have highlighted a link 
between TLR4 and both GABA A2 and tyrosine hydroxylase potentially providing an 
explanation behind the effects of (+)-Naltrexone on alterations in reward behavior later 
in life (Harris et al., 2017; Aurelian et al., 2016; June et al., 2015; Yan, 2015; Bajo et 
al., 2014; Liu et al., 2011). However, future experiments are required to fully elucidate 
these links. 
 
A limitation of this study is that the cell-type(s) responsible for the persistent rise in 
immune-related genes was not explored. Substantial evidence has established the role 
of neurons in mediating the actions of TLR4 and alcohol in adult rodents (Aurelian et 
al., 2016; June et al., 2015; Liu et al., 2011). However, these cells may lack 
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components of the TLR4 pathway that were elevated following our model of exposure 
(for example, Trif and Ifnb mRNA). For example, it is unclear whether neurons can 
transcribe IFNβ with the differing results likely attributable to the different mechanism 
of IFNβ activation. For example, LPS does not initiate the transcription of Ifnb or 
activate JNK or NFκB in neurons; raising doubts whether these cells can signal through 
the MyD88 or TRIF pathway (Okun et al., 2011). However, other studies have found 
neurons produce IFNβ in response to rabies virus infection (Prehaud et al., 2005). 
Given the conjecture, it is likely, that the primary immunocompotent cells (microglia 
and astrocytes) of the CNS are primarily responsible for mediating this effect as in vitro 
and in vivo experiments have demonstrated that alcohol indirectly activates TLR4 
culminating in the increase expression of inflammatory cytokines and proteins 
(Fernandez-Lizarbe et al., 2009; Blanco et al., 2005). 
 
It is becoming increasingly apparent that the neuroimmune system plays a profound 
role in neurodevelopment, behaviour and the molecular responses towards alcohol 
and other drugs of abuse. This study demonstrated that short exposure to alcohol 
during adolescence perturbs reward-related neurodevelopment increasing the 
preference for alcohol seeking and drinking later in life. In addition, this model 
demonstrated that alcohol exposure during adolescence increased the transcription of 
genes relating to the TLR4 pathway, an effect that persisted during adulthood. 
Attenuation of the TLR4-TRIF pathway, using (+)-Naltrexone, decreased adverse later 
life outcomes such as alcohol drinking (an effect potentially attributable to a TLR4-
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5.8 Supplementary material 
 
Table 1 Nucleotide sequence of primers. 
Gene Forward Primer 5’ – 3’ Reverse Primer 5’ – 3’ 























variant 1, 2, 3, 











Drd2 –  
Dopamine 

























Gene Forward Primer 5’ – 3’ Reverse Primer 5’ – 3’ 






















variant 1, 2, 3 
CCTATGACAAGCGCGGA AGCAGAGCCGTCACATTCTT 
Hmgb1 –  
High mobility 




Ifnb –  
Interferon beta 
1, fibroblast  
TGGGAGATGTCCTCAACTGC CCAGGCGTAGCTGTTGTACT 




Il10 –  
Interleukin 10  
GCTCTTACTGACTGGCATGAG CGCAGCTCTAGGAGCATGTG 




variant 1, 2 
CGCTGCTTTCTCCCATATTGA CCTCAGTCTTATGCAGGGTTCA 




















Gene Forward Primer 5’ – 3’ Reverse Primer 5’ – 3’ 







Th – Tyrosine 
hydroxylase 
CCTTCCGTGTGTTTCAGTGC TCAGCCAACATGGGTACGTG 















5.8.1 Statistics for in-text figures 
 
Figure 8 Antagonising TLR4 signalling either before (a, c, e, g) or after (b, d, f, 
h) adolescent alcohol exposure has no effect on time spent (a and b), distance 
travelled (c and d), number of exits (e and f) or immobile episodes (g and h) in 
the elevated plus maze in adult mice.  All data was analysed using a four-way 
ANOVA with Tukey post hoc. 
 
Time (a – b) 
Arm, F(1, 144) = 39.71, p < 0.0001 
Order, F(1, 144) = 0.799, p = 0.37 
Gavage, F(1, 144) = 0.12, p = 0.73 
Intervention, F(1, 144) = 0.082, p = 0.77  
Interaction (arm x order), F(1, 144) = 39.87, p < 0.0001 
Interaction (arm x drug), F(1, 144) = 3.11, p = 0.080 
Interaction (order x drug), F(1, 144) = 0.12, p = 0.73 
Interaction (arm x intervention), F(1, 144) = 2.28, p = 0.14 
Interaction (order x intervention), F(1, 144) = 0.082, p = 0.77 
Interaction (drug x intervention), F(1, 144) = 0.034, p = 0.85 
Interaction (arm x order x drug), F(1, 144) = 3.10, p = 0.0805 
Interaction (arm x order x intervention), F(1, 144) = 2.24, p = 0.14 
Interaction (arm x drug x intervention), F(1, 144) = 3.73, p = 0.06 
Interaction (order x drug x intervention), F(1, 144) = 0.034, p = 0.85 
Interaction (arm x order x drug x intervention), F(1, 144) = 3.72, p = 0.06 
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Distance travelled (c – d) 
Arm, F(1, 144) = 730.88, p < 0.0001 
Order, F(1, 144) = 0, p = 1 
Gavage, F(1, 144) = 0, p = 1 
Intervention, F(1, 144) = 0, p = 1  
Interaction (arm x order), F(1, 144) = 6.40, p = 0.012 
Interaction (arm x drug), F(1, 144) = 1.18, p = 0.28 
Interaction (order x drug), F(1, 144) = 0, p = 1 
Interaction (arm x intervention), F(1, 144) = 3.60, p = 0.060 
Interaction (order x intervention), F(1, 144) = 0, p = 1 
Interaction (drug x intervention), F(1, 144) = 0, p = 1 
Interaction (arm x order x drug), F(1, 144) = 13.13, p = 0.0004 
Interaction (arm x order x intervention), F(1, 144) = 20.63, p < 0.0001 
Interaction (arm x drug x intervention), F(1, 144) = 24.48, p < 0.0001 
Interaction (order x drug x intervention), F(1, 144) = 0, p = 1 
Interaction (arm x order x drug x intervention), F(1, 144) = 6.16, p = 0.014 
 
Exits (e – f) 
Arm, F(1, 144) = 50.41, p < 0.0001 
Order, F(1, 144) = 0, p = 1 
Gavage, F(1, 144) = 0, p = 1 
Intervention, F(1, 144) = 0, p = 1  
Interaction (arm x order), F(1, 144) = 1.98, p = 0.16 
Interaction (arm x drug), F(1, 144) = 3.71, p = 0.056 
Interaction (order x drug), F(1, 144) = 0, p = 1 
Interaction (arm x intervention), F(1, 144) = 11.79, p = 0.00078 
Interaction (order x intervention), F(1, 144) = 0, p = 1 
Interaction (drug x intervention), F(1, 144) = 0, p = 1 
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Interaction (arm x order x drug), F(1, 144) = 10.26, p = 0.0017 
Interaction (arm x order x intervention), F(1, 144) = 13.17, p = 0.00039 
Interaction (arm x drug x intervention), F(1, 144) = 29.40, p < 0.0001 
Interaction (order x drug x intervention), F(1, 144) = 0, p = 1 
Interaction (arm x order x drug x intervention), F(1, 144) = 4.58, p = 0.034 
 
Immobile episodes (g – h) 
Arm, F(1, 144) = 50.305, p < 0.0001 
Order, F(1, 144) = 0, p = 1 
Gavage, F(1, 144) = 0, p = 1 
Intervention, F(1, 144) = 0, p = 1  
Interaction (arm x order), F(1, 144) = 1.98, p = 0.16 
Interaction (arm x drug), F(1, 144) = 3.71, p = 0.056 
Interaction (order x drug), F(1, 144) = 0, p = 1 
Interaction (arm x intervention), F(1, 144) = 11.79, p < 0.0001 
Interaction (order x intervention), F(1, 144) = 0, p = 1 
Interaction (drug x intervention), F(1, 144) = 0, p = 1 
Interaction (arm x order x drug), F(1, 144) = 10.26, p = 0.0017 
Interaction (arm x order x intervention), F(1, 144) = 13.18, p < 0.0001 
Interaction (arm x drug x intervention), F(1, 144) = 29.40, p < 0.0001 
Interaction (order x drug x intervention), F(1, 144) = 0, p = 1 
Interaction (arm x order x drug x intervention), F(1, 144) = 4.58, p = 0.034 
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Figure 9 Attenuating TLR4 either before (c) or after (d) adolescent alcohol 
exposure has no effect on preference for an alcohol-conditioned stimulus in 
adult mice. All data was analysed using a four-way ANOVA with Tukey post hoc. 
 
Conditioning chamber, F(1, 144) = 56.09, p < 0.0001 
Order, F(1, 144) = 0.018, p = 0.89 
Intervention, F(1, 144) = 0.051, p = 0.82 
Gavage, F(1, 144) = 0.164, p = 0.69 
Interaction (adolescent gavage x intervention), F(1, 144) = 0.012, p = 0.91 
Interaction (adolescent gavage x order), F(1, 144) = 0.011, p = 0.92 
Interaction (intervention x order) , F(1, 144) = 0.038, p = 0.85 
Interaction (adolescent gavage x conditioning chamber), F(1, 144) = 3.63, p = 0.059 
Interaction (intervention x conditioning chamber), F(1, 144) = 0.011, p = 0.92 
Interaction (order x conditioning chamber), F(1, 144) = 3.19, p = 0.076 
Interaction (adolescent gavage x intervention x order), F(1, 144) = 0.026, p = 0.87 
Interaction (adolescent gavage x intervention x conditioning chamber), F(1, 144) = 2.63, 
p = 0.11 
Interaction (adolescent gavage x order x conditioning chamber), F(1, 144) = 0.47, p = 
0.50 
Interaction (intervention x order x conditioning chamber), F(1, 144) = 4.38, p = 0.038 
Interaction (adolescent gavage x intervention x order x conditioning chamber), F(1, 144) 
= 1.48, p = 0.23 
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Figure 10 Attenuating TLR4 either before (a) or after (b) adolescent alcohol 
exposure decreases alcohol intake in adult mice. All data was analysed using a 
four-way ANOVA with Tukey post hoc. 
 
Testing day, F(3, 256 ) = 8.81, p < 0.0001 
Order, F(1, 256 ) = 0.004, p = 0.95 
Intervention, F(1, 256) = 82.58, p < 0.0001 
Gavage, F(1, 256) = 4.64, p = 0.032 
Interaction (testing day x order), F(3, 256) = 0.26, p = 0.85 
Interaction (testing day x intervention), F(3, 256) = 0.036, p = 0.99 
Interaction (order x intervention), F(1, 256) = 0.269, p = 0.60 
Interaction (testing day x adolescent gavage), F(3, 256) = 12.096, p < 0.0001 
Interaction (order x adolescent gavage), F(1, 256) = 1.484, p = 0.2242 
Interaction (intervention x adolescent gavage), F(1, 256) = 38.40, p < 0.0001  
Interaction (testing day x order x intervention), F(3, 256) = 0.81, p = 0.49 
Interaction (testing day x order x adolescent gavage), F(3, 256) = 0.424, p = 0.73 
Interaction (testing day x intervention x adolescent gavage), F(3, 256) = 2.57, p = 0.054 
Interaction (order x intervention x Adolescent gavage), F(1, 256) = 42.14, p < 0.0001 




5.8.2 Supplementary figures  
 
Figure s1 Serum alcohol concentration 1 h following the last gavage of alcohol 
in adolescence. All data was analysed using a one-way ANOVA with Tukey post 





Figure s2 Attenuating TLR4 either before or after adolescent alcohol exposure 
has no effect on serum alcohol concentration. All data was analysed using a two-
way ANOVA with Tukey post hoc. Summary values represented as mean±SEM; n=5, 
*p < 0.05; **p < 0.01, *** p < 0.001. 
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Figure s3 Attenuating TLR4 either before or after adolescent alcohol exposure 
has no effect on the level of expression of genes relating to the TLR4 pathway 
nucleus accumbens of adult mice. All data was analysed using a two-way ANOVA 
with Bonferonni post hoc. Summary values represented as mean±SEM; n=4, *p < 

















































































































































































































































































































































































































































































































































































































































































Figure s4 Attenuating TLR4 either before or after adolescent alcohol exposure 
has no effect on the level of expression of genes relating to alcohol reward and 
plasticity in the nucleus accumbens of adult mice. All data was analysed using a 
two-way ANOVA with Bonferonni post hoc. Summary values represented as 




Figure s5 Attenuating TLR4 either before (a) or after (b) adolescent alcohol 
exposure reduces blood alcohol concentration following drinking in the dark in 
adulthood. All data was analysed using a two-way ANOVA with Tukey post hoc. 



















































































5.8.3 Statistics for supplementary figures  
 
Figure s1 Blood ethanol concentration one hour following the last gavage of 
alcohol in adolescence. All data was analysed using a one-way ANOVA with Tukey 
post hoc. 
 
Dose F(3, 16) = 201.5, p < 0.0001 
Multiple comparisons: all data point significantly different from each other p < 0.0001  
 
Figure s2 Attenuating TLR4 either before or after adolescent alcohol exposure 
has no effect on blood alcohol concentration. All data was analysed using a two-
way ANOVA with Tukey post hoc. 
 
Treatment, F(1, 4) = 0.74, p = 0.44 
Order, F(1, 4) = 0.24, p = 0.65 
Interaction (treatment x order), F(1, 4) = 0.0083, p = 0.93 
 
Figure s3 Attenuating TLR4 either before or after adolescent alcohol exposure 
has no effect on the level of expression of genes relating to the TLR4 pathway 
nucleus accumbens of adult mice. All data was analysed using a two-way ANOVA 
with Bonferonni post hoc. 
 
Pretreatment 
(a) Cd14: gavage (F(1, 3) = 2.07, p = 0.29), intervention (F(1, 3) = 1.48, p = 0.35), 
interaction (F(1, 3) = 1.32, p = 0.37).  
 
(b) Md2: gavage (F(1, 3) = 8.21, p = 0.10), intervention (F(1, 3) = 0.28, p = 0.65), 
interaction (F(1, 3)  = 1.15, p = 0.40).  
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(c) Myd88: gavage (F(1, 3) = 3.43, p = 0.21), intervention (F(1, 3) = 0.72, p = 0.49), 
interaction (F(1, 4) = 2.12, p = 0.28).  
 
(d) Il1b: gavage (F(1, 3) = 7.19, p = 0.12), intervention (F(1, 3) = 4.96, p = 0.16), 
interaction (F(1, 3) = 0.06, p = 0.82).  
 
(e) Il10: gavage (F(1, 3) = 0.009, p = 0.93), intervention (F(1, 3) = 0.13, p = 0.75), 
interaction (F(1, 3) = 46.89, p = 0.021).  
 
(f) Ccl2: gavage (F(1, 3) = 0.22, p = 0.68), intervention (F(1, 3) = 18, p = 0.72), 
interaction (F(1, 3) = 1.3, p = 0.37).  
 
Post-treatment 
(a) Cd14: gavage (F(1, 3) = 0.066, p = 0.80), intervention (F(1, 3) = 0.48, p = 0.51), 
interaction (F(1, 3) = 0.039, p = 0.85).  
 
(b) Md2: gavage (F(1, 3) = 0.20, p = 0.67), intervention (F(1, 3) = 0.48, p = 0.51), 
interaction (F(1, 3)  = 0.75, p = 0.41).  
 
(c) Myd88: gavage (F(1, 3) = 0.12, p = 0.74), intervention (F(1, 3) = 0.95, p = 0.35), 
interaction (F(1, 4) = 5.76, p = 0.043).  
 
(d) Il1b: gavage (F(1, 3) = 2.74, p = 0.15), intervention (F(1, 3) = 0.18, p = 0.68), 
interaction (F(1, 3) = 1.11, p = 0.33).  
 
(e) Il10: gavage (F(1, 3) = 0.51, p = 0.50), intervention (F(1, 3) = 0.047, p = 0.83), 
interaction (F(1, 3) = 0.016, p = 0.90).  
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(f) Ccl2: gavage (F(1, 3) = 0.18, p = 0.68), intervention (F(1, 3) = 0.031, p = 0.87), 
interaction (F(1, 3) = 1.63, p = 0.25).  
 
Figure s4 Attenuating TLR4 either before or after adolescent alcohol exposure 
has no effect on the level of expression of genes relating to alcohol reward and 
plasticity in the nucleus accumbens of adult mice. All data was analysed using a 
two-way ANOVA with Bonferonni post hoc. 
 
Pretreatment  
(a) Drd1: gavage (F(1, 3) = 0.80, p = 0.47), intervention (F(1, 3) = 5.25 p = 0.15), 
interaction (F(1, 3) = 0.0015, p = 0.97).  
 
(b) Drd2: gavage (F(1, 3) = 0.12, p = 0.76), intervention (F(1, 3) = 6.18, p = 0.13), 
interaction (F(1, 3)  = 1.25, p = 0.38).  
 
(c) Gabra1: gavage (F(1, 3) = 28.11 p = 0.034), intervention (F(1, 3) = 4.58, p = 0.17), 
interaction (F(1, 4) = 0.095, p = 0.78).  
 
(d) Oprm1: gavage (F(1, 3) = 24.9, p = 0.038), intervention (F(1, 3) = 0.72, p = 0.49), 
interaction (F(1, 3) = 0.00047, p = 0.99).  
 
(e) Bdnf: gavage (F(1, 3) = 0.43, p = 0.58), intervention (F(1, 3) = 1.58, p = 0.33), 
interaction (F(1, 3) = 0.34, p = 0.62).  
 
(f) Ntrk2: gavage (F(1, 3) = 4.69, p = 0.16), intervention (F(1, 3) = 2.12, p = 0.28), 
interaction (F(1, 3) = 7.28, p = 0.11).  
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(g) Gria1: gavage (F(1, 3) = 31.3, p = 0.031), intervention (F(1, 3) = 0.22, p = 0.69), 
interaction (F(1, 3) = 0.070, p = 0.82).  
 
(h) Grin1: gavage (F(1, 3) = 22.83, p = 0.041), intervention (F(1, 3) = 0.29, p = 0.66), 
interaction (F(1, 3) = 0.03, p = 0.88).  
 
(i) Creb1: gavage (F(1, 3) = 0.27, p = 0.70), intervention (F(1, 3) = 22, p = 0.041), 
interaction (F(1, 3) = 1.2, p = 0.69).  
 
Post-treatment 
(a) Drd1: gavage (F(1, 3) = 0.021, p = 0.69), intervention (F(1, 3) = 2.01, p = 0.29), 
interaction (F(1, 3) = 5.24, p = 0.15).  
 
(a) Drd2: gavage (F(1, 3) = 0.018, p = 0.91), intervention (F(1, 3) = 0.09, p = 0.79), 
interaction (F(1, 3)  = 0.68, p = 0.50).  
 
(b) Gabra1: gavage (F(1, 3) = 0.086 p = 0.80), intervention (F(1, 3) = 7.49, p = 0.11), 
interaction (F(1, 4) = 0.095, p = 0.78).  
 
(c) Oprm1: gavage (F(1, 3) = 0.26, p = 0.66), intervention (F(1, 3) = 7.59, p = 0.11), 
interaction (F(1, 3) = 0.75, p = 0.38).  
 
(d) Bdnf: gavage (F(1, 3) = 0.48, p = 0.55), intervention (F(1, 3) = 4.01, p = 0.18), 
interaction (F(1, 3) = 1.28, p = 0.38).  
 
(e) Ntrk2: gavage (F(1, 3) = 2.53, p = 0.25), intervention (F(1, 3) = 3.53, p = 0.20), 
interaction (F(1, 3) = 2.67, p = 0.24).  
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(f) Gria1: gavage (F(1, 3) = 1.55, p = 0.34), intervention (F(1, 3) = 1.08, p = 0.41), 
interaction (F(1, 3) = 0.67, p = 0.50).  
 
(g) Grin1: gavage (F(1, 3) = 3.46, p = 0.20), intervention (F(1, 3) = 21.48, p = 0.043), 
interaction (F(1, 3) = 1.38, p = 0.36).  
 
(h) Creb1: gavage (F(1, 3) = 0.17, p = 0.72), intervention (F(1, 3) = 8.24, p = 0.10), 
interaction (F(1, 3) = 2.17, p = 0.28).  
 
Figure s5 Attenuating TLR4 either before (a) or after (b) adolescent alcohol 
exposure reduces blood alcohol concentration following drinking in the dark in 
adulthood. All data was analysed using a two-way ANOVA with Tukey post hoc. 
 
(a) Pretreatment 
Intervention, F(1, 4) = 6.94, p = 0.03 
Gavage, F(1, 4) = 7.19, p = 0.029 
Interaction, F(1, 4) = 8.30, p = 0.025 
 
(b) Post treatment 
Intervention, F(1, 4) = 5.1, p = 0.049 
Gavage, F(1, 4) = 24.81, p = 0.0011 








The preceding manuscript highlighted that adolescent alcohol exposure sensitises the 
reward and TLR4 signalling pathways and leads to increases in the “liking” and 
“wanting” component of alcohol reward in adulthood (Table 2). Interestingly, however, 
there was no effect of adolescent alcohol exposure on elevated plus maze 
performance, indicating that this model was insufficient to induce persistent alterations 
to brain regions involved in stress and anxiety (anti-reward). The engagement, or lack 
thereof in differential brain regions may be due to relative resilience of the amygdala 
towards alcohol, requiring multiple alcohol cycles before it is engaged (He & Crews, 
2008). Alternatively, the lack of anxiety differences may be attributable to the 
background strain of mouse used in the study (Balb/c) - which may be masking the 
effects of alcohol (Carola et al., 2002).  
 
An important finding of this study was that a shorter adolescent alcohol exposure 
model could lead to long-lasting increases (sensitised) in the expression of reward- 
and TLR4-related mRNAs. Adolescent alcohol exposure potentiated the expression of 
genes relating to the “wanting” and “liking” component of alcohol reward (for example 
Drd1 and Oprm1) and aspects of the TLR4 signalling pathway in adulthood. 
Interestingly, while both TLR4 pathways (TRIF and MyD88) exhibited increases in 
prototypical end products such as Il1b and Ifnb mRNA following adolescent alcohol 
exposure, only the TRIF pathway exhibited additional increases in the expression of 
upstream signalling products.  
 
Attenuating TLR4-TRIF signalling either before or after exposure to alcohol prevented 
the increase in alcohol “liking” but not “wanting” in adulthood as inferred by the drinking 
in the dark and conditioned place preference respectively. While, there was no 
difference of (+)-Naltrexone on Oprm1 (µ opioid receptor) expression, this drug may 
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influence other mediators of the “liking” component of reward such as endogenous 
cannabinoids, orexins or other opioid receptor systems. Future experiments will 
therefore be required to address this hypothesis. The differing effects of (+)-Naltrexone 
on the “liking” and “wanting” components of reward may additionally be due to the 
differences in neuroanatomical regions and psychological processes responsible for 
each behavioural test. For example, conditioned place preference is dependent on 
numerous cellular processes involving multiple brain regions (amygdala, 
hippocampus, insula, nucleus accumbens, ventral tegmental area) integrating aspects 
of memory and reward (Tzschentke, 2007). By contrast, drinking in the dark is 
dependent on amygdala, nucleus accumbens and ventral tegmental area; and is 
largely dependent on thirst and reward (for example, Cozzoli et al., 2012; Hendrickson 
et al., 2009). Given the neuroanatomical differences and psychological components 
required for both behaviours, it is hypothesised that TLR4 may be expressed more in 
areas associated with drinking in the dark rather than conditioned place preference. 
Consequently, antagonising TLR4-TRIF with (+)-Naltrexone would have a more 
pronounced effect on alcohol-drinking than conditioned place preference.  
 
Key to this study was the use of a post treatment paradigm. Adolescents do not take 
prophylactic medication prior to binge drinking. Consequently, the therapeutic window 
to mitigate the detrimental effects of alcohol-induced TLR4 signalling on 
neurodevelopment occurs after alcohol has activated TLR4. Therefore, a post-
treatment paradigm was implemented into this study. Interesting, results from the 
three- and four-way ANVOAs demonstrated there was no difference in terms of 
administering (+)-Naltrexone as a pre- or post-treatment for drinking in the dark, 
conditioned place preference or elevated plus maze indicating this drug works 
irrespective of whether alcohol has already activated TLR4. However, given this drug 
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was administered only 30 mins after alcohol exposure, conclusions relating to its 
efficacy are somewhat limited.  
  
Collectively, this study highlights the importance of TLR4 in mediating the enduring 
effects of adolescent alcohol exposure. Specifically, TLR4 is pivotal to adolescent 
alcohol potentiated “liking” but not “wanting” components of alcohol reward in 
adulthood. 
 
Table 2 A brief summary of behavioural data (main effects) from chapter 5 
Behaviour Effect of adolescent 
alcohol 
Effect of (+)-Naltrexone 
Liking 




­ place preference ¾ 
Anxiety 
Elevated plus maze ¾ ¾ 
¾, no effect 
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Chapter 6: Long-term alcohol exposure, reward and TLR4 
6.1 Introduction 
Acute alcohol exposure activates TLR4 leading to altered reward-like behaviour in 
mice (chapter 3). The TLR4 pathway can remain in a sensitised state following acute 
alcohol use which subsequently influences the behavioural response to alcohol 
(chapter 5). Upon re-exposure to alcohol, the TLR4 response is amplified as is the 
“liking” and “wanting” components of reward thereby promoting further intake. 
Consequently, sensitisation leads to the resumption of drinking, which over prolonged 
periods causes the transition from impulsive drinking to compulsive drinking – a 
prerequisite for alcohol dependence (1.2.1 and 1.3.4). Repeated cycles of binge 
drinking followed by periods of deprivation results in neuroplastic and epigenetic 
events designed to limit the effects of alcohol on the brain. These processes 
desensitise the reward pathway and recruit stress, anxiety and pain pathways. This in 
turn promotes tolerance in the presence of, and, stress and anhedonia in the absence 
of alcohol (Koob & Le Moal, 2001). This further perpetuates alcohol consumption to 
alleviate these dysphoric sensations.   
 
6.2 Study 3 aims and hypothesis 
Chronic exposure to alcohol activates the TLR4 pathway causing robust increases in 
microglia and astrocyte reactivity and the expression of inflammatory transcription 
factors, cytokines and reactive oxygen-producing enzymes (Alfonso-Loeches et al., 
2010; Blanco et al., 2005; Fernandez-Lizarbe et al., 2009). As outlined in the sections 
1.6 – 1.8, these immune molecules interact with classical reward and anti-reward 
neurotransmitters, alter plasticity and epigenetic processes and cause cell death which 
assists in the development of tolerance, dependence, anxiety and anhedonia (Cui et 
al., 2014). Specifically, research has shown that TLR4-/- mice are protected against 
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alcohol-induced cognitive deficits, memory and motor impairments, and exhibit 
reductions in the “wanting” component of reward following long-term exposure (Harris 
et al., 2017; Pascual et al., 2011). However, genetic knockout studies assessing 
chronic alcohol consumption are potentially confounded given TLR4s role in acute 
alcohol consumption (Harris et al., 2017; Liu et al., 2011; Appendix). The reduced 
intake may limit the neuroplastic alterations to brain regions mediating reward and anti-
reward. Consequently, tolerance, anhedonia and anxiety may not develop in these 
mice. This confounds the interpretations of these studies as TLR4 may not be involved 
in these processes rather it limited the ability of these processes to occur. Further, the 
background strain of rodents used to generate TLR4-/- mice are alcohol preferring 
(C57BL/6J) (Harris et al., 2017; Pascual et al., 2011). Therefore, inherent genetic 
predispositions may be masking the effects of TLR4 during and following long-term 
alcohol use. 
 
 Only one study has briefly considered the relative role of the MyD88 or TRIF pathways 
in mediating the long-term effects of alcohol on reward; and no study has considered 
how the “liking” component of reward is modified following long-term alcohol use or, 
controlled for confounding variables such as thirst and taste. Consequently, the aims 
of this study were to determine: 
1. the expression of reward, anti-reward and TLR4 signalling pathways following 
long-term alcohol exposure in non-alcohol preferring mice; and 
a. determine whether long-term use preferentially modifies the TRIF or 
MyD88 pathways;  
2. how anti-reward and the “liking” and “wanting” components of alcohol reward 
are modified following long-term intake (controlling for thirst and taste) in non-
alcohol preferring mice; and 
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3. whether attenuating the TLR4-TRIF signalling pathway prevents alterations to 
reward and anti-reward behaviours induced by long-term alcohol exposure. 
Given that long-term alcohol exposure results in robust increases in immune mediators 
and TLR4 activity, it was hypothesised that both TLR4 signalling pathways are 
activated following long-term alcohol exposure and contribute to the presentation of 
reward and anti-reward behaviour. 
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Long-term alcohol use results in numerous neuroadaptations to reward, stress and 
immune pathways within the brain. In the presence of alcohol, these adaptions typically 
manifest as tolerance towards alcohol’s rewarding effects and in the absence of 
alcohol cause anhedonia, anxiety and craving. Key to the development and 
appearance of these adaptions and behaviours is Toll-like receptor 4 (TLR4), an innate 
immune pattern recognition receptor. However, studies examining the role of TLR4 are 
conflicting - an effect potentially attributable to the use of global knockouts and the use 
of genetically predisposed alcohol-preferring rodents. Therefore, this study sought to 
characterise whether non-alcohol preferring mice exhibit signs of tolerance, anhedonia 
and anxiety on a behavioural and molecular level following long-term alcohol use and 
whether the antagonising the TLR4-TRIF signalling pathway alleviates adverse effects 
attributable to long-term alcohol use. 
 
This study demonstrated that Balb/c, a non-alcohol preferring mouse strain, exhibit 
increased alcohol and decreased sucrose preference immediately following long-term 
alcohol use. This effect coincided with escalated alcohol and alcohol + quinine, 
reduced sucrose intake and some indications of anxiety-like behaviour during 
withdrawal. The alterations in behaviour following long-term alcohol use were 
potentially explained by differences in reward, stress and TLR4-related genes. 
Collectively suggesting non-alcohol preferring mice exhibit signs of dependence on a 
molecular and behavioural level following long-term alcohol use. Administration of (+)-
Naltrexone, a biased TLR4-TRIF antagonist, failed to modify increases in alcohol, and 
deficits in sucrose intake immediately following long-term alcohol use and during 
withdrawal. Further, this drug failed to attenuate increases in anxiety-like behaviour 
during the withdrawal period. Crucially, (+)-Naltrexone did not alter the expression of 
reward, stress or TLR4-related genes indicating acute administration of this drug 
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following long-term use has limited efficacy. Given that TLR4-/- mice are protected 
against measures of reward and anti-reward during withdrawal it suggests the MyD88 
pathway (alone or in combination with the TRIF pathway) may underlie the effects of 
long-term alcohol use. 
 




Alcohol dependence is a disabling psychiatric disorder characterised by periods of 
compulsive drinking, withdrawal, craving and relapse (Koob & Le Moal, 2001). Pivotal 
to the development and maintenance of these stages are positive and negative 
reinforcement mechanisms imbued by alcohol. The occasional consumption of alcohol 
is largely characterised by positive reinforcement and manifests as hedonia/reward 
(Berridge & Robinson, 2016; Nestler, 2005). By contrast, alcohol dependence is largely 
driven by negative reinforcement manifesting as anhedonia and anxiety (anti-reward); 
however, some degree of positive reinforcement remains (Wise & Koob, 2013).  
 
The transition from positive to negative reinforcement is dependent on numerous 
neuroplastic events and processes. Of particular importance is the desensitisation of 
the reward pathway (ventral tegmental area (VTA) and nucleus accumbens). Under 
non-dependent circumstances, this pathway generates alcohol-induced hedonia 
(euphoria or liking) and confers motivational importance towards the drug (wanting) 
collectively creating the process of reward (Robinson & Robinson, 2013; Nestler, 
2005). On a molecular level, hedonia is mediated by increased concentration of 
endorphins and cannabinoids within the nucleus accumbens following alcohol intake 
(Olive et al., 2001). The motivational/wanting component of reward is mediated by 
increases in accumbal dopamine (Weiss & Porrino, 2006; Weiss et al.,1993). However, 
prolonged exposure to alcohol desensitises the reward pathway reducing the 
extracellular concentration of endorphins and dopamine following alcohol consumption 
(Weiss et al., 1996; Diana et al., 1992; Rossetti et al., 1992; Hutchinson et al., 1988). 
Consequently, the individual becomes tolerant to the effects of alcohol. The liking 
component of reward is reduced and more alcohol is wanted in an attempt to reach 
the same hedonic sensation (Weiss et al., 1993). During periods of withdrawal, the 
concentration of dopamine is further reduced, creating a state of anhedonia (a reduced 
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ability to feel pleasure). Consequently, the individual experiences increased drive to 
consume alcohol (craving) to alleviate this sensation – perpetuating relapse (Berridge 
& Robinson, 2016; Weiss & Porrino, 2006).  
 
In addition, pathways responsible for stress and pain are also activated following long-
term alcohol use. Of particular importance is the amygdala. This region contains high 
levels of stress (corticotrophin releasing hormone and dynorphin) and anti-stress 
(neuropeptide Y) peptides, which under basal conditions are succinctly regulated to 
ensure homeostatic functioning of the individual. However, prolonged alcohol 
consumption dysregulates this system, with elevated and depressed levels of stress 
and anti-stress peptides respectively. This effect is particularly apparent in the absence 
of alcohol and is thought to induce the negative behaviours associated with withdrawal 
such as anxiety, pain and craving (Gilpin et al., 2015; Koob & Le Moal, 2001).  
 
The mechanisms behind reward desensitisation and the engagement of the stress 
pathway have been inferred by studies examining alcohol-preferring rodents (for 
example, Mayfield et al., 2016; McBride and Li, 1998). These rodents are genetically 
predisposed to consuming high levels of, and exhibiting exaggerated response 
towards alcohol. While these studies have served as an important foundation in 
establishing the mechanisms behind alcohol dependence, they are translationally only 
pertinent to humans who are genetically predisposed to developing an alcohol use 
disorder. While this population is hypothesised to encompass 50 per cent of those who 
go on to develop an alcohol use disorder, it highlights that other factors aside from 
genetic biases influence the response to alcohol (Prescott et al., 1999). Thus, to better 
understand and develop more translationally appropriate models, non-alcohol 
preferring rodents should also be used. 
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The importance of neuronal mechanisms in mediating the long-term effects of alcohol 
use cannot be understated. However, increasing evidence supports the involvement 
of the neuroimmune system in mediating many of the effects associated with long-term 
alcohol use (Crews et al., 2017). Particular emphasis has been placed on Toll-like 
receptor 4 (TLR4), an innate immune pattern recognition receptor (Montesinos et al., 
2016a). Alcohol indirectly activates TLR4 culminating in the induction of its two 
signalling pathways: the MyD88 and TRIF pathways (Blanco et al., 2005). The MyD88 
pathway leads to the activation of NFκB and MAPKs that result in the transcription of 
inflammatory cytokines such as IL-1β. By contrast, activation of TRIF culminates in the 
induction of IRF3 and type 1 interferons (Akira & Takeda, 2004). The activation of both 
TLR4 signalling pathways has been exclusively examined in vitro or ex vivo (Lawrimore 
& Crews, 2017; Fernandez-Lizarbe et al., 2009; Blanco et al., 2005). Studies are yet 
to determine whether both pathways are activated in vivo and if they contribute to 
alcohol-related behaviours. 
 
Acute alcohol-induced TLR4 signalling results in a transient increase in immune 
mediators, which in addition to their immunomodulatory role, are hypothesised to act 
in a manner congruent with neurotransmitters (Lacagnina et al., 2016; Jacobsen et al., 
2014). Long-term alcohol use results in higher expression of these mediators which 
further modify the function and behaviour of neurons and glia. For example, alcohol-
induced TLR4 signalling regulates epigenetic processes relating to, (Montesinos et al., 
2016b; Pascual et al., 2011) and the expression of transcription factors (CREB and 
NFκB) and signaling molecules (BDNF) involved in, plasticity (Montesinos et al., 
2016b). These TLR4-induced processes are hypothesised to assist in the 
desensitisation and recruitment of the reward and stress pathways respectively 
thereby contributing to the emergence of alcohol dependence.  
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Furthermore, TLR4 influences the transcription of genes involved in reward and stress 
(Aurelian et al., 2016; June et al., 2015) and can directly influence GABAergic and CRF 
signalling in the central nucleus of the amygdala (Bajo et al., 2014; Ming et al., 2013), 
which sensitise mice to alcohol withdrawal (Breese & Knapp, 2016; Knapp et al., 2011).  
This raises the prospect that blockade of TLR4 during the withdrawal period may 
alleviate symptoms of anxiety and stress. 
 
However, the behavioural effects of TLR4 on tolerance, anhedonia, anxiety and 
craving are only just beginning to be studied. For example, injection of LPS, a TLR4 
agonist, perpetuated alcohol intake (Blednov et al., 2011), and sensitised mice to 
anxiety behaviour during withdrawal (Knapp et al., 2011; Breese et al., 2007). 
Furthermore, attenuating TLR4 protects against alcohol-induced cognitive 
impairments and anxiety following two weeks withdrawal from long-term alcohol use 
(Pla et al., 2016; 2014; Pascual et al., 2011) and reduces or has no effect on the 
resumption of alcohol intake following long-term use (Harris et al., 2017; Bajo et al., 
2016; Pascual et al., 2011). However, studies assessing the impact of TLR4 
predominately examine the protracted withdrawal period (2 weeks after alcohol 
cessation) and do not consider how TLR4 influences the acute withdrawal. Lastly, 
studies using TLR4-/- mice are inherently confounded, as there is evidence to suggest 
TLR4 is involved in the acute consumption of alcohol (Harris et al., 2017; Aurelian et 
al., 2016; June et al., 2015). Therefore, it is unclear whether TLR4-/- mice are protected 
against the effects of withdrawal because TLR4 is involved in anhedonic and stress 
behaviours or because these mice consumed less alcohol and thus these brain regions 
are not as engaged. 
 
Consequently, the aims of this study were to determine whether non-alcohol preferring 
mice (Balb/c) develop symptoms congruent with alcohol dependence (tolerance, 
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anhedonia and anxiety) following long-term alcohol use and to determine whether 
alcohol activates TLR4 signalling pathways in reward and stress-associated brain 
regions (nucleus accumbens and amygdala respectively). Further, this studied aimed 
to determine whether attenuation of the TLR4-TRIF pathway could reduce adverse 




Eight-week-old male Balb/c mice (obtained from the Laboratory Animal Services, 
University of Adelaide) were used for the following experiments. Mice were housed in 
a temperature (23 ± 3°C) and light/dark (12/12 h) controlled room, with food and water 
available ad libitum. Mice were acclimatised to their new environment for seven days 
and were handled for a further five days prior to experimentation. All animal care and 
experiments complied with the principles of the Australian Code of Practice for the care 
and use of animals for scientific purposes and was approved by the University of 
Adelaide’s Animal Ethics Committee. 
 
7.3.2 Drugs 
Ethanol (99.5%) (herein referred to as alcohol) was purchased from Chemsupply 
(Gliman, SA, Australia). Sucrose and quinine were purchased from Sigma Aldrich (St 
Louis, MO, USA).  
 
(+)-Naltrexone, a TLR4 antagonist, was synthesised and kindly supplied by Dr Kenner 
Rice (Chemical Biology Research Branch, National Institute on Drug Abuse and 
National Institute of Alcohol Abuse and Alcoholism, Bethesda, MD, USA). (+)-
Naltrexone was administered via intraperitoneal injections with doses ranging from 1 
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to 75 mg/kg (dose volume 10 ml/kg). Saline intraperitoneal injections were volume-
matched. 
 
7.3.3 Experimental design 
7.3.3.1 Rationale of behavioural tests 
Long-term alcohol exposure modifies many brain regions including those associated 
with reward (VTA and nucleus accumbens) and stress (amygdala and HPA axis). 
Repeated cycles of exposure and deprivation causes neuroadaptations within these 
brain regions resulting in tolerance and sensitisation of reward and stress pathways 
respectively. The behavioural consequence of which typically occur during and post 
alcohol intake. For example, to determine whether the reward pathway has undergone 
tolerance (desensitised), mice were tested immediately following the last drinking 
session before other motivational factors influencing intake become active. By 
contrast, to determine whether the reward and stress pathways are sensitised in the 
absence of alcohol (creating anhedonia and anxiety) mice were tested 48 h after the 
last drinking session (in withdrawal) (figure 1). 
 
7.3.3.2 Experimental procedure 
Following 36 days of intermittent alcohol exposure, mice were tested immediately (T0) 
or were left for 48 h (T48) before testing (figure 1). Mice immediately tested underwent 
the two-bottle choice test to examining hedonic-like behaviour (liking) as inferred by 
alcohol or sucrose intake. Quinine intake and preference was additionally assessed to 
determine whether these mice had altered gustatory or olfactory senses (figure 1a). 
Mice undergoing 48 h of withdrawal were subjected to alcohol, alcohol + quinine, 
quinine or sucrose two-bottle choice, elevated plus maze or open field test (figure 1b). 
All mice received two injections of (+)-Naltrexone (or saline) 48 h and 24 h before 
behavioural testing. This overlapped with the last alcohol drinking session in mice 
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tested immediately (T0). Previous studies demonstrated an effect of light cycle on the 
presentation of reward-like behaviour, to control for this potential variable, all testing 
occurred during the rodents’ dark cycle (ZT12).  
 
7.3.3.3 Long-term alcohol exposure 
Following acclimatisation, mice were individually housed. After a further week of 
acclimatisation, mice were presented with two bottles at the beginning of their dark 
cycle for 24 h. One bottle contained 5 per cent (v/v) alcohol and the other water. After 
24 h, bottles were removed, weighed and replaced by a single bottle of water randomly 
allocated to either side of the cage lids for the next 24 h. Following three drinking 
sessions with 5 per cent alcohol, the concentration was increased to 10 per cent for 
the remainder of the study. This intermittent exposure cycle was repeated for a total of 
36 days. This method of alcohol exposure was used as repeated cycles of alcohol 
intake following periods of deprivation is thought to promote higher levels of intake and 
withdrawal symptoms in mice (Ron & Barak, 2016). 
  
The amount of alcohol consumed was calculated by the difference in bottle weights 
before and after drinking sessions. This enabled the amount of alcohol per bodyweight 
(grams/kilogram) and the preference ratio (alcohol intake obtained ÷ (total eight-hour 
water + alcohol intake)) to be calculated for each mouse and averaged for each 
treatment group. An empty cage with two bottles of either alcohol, alcohol + quinine, 
quinine, sucrose or water was used to determine the rate of evaporation. The rate of 
evaporation was subtracted from the results. 
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7.3.3.4 Behavioural tests 
7.3.3.4.1 Elevated plus maze 
To infer basal anxiety-like and exploratory behaviour, mice underwent the elevated 
plus maze (Walf & Frye, 2007). The elevated plus maze consisted of two areas 
characterised by a relatively dark environment and an open area. 
 
Apparatus 
The maze is made of black PVC and consists of four arms: two open and two closed. 




Mice were acclimatised to the behavioural testing room 30 min prior to experimentation 
after which they were placed into the centre of the elevated plus maze with their head 
facing towards the open arm and they were allowed to explore the apparatus for 10 
min. The time spent, distance travelled and the number of immobile episodes was 
recorded using a Logitech Quickcam Pro 5000s and AnyMaze (Stoelting co., 
Wooddale, IL, USA). Mice underwent a pre- and post-test before long-term alcohol 
exposure and 48 hrs into withdrawal respectively. This was implemented to reduce 
inter-mouse variability – an effect more apparent in shorter behavioural tests. The 
difference between the two tests was used to infer exploratory and anxiety behaviour. 
 
7.3.3.4.2 Open field test  
To reinforce observations made by the elevated plus maze, the open field test was 
performed. This test offers additional measure of anxiety and exploratory behaviour 




The open field test occurs within an opaque square box (40 cm long x 40 cm high x 40 
cm wide).  
 
Procedure 
Mice were acclimatised to the behavioural testing room 30 min prior to experimentation 
after which they were placed into the centre of the field and were allowed to explore 
the apparatus for 10 min. The relatively shorter test time emphasises exploratory 
behaviour, response to novelty and thus anxiety-like behaviour (Gould et al., 2009). 
The time spent in the centre, on the sides of the apparatus, immobile time and distance 
travelled was recorded using a Logitech Quickcam Pro 5000s and AnyMaze (Stoelting 
co., Wooddale, IL, USA). Mice underwent a pre- and post-test before long-term alcohol 
exposure and 48 h into withdrawal respectively. The difference between the two tests 
was used to infer exploratory and anxiety behaviour. 
 
7.3.3.4.3 Two-bottle choice tests 
Alcohol, alcohol + quinine, quinine and sucrose preference test 
Two-bottle choice preference tests were used to infer tolerance to alcohol’s rewarding 
effects, anhedonic-like behaviour, and the desire to consume alcohol again following 
the withdrawal period. 
 
Immediately following the last alcohol exposure or 48 h after the last drinking session, 
mice were presented with two bottles – one containing water, and the other 12 per cent 
(v/v) alcohol, 12 per cent alcohol plus 0.1 mM quinine, 0.1 mM quinine or 1 per cent 
sucrose. The paradigm lasted for 2 and 24 h for mice undergoing the two-bottle choice 
test at T0 and T48, respectively. At the end of the test, bottles were removed, weighed 
and replaced with a single bottle randomised to either side of the cage. 
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Only mice undergoing the sucrose two-bottle choice test underwent a pre- and post-
test to determine whether anhedonia occurred (as inferred by a reduction in intake and 
preference relative to the pretest). 
 
7.3.4 Blood alcohol concentration assay 
Serum alcohol concentration was measured using a commercial kit (ADH-NAD 
Reagent Multiple Test Vial; Sigma-Aldrich) and performed as per the manufacturer 
instructions. In brief, it estimates alcohol induced reduction of nicotinamide adenine 
dinucleotide (NAD+) to NADH in the presence of alcohol dehydrogenase. The reaction 
is observed by recording the absorbance of 340 nM by the solution. Blood was isolated 
from the tail vein following the intermittent exposure paradigm and the 2 and 24 h two-
bottle choice tests.  An additional cohort of mice underwent the intermittent exposure 
paradigm and received the injections of saline or 60mg/kg of (+)-Naltrexone during the 
withdrawal period. 30 mins after the last injection, mice were gavaged with 3g/kg of 
alcohol and tail blood was isolated 20, 40, 60 and 180 min later. This experiment was 
designed to assess whether (+)-Naltrexone modified the pharmacokinetics of alcohol 
following long-term exposure. 
 
7.3.5 RNA isolation, reverse transcription and quantitative PCR (qPCR) 
The nucleus accumbens and the amygdala region were isolated using micropunches 
(Kai Medical, Seki City, Japan) from whole brains and submerged in RNAlater® ICE 
(ThermoFisher Scientific, Waltham, MA, USA) prior to performing RNA isolation. RNA 
was isolated using Maxwell® 16 LEV simply RNA Tissue Kit (Promega, Madison, WI, 
USA) as per manufacturer instructions. RNA was quantified using spectrophotometric 
analysis, with the quality of RNA verified by the OD260/280 ratio. Isolated RNA (900 
ng) was reverse transcribed into cDNA using iScriptTM cDNA reverse transcription kit 
(BioRad, Hercules, CA, USA), as per manufacturer instructions.  
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Gene expression was assessed using iTaqTM Universal SYBR® Green Supermix, as 
per manufacturer instructions. Real time PCR was performed using the CFX96 
TouchTM Real-Time PCR Detection System (BioRad). Mouse Bdnf, Cd14, Creb1, Crh, 
Crhr1, Crhr2, Drd1, Drd2, Gabra1, Gabra2, Gapdh, Gria1, Grin1, hmgb1, ifnb, il1b, 
il10, Md2, Myd88, Npy, Npyr1, Npyr2, Ntrk2, Oprm1, Oprk1, Prkca, Prkce, Ucn, Th, 
Tirap, Tlr2, Tlr4, Tram and Trif forward and reverse primers were synthesised by 
Integrated DNA Technologies Pty. Ltd. (Baulkham Hills, NSW, Australia). For primer 
sequences refer to supplementary materials (Table 1). The genes assessed for this 
study reflect mediators pertinent to plasticity, reward, stress and TLR4 pathways. 
 
The relative difference in expression level of each of the genes of interest were 
normalised to the CT of GAPDH for both the test and control sample. The ΔCT of the 
test sample was normalised to the ΔCT a control sample (equal amount of cDNA 
from all samples), and then expressed as a ratio (2-ΔΔCT). The primer sequence can 
be found in the supplementary materials. 
 
Only mice undergoing 48 h of deprivation of alcohol were used for the following qPCR 
experiments as preliminary experiments noted there were no difference in the 
expression of TLR4 pathway genes between mice immediately tested and those 
undergoing 48 h of withdrawal.  
 
7.3.6 Statistical analysis 
All data was analysed using Graphpad Prism 6.0h (Graphpad Software, Inc. San 
Diago, CA, USA) and R Studio (RStudio Team, 2015. RStudio: Integrated 
Development for R. RStudio, Inc., Boston, MA, USA).  
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Experiment 1: Alcohol, sucrose and quinine drinking behaviour at T0 and T48 was 
analysed using a two-tail t-test (alcohol vs water) (figures 2 – 3). The elevated plus 
maze and open field test was analysed two-way ANOVA (arm x solution) with Tukey 
post hoc (figure 4). 
Experiment 2: qPCR results were analysed using a two-tail t-test (alcohol vs water) 
(figures 5 – 6). 
Experiment 3: Alcohol, sucrose and quinine drinking behaviour at T0 and T48 analysed 
two-way ANOVA (dose x solution) with Tukey post hoc. Elevated plus maze and open 
field test were measured using a three-way ANOVA (arm x solution x dose) (figures 7 
– 9). 
Experiment 4: qPCR results were analysed using a two-way ANOVA (solution x 
treatment) (figures 10 – 11). 
 
All summary values presented as mean ± standard error of mean (SEM). p-values ≤ 






Figure 1 Timeline of behavioural experiments. Following 2 weeks of acclimatisation, 
mice were singly housed and underwent a 36 d intermittent two-bottle choice drinking 
paradigm. Alcohol and water was offered for 24 h followed by 24 h of water only. After 
36 d of alcohol exposure, mice were immediately tested (a, T0) or were withdrawn from 
alcohol for 48 h (b, T48). Mice tested immediately underwent sucrose, alcohol or quinine 
two-bottle choice (T0). Mice tested at T48 underwent sucrose, alcohol, quinine or 
alcohol + quinine two-bottle choice, elevated plus maze, open field test or were culled 
for qPCR.  
 355 
7.4 Results 
7.4.1 Experiment 1: Do non-alcohol preferring mice exhibit signs of tolerance, 
anhedonia and anxiety following long-term alcohol use? 
To determine whether long-term alcohol exposure induces tolerance to rewarding 
stimuli in non-alcohol preferring mice, Balb/c mice underwent the two-bottle choice 
paradigm for 2 h immediately after the last drinking session (figure 2a - b). The two-tail 
t-test determined a significant effect of long-term drinking solution (water vs alcohol) 
on alcohol intake and preference (effect of solution, t = 1.92 df = 10, p = 0.049; and t 
= 2.65 df = 10, p = 0.028, respectively). Mice exposed to alcohol for 36 d had greater 
intake of, and preference for alcohol compared to mice who received water. Similarly, 
there was a significant effect of solution on sucrose intake and preference (effect of 
solution, t = 2.29 df = 10, p = 0.036; and t = 2.74 df = 10, p = 0.017, respectively) with 
mice exposed to alcohol exhibiting decreased intake and preference compared to 
those exposed to water (figure 2c – d). There was no difference in quinine intake or 
preference indicating the exposure to alcohol does not alter the sense of taste in Balb/c 
mice (effect of solution, t = 1.06 df = 10, p = 0.31; and t = 1.84 df = 10, p = 0.09, 
respectively) (figures 2e – f). Collectively, the results indicate mice exposed to alcohol 
long-term may be limited in their ability to generate reward to innately likable solutions, 
but are primed towards alcohol despite the decreased rewarding value.  
 
To determine whether the reward pathway was sensitised following long-term use, 
mice underwent a 24 h two-bottle choice 48 h after the last drinking session. A two tail 
t-test determined a significant effect of solution on alcohol intake and preference (effect 
of solution, t = 6.02 df = 10, p = 0.027; and t = 15.02 df = 10, p = 0.0044, respectively) 
(Figure 3a – b). Mice exposed to alcohol exhibited greater intake and preference 
compared to those which received water. 
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However, the two-bottle choice is limited in its assessment of motivated behaviour, 
consequently alcohol was blended with quinine to create a more aversive substance 
to further infer motivation. Again, there was a significant effect of solution on alcohol + 
quinine intake and preference as inferred by two tail t-tests (effect of solution, t = 2.13 
df = 10, p = 0.05; and t = 2.38 df = 10, p = 0.037, respectively) (figure 3e – f). Similarly, 
mice previously exposed to alcohol exhibited greater intake and preference to water 
controls. Quinine intake and preference was similar between the two groups (effect of 
solution, t = 0.13 df = 10, p = 0.90 and t = 0.47 df = 10, p = 0.65 respectively) (figure 
3g – h). To infer whether anhedonia may be present and propagating alcohol intake, 
sucrose intake and preference was assessed (figure 3c – d). A two-tail t-test 
determined a significant effect of solution on sucrose intake but not preference (effect 
of solution, t = 2.36 df = 10, p = 0.032 and t = 1.92 df = 10, p = 0.080). Mice exposed 
to alcohol long-term exhibited a greater negative change (post-test intake – pretest 
intake) in sucrose intake but not preference compared to water control mice. The 
reduction in sucrose but increase in alcohol reinforce the suggestion that mice exposed 
to alcohol long-term may be anhedonic, an effect which may perpetuate the motivation 
to consume alcohol. 
 
Anxiety was assessed using the elevated plus maze and open field test 48 h following 
the last drinking session (figure 4a – f). Mice spent more time, travelled further, and 
had more immobile episodes in the closed arm or sides of the elevated plus maze and 
open field test respectively (see supplementary materials). However, the effect of 
solution was inconsistent across the variables assessed in each test. For example, a 
two-way ANOVA calculated a significant effect of solution for immobile episodes in the 
elevated plus maze and open field test (effect of solution, F(1, 7) = 5, p = 0.076; and F(1, 
7) = 10.4, p = 0.015, respectively). All other variables in the elevated plus maze and 
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open field test including time and distance had no effect of solution (see supplementary 
materials).   
 
7.4.2 Experiment 2: Does long-term alcohol exposure alter the expression of 
molecular mediators of reward, stress and the TLR4-signalling pathway during 
withdrawal? 
The alcohol-induced differences in sucrose and alcohol intake before and during 
withdrawal are potentially explained by alterations in the expression of reward, stress 
and anxiety-related genes. Consequently, qPCR was used to examine an array of 
genes relating to key mediators of reward and stress in the nucleus accumbens and 
the amygdala respectively (figure 5a – b). A two-tail t-test determined a significant 
effect of solution in the expression on Th, Drd1 and Gabra2 mRNA in the nucleus 
accumbens (effect of solution; Th, t = 10.62 df = 16, p = 0.0004; Drd1, t = 2.36 df = 16, 
p = 0.05; and Gabra2, t = 3.14 df = 16, p = 0.013, respectively) and Crh, Crhr1, Gabra2 
and Npyr1 mRNA in the amygdala (effect of solution; Crh, t = 4.09 df = 16, p = 0.0008; 
Crhr1, t = 3.71 df = 16, p = 0.0019; Gabra2, t = 1.89 df = 16, p = 0.014; and Npyr1, t = 
2.73 df = 16, p = 0.021, respectively). No differences were observed for Crhr2, Urn, 
Npy, Npyr2, Oprm1, Oprk1, Gabra1, Prkca, Prkce, Fos and Creb1 mRNA in the 
amygdala and Drd2, Oprm1, Gabra1, Prkca, Prkce, Fos and Creb1 mRNA in the 
nucleus accumbens (see supplementary materials for results of the statistical 
analysis). 
 
Emerging evidence suggests the TLR4 pathway additionally regulates the effects of 
long-term alcohol use (Harris et al., 2017; Pascual et al., 2011). Therefore, the 
expression of this pathway was also assessed (figure 6a – b). There was a significant 
effect of solution on the expression of Tlr4, Myd88, Hmgb1, Il1b and Tnfa mRNA in the 
nucleus accumbens (effect of solution; Tlr4, t = 2.31 df = 16, p = 0.05; Myd88, t = 4.76 
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df = 16, p = 0.009; Hmgb1, t = 2.80 df = 16, p = 0.045; Il1b, t = 3.59 df = 16, p = 0.023; 
and Tnfa, t = 6.28 df= 16, p = 0.0033, respectively) as determined by a two tail t-test. 
Similarly, Tlr4, Tlr2, Md2, Tram, Irf3, Il1b, Ifnb, Tnfa, and Hmgb1 mRNA in the 
amygdala was significantly altered by solution (effect of solution; Tlr4, t = 2.26 df = 16, 
p = 0.039; Tlr2, t = 2.52 df = 16, p = 0.038; Md2, t = 2.23 df = 16, p = 0.04; Tram, t = 
2.86 df = 16, p = 0.01; Irf3,  t = 2.23 df = 16, p = 0.04; Il1b,  t = 2.32 df = 16, p = 0.034; 
Ifnb, t = 3.17 df = 16, p = 0.0059; Tnfa, t = 2.40 df = 16, p = 0.028; and Hmgb1, t = 2.93 
df = 16, p = 0.009, respectively). No differences were observed in the expression of 
Tlr2, Cd14, Md2, Tirap, Tram, Ifnb or Hmgb1 mRNA in the nucleus accumbens and 
Cd14, Myd88, Tirap and Trif mRNA in the amygdala and (see supplementary material 
for results of the statistical analysis). 
 
7.4.3 Experiment 3: Does (+)-Naltrexone modify tolerance, anhedonia and 
anxiety-behaviour following long-term alcohol use? 
The results above highlight that in addition to alteration in the expression of reward, 
stress and anxiety-related genes, the TLR4 signalling pathway is modified by long-
term alcohol exposure. Consequently, the aim of the second series of experiments was 
to ascertain whether TLR4 and its signalling pathways were associated with or 
causative in the effects generated by long-term alcohol exposure. Specifically, the 
TLR4-TRIF pathway was examined given previous human studies linking the 
expression of its downstream signalling proteins in the severity of alcohol dependence 
(Johnson et al., 2015) and attenuating the TLR4-TRIF pathway successfully reduced 
opioid craving and relapse in rats (Theberge et al., 2013). Therefore, (+)-Naltrexone, 
a biased TLR4-TRIF antagonist, was used for the following experiments.  
 
There was a significant effect of solution (alcohol vs water) for all the following 
experiments except for quinine intake and preference 48 h post long-term exposure 
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(supplementary data). In line with earlier experiments, mice exposed to alcohol 
exhibited increased alcohol and reduced sucrose intake/preference (supplementary 
data). 
 
To determine whether TLR4 influences tolerance, mice were administered with (+)-
Naltrexone twice before undergoing a 2 h two-bottle choice test immediately following 
the last drinking session (figure 7). Overall, a two-way ANOVA determined an effect of 
(+)-Naltrexone’s dose on alcohol intake and preference (effect of dose, F(6, 42) = 2.35, 
p = 0.005; and F(6, 42) = 10.26, p = 0.019, respectively). No interactive effects were 
observed (see supplementary materials) (figure 7a – b). The main effect of dose was 
largely attributable to the water control group as post hoc analysis determined mice 
receiving 60 - 75 mg/kg (+)-Naltrexone demonstrated reduced intake relative to the 
vehicle group for mice in the water but not alcohol group. Serum alcohol concentration 
quantification was attempted. However, all groups were below the threshold of 
detection (limit of quantification 100 – 700 mg/100mL).  
 
There was a significant effect of (+)-Naltrexone dose on sucrose intake and preference 
(effect of dose, F(6, 42) = 9.90, p = 0.021; and F(6, 42) = 10.26, p = 0.019) with an 
interactive effect observed only for intake (F(6, 42) = 5.44, p = 0.0004) (two-way ANOVA, 
figure 7c – d). Again, the difference in intake appears largely attributable to the water 
exposed mice. Post hoc analysis calculated a significant reduction in sucrose intake 
from 45 – 75 mg/kg of (+)-Naltrexone in mice exposed to water but not alcohol. 
Significant reductions in sucrose preference were only observed at 75 mg/kg of (+)-
Naltrexone in water and alcohol-exposed mice. No other post hoc differences were 
observed for mice exposed to alcohol. Quinine intake and preference was not 
significantly influenced by (+)-Naltrexone’s dose (effect of dose, F(6, 42) = 1.05, p = 0.41; 
and F(6, 42) =  2.27,  p = 0.06 respectively) (figure 7e – f). Collectively, the results 
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indicate, (+)-Naltrexone was unable to modify alcohol or sucrose intake and 
preference, suggesting it is unable to alter behaviours associated with alcohol 
tolerance. 
 
Previous work demonstrated (+)-Naltrexone attenuated heroin craving and relapse 
(Theberge et al., 2013). Based on this study, mice received two injections of (+)-
Naltrexone over the 48 h withdrawal period, at the end of which they underwent a 24 
h two-bottle choice using sucrose or alcohol (figure 8). There was no significant effect 
of (+)-Naltrexone’s dose on sucrose or alcohol intake and preference (effect of dose; 
sucrose intake, F(6, 42) = 0.83, p = 0.55; preference F(6, 42) = 0.59, p = 0.73; and alcohol 
intake, F(6, 42) = 0.89, p = 0.51; preference F(1, 7) = 42.86, p = 0.60) (figure 8a – d). No 
interactive effects were observed for any variable (see supplementary materials). A 
separate cohort of mice treated with 60 mg/kg (+)-Naltrexone or vehicle were assessed 
for quinine and alcohol + quinine intake and preference (Figure s4). Only one dose of 
(+)-Naltrexone was selected to reduce the number of mice required for the experiments 
given that no differences were observed in alcohol intake or preference. There was no 
effect of drug (saline vs. (+)-Naltrexone) on these variables (see supplementary 
materials). Further, serum alcohol concentrations were below threshold of detection. 
Collectively, (+)-Naltrexone did not modify behavioural manifestations of relapse or 
anhedonia suggesting acute attenuation of TLR4-TRIF does not modify alcohol-
induced alterations to the reward pathway.  
 
(+)-Naltrexone was additionally screened for its ability to reverse alterations to anxiety-
like behaviour (figure 9). There was a significant effect of arm and test area for all 
variables of the elevated plus maze and the open field test respectively (see 
supplementary materials). Mice spent more time, travelled further, and had immobile 
episodes in the closed arm or side of the elevated plus maze and open field test 
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respectively (see supplementary materials). Again, there was a significant effect of 
solution for immobile episodes for both the elevated plus maze and open field test (see 
supplementary). However, solution did not modify any other variable associated with 
these tests. Furthermore, there was no significant effect of (+)-Naltrexone’s dose for 
any variable of the elevated plus maze or open field test (see supplementary) indicating 
(+)-Naltrexone did not modify the presentation of anxiety-like behaviour. 
 
7.4.4 Experiment 4: Does (+)-Naltrexone modify genes associated with reward, 
anti-reward and TLR4? 
qPCR was used to investigate why (+)-Naltrexone failed to modify behaviour 
associated with reward and anxiety before and during withdrawal. In the nucleus 
accumbens, there was a significant effect of drug (saline vs (+)-Naltrexone) but not 
solution on the expression of Cd14, Tlr4 and Hmgb1 mRNA (effect of drug, F(1, 3) = 
23.58, p = 0.04; F(1, 3) = 492.7, p = 0.02; and F(1, 3) = 28.6, p = 0.03, respectively) as 
determined by two-way ANOVAs. In contrast, only Md2 expression in the amygdala 
exhibited a significant effect of drug (effect of drug, F(1, 3) = 7.07, p = 0.03). The 
remaining genes were not influenced by (+)-Naltrexone or saline (see supplementary 
materials). No TLR4-related gene exhibited both a solution and drug effect in either 
brain region. The remaining TLR4 pathway genes are presented in the supplementary 
material. 
 
However, a two-way ANOVA determined a significant effect of solution and drug on 
the expression of Gabra2 mRNA in the nucleus accumbens and amygdala (NAcc: 
effect of solution, F(1, 3) = 35.54, p = 0.027; effect of drug, F(1, 3) = 24.31, p = 0.039) 
(amygdala: effect of solution, F(1, 8) = 23.13, p = 0.0013; effect of drug, F(1, 8) = 5.87, p 
= 0.047) (figure 11a – b). There was no interactive effect in either brain region (NAcc, 
F(1, 3) = 2.48, p = 0.13; Amygdala, F(1, 8) = 4.48, p = 0.067).  Post hoc analysis 
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determined the (+)-Naltrexone + alcohol significantly reduced the expression of 
Gabra2 mRNA compared to and saline + alcohol in the nucleus accumbens. The 
expression of Th in the nucleus accumbens was significantly altered by solution and 
drug with an interaction observed between the two variables (effect of solution, F(1, 3) = 
25.2, p = 0.038; effect of drug (1, 3) = 24.31, p = 0.038; and interaction, 21.37, p = 0.044). 
Post hoc analysis determined saline + alcohol, (+)-Naltrexone + alcohol and (+)-
Naltrexone + water cohorts exhibited significant reductions in Th expression compared 







Figure 2 Long-term exposure to alcohol affected the intake and preference of 
alcohol (a – b), sucrose (c – d) but not quinine (e – f) before withdrawal in non-
alcohol preferring mice (Balb/c). The intake and preference for alcohol and sucrose 
were significantly increased and decreased immediately following long-term alcohol 
exposure. However, long-term alcohol exposure has no effect on quinine intake and 
preference. All data was analysed using a paired two-tail t-test. Summary values 

































































































































































































Figure 3 Long-term exposure to alcohol affected the intake and preference of 
alcohol (a – b), sucrose (c – d), alcohol + quinine (e – f) but not quinine (g – h) 
during withdrawal in non-alcohol preferring mice (Balb/c). The intake and 
preference for alcohol and sucrose were significantly increased and decreased 
following long-term alcohol exposure respectively. Further, long-term alcohol exposure 
increased alcohol + quinine intake and preference compared to control mice. However, 
long-term alcohol exposure has no effect on quinine intake and preference. All data 
was analysed using a paired two-tail t-test. Summary values represented as 




















































































































































































































































































Figure 4 Long-term exposure to alcohol did not alter time spent (a – b) or 
distance (c – d) but increased immobile episodes (e – f) in the elevated plus maze 
and open field test) in non-alcohol preferring mice (Balb/c). Long-term exposure 
to alcohol did not alter the time spent or distance travelled in the open or closed arms 
of the elevated plus maze, or the sides, middle or centre of the open field test. 
However, alcohol increased the number of immobile episodes in the light and dark 
area of the elevated plus maze and the sides of the open field test. All data was 
analysed using a two-way ANOVA with Tukey post hoc. Summary values represented 




Figure 5 Long-term exposure to alcohol selectively altered the expression of 
reward and stress-related genes in the nucleus accumbens (a) and amygdala (b) 
during withdrawal in non-alcohol preferring mice (Balb/c). The expression of Drd1 
mRNA was increased, and Gabra2 and Th mRNA was decreased in the nucleus 
accumbens following alcohol exposure. Further, the amygdala exhibited increases in 
Crh, Crhr1 and Gabra2 and decreases in Npyr1 mRNA following alcohol exposure. All 
data was analysed using a paired two-tail t-test. Summary values represented as 
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Figure 6 Long-term exposure to alcohol increased the expression of TLR4-
related genes in the nucleus accumbens (a) and amygdala (b) during withdrawal 
in non-alcohol preferring mice (Balb/c). The expression of Tlr4, Myd88, Il1b, Tnfa 
and Hmgb1 mRNA were significantly increased nucleus accumbens following alcohol 
exposure. Similarly, the amygdala exhibited increases in Tlr4, Tlr2, Md2, Tram, Irf3, 
Il1b, Ifnb, Tnfa and Hmgb1 mRNA following alcohol exposure. All data was analysed 


















































































































Figure 7 (+)-Naltrexone did not affect the intake and preference for alcohol (a – 
b), sucrose (c – d) or quinine (e – f) before withdrawal in alcohol-exposed mice. 
While there was a main effect of (+)-Naltrexone’s dose on the intake and preference 
for alcohol and sucrose post hoc analysis determined this affect was apparent in water-
exposed mice only. However, (+)-Naltrexone had no effect on quinine intake and 
preference. All data was analysed using a two-way ANOVA with Tukey post hoc. 
Summary values represented as mean±SEM; n=8; alcohol group #p < 0.05 difference 
compared to the absence of (+)-Naltrexone (x = 0); water group *p < 0.05 difference 
compared to the absence of (+)-Naltrexone (x = 0). 
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Figure 8 (+)-Naltrexone did not affect the intake and preference for alcohol (a – 
b), sucrose (c – d) or quinine (e – f) during withdrawal in alcohol-exposed mice. 
The intake and preference for alcohol and sucrose were not altered by (+)-Naltrexone 
dose. However, post hoc analysis determined significant reductions in alcohol 
preference at 30 – 45m/kg in alcohol-exposed and at 30, 60 and 75mg/kg in water-
exposed mice. All data was analysed using a two-way ANOVA with Tukey post hoc. 
Summary values represented as mean±SEM; n=8; alcohol group #p < 0.05 difference 
compared to the absence of (+)-Naltrexone (x = 0); water group *p < 0.05 difference 
compared to the absence of (+)-Naltrexone (x = 0). 
 































































































































Figure 9 (+)-Naltrexone did not alter the time spent (a – b), distance (c – d) or 
immobility time (e – f) in the arms or area of the elevated plus maze and open 
field test respectively during withdrawal. (+)-Naltrexone did not modify the time 
spent, distance travelled or time immobile in each arm or area of the elevated plus 
maze or open field test at any dose in alcohol or water exposed mice.  All data was 
analysed using a three-way ANOVA with Tukey post hoc. Summary values 




Figure 10 (+)-Naltrexone modified the expression of TLR4, its co-receptors and 
endogenous agonist in the nucleus accumbens (a, c, e, g) and amygdala (b, d, f, 
h) during withdrawal. There was a main effect of drug (saline vs (+)-Naltrexone) on 
the expression of Tlr4, Cd14 and Hmgb1 mRNA in nucleus accumbens but not the 
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amygdala 48 h following the last long-term drinking session. Md2 mRNA in the 
amygdala but not nucleus accumbens was significantly modified by drug. All data was 
analysed using a two-way ANOVA with Bonferonni post hoc. Summary values 
represented as mean±SEM; n=4, *p < 0.05; **p < 0.01. 
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Figure 11 (+)-Naltrexone altered the expression of Gabra2 (a – b) and Th (c) 
mRNA during withdrawal from alcohol. (+)-Naltrexone augmented the alcohol-
induced reduction in Gabra2 mRNA expression in the nucleus accumbens (+)-
Naltrexone additionally decreased Gabra2 mRNA expression in water-exposed mice 
in the amygdala. (+)-Naltrexone reduced the expression of Gabra2 and Th mRNA 
compared to control mice (saline + water). All data was analysed using a two-way 
ANOVA with Bonferonni post hoc. Summary values represented as mean±SEM; n=4, 
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Long-term alcohol use results in numerous neuroadaptations to reward, stress and 
immune pathways within the brain. These adaptions result in tolerance to the 
rewarding effects of alcohol and anhedonia and anxiety in the absence of alcohol. The 
role of the neuroimmune system, specifically TLR4 in mediating these behaviours are 
becoming increasingly appreciated. Therefore, this study sought to determine the 
impact of TLR4 on the manifestation of tolerance, anhedonia and anxiety in Balb/c 
mice. The current study demonstrates that Balb/c, a non-alcohol preferring strain of 
mouse, can exhibit behaviours consistent with symptoms of alcohol dependence 
including tolerance, anhedonia, the motivation to consume alcohol and some aspects 
of anxiety during withdrawal. These effects were inferred by increased alcohol 
preference and immobility time, decreased sucrose preference immediately following 
and 48 h after the last drinking session. These effects coincided with alterations to a 
select number of reward-, stress- and immune-related genes. This study further 
indicated that acute attenuation of the TLR4-TRIF pathway (by administration of (+)-
Naltrexone) had limited efficacy reducing alcohol preference, immobility time and 
sucrose deficits. Given that TLR4-/- mice are protected against tolerance, anhedonia 
and anxiety (Montesinos et al., 2016b; Pascual et al., 2011) it suggests either the 
MyD88 or both TLR4 pathways mediate these behaviours following long-term alcohol 
use.   
 
The published alcohol research literature predominately uses rodents genetically 
predisposed to consume high levels of alcohol and exhibit exaggerated symptoms 
during withdrawal. Using these strains to elucidate and infer the genetic basis of 
dependence is extremely useful (McBride & Li, 1998). However, given the diverse 
nature of alcohol dependence, it is important to consider whether, and how other 
strains of rodents can exhibit features of dependence without necessarily having an 
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inherent genetic bias. This may assist in isolating common pathways causing 
dependence or identify a different a subgroup of individuals with dependence. 
Consequently, the first aim of this study was to characterise the effects of long-term 
alcohol exposure on reward and anxiety behaviours in non-alcohol preferring mice. 
Results presented in this study indicate that following long-term alcohol use, Balb/c 
mice increase alcohol intake. This potentially suggests the formation of tolerance 
towards alcohol; as more alcohol is required to achieve the desired pharmacological 
effects. An alternative interpretation is that Balb/c mice “like” alcohol more and thus will 
consume more when tested. However, the reduced intake of sucrose, an innately 
likable solution supports the former conclusion. Further, these effects were unlikely 
due to altered sense of taste as quinine preference was unchanged. This exposure 
paradigm additionally elicited anhedonic behaviour during withdrawal as inferred by a 
reduction in sucrose intake and escalated alcohol intake when re-tested. Adulterating 
alcohol to make it more aversive using quinine failed to reduce the amount consumed 
indicating that the motivation to consume alcohol is increased regardless of the taste. 
Importantly, these behaviours are consistent with alcohol-preferring mice, indicating 
commonalities between the different strains (Mayfield et al., 2016; McBride & Li, 1998).  
It is likely the increased to desire to consume alcohol observed in this study, stemmed 
from alterations to reward-related genes with a decreased and increased expression 
of tyrosine hydroxylase and dopamine D1 receptors respectively. This suggests, 
dopamine production is reduced despite the system being in a dopamine sensitive 
state. Further, the downregulation of Gabra2 mRNA suggest the system lacks 
inhibitory control conferred by GABA, increasing the likelihood of engaging in impulsive 
behaviours. There were no alterations to the µ opioid receptor gene, Oprm1, 
suggesting the induction of tolerance may not be reflected by the genes examined or 
alterations may be occurring at the translation or post-translation stage. Lastly, there 
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were no alterations to genes regulating plasticity indicating that unlike alcohol-
preferring mice, Balb/c mice are potentially more resilient to the effects of alcohol. 
 
By contrast, there was little effect of alcohol on anxiety-like behaviour as inferred by 
performance in the elevated plus maze and open field test despite an up regulation of 
genes associated with stress (CRF) and down-regulation of genes associated anti-
stress (NPY). Again, the behavioural and molecular responses towards alcohol were 
limited compared to alcohol-preferring mice. However, it is unclear whether the lack of 
effects observed with Balb/c mice is because they are resilient to the effects of alcohol 
or because they (likely) consumed less alcohol than alcohol preferring mice thus 
reducing the potential neuroadaptations occurring in response to long-term alcohol 
intake. Further, the lack of effect of alcohol may be attributable to the genetic 
background of Balb/c mice which renders them particularly “sensitive” to anxiety 
(Carola et al., 2002). Despite anxiety being a crucial personality trait associated with 
developing dependence (Smith & Randall, 2012), it suggests that non-alcohol 
preferring mice can exhibit some signs of dependence with the greatest effects 
observed in reward-related behaviours. 
 
Given the emerging role of the neuroimmune system in mediating reward and anxiety 
following long-term alcohol use, the expression of TLR4 was examined (Pascual et al., 
2011). TLR4 was selected as it is a unique immune receptor capable of integrating 
signals from stress hormones and danger signals to generate immune responses, both 
of which are present during and following long-term alcohol use (Gárate et al., 2013; 
Yu et al., 2006). Further, TLR4 regulates: alcohol-induced cell death which propagates 
neuroinflammation; the expression of stress hormones which sensitise withdrawal 
behaviours; and epigenetic events which may contribute to the enduring behavioural 
deficits such as anxiety and reward following chronic alcohol exposure (Montesinos et 
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al., 2016b; Alfonso-Loeches et al., 2012; 2010; Pascual et al., 2011). These processes 
interact with reward and anti-reward behaviours. For example, epigenetic process may 
contribute to the persistent upregulation of cytokines and chemokines in the absence 
of an overt TLR4 signal. These cytokines regulate the stress response system which 
in turn, sensitise mice to alcohol withdrawal and anxiety-like behaviour (Breese et al., 
2007). Given TLR4s importance to many of the processes following long-term alcohol 
use, it was hypothesised that acutely blocking TLR4 may reduce symptoms of 
withdrawal, such as anhedonia and anxiety. However, it is unclear whether this is 
driven by MyD88 or TRIF pathways. 
 
Results from this study suggest long-term alcohol use increased the mRNA pertaining 
to aspects of the MyD88 and TRIF signalling pathways (Il1b,Tnfa and Ifnb) a finding 
largely in accordance with studies examining alcohol-preferring mice (Pascual et al., 
2016; 2015). Interestingly, unlike genes relating to reward and stress which exhibited 
limited alterations following alcohol exposure, almost all aspects of the TLR4 pathway 
were upregulated in the amygdala including co-receptors, signalling proteins and 
cytokines. The difference in TLR4 response between the amygdala and the nucleus 
accumbens is potentially attributable to the number of glial cells, the primary 
immunocompetent cell within the CNS, innervating each area (Grabert et al., 2016; 
Doorn et al., 2015). These findings contrast studies by other researchers (He & Crews, 
2008; Whitman et al., 2013) who demonstrate that the amygdala is relatively resilient 
towards the immunological effects of alcohol. Differences in the long-term drinking 
paradigm, the time tissue was collected post exposure and rodent species used may 
underscore the differing results.  
 
The TLR4-TRIF pathway was examined as aspects of this pathway are associated 
with dependence in humans and attenuation of this pathway blocked heroin (a TLR4 
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agonist) craving and relapse (Johnson et al., 2015; Theberge et al., 2013). (+)-
Naltrexone, a biased TLR4-TRIF antagonist (Wang et al., 2016), was used to 
investigate the effects of this pathway on alcohol-induced behaviours. (+)-Naltrexone 
failed to alleviate the behavioural manifestations of tolerance, anhedonia and craving 
for alcohol as inferred by the two-bottle choice test results. Specifically, (+)-Naltrexone 
did not alter alcohol intake and preference before and during withdrawal suggesting it 
cannot modify tolerance or wanting of alcohol in mice exposed to alcohol. This finding 
parallels that of Harris et al., (2017) who demonstrated (+)-Naloxone, a chemically 
similar compound, did not alter alcohol intake following prior alcohol exposure. 
Furthermore, (+)-Naltrexone increased the sucrose deficit indicating a worsened 
symptom of anhedonia. This effect is consistent with previous findings demonstrating 
siRNA knock down of TLR4 reduces the expression of tyrosine hydroxylase – a key 
enzyme underlying dopaminergic transmission (Aurelian et al., 2016). 
 
Furthermore, (+)-Naltrexone failed to modify the performance in the elevated plus 
maze or open field test indicating it was unable to modify anxiety-like behaviour during 
withdrawal. This finding contrasts previous studies suggesting TLR4-/- mice are 
protected against withdrawal induced cytokine increases and anxiety behaviour 
following long-term alcohol exposure (Montesinos et al., 2016b; Pascual et al., 2011). 
Given TLR4-/- mice are protected it suggests that both the MyD88 and TRIF signalling 
pathways are required for molecular and behavioural alterations following long-term 
alcohol use. 
 
To determine why (+)-Naltrexone had limited efficacy on reward- and anxiety-like 
behaviour, genes relating to the TLR4, reward and stress pathways were assessed. 
(+)-Naltrexone reduced alcohol-induced alterations to Gabra2 mRNA in the nucleus 
accumbens and the amygdala. No other gene reported a significant effect of both 
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alcohol and (+)-Naltrexone. While GABA receptors are associated with alcohol 
dependence (Edenberg et al., 2004; Soyka et al., 2008), it is unclear whether the 
reduction in Gabra2 mRNA would be beneficial following long-term alcohol use as this 
period is typically characterised by a lack of inhibitory control.  
 
The limited efficacy of (+)-Naltrexone is unlikely attributable to an altered metabolism 
of alcohol, as blood alcohol concentrations were similar between saline and (+)-
Naltrexone-treated mice following a bolus dose of alcohol. However, the 
pharmacokinetics of (+)-Naltrexone may underscore its limited efficacy. In mice, (+)-
Naltrexone has a short half-life and is metabolised to Naltrexone-glucuronide, a 
potential agonist at TLR4 given its glucuronide moiety (Lewis et al., 2013). Therefore, 
it is unclear whether (+)-Naltrexone could attenuate a TLR4 signal following long-term 
use of alcohol, which is characterised by high levels of circulating cytokines and 
endogenous danger signals. In addition, long-term alcohol use engages multiple 
immune pathways (Crews et al., 2017). For example, HMGB1 signals via TLR2, 4 and 
5 leading to activation of many immune pathways and processes (Das et al., 2016; Yu 
et al., 2006). Therefore, targeting one component of the innate immune system is 
unlikely to attenuate the global neuroimmune response. Future experiments should 
increase the duration and frequency of (+)-Naltrexone and use broad glial targeted 
anti-inflammatory agents to determine whether the immune system is of functional 
importance in the presentation of anxiety, anhedonia and tolerance following long-term 
alcohol exposure. 
 
The results suggest that non-alcohol preferring mice can exhibit signs of dependence 
including tolerance towards alcohol; increased motivation to consume alcohol during 
withdrawal; anhedonia; and some but not all aspects of anxiety-like behaviour. This 
effect is potentially attributable to the altered expression of genes relating to reward, 
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stress and TLR4 pathways. However, attenuating the TLR4-TRIF pathway via (+)-
Naltrexone did not modify any aspect of reward or anxiety before and during 
withdrawal. Further, there was no alteration at a gene level suggesting acute blockade 
of TLR4 during withdrawal may have limited efficacy. Since TLR4-/- mice are protected 
against the effects of acute and prolonged withdrawal it raises the possibility MyD88 
or both TLR4 pathways are required for reward and anxiety behaviours following long-
term alcohol use.  
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7.8 Supplementary material 
 
Table 1 Primer sequence used in qPCR 
Gene Forward Primer 5’ – 3’ Reverse Primer 5’ – 3’ 
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Cluster of 
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Dopamine 
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variant 1, 2, 3 
CCTATGACAAGCGCGGA AGCAGAGCCGTCACATTCTT 
Hmgb1 –  
High mobility 
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variant 1, 2 
CGCTGCTTTCTCCCATATTGA CCTCAGTCTTATGCAGGGTT
CA 














































Th – Tyrosine 
hydroxylase 
CCTTCCGTGTGTTTCAGTGC TCAGCCAACATGGGTACGTG 





































7.8.1 Statistics for in-text figures 
 
Figure 4 Long-term exposure to alcohol did not alter time spent (a – b) or 
distance (c – d) but increased immobility time (e – f) in the elevated plus maze 
and open field test) in non-alcohol preferring mice (Balb/c). 
 
(a) Elevated plus maze time  
Effect of arm, F(1, 7) = 2.5, p = 0.17 
Effect of solution, F(1, 7) = 5.56, p = 0.065 
Interaction (arm x solution), F(1, 7) = 5.72, p = 0.062 
 
(b) Open field test time 
Effect of area, F(2, 14) = 24.52, p < 0.0001 
Effect of solution, F(1, 7) = 0.87, p = 0.38 
Interaction (arm x solution), F(2, 14) = 1.44, p = 0.27 
 
(c) Elevated plus maze distance 
Effect of arm, F(1, 7) = 5.0, p = 0.075 
Effect of solution, F(1, 7) = 2.08, p = 0.21 
Interaction (arm x solution), F(1, 7) = 2.53, p = 0.17 
 
(d) Open field test distance 
Effect of area, F(2, 14) = 18.11, p < 0.0001 
Effect of solution, F(1, 7) = 0.24, p = 0.64 
Interaction (arm x solution), F(2, 14) = 7.32, p = 0.0015 
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(e) Elevated plus maze time immobile 
Effect of arm, F(1, 7) = 4.89, p = 0.078 
Effect of solution, F(1, 7) = 2.83, p = 0.15 
Interaction (arm x solution), F(1, 6) = 0.28, p = 0.62 
 
(f) Open field test immobile time  
Effect of area, F(2, 14) = 39.62, p < 0.0001 
Effect of solution, F(1, 7) = 10.4, p = 0.0146 
Interaction (arm x solution), F(2, 14) = 6.29, p = 0.0033 
 
Figure 5 Long-term exposure to alcohol selectively altered the expression of 
reward and stress-related genes in the nucleus accumbens (a) and amygdala (b) 
during withdrawal in non-alcohol preferring mice (Balb/c). 
 
Nucleus accumbens (a) 
Drd2, t = 0.41 df = 4, p = 0.71 
Oprm1, t = 0.48 df = 4, p = 0.66 
Gabra1, t = 0.86 df = 4, p = 0.45 
Prkca, t = 0.93 df = 4, p = 0.40 
Prkce, t = 1.42 df = 3, p = 0.25 
Fos, t = 2.46 df = 4, p = 0.07 
Creb1, t = 0.92 df = 4, p = 0.41 
 
Amygdala (b) 
Ucn, t = 1.39 d f= 4, p = 0.18 
Crhr2, t = 0.24 df = 4, p = 0.82 
Oprm1, t = 0.58 df = 4, p = 0.57 
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Okr1, t = 0.29 df = 4, p = 0.77 
Npy, t = 1.60 df= 4, p = 0.13 
Npyr1, t = 0.81 df= 4, p = 0.43 
Npyr2, t = 0.0038 df= 4, p = 0.99 
Gabra1, t = 1.90 df = 4, p = 0.13 
Prkca, t = 1.62 df = 4, p = 0.31 
Prkce, t = 2.21 df = 4, p = 0.092 
Fos, t = 1.64 df = 4, p = 0.12 
Creb1, t = 0.79 df= 4, p = 0.44 
 
Figure 6 Long-term exposure to alcohol increased the expression of TLR4-
related genes in the nucleus accumbens (a) and amygdala (b) during 
withdrawal in non-alcohol preferring mice (Balb/c). 
 
Nucleus accumbens (a) 
Tlr2, t = 0.98 df = 4, p = 0.38 
Cd14, t = 1.0 df = 4, p = 0.37 
Md2, t = 1.0 df = 4, p = 0.37 
Tirap, t = 0.56 df = 4, p = 0.60 
Tram, t = 1.09 df = 4, p = 0.34 
Irf3, t = 1.11 df = 4, p = 0.33 
Rela, t = 0.31 df = 4, p = 0.77 
Ifnb, t = 0.39 df = 4, p =  0.72 
Il10, t = 0.081 df = 4, p = 0.94 





Cd14, t = 0.70 df = 16, p = 0.49 
Myd88, t = 1.27 df = 16, p =  0.22 
Tirap, t = 1.87 df = 16, p = 0.08 
Trif, t = 1.59 df =16. p = 0.13 
Rela, t = 1.43 df = 16, p = 0.17 
Il10, t = 1.01 df = 16, p = 0.33 
 
Figure 7 (+)-Naltrexone did not affect the intake and preference for alcohol (a – 
b), sucrose (c – d) or quinine (e – f) before withdrawal in alcohol-exposed mice. 
 
(a) Alcohol intake  
Effect of solution, F(1, 7) = 2.88, p = 0.02 
Effect of dose, F(6, 42) = 9.90, p = 0.021 
Interaction (dose x solution), F(6, 42) = 5.44, p = 0.0004 
 
(b) Alcohol preference  
Effect of solution, F(1, 7) = 1.46,  p = 0.22 
Effect of dose, F(6, 42) = 10.26, p = 0.019 
Interaction (dose x solution), F(6, 42) = 1.04, p = 0.42 
 
(c) Sucrose intake  
Effect of solution, F(1, 7) = 2.88, p = 0.02 
Effect of dose, F(6, 42) = 9.90, p = 0.021 
Interaction (dose x solution), F(6, 42) = 5.44, p = 0.0004 
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(d) Sucrose preference  
Effect of solution, F(1, 7) = 1.46,  p = 0.22 
Effect of dose, F(6, 42) = 10.26, p = 0.019 
Interaction (dose x solution), F(6, 42) = 1.04, p = 0.42 
 
(e) Quinine intake  
Effect of solution, F(1, 7) = 306.5, p < 0.0001 
Effect of dose, F(6, 42) = 1.05, p = 0.41 
Interaction (dose x solution), F(6, 42) = 2.92, p = 0.02 
 
(f) Quinine preference 
Effect of solution, F(1, 7) = 0.66, p = 0.45 
Effect of dose, F(6, 42) =  2.27,  p = 0.059 
Interaction (dose x solution), F(6, 42) = 1.35 p = 0.26 
 
Figure 8 (+)-Naltrexone did not affect the intake and preference for alcohol (a – 
b), sucrose (c – d) or quinine (e – f) during withdrawal in alcohol-exposed mice. 
 
(a) Alcohol intake  
Effect of solution, F(1, 7) = 11.87, p = 0.014 
Effect of dose, F(6, 42) = 0.89, p = 0.51 
Interaction (dose x solution), F(7, 42) = 0.72, p = 0.63 
 
(b) Alcohol preference  
Effect of solution, F(1, 7) = 5.38, p = 0.0005 
Effect of dose, F(6, 42) = 42.86, p = 0.006 
Interaction (dose x solution), F(6, 42) = 1.37, p = 0.26 
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(c) Sucrose intake  
Effect of solution, F(1, 7) = 77.25, p < 0.0001 
Effect of dose, F(6, 42) = 0.83, p = 0.55 
Interaction (dose x solution), F(6, 42) = 0.67, p = 0.67 
 
(d) Sucrose preference  
Effect of solution, F(1, 7) = 115.1, p < 0.0001 
Effect of dose, F(6, 42) = 0.59, p = 0.73 
Interaction (dose x solution), F(6, 42) = 0.47, p = 0.82 
 
Figure 9 (+)-Naltrexone did not alter the time spent (a – b), distance (c – d) or 
immobility time (e – f) in the arms or area of the elevated plus maze and open 
field test respectively during withdrawal. 
 
(a) Elevated plus maze Time  
Effect of dose, F(6, 196) = 0.0026, p > 0.99 
Effect of solution, F(1, 196) = 0.0026, p = 0.96 
Effect of arm, F(1, 196) = 83.24, p < 0.0001 
Interaction (dose x solution), F(6, 196) = 0.0026, p > 0.99 
Interaction (dose x arm), F(6, 196) = 1.52, p = 0.17 
Interaction (arm x solution), F(1, 196) = 12.43, p = 0.0005 
Interaction (dose x arm x solution), F(6, 196) = 1.16, p = 0.33 
 
(b) Open field test time  
Effect of test area, F(2, 84) = 310.7, p < 0.0001 
Effect of solution, F(1, 84) = 0.029, p = 0.87 
Effect of treatment, F(1, 84) = 0.0019, p = 0.97 
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Interaction (test area x solution), F(2, 84) = 21.48, p < 0.0001 
Interaction (test area x arm), F(2, 84) = 2.32, p = 0.10 
Interaction (solution x treatment), F(6, 196) = 0.016, p = 0.90 
Interaction (test area x solution x treatment), F(6, 196) = 2.19, p = 0.12 
 
(c) Elevated plus maze Distance  
Effect of dose, F(6, 196) = 0.0020, p = 0.98 
Effect of solution, F(1, 196) = 1.7, p = 0.20 
Effect of arm, F(1, 196) = 16.99, p < 0.0001 
Interaction (dose x solution), F(6, 196) = 0.0020, p = 0.98 
Interaction (dose x arm), F(6, 196) = 4.37, p = 0.004 
Interaction (arm x solution), F(1, 196) = 0.23, p = 0.63 
Interaction (dose x arm x solution), F(6, 196) = 1.64, p = 0.13 
 
(d) Open field test distance 
Effect of test area, F(3, 112) = 27.32, p < 0.0001 
Effect of solution, F(1, 112) = 6.50, p = 0.012 
Effect of treatment, F(1, 112) = 5.06, p = 0.027 
Interaction (test area x solution), F(3, 112) = 9.33, p < 0.0001 
Interaction (test area x arm), F(3, 112) = 0.76, p = 0.52 
Interaction (solution x treatment), F(1, 112) = 0.96, p = 0.33 
Interaction (test area x solution x treatment), F(3, 112) = 0.43, p = 0.73 
 
(e) Elevated plus maze immobility time 
Effect of dose, F(6, 196) = 0.20, p = 0.98 
Effect of solution, F(1, 196) = 1.38, p = 0.24 
Effect of arm, F(1, 196) = 11.82, p = 0.0007 
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Interaction (dose x solution), F(6, 196) = 0.20, p = 0.98 
Interaction (dose x arm), F(6, 196) = 4.70, p = 0.0002 
Interaction (arm x solution), F(1, 196) = 7.14, p = 0.0083 
Interaction (dose x arm x solution), F(6, 196) = 5.19, p < 0.0001 
 
(f) Open field test immobility time count  
Effect of test area, F(3, 112) = 82.47, p < 0.0001 
Effect of solution, F(1, 112) = 12.65 p = 0.0006 
Effect of treatment, F(1, 112) = 0.0014, p = 0.97 
Interaction (test area x solution), F(3, 112) = 5.65, p = 0.0012 
Interaction (test area x arm), F(3, 112) = 0.0866, p = 0.97 
Interaction (solution x treatment), F(1, 112) = 0.015, p = 0.90 
Interaction (test area x solution x treatment), F(3, 112) = 0.16, p = 0.92 
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7.8.2 Supplementary figures  
 
 
Figure s1 Average alcohol intake (a) and preference (b) for each drinking session 
during the intermittent alcohol access protocol and the average serum alcohol 
concentration (c) following the last drinking session in Balb/c mice. Summary 
values represented as mean±SEM; n=8-20 
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Figure s2 Average alcohol intake (a) and preference (b) for each drinking session 
during the intermittent alcohol access protocol and the average serum alcohol 
concentration (c) following the last drinking session in saline or (+)-Naltrexone 
grouped mice. Mice anticipated to receive saline or (+)-Naltrexone did not exhibit 
differences in the intake, preference or serum alcoholl concentration following the last 
drinking session. All data was analysed using a two-way ANOVA with Tukey post hoc 
(a – b) or one-way ANOVA with Tukey post hoc (c). Summary values represented as 
mean±SEM; n=16-24. 
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Figure s3 Water intake during withdrawal in saline or (+)-Naltrexone grouped 
mice. Mice receiving saline or (+)-Naltrexone did not differ in their intake of water 
during the withdrawal period. All data was analysed using a one-way ANOVA with 
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Figure s4 (+)-Naltrexone did not alter the intake and preference of alcohol + 
quinine (a – b) or quinine (c – d). The intake and preference for alcohol + quinine or 
quinine was similar between mice treated with saline or (+)-Naltrexone during 
withdrawal. All data was analysed using a two-way ANOVA with Tukey post hoc. 





















































































































































Figure s5 (+)-Naltrexone does not alter the pharmacokinetics of alcohol (a – b). 
Mice exposed to alcohol long-term exhibited lower serum alcohol concentrations 
compared water control mice after 60 minutes. However, (+)-Naltrexone did not alter 
the serum alcohol concentration in water or alcohol-exposed mice (a). Similarly, mice 
exposed to alcohol long-term did not differ in the rate of alcohol metabolism following 
injections of saline or (+)-Naltrexone (b). All data was analysed using a two-way 
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Figure s6 Neither alcohol or (+)-Naltrexone modified the expression of Tlr2 
mRNA in the nucleus accumbens (a) or amygdala (b) following 48 h of 
withdrawal. All data was analysed using a two-way ANOVA with Bonferonni post hoc.  
Summary values represented as mean±SEM; n=4. 
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Figure s7 Alcohol but not (+)-Naltrexone modified the expression of TRIF-related 
mRNA in the amygdala (b, d, f) but not nucleus accumbens (a, c, e) following 48 
h of withdrawal. There was a main effect of solution but not drug on the expression 
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of Trif, Tram, Ifnb and Irf3 mRNA in the amygdala following withdrawal. Post hoc 
analysis determined the expression of Trif, Ifnb and Irf3 mRNA was increased in the 
alcohol + saline cohort compared to the water + saline cohort. However, the expression 
TRIF-related genes were not modified by solution or drug in the nucleus accumbens. 
All data was analysed using a two-way ANOVA with Bonferonni post hoc. Summary 





Figure s8 Alcohol but not (+)-Naltrexone modified the expression of MyD88-
related mRNA in the amygdala (b, d, f, h, j, l, n) but not nucleus accumbens (a, c, 
e, g, I, k, m) following 48 h of withdrawal. There was a main effect of solution but 
not drug on the expression of Myd88, Tirap, Il1b, Tnfa, Ccl2 and Rela mRNA in the 
amygdala following withdrawal. The expression of these genes were not modified by 
solution or drug in the nucleus accumbens. Post hoc analysis determined the 
expression of Myd88 and Rela mRNA in the amygdala and Il1b and Ccl2 mRNA in the 
amygdala and nucleus accumbens was significantly increased in the alcohol + saline 
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cohort compared to the water + saline cohort.  All data was analysed using a two-way 
ANOVA with Bonferonni post hoc. Summary values represented as mean±SEM; n=4, 





Figure s9 There was no effect of solution or drug on the expression of reward-
related genes in the nucleus accumbens following 48 h of withdrawal. There was 
no main effect of solution or drug on the expression of Drd1, Drd2 and Opmr1. 
However, post hoc analysis determined alcohol + saline mice exhibited increased 
expression of Drd1 and Drd2 mRNA compared to water + saline mice. All data was 
analysed using a two-way ANOVA with Bonferonni post hoc. Summary values 
represented as mean±SEM; n=4, *p < 0.05. 
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Figure s10 There was no effect of solution and drug on the expression of 
plasticity-related genes in the nucleus accumbens (a, c) and amygdala (b, d) 
following 48 h of withdrawal. There were no main effects or post hoc differences in 
the expression of Creb1 or Fos mRNA in the amygdala or nucleus accumbens 
following withdrawal. All data was analysed using a two-way ANOVA with Bonferonni 





Figure s11 There was no effect of solution or drug on the expression of stress-
related genes in the amygdala following 48 h of withdrawal. There was no main 
effect of solution or drug on the expression of Crh, Crhr1, Crhr2, Urn, Opmr1 and 
Oprk1. However, post hoc analysis determined the expression of Crh, Crhr1 and Urh 
mRNA was increased in alcohol + saline cohorts compared to water + saline cohorts. 
All data was analysed using a two-way ANOVA with Bonferonni post hoc. Summary 
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Figure s12 Alcohol but not (+)-Naltrexone modified the expression of anti-stress-
related mRNA in the amygdala following 48 h of withdrawal. There was a main 
effect of solution but not drug on the expression of Npy, Npyr1 and Npyr2 mRNA 
following withdrawal. Post hoc analysis determined alcohol + saline cohorts exhibited 
reduced expression of Npyr1 and Npyr2 mRNA compared to water + saline cohorts. 
All data was analysed using a two-way ANOVA with Bonferonni post hoc. Summary 
values represented as mean±SEM; n=4, *p < 0.05. 
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Figure s13 Alcohol but not (+)-Naltrexone modified the expression of GABA-
related mRNA in the amygdala (b, d, f) but not nucleus accumbens (a, c, e) 
following 48 h of withdrawal. There was a main effect of solution on the expression 
of Gabra1, Prkca and Prkce mRNA in the amygdala but not nucleus accumbens 
following withdrawal. Post hoc analysis determined alcohol + saline cohorts exhibited 
significantly reduced expression of Gabra1, Prkca and Prkce mRNA in the amygdala 
but not nucleus accumbens compared to water + saline cohorts. All data was analysed 
using a two-way ANOVA with Bonferonni post hoc. Summary values represented as 
mean±SEM; n=4, *p < 0.05. 
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7.8.3 Supplementary figure statistics 
 
Figure s2 Alcohol intake (a) and preference (b) and average serum alcohol 
concentration (c) following the last drinking session in saline or (+)-Naltrexone 
grouped mice. All data was analysed using a two-way ANOVA with Tukey post hoc 
(a – b) or a one-way ANOVA with Tukey post hoc (c). 
 
(a) Intake  
Effect of solution F(17, 102) = 20.62, p < 0.0001 
Effect of dose F(17, 102) = 0.73, p = 0.63 
Interaction F(17, 102) = 3.64, p < 0.0001 
 
(b) Preference  
Effect of solution F(17, 102) = 6.67, p < 0.0001 
Effect of dose F(17, 102) = 3.23, p = 0.012 
Interaction F(17, 102) = 1.87, p < 0.0001 
 
(c) Serum ethanol concentration  
Effect of dose F(6, 13) = 0.14, p = 0.98 
 
Figure s3 Water intake during withdrawal in saline or (+)-Naltrexone grouped 
mice.  All data was analysed using a one-way ANOVA with Tukey post hoc. 
 
Effect of dose F(6, 41) = 0.96, p = 0.46 
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Figure s4 (+)-Naltrexone does not alter the intake and preference of alcohol + 
quinine l (a – b) or quinine (c – d). All data was analysed using a two-way ANOVA 
with Tukey post hoc. 
 
(a) Alcohol + quinine intake  
Effect of solution F(1, 7) = 2.71, p = 0.15 
Effect of treatment F(1, 7) = 0.36, p = 0.57 
Interaction F(1, 7) = 1.25, p = 0.31 
 
(b) Alcohol + quinine preference  
Effect of solution F(1, 7) = 7.04, p = 0.038 
Effect of treatment F(1, 7) = 0.028, p = 0.87 
Interaction F(1, 7) = 0.76, p = 0.42 
 
(c) Quinine intake  
Effect of solution F(1, 7) = 2.46, p = 0.17 
Effect of treatment F(1, 7) = 0.002, p = 0.97 
Interaction F(1, 7) = 4.44, p = 0.08 
 
(d) Quinine preference  
Effect of solution F(1, 7) = 0.024, p = 0.88 
Effect of treatment F(1, 7) = 0.11, p = 0.75 
Interaction F(1, 7) = 2.14, p = 0.19 
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Figure s5 (+)-Naltrexone does not alter the average alcohol alcohol 
concentration reached following a bolus gavage of alcohol (a – b). All data was 
analysed using a two-way ANOVA with Tukey post hoc. 
 
(a) Peak blood alcohol concentration  
Effect of solution, F(1, 4) = 61.82, p = 0.0043 
Effect of drug, F(1, 4) = 1.42, p = 0.31 
Interaction (solution x drug), F(1, 4) = 8.05, p = 0.066 
 
(b) Time course of blood alcohol concentration  
Effect of time, F(3, 9) = 23.8, p = 0.0001 
Effect of drug, F(3, 9) = 0.63, p = 0.48 
Interaction (solution x drug), F(3, 9) = 1.54, p = 0.27 
 
Figure s6 Neither alcohol or (+)-Naltrexone modified the expression of Tlr2 
mRNA in the nucleus accumbens or amygdala following 48 h of withdrawal. All 
data was analysed using a two-way ANOVA with Bonferonni post hoc. 
 
(a) Nucleus accumbens Tlr2 
Effect of solution, F(1, 3) = 0.009, p = 0.93 
Effect of treatment, F(1, 3) = 4.92, p = 0.08 
Interaction, F(1, 3) = 0.095, p = 0.79 
 
(b) Amygdala Tlr2 
Effect of solution, F(1, 3) = 4.0, p = 0.08 
Effect of treatment, F(1, 3) = 4.0, p = 0.08 
Interaction, F(1, 3) = 5.43, p = 0.05 
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Figure s7 Alcohol but not (+)-Naltrexone modified the expression of TRIF-related 
mRNA in the amygdala (b, d, f) but not nucleus accumbens (a, c, e) following 48 
h of withdrawal. All data was analysed using a two-way ANOVA with Bonferonni post 
hoc. 
 
(a) Nucleus accumbens Trif 
Effect of solution, F(1, 3) = 3.25, p = 0.21 
Effect of treatment, F(1, 3) = 2.81, p = 0.24 
Interaction, F(1, 3) = 0.021, p = 0.89 
 
(b) Amygdala Trif 
Effect of solution, F(1, 3) = 26.85, p = 0.008 
Effect of treatment, F(1, 3) = 0.70, p = 0.43 
Interaction, F(1, 3) = 0.10, p = 0.76 
 
(c) Nucleus accumbens Tram 
Effect of solution, F(1, 3) = 0.41, p = 0.59 
Effect of treatment, F(1, 3) = 0.015, p = 0.91 
Interaction, F(1, 3) = 1.89, p = 0.30 
 
(d) Amygdala Tram 
Effect of solution, F(1, 3) = 16.12, p = 0.0039 
Effect of treatment, F(1, 3) = 0.30, p = 0.60 
Interaction, F(1, 3) = 0.00057, p = 0.98 
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(e) Nucleus accumbens Ifnb 
Effect of solution, F(1, 3) = 0.77, p = 0.47 
Effect of treatment, F(1, 3) = 0.55, p = 0.53 
Interaction, F(1, 3) = 1.21, p = 0.39 
 
(f) Amygdala Ifnb 
Effect of solution, 7.41, p = 0.027 
Effect of treatment, F(1, 3) = 0.0076, p = 0.93 
Interaction, F(1, 3) = 0.99, p = 0.38 
 
(g) Nucleus accumbens Irf3 
Effect of solution, F(1, 3) = 1.81, p = 0.30 
Effect of treatment, F(1, 3) = 1.06, p = 0.41 
Interaction, F(1, 3) = 0.15, p = 0.73 
 
(h) Amygdala Irf3 
Effect of solution, F(1, 3) = 10.35, p = 0.012 
Effect of treatment, F(1, 3) = 0.048, p = 0.83 
Interaction, F(1, 3) = 0.167, p = 0.69 
 
Figure s8 Alcohol but not (+)-Naltrexone modified the expression of MyD88-
related mRNA in the amygdala (b, d, f, h, j, l, n) but not nucleus accumbens (a, c, 
e, g, I, k, m) following 48 h of withdrawal. All data was analysed using a two-way 
ANOVA with Bonferonni post hoc. 
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(a) Nucleus accumbens Myd88 
Effect of solution, F(1, 3) = 0.38, p = 0.60 
Effect of treatment, F(1, 3) = 3.56, p = 0.20 
Interaction, F(1, 3) = 0.0020, p = 0.97 
 
(b) Amygdala Myd88 
Effect of solution, F(1, 3) = 7.22, p = 0.028 
Effect of treatment, F(1, 3) = 2.35, p = 0.16 
Interaction, F(1, 3) = 1.54, p = 0.25 
 
(c) Nucleus accumbens Tirap 
Effect of solution, F(1, 3) = 4.16, p = 0.18 
Effect of treatment, F(1, 3) = 6.35, p = 0.13 
Interaction, F(1, 3) = 0.00054, p = 0.98 
 
(d) Amygdala Tirap 
Effect of solution, F(1, 3) = 4.17, p = 0.08 
Effect of treatment, F(1, 3) = 0.89, p = 0.37 
Interaction, F(1, 3) = 0.68, p = 0.43 
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(e) Nucleus accumbens Il1b 
Effect of solution, F(1, 3) = 0.63, p = 0.51 
Effect of treatment, F(1, 3) = 2.12, p = 0.28 
Interaction, F(1, 3) = 2.20, p = 0.28 
 
(f) Amygdala Il1b 
Effect of solution, F(1, 3) = 29.66, p = 0.0006 
Effect of treatment, F(1, 3) = 0.015, p = 0.91 
Interaction, F(1, 3) = 6.09, p = 0.039 
 
(g) Nucleus accumbens Tnfa 
Effect of solution, F(1, 3) = 14.66, p = 0.062 
Effect of treatment, F(1, 3) = 3.01, p = 0.22 
Interaction, F(1, 3) = 0.66, p = 0.50 
 
(h) Amygdala Tnfa 
Effect of solution, F(1, 3) = 0.091, p = 0.77 
Effect of treatment, F(1, 3) = 0.10, p = 0.76 
Interaction, F(1, 3) = 4.62, p = 0.06 
 
(i) Nucleus accumbens Ccl2 
Effect of solution, F(1, 3) = 3.62, p = 0.19 
Effect of treatment, F(1, 3) = 0.67, p = 0.49 
Interaction, F(1, 3) = 63.65, p = 0.015 
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(j) Amygdala Ccl2 
Effect of solution, F(1, 3) = 5.3, p = 0.051 
Effect of treatment, F(1, 3) = 0.0043, p = 0.94 
Interaction, F(1, 3) = 5.62, p = 0.045 
 
(k) Nucleus accumbens Il10 
Effect of solution, F(1, 3) = 1.19, p = 0.39 
Effect of treatment, F(1, 3) = 0.14, p = 0.74 
Interaction, F(1, 3) = 1.50, p = 0.35 
 
(l) Amygdala Il10 
Effect of solution, F(1, 3) = 2.58, p = 0.25 
Effect of treatment, F(1, 3) = 0.30, p = 0.64 
Interaction, F(1, 3) = 55.82, p = 0.017 
 
(m) Nucleus accumbens Rela 
Effect of solution, F(1, 3) = 0.13, p = 0.75 
Effect of treatment, F(1, 3) = 3.07, p = 0.22 
Interaction, F(1, 3) = 0.25, p = 0.67 
 
(n) Amygdala Rela 
Effect of solution, F(1, 3) = 4.9, p = 0.058 
Effect of treatment, F(1, 3) = 0.037, p = 0.85 
Interaction, F(1, 3) = 1.98, p = 0.20 
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Figure s9 There was no effect of solution or drug on the expression of reward-
related genes in the nucleus accumbens following 48 h of withdrawal. All data 
was analysed using a two-way ANOVA with Bonferonni post hoc. 
 
(a) Drd1 
Effect of solution, F(1, 3) = 2.65, p = 0.24 
Effect of treatment, F(1, 3) = 0.10, p = 0.77 
Interaction, F(1, 3) = 8.22, p = 0.10 
 
(b) Drd2 
Effect of solution, F(1, 3) = 234.4, p = 0.0042 
Effect of treatment, F(1, 3) = 0.21, p = 0.69 
Interaction, F(1, 3) = 2.66, p = 0.23 
 
(c) Oprm1 
Effect of solution, F(1, 3) = 1.40, p = 0.36 
Effect of treatment, F(1, 3) = 0.074, p = 0.81 
Interaction, F(1, 3) = 1.31, p = 0.37 
 
Figure s10 There was no effect of solution and drug on the expression of 
plasticity-related genes in the nucleus accumbens (a, c) and amygdala (b, d) 
following 48 h of withdrawal. All data was analysed using a two-way ANOVA with 
Bonferonni post hoc. 
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(a) Nucleus accumbens Creb1 
Effect of solution, F(1, 3) = 3.58, p = 0.19 
Effect of treatment, F(1, 3) = 0.0050, p = 0.95 
Interaction, F(1, 3) = 2.07, p = 0.27 
 
(b) Amygdala Creb1 
Effect of solution, F(1, 3) = 1.06, p = 0.33 
Effect of treatment, F(1, 3) = 0.16, p = 0.70 
Interaction, F(1, 3) = 0.029, p = 0.87 
 
(c) Nucleus accumbens Fos 
Effect of solution, F(1, 3) = 7.75, p = 0.11 
Effect of treatment, F(1, 3) = 0.086, p = 0.79 
Interaction, F(1, 3) = 0.028, p = 0.88 
 
(d) Amygdala Fos 
Effect of solution, F(1, 3) = 0.012 p = 0.92 
Effect of treatment, F(1, 3) = 0.97, p = 0.35 
Interaction, F(1, 3) = 0.69, p = 0.43 
 
Figure s11 There was no effect of solution or drug on the expression of stress-
related genes in the amygdala following 48 h of withdrawal. All data was analysed 




Effect of solution, F(1, 3) = 2.5, p = 0.15 
Effect of treatment, F(1, 3) = 0.00054, p = 0.99 
Interaction, F(1, 3) = 0.16, p = 0.70 
 
(b) Urn 
Effect of solution, F(1, 3) = 4.67, p = 0.06 
Effect of treatment, F(1, 3) = 2.20, p = 0.18 
Interaction, F(1, 3) = 0.60, p = 0.46 
 
(c) Crhr1 
Effect of solution, F(1, 3) = 2.37, p = 0.16 
Effect of treatment, F(1, 3) = 0.038, p = 0.85 
Interaction, F(1, 3) = 4.15, p = 0.076 
 
(d) Crhr2 
Effect of solution, F(1, 3) = 0.17, p = 0.69 
Effect of treatment, F(1, 3) = 0.97, p = 0.35 
Interaction, F(1, 3) = 5.08, p = 0.054 
 
(e) Oprm1 
Effect of solution, F(1, 3) = 3.13, p = 0.12 
Effect of treatment, F(1, 3) = 0.39, p = 0.55 




Effect of solution, F(1, 3) = 1.49, p = 0.28 
Effect of treatment, F(1, 3) = 1.60, p = 0.24 
Interaction, F(1, 3) = 0.065, p = 0.80 
 
Figure s12 Alcohol but not (+)-Naltrexone modified the expression of anti-stress-
related mRNA in the amygdala following 48 h of withdrawal. All data was analysed 
using a two-way ANOVA with Bonferonni post hoc. 
 
(a) Npy 
Effect of solution, F(1, 3) = 5.20, p = 0.051 
Effect of treatment, F(1, 3) = 0.0081, p = 0.93 
Interaction, F(1, 3) = 1.56, p = 0.25 
 
(b) Npyr1 
Effect of solution, F(1, 3) = 12.54, p = 0.0076 
Effect of treatment, F(1, 3) = 1.17, p = 0.31 
Interaction, F(1, 3) = 7.46, p = 0.026 
 
(c) Npyr2 
Effect of solution, F(1, 3) = 10.72, p = 0.013 
Effect of treatment, F(1, 3) = 0.793, p = 0.40 
Interaction, F(1, 3) = 1.43, p = 0.26 
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Figure s13 Alcohol but not (+)-Naltrexone modified the expression of GABA-
related mRNA in the amygdala (b, d, f) but not nucleus accumbens (a, c, e) 
following 48 h of withdrawal. All data was analysed using a two-way ANOVA with 
Bonferonni post hoc. 
 
(a) Nucleus accumbens Gabra1 
Effect of solution, F(1, 3) = 0.25, p = 0.67 
Effect of treatment, F(1, 3) = 0.039, p = 0.86 
Interaction, F(1, 3) = 5.38, p = 0.15 
 
(b) Amygdala Gabra1 
Effect of solution, F(1, 3) = 14.12, p = 0.0056 
Effect of treatment, F(1, 3) = 0.010, p = 0.92 
Interaction, F(1, 3) = 3.19, p = 0.11 
 
(c) Nucleus accumbens Prkca 
Effect of solution, F(1, 3) = 0.0051, p = 0.94 
Effect of treatment, F(1, 3) = 1.3, p = 0.37 
Interaction, F(1, 3) = 0.24, p = 0.67 
 
(d) Amygdala Prkca 
Effect of solution, F(1, 3) = 4.28, p = 0.072 
Effect of treatment, F(1, 3) = 1.33, p = 0.28 
Interaction, F(1, 3) = 7.22, p = 0.028 
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(e) Nucleus accumbens Prkce 
Effect of solution, F(1, 3) = 0.12, p = 0.77 
Effect of treatment, F(1, 3) = 0.30, p = 0.64 
Interaction, F(1, 3) = 0.47, p = 0.56 
 
(f) Amygdala Prkce 
Effect of solution, F(1, 3) = 12.84, p = 0.0072 
Effect of treatment, F(1, 3) = 0.48, p = 0.51 





Long-term alcohol use recruits and modifies many neurotransmitter systems in brain 
regions associated with reward and stress (Koob & Volkow, 2009). This in turn alters 
the “liking” and “wanting” components of reward and induces anxiety (Berridge & 
Robinson, 2016; Koob & Le Moal, 2001). In addition to these neuronal processes, the 
TLR4 pathway is activated inducing the expression of immune mediators (Alfonso-
Loeches, et al., 2010). These mediators, specifically cytokines, sensitise rodents to, 
and mediate alcohol reward and anxiety behaviours following long-term use (Marshall 
et al., 2016a; Marshall et al., 2016b; Breese et al., 2007). It was therefore hypothesised 
that acute attenuation of TLR4 would reduce cytokine levels and in turn assist in 
alleviating anxiety and reward-related behaviours during withdrawal.  
 
However, the preceding manuscript highlighted the lack of involvement of the TLR4-
TRIF pathway in the altering the “liking” and “wanting” components of alcohol-induced 
reward following long-term use (Table 2). In brief, (+)-Naltrexone failed to reduce the 
potentiated alcohol intake and reduced sucrose intake induced by long-term exposure 
immediately proceeding the last drinking session. This suggests (+)-Naltrexone was 
unable to modify tolerance of the “liking” component of reward. In accordance with 
Chapter 3 however, mice exposed to water exhibited significant reductions in sucrose 
and alcohol intake following (+)-Naltrexone. The “wanting” component of alcohol 
reward was assessed 48 h after the last drinking session – a time where the motivation 
and “want” to consume alcohol is high. (+)-Naltrexone did not attenuate the 
subsequent intake of alcohol or alcohol + quinine or restore sucrose deficits suggesting 
it was unable to reduce the “wanting” component of reward and alleviate symptoms of 
anhedonia respectively. To ascertain why (+)-Naltrexone failed to modify these 
behaviours the serum alcohol concentration and expression of reward-, stress- and 
TLR4-related genes was assessed. (+)-Naltrexone did not modify peak serum alcohol 
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concentration compared to saline in water or alcohol exposed mice, nor did it modify 
the time-course of alcohol clearance. This suggests the lack of effect was not simply 
attributable to alterations in the pharmacokinetics of alcohol. Interestingly, mice 
exposed to alcohol long-term exhibit enhanced serum alcohol clearance suggesting 
more alcohol is required to achieve the same serum alcohol concentration in naïve 
mice. In contrast to previous chapters (3 and 5), there was no significant effect of (+)-
Naltrexone on Trif or Ifnb mRNA expression in either the nucleus accumbens or 
amygdala. Further, there was no effect of both (+)-Naltrexone and alcohol on any gene 
except Gabra2. It is unlikely that a reduction in Gabra2 mRNA following long-term 
alcohol use is likely to be beneficial to an individual given long-term alcohol exposure 
is characterised by a lack of inhibitory GABAergic control, an effect which underlies 
compulsivity and stress (Silberman et al., 2009; Koob, 2004). This effect may offer 
some explanation to the limited efficacy of (+)-Naltrexone following long-term alcohol 
use.  
 
There are additional explanations why (+)-Naltrexone exhibited limited efficacy 
following long-term use. For example, prolonged use of alcohol results in numerous 
neuroplastic and epigenetic modifications which collectively desensitise and sensitise 
the reward pathway and stress pathways, respectively (Koob & Volkow, 2009). 
Consequently, these pathways may be somewhat more resilient to the effects of an 
acute pharmacological blockade, and would better respond to a chronic treatment 
regiment. This idea is further supported owing to the relatively fast metabolism of 
Naltrexone in mice (Malspeis et al., 1975). Consequently, the limited blockade of TLR4 
is unlikely to result in large modifications to behaviour or genes. In contrast to rodents, 
the half-life of Naltrexone in humans is longer (on the order of several hours) and 
extended-release injections are available, further increasing Naltrexone’s efficacy 
(Dunbar et al., 2006; Verebey et al., 1976). Therefore, in humans, Naltrexone may be 
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more successful in reducing the neuroimmune response following long-term alcohol 
use.  
 
The high levels of immune mediators following long-term alcohol is likely due to 
DAMPs from apoptosing neurons and glia (Crews et al., 2017) and epigenetic 
modifications to immune-related genes increasing the likelihood of their transcription 
(Hennessy & McKernan, 2016; Montesinos et al., 2016). Consequently, multiple 
immune pathways are engaged and potentially contribute together to result in alcohol-
related behaviours. Therefore, attenuating one receptor within this complex system is 
unlikely to successfully reduce all neuroimmune mediators (Crews et al., 2017). A 
better therapeutic strategy is to attenuate global, overlapping immune-related 
transcription factors such as NFκB. This is particularly relevant to humans, as post 
mortem studies have found that the NFκB system in the PFC is dysregulated among 
alcohol dependents (Ökvist et al., 2007). Therefore, restoring its activity to basal 
homeostatic levels may alleviate symptoms associated with long-term alcohol use. 
 
In conclusion, this study highlights the limited efficacy of attenuating the TLR4-TRIF 
pathway on restoring and reducing “liking” and “wanting” components of reward of 
alcohol following long-term use.  
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Table 2 Brief summary of behavioural data (post hoc differences) from chapter 7 
Behaviour 
 
Effect of (+)-Naltrexone 
Water exposed mice 
Effect of (+)-Naltrexone 
Alcohol exposed mice 
Liking 




2 h sucrose exposure ¯ intake 45 – 75 mg/kg 
¯ preference 75 mg/kg 
¾ intake 
¯ preference 75 mg/kg 





24 h alcohol exposure ¯ intake 60 mg/kg 










24 h sucrose exposure ¾ intake 





Elevated plus maze ¾ time, distance, 
immobile episodes 
¾ time, distance, 
immobile episodes 
Open field test ¾ time, distance, 
immobile episodes 
¾ time, distance, 
immobile episodes 
N/A, not applicable; ­, increased intake/preference relative to saline; ¯ decreased 
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Chapter 8: Discussion 
8.1 Introduction 
Occasional and long-term alcohol use confers substantial health and economic costs 
to both individuals and the society at large (Rehm & Shield, 2014; World Health 
Organisation, 2014). Despite this, alcohol use is normative among adults in western 
cultures (NIAAA, 2017), an effect attributed to the rewarding and anti-rewarding 
properties of alcohol (Wise & Koob, 2013; Koob & Nestler, 1997). Pivotal to the 
emergence, persistence and alterations to alcohol-induced reward and anti-reward is 
the neuroimmune system (Cui et al., 2014; Mayfield et al., 2013). Specifically, research 
has emphasised TLR4, an innate immune pattern recognition receptor, as a key 
contributor to the neuroimmune involvement in alcohol-induced reward and anti-
reward behaviours (for example, Pascual et al., 2015; Liu et al., 2011). However, 
whether alcohol activates both TLR4 pathways (TRIF and MyD88) in vivo and the 
relative contribution of each pathway towards reward and anti-reward is still unknown.  
 
Therefore, the aim of this thesis was to characterise the TLR4 signalling pathway 
following acute and chronic alcohol exposure and to determine whether attenuating 
the TLR4-TRIF pathway reduces reward and anti-reward behaviour in naïve, 
sensitised and alcohol-dependent mice. The work presented herein suggest both the 
MyD88 and TRIF pathways are activated by acute and chronic exposure but only the 
TRIF pathway remains elevated for prolonged periods of time post exposure 
(sensitised). Attenuating the activation of the TLR4-TRIF signalling pathway using (+)-
Naltrexone, prevented alcohol reward behaviour in naïve mice (“liking” and “wanting”), 
partially prevented reward behaviour in sensitised mice (“liking” only), but had no effect 
on reward or anti-reward in dependent mice. Collectively, the results suggest (+)-
Naltrexone may only prove beneficial for attenuating occasional drinking but is unlikely 
to alter drinking following long-term alcohol use.  
 438 
8.2 Alcohol-induced TLR4 signalling 
A growing body of evidence implicates TLR4 in the molecular and behavioral 
consequences of alcohol exposure as TLR4 genetic knockout, siRNA knockdown or 
pharmacological antagonism in vitro and in vivo reduces the rise in TLR4-related 
immune mediators following alcohol exposure (Pascual et al., 2015; Alfonso-Loeches 
et al., 2010; Blanco et al., 2005). Importantly, this phenomenon translates into humans. 
Post-mortem studies demonstrate increased expression of TLR4 and downstream 
signaling pathways in alcohol dependents compared to healthy controls (Crews et al., 
2013; Liu et al., 2005; Ökvist et al., 2007). Further, the expression of TLR4 and HMGB1 
(an endogenous agonist of TLR4) correlate with the estimated life-time alcohol intake 
in humans (Crews et al., 2013). However, few studies have considered whether the 
MyD88 or TRIF (or both) signaling pathways are triggered, or remain activated 
following alcohol exposure in rodents and humans. 
 
It is important to discern which TLR4 pathway alcohol activates because there are 
specific behavioral outcomes associated with the MyD88 and TRIF pathways. For 
example, the expression of interferons, and their receptors (regulated by the TRIF 
pathway) correlates with alcohol dependence in humans (Johnson et al., 2015) 
whereas NFκB (a TRIF and MyD88 shared transcription factor) underlies much of the 
neuroplastic adaptations which have occurred in long-term alcohol users (Ökvist et al., 
2007). In rodents, MyD88 and its prototypical product IL-1β, additionally regulate 
alcohol-induced motor impairment and sedation (Blednov et al., 2017b; Wu et al., 
2012). Under alcohol naïve circumstances however, these proteins play little role in 
regulating alcohol intake (Blednov et al., 2017b). If a specific alcohol-related behavior 
preferentially results in or is caused by MyD88 or TRIF signaling in the brain, a 
therapeutic agent targeting the causative pathway whilst leaving the other pathway 
undisturbed would be ideal. This is pertinent for occasional and long-term alcohol 
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users, who often have compromised peripheral immune systems because of alcohol 
exposure (Muralidharan et al., 2014). 
 
The studies presented herein are the first to assess whether acute and chronic alcohol 
upregulates either (or both) the MyD88 or TRIF pathways in vivo. In brevity, my 
research demonstrates that all aspects of the TLR4 pathway were upregulated by 
acute and chronic alcohol exposure including; endogenous agonists, co-receptors and 
aspects of the MyD88 and TRIF pathway. This suggests, like a general immune 
response towards LPS, both pathways are required to create a maximal immune 
response. It is interesting that acute exposure mirrors (albeit to a lesser extent) chronic 
exposure, suggesting that even a low amount of alcohol can activate the neuroimmune 
system. Further, these findings suggest that unlike LPS which undergoes tolerance 
following chronic exposure, alcohol (at an mRNA output measure) does not. Given we 
observed these increases in TLR4-related mRNA expression in brain regions typically 
associated with the “wanting” and “liking” of alcohol (nucleus accumbens, 
hypothalamus and amygdala) it was hypothesised that these immune mediators are 
interacting with neurons altering synaptic transmission, plasticity and function thereby 
influencing reward and anti-reward behaviours. 
 
In contrast to acute and chronic exposure, alcohol exposure during adolescence 
preferentially elevated the expression of TLR4, its co-receptor (MD2) and aspects of 
the TRIF in adulthood. Interestingly, the MyD88 pathway did not exhibit elevations in 
mRNA. It is unclear how or why alcohol preferentially upregulates the TRIF pathway. 
However, Shen et al., (2008) in their work examining the effects of relative role of each 
TLR4 signaling pathway in macrophages found the TRIF pathway regulates the 
expression and release of most LPS-induced cytokines compared to the MyD88 
pathway. The authors concluded that from an immunological standpoint, the TRIF 
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pathway has a much greater role in LPS-TLR4 signaling. By extending these results 
to the current studies, it is hypothesized that from a purely immunological viewpoint, 
the TRIF pathway remains elevated because it is more immunologically pertinent to 
alcohol. However, the effect observed by Shen et al., (2008) was cell specific, with 
differing results observed between macrophages and dendritic cells. This raises a 
crucial limitation of my present studies; the cell type(s) within which the mRNA 
expression changes occurred remains unknown.  
 
It is important to identify the specific cell types underlying the alterations in alcohol-
induced TLR4 signalling as each cell type would undoubtedly result in different 
behavioural and molecular outcomes. The results presented in the appendix aimed to 
partly address this by examining the alcohol-induced immune response in BV2 
microglia-like cells. However, in stark contrast to previous studies (Lawrimore & Crews, 
2017) alcohol was unable to induce an immune response. Methodological 
considerations such as the use of a chamber to maintain alcohol saturation may 
underscore the different results obtained by the two studies. This apparatus lessens 
the effects of alcohol evaporation maintaining a constant concentration of alcohol in 
the culture media. This is thought to maintain the alcohol-induced stress placed on 
cells which in turn, releases danger molecules (such as HMGB1) initiating a TLR4 
response. However, my study did not use this apparatus and consequently alcohol 
evaporated relatively quickly from the culture media. This may have reduced the stress 
placed on these cells and consequently, the released danger molecules thus 
preventing a TLR4 response.  
 
To date only one study has directly compared how an alcohol-induced immune signal 
differs between cell types. Lawrimore & Crews, (2017) evaluated an immune response 
following alcohol exposure in BV2 and SH-SY5Y cells, microglia- and neuronal-like 
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cells respectively. Following 24 h of alcohol exposure, TNFα, IL-1β and IRF-3 but not 
MAPKs or NFκB were elevated in BV2 cells. By contrast, SH-SY5Y cells, exhibited 
increases in IRF-3, MAPKs and NFκB following alcohol exposure. However, the 
expression of TNFα and IL-1β was unaltered in the latter. Neither cell type exhibited 
increases in MyD88 gene expression and the TRIF-IFNβ pathway was not widely 
explored despite the increases in IRF-3. Collectively, the results suggest that alcohol 
exposure potentially increases the TLR4-TRIF pathway in microglia (with some 
aspects of the MyD88 pathway upregulated). By contrast, while alcohol increases the 
expression of IRF-3, MAPKs and NFκB in neurons, the outcome is likely non-immune 
related. This concept is supported by in vivo findings. For example, in neurons, TLR4 
activation induces the expression of tyrosine hydroxylase and CRF and alters GABA-
related activity (Aurelian et al., 2016; June et al., 2015; Bajo et al., 2014). In glia, 
alcohol-induced TLR4 signalling increases the expression and release of inflammatory 
cytokines and reactive oxygen creating enzymes (Fernandez-Lizarbe et al., 2009; 
Blanco et al., 2005). While glia and neurons likely respond to long-term alcohol use, it 
is presently unclear the degree to which the shorter alcohol exposure models such as 
those described in chapters 3 and 5 engage microglia in vivo. Furthermore, it is 
presently unclear whether neurons in vivo express all proteins pertinent to the TRIF 
pathway (Okun et al., 2011) and if they remain in a primed state following alcohol 
exposure. Therefore, the prolonged increases in the TLR4-TRIF pathway (which 
signals to IRF3) are more likely to originate from microglia than neurons in vivo. 
However, the cell type underlying the acute effects of TLR4 activation remains a key 
question to be addressed by future experiments.  
 
Examining how alcohol influences the TLR4 pathway from an mRNA perspective can 
provide us with crucial information regarding how transcription factors are working and 
can infer what genomic and epigenetic processes have occurred in response to alcohol 
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exposure. However; the degree to which a gene is up or downregulated does not 
necessarily correlate to the protein level changes (Gry et al., 2009; Greenbaum et al., 
2003). Further, these alterations are often transient and are dependent on numerous 
transcription factors; not all of which are related to TLR4. Given the fundamental 
importance of proteins in signal transduction, not having this information limits the type 
of conclusions drawn from these studies. This is especially pertinent when considering 
the neuroimmune effects of alcohol. Four gavages of alcohol are required before 
neuroimmune-related protein changes occur (Qin et al., 2008). This highlights that a 
single dose of alcohol might initialise/prepare for a neuroimmune response. However, 
further immune-related stimulation may be required before the effect of this 
neuroimmune response translates into functional effectors. Interestingly, novel 
microRNAs are induced by low doses of alcohol and may additionally influence 
subsequent TLR4 immune responses towards alcohol (Lippai et al., 2013). 
Consequently, the neuroimmune system, specifically, the glial component, may not be 
as involved in the initial components of alcohol-related behaviour, but are gradually 
recruited and assist in the propagation of its effects. Instead, non-immunological TLR4 
signalling such as those observed in GABAergic neurons (Bajo et al., 2014) may 
underlie the acute effects of alcohol. 
 
This has further implications in the adolescent study and the concept of sensitisation. 
It is hypothesised that neuroimmune sensitisation following immune stimulation does 
not cause a persistent upregulation of protein. Rather, the cells remain in a 
phenotypically activated state with concurrent epigenetic processes increasing the 
likelihood of gene expression. Consequently, there may be an upregulation of 
neuroimmune genes following alcohol exposure during adolescence which persist 
through to adulthood. However, the functional outcomes attributable to the persistent 
upregulation of these inflammatory-related genes remains to be determined. 
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The quantification of protein was attempted using BD Bioscience and BioSearch ELISA 
kits. However, the limited sensitivity of these kits did not allow the detection of proteins 
from ex vivo samples. This is an outcome that has plagued many attempts to quantify 
scarce, but potent immune-related proteins in the CNS. Future development of 
cytokine detection tools, such as the spatial ELISA (Liu et al., 2017) may provide 
alternative methods that will allow the quantification of these critical protein levels at 
behaviourally meaningful concentrations. 
 
8.3 (+)-Naltrexone’s mechanism of action 
Given the TLR4-TRIF pathway was up-regulated in all the studies, we sought to 
examine its functional importance in alcohol-induce reward and anti-reward behaviour. 
These studies are among the first to assess the relative importance of TLR4-TRIF 
signalling across a range of alcohol-related behaviours. The impact of this pathway 
was assessed using (+)-Naltrexone an enantiomer of the µ opioid receptor antagonist 
(-)-Naltrexone.  
 
The most comprehensive pharmacological characterisation of (+)-Naltrexone was 
undertaken using microglia and macrophage-like cells (BV2 and RAW247.2 cells 
respectively). This work demonstrated (+)-Naltrexone selectively modifies the TLR4-
TRIF-IRF3 pathway as inferred by a reduction in phosphorylated IRF-3 (Wang et al., 
2016) but not NFκB, p38 or JNK levels following LPS (an effect which is mimicked in 
ex vivo hippocampal cells (Wu et al., 2012)). This further coincided with a reduction in 
IFNβ, NO, TNFα but not IL-1β production (Wang et al., 2016). Importantly, (+)-
Naltrexone did not inhibit IFNg or TNFα-induced NO production (which signal via IFNg 
and TNF receptors respectively) indicating this effect was exclusive to TLR4 (Wang et 
al., 2016). However, results presented in this appendix suggest (+)-Naloxone, another 
TLR4 inhibitor, exhibit biased antagonism only at specific doses of LPS. It is thought 
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that at low concentrations of LPS, (+)-Naloxone inhibits both MyD88 and TRIF-
dependent signalling outcomes. However, inducing a stronger immune response by 
using higher doses of LPS, such as those used by Wang et al., (2016), (+)-Naloxone 
only attenuates the TRIF pathway. Whether this phenomenon also occurs for (+)-
Naltrexone remains to be determined.  However, the collective results from chapters 3 
and 5 largely support the conclusions by Wang et al., (2016): (+)-Naltrexone reduced 
the expression of TLR4, TRIF and IFNβ genes but did not alter the expression of 
MyD88 or IL-1β genes.  
 
How and if (+)-Naltrexone results in a biased antagonism of the TRIF pathway still 
remains to be fully determined. In silico docking demonstrates (+)-Naltrexone (and (-)-
Naltrexone) bind to the LPS binding pocket in MD2 interacting specifically with amino 
acids phenylalanine, isoleucine and valine at residues 76 and 147, 63 and 48 
respectively (Hutchinson et al., 2010). It is unclear how this interaction translates to a 
potentially biased antagonism of TLR-TRIF and caution must be taken when 
interpreting computer simulations to model ligand binding as interactions from water 
molecules are largely ignored despite their importance. 
 
The in vivo studies largely support the biased antagonistic nature of (+)-Naltrexone. 
However, there are conflicting studies regarding (+)-Naltrexone’s mechanism of action. 
For example, (+)-Naltrexone significantly reduced cocaine-induced IL-1β signalling in 
the nucleus accumbens of rats potentially by blocking the docking of cocaine to MD2 
(Northcutt et al., 2015); and reduced or had no effect on LPS-induced NFκB SEAP 
reported expression in HEK-Blueä-hTLR4 cells (Wang et al., 2016; Skolnick et al., 
2014; Lewis et al., 2013; Stevens et al., 2013; Hutchinson et al., 2008). HEK-Blueä-
hTLR4 cells are human embryonic kidney cells transfected with plasmids to over-
express the genes for SEAP, TLR4 and co-receptors CD14 and MD2. The lack of 
 445 
biased antagonism observed in HEK-Blueä-hTLR4 cells is likely due to the fact that 
embryonic kidney cells are not immunologically competent and may not express all the 
required downstream signalling proteins necessary for the detection of biased 
antagonism. For example, LPS does not induce NO production in HEK-Blueä-hTLR4 
cells, a key indicator of TRIF-IRF3 activation (Wang et al., 2016). Further, it is unclear 
how much TLR4 and co-receptors are over produced in HEK cells limiting the 
applicability of these cells to assess a TLR4 signal (Ashwood et al. unpublished).  
 
Skolnick et al., (2014) additionally claim that the lack of efficacy of (+)-Naltrexone in 
attenuating LPS-induced SEAP expression limits its translational applicability. This 
statement largely ignores the diverse non-immunological role of TLR4 in the central 
nervous system and does not consider that TLR4 activation has divergent signalling 
outcomes reflecting on the type of cell it is expressed in. For example, LPS or alcohol-
induced TLR4 signalling modulates GABA and dopamine release by neurons (Harris 
et al., 2017; Aurelian et al., 2016; Bajo et al., 2014; Blednov et al., 2011) and induces 
NFκB, AP-1 and IRF3 leading to the upregulation of IL-1β, TNFα, IFNb, COX-2 and 
iNOS in microglia and astrocytes (Fernandez-Lizarbe et al., 2013; Blanco et al., 2005). 
Therefore, it is likely that a LPS or alcohol-induced TLR4 signal is unique to each cell 
type. Consequently, when assessing TLR4 function it is important to include an array 
of cell types. 
 
The in vitro characterising of (+)-Naltrexone is fundamentally necessary for 
ascertaining how this drug interacts with and attenuates TLR4. However, this system 
is inherently confounded as it negates how (+)-Naltrexone interacts with a complex 
environment such as the brain that can lead to different results (as alluded to above). 
For example, (+)-Naltrexone significantly reduced cocaine-induced IL-1β signalling in 
the nucleus accumbens of rats (Northcutt et al., 2015) and down-regulated the mRNA 
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expression of Lepr, Rxfp1, Creb1, Grin and Md2 in the preceding chapters. This 
highlights that (+)-Naltrexone may indirectly modulate the expression of other 
inflammatory mediators and neurotransmitter systems by inhibiting the expression of 
NO, TNFα and IFNβ. Alternatively, the divergent signalling TLR4-TRIF outcomes in 
neurons may additionally underscore the effects of (+)-Naltrexone on neurotransmitter 
genes. 
 
By exclusively using (+)-Naltrexone to probe the TLR4-TRIF pathway, the effect of 
MyD88 signaling in reward and anti-reward was not assessed in this thesis. 
Interestingly, there is some evidence to suggest the MyD88 pathway contributes to 
reward behavior, however, these effects are inconsistent (Blednov et al., 2017b). 
Owing to time constraints and feasibility of obtaining a selective pharmacological 
MyD88 inhibitor this study did not address the role of MyD88 in reward and anti-reward 
behaviors. Consequently, future studies should ascertain the relative contribution of 
MyD88 signaling in reward and anti-reward behavior. 
 
Results from our study suggested that aspects of the MyD88 pathway are activated 
following our three different regimes of alcohol exposure. For example, acute alcohol 
exposure (study 1) increased Il1b and Ccl2, alcohol priming (study 2) increased Ccl2 
and chronic exposure of alcohol (study 3) increased Tirap, Rela (NFκB), Il1b and Ccl2 
in addition to the increased TRIF-IFNβ signalling we observed. CCL2, IL-1β and NFκB 
are all downstream of MyD88 (Akira & Takeda, 2004) suggesting this pathway is 
potentially involved in alcohol-induced neuroinflammation. However, IL-1β expression 
can be induced by non-TLR receptors including; P2X7 (an ATP receptor), RIG-1 and 
AIM2 receptors (Guo et al., 2015; Kanneganti, 2010) indicating other mechanisms may 
potentially underlie alcohol-induced neuroinflammation.   
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As (+)-Naltrexone did not modify behaviours associated with reward and anti-reward 
following chronic alcohol, it highlights the possibility that MyD88 signalling alone or 
together with TRIF signalling may be involved in these behaviours as TLR4-/- mice are 
protected against the behavioural effects of protracted withdrawal (Pascual et al., 
2011).  
 
8.4 Is an immune response towards alcohol the same as ethanol? 
An important consideration when assessing the translational potential of this study is 
the use of ethanol as a surrogate marker for alcohol. Ethanol often comprises less than 
half the total volume of alcoholic beverages with the remaining 50 – 99% consisting of 
carbohydrates, alditols, n-chain alcohols, proteins, amino acid, amines, inorganic and 
organic anions, vitamins, phenolic acid, yeast products and sulphur compounds 
(Heymann & Ebeler, 2016; Piggott, 2011). Many of these compounds exhibit pro- and 
anti-inflammatory actions, collectively influencing the immune response induced by 
ethanol. For example, a comparison of the immunogenicity of ethanol, stout and pilsner 
(matched ethanol concentration) determined stout and pilsner caused less liver 
dysfunction (as inferred by serum alanine aminotransferase, oxidised lipids and 
hepatic lipid levels), reduced intestinal permeability and TLR4 inflammation markers 
including MyD88, iNOS, TNFα and IκBα, NFκB p65 expression compared to ethanol 
(Landmann et al., 2015; Kanuri et al., 2014) in the livers of mice. However, the effects 
of beer, wine and spirits on the human peripheral immune system are mixed with 
studies demonstrating both increases, decreases and no effect on the immune 
response (for example Romeo et al., 2007; Watzl et al., 2004; 2002). 
No study has currently examined the net effects of these beverages on the immune 
response within the central nervous system. However, individual components of 
alcoholic beverages have been assessed for the capability to alter immune responses 
by microglia. For example, the flavonoid resveratrol is hypothesised to be a natural 
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TLR4 antagonist (Rahimifard et al., 2017) as studies using primary microglia have 
shown it supresses LPS-induced IL-1β, TNFα, NO and PGE production by inhibiting 
the phosphorylation of MAPK and IκBα and NFκB (Capiralla et al., 2011; Meng et al., 
2008; Kim et al., 2007; Bi et al., 2005). In peripheral macrophages, resveratrol 
suppresses LPS-induced NO, IFNβ, TNFα, MyD88, IκK, TRAM, TRIF and TBK1, and 
reduced the translocation of IRF-3, AP-1, STAT-1 and NFκB following LPS, suggesting 
it attenuates both the MyD88 and TRIF pathways (Yang et al., 2014; Zong et al., 2012; 
Qureshi et al., 2012; Kim et al., 2011; Youn et al., 2005). It is important to note while 
these pre-clinical models have established an anti-inflammatory role for resveratrol it 
is unknown whether it has the same effect on humans or rodents when consumed in 
alcohol beverages. The oral absorption for resveratrol is approximately 75 per cent. 
However, the bioavailability in systemic circulation is less than one per cent and 
therefore whether resveratrol can enter the brain to exert anti-inflammatory effects 
remains to be determined (Walle, 2011). Therefore, while there are many compounds 
within alcoholic beverages that have the potential to be anti-inflammatory, the low 
levels and limited bioavailability of these compounds limit their efficacy. Further, long-
term use of alcohol causes inflammation within the liver (Lieber, 1997) and brain 
(Crews et al., 2017) suggesting these compounds may simply slow the inflammatory 
actions of ethanol but do not prevent it.  
 
Collectively, this highlights a fundamental problem inferring the actions of ethanol onto 
alcoholic beverages, it is much more inflammatory and can induce more profound 
addictive tendencies in rodents compared to the parent beverage. Consequently, 
future research should focus on how these two differ and how we can better reconcile 
the effects of ethanol to that of alcoholic beverages.  
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8.5 Inferring reward from the behavioural paradigms 
Another important caveat when considering the translational potential of this study is 
the manner in which reward behaviour was inferred. Achieving consilience between a 
rodent’s behaviour and molecular events, with that observed in humans is one of the 
greatest problems facing translational medical science, especially in complex areas 
like addiction research. Addiction is an entirely human phenomenon, and while some 
behavioural characteristics associated with the disorder can be successfully modelled, 
creating models with predictive, construct and face validity is difficult (Ripley & 
Stephens, 2012; Sanchis-Segura & Spanagel, 2006). Oral self-administration 
procedures such as two-bottle choice, demonstrate face and construct validity of 
human alcohol consumption. Like humans, this paradigm enables rodents to choose 
to drink alcohol (or not), and has been used to identify pharmacological targets which 
prevent excessive drinking, such as (-)-Naltrexone (Hendershot et al., 2016; Middaugh 
& Bandy, 2000; Phillips et al., 1997). Further, these methods are technically simple 
and can create reproducible results. However, alterations in the experimental design, 
the theory behind alcohol drinking and the interpretation of results often cloud the 
conclusions of this paradigm (Ripley & Stephens, 2012). For example, the 
concentration of alcohol influences the outcome as low or high concentrations are 
readily consumed or rejected owing to their sweet or aversive tasting properties 
respectively (Kiefer, 1995; Kiefer et al., 1995). Further, the fast metabolic rate in mice 
and the temporal pattern of consumption (rodents drink in bouts rather than all at once 
as observed in humans) often makes it difficult to reach physiologically relevant ethanol 
concentrations within the brain (Crabbe et al., 2011). Consequently, using low 
concentrations of alcohol in the two-bottle choice preference test may reflect different 
aspects of drinking but does not model one of the key features of human alcoholism; 
drinking to the point of intoxication. Thus, a range of concentrations must be used to 
assess factors influencing the consumption of alcohol at low (primarily a taste 
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phenomenon) and high (a balance between aversive taste, hedonic, and reward) 
concentrations. 
 
Another important consideration are the variables used to infer the “wanting” and 
“liking” components of reward in two-bottle choice: water, alcohol and total fluid intake. 
However, the interpretation of the results is often convoluted. For example, consider 
two rodents, A and B. Rodent A typically has high levels of intake, whereas rodent B 
displays low levels of intake. Given rodent A’s higher intake, we would assume that A 
finds alcohol more “pleasurable” and therefore is more likely to consume it. However, 
is alcohol more “pleasurable” to rodent B because they reach the same rewarding 
effects at a much lower amount of alcohol (and consequently exhibit reduced intake)? 
This is impossible to tell using two bottle choice. Additionally, are the aversive effects 
of alcohol (such as the bitter taste) more prevalent in rodent B? Consequently, this 
technique is often considered a rough measure of “liking” and provides limited 
information regarding the motivational (“wanting”) component of alcohol reward 
because the effort to consume alcohol is minimal (Ripley & Stephens, 2012). 
Therefore, this technique should primarily be used to assess the “liking” component of 
reward behaviour and, techniques such as the operant self-administration model, may 
be more suitable to assess the “wanting” component of reward. 
 
Conditioned place preference assesses the “wanting” component of drug-induced 
reward as well as memory (Bardo & Bevins, 2000). In brief, it measures the ability of a 
drug to cause preference for an environment in which the drug is paired compared to 
an environment in which the subject receives vehicle control. Conditioned place 
preference is relatively easy to perform and can generate replicable dose-response 
effects. And while conditioned place preference lacks face validity, it has demonstrated 
construct validity and has reinforced findings relating to the “rewarding” effects of 
 451 
alcohol in the two-bottle choice tests (Huston et al., 2013; Bardo & Bevins, 2000). 
However, this procedure is sensitive to methodological variations for example, the 
“preference” for a chamber changes reflecting the duration of the test; differs across 
species; and the psychological underpinnings are not well understood (it involves 
learning, spatial discrimination, memory, reward) (Sanchis-Segura & Spanagel, 2006). 
Therefore, it is unclear how minor methodological variations may alter the 
psychological processes and consequently, the final outcome may not reflect reward 
behaviour (Sanchis-Segura & Spanagel, 2006). However, these two paradigms are 
among the most replicable and feasible used in addiction research. Experiments using 
more complex models such as operant self-administration should be performed in the 
future to validate and expand upon the results of this study.  
 
A final caveat to consider when examining reward-like behaviour in rodents is the 
background strain of the rodents. Typically, studies investigating the rewarding (or anti-
rewarding) properties of alcohol use alcohol-preferring mice such as the C57BL/6J 
strain. This strain has an inherit predisposition to exhibit exaggerated responses 
towards alcohol such as high alcohol intake (Yoneyama et al., 2008). When assessing 
the effects of an intervention, the behavioural response may be exaggerated or 
minimised owing to floor or ceiling effects owing to C57BL/6J’s genetic predispositions, 
which in turn, mitigate or enhance the effect of intervention. Consequently, C57BL/6J 
mice may be used as a model designed to reflect humans who are genetically 
predisposed to developing alcohol dependence. By contrast, the studies presented in 
this thesis used Balb/c mice a strain of mice which does not exhibit preference or 
avoidance towards alcohol (Yoneyama et al., 2008). Consequently, the effects of an 




8.6 The effects of TLR4 on reward  
The role of the TLR4 pathway in reward behavior (as inferred by the results presented 
in this thesis) are complex and depends upon brain region examined, ontological 
period and duration of alcohol exposure. Therefore, to ensure clarity in the ideas 
presented, the discussion of the results will focus on each study individually rather than 
considering whether TLR4 is involved in all reward behaviours.  
 
8.7 The effects of TLR4 on acute reward  
8.7.1 Action of (+)-Naltrexone 
There is a growing body of evidence implicating TLR4 in the acute rewarding effects 
of alcohol (Harris et al., 2017; Mayfield et al., 2016). However, the results are far from 
uniform with studies demonstrating TLR4 reduces or has no effect on reward behaviour 
in rodents (Harris et al., 2017). The differing conclusions are likely attributable to the 
differences in strain and the method of attenuating TLR4 and inferring reward 
behaviour. The results presented in this thesis suggest (+)-Naltrexone reduces both 
the “liking” and “wanting” components of alcohol reward, as inferred by a reduction in 
the amount of alcohol consumed and time spent in the conditioned environment during 
the two-bottle choice tests and conditioned place preference tests respectively. 
However, (+)-Naltrexone additionally reduced saccharin intake – an effect consistent 
with other TLR4 antagonists (Bajo et al., 2016). This suggests TLR4 is pivotal to the 
normal homeostatic functioning of the reward pathway as blockade of TLR4 reduces 
the ability to feel reward immediately following an innately likable solution. 
 
The effect of TLR4 on reducing the “wanting” component of reward is potentially 
attributable to a downregulation of tyrosine hydroxylase (Th) mRNA – the key enzyme 
responsible for dopamine synthesis. This supports the observations demonstrating 
that TLR4 regulates the expression of TH in the VTA via PKC and CREB (Aurelian et 
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al., 2016). Further, (+)-Naltrexone and (+)-Naloxone, a chemically and functionally 
similar compound, reduced cocaine and morphine-induced dopamine release in the 
nucleus accumbens within 10 minutes of administration (Northcutt et al., 2015; 
Hutchinson et al., 2012). This suggests TLR4’s effect on the dopamine system is not 
limited to gene regulation but also occurs at the level of protein/neurotransmitter 
release as well. Whether this effect occurs with alcohol is an important experiment 
which needs to be performed in the future.  
 
Having a drug which blocks the rise in dopamine following acute alcohol exposure may 
be beneficial as it prevents the transfer of motivational significance towards alcohol (or 
any drug of abuse). This would prevent the increase in the “wanting” component of 
reward; a key feature assisting the transition from occasional drinking to dependence 
(Berridge & Robinson, 2016). This may also prove fruitful for other disorders which 
have a motivation or a learnt aspect to them such as phobias. Unfortunately, drugs 
which exclusively block dopamine signalling following long-term alcohol use have 
failed to prevent relapse or alcohol drinking in humans. Further these drugs have 
pronounced adverse side effects such as anhedonia and loss of enjoyment in 
individuals (Swift, 2010). Consequently, the timing of administration is crucial to 
prevent the transfer of motivational importance following alcohol use and may therefore 
be only beneficial for people at risk of developing, but do not currently have an alcohol 
use disorder.  
 
It is unclear how (+)-Naltrexone, and other TLR4 antagonists modify the “liking” 
component of reward. Given the “liking” component is a rapid molecular event, it is 
presently unclear whether alcohol-induced neuroimmune signalling could occur on this 
time scale given that four doses of alcohol are required before neuroimmune protein 
changes are observed (Qin et al., 2008). Despite this, (+)-Naltrexone reduced 
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saccharin and alcohol intake after the second day of consumption in the 2 h limited 
access paradigms (post hoc analysis). Importantly, the intake in g/kg was significantly 
less than that of the oral gavages required to elicit a neuroimmune protein change by 
alcohol (as inferred by Qin et al., (2008)) and it is unclear whether or how basal 
neuroimmune signalling modifies a response from a non-drug of abuse like saccharin. 
This suggests that (+)-Naltrexone may be modifying the release of protein from glia or 
is directly modifying basal/or induced TLR4 signalling on neurons altering their function 
and subsequent neurotransmitter output. This in turn would modify the behavioural 
response to alcohol and saccharin.  
 
Alternatively, Thomas et al. (in preparation) demonstrated in silico that (+)-Naltrexone 
binds to the µ opioid receptor (a key component of “liking”) at high micromolar 
concentrations. Further the binding energy was similar to DAMGO, a synthetic high 
affinity µ opioid receptor agonist. This study additionally demonstrated (+)-Naltrexone 
at high concentrations can displace [H3]Diprenorphine in HEK  µ opioid receptor over-
expression cell lines and rat brain membrane preparations. However, caution must be 
used when interpreting these findings as the concentrations of (+)-Naltrexone are 
much greater than those used in vivo and result in saturation causing non-specific 
binding.  
 
The concentrations of (+)-Naltrexone used in the aforementioned studies are thought 
to be insufficient to antagonize µ opioid receptor. Interestingly, a metabolite of 
Naltrexone, 6-β-Naltexol, is a µ opioid receptor antagonist in vitro and in vivo (Akala et 
al., 2008; Rodgers et al., 1980; Dayton & Inturrisi, 1976; Malspeis et al., 1975). 
Importantly, peripheral injection of 6-β-Naltrexol significantly reduces alcohol and 
sucrose drinking in rodents. However, higher concentrations were required compared 
to Naltrexone (Stromberg et al., 2002). Given that Naltrexone has a half-life of 
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approximately one hour in rodents, it raises the possibility that some of the effects such 
as reduced alcohol drinking and saccharin drinking in the acute studies (where (+)-
Naltrexone is administered up to 8 times over the course of the tests) may be 
attributable to 6-β-Naltexol and not to the parent compound. However, whether 6-β-
Naltrexol is found within the brain at physiologically relevant concentrations and is in 
the correct stereochemistry to exert biological activity following administration of (+)-
Naltrexone remains to be determined.  
  
Given the effects on the “liking” component of reward, the translational applicability of 
(+)-Naltrexone is questionable. Under naïve circumstances, alcohol is consumed 
principally for its euphoric properties – an effect attributable to the “liking” component 
of reward. Using (+)-Naltrexone to attenuate this effect is unlikely to be well received 
for occasional drinkers (unlike the benefit of attenuating dopamine) as it blocks the 
desired pharmacological effects. However, it may serve a purpose for teenagers or 
people at risk for developing an alcohol use disorder. By blocking the “liking” 
component of reward, the very reason to drink is removed potentially preventing the 
desire to consume more.  
 
8.7.2 Influence of circadian rhythm 
This is the first study to highlight how the efficacy of a TLR4-TRIF antagonist on 
alcohol-induced reward is dependent on circadian rhythm. While it may seem obvious 
that (+)-Naltrexone’s effect would be greatest during the phase in which rodents 
consume the most alcohol - as it is not limited by floor/ceiling effects owing to low levels 
of intake observed during the day; it does not explain why the preference ratio or 
conditioned place preference was reduced. In this thesis, it was postulated that the 
circadian fluctuation in genes pertaining to TLR4-TRIF pathway, thirst and the “liking” 
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and “wanting” components of reward underlie the altered efficacy of the drug. However, 
it is unclear whether and how this finding would impact human drinking behaviour.  
 
Interestingly specific polymorphisms within clock-related proteins such as PER and 
BMAL1 are correlated with alcohol consumption, abuse and anxiety in humans 
(Perreau-Lenz & Spanagel, 2015 for review) and like rodents, chronic alcohol 
consumption in humans disrupts the rhythmic expression of CLOCK proteins (Huang 
et al., 2010). Similarly, dopamine concentrations fluctuate throughout the day in 
humans, as does the function and cellular distribution profile of the immune system 
(Korshunov et al., 2017; Boivin, 2003). However, unlike rodents which exhibit a greater 
preference and intake of alcohol corresponding to the phase in which dopamine 
transmission and immune signalling is highest, humans do not. Rather, the acute 
consumption of alcohol is constrained by environmental factors such as work, school 
or social commitments. Consequently, alcohol intake usually occurs when humans 
have free times which is typically in the evening or afternoon (heading towards the 
inactive phase); a time of enhanced inflammatory immune activity and metabolism 
(Marcheva et al., 2013; Lange et al., 2010).  
 
This study adds to the growing field of chronotherapeutics: a field which considers 
circadian fluctuation in immune and neuronal behaviour as well as absorption, 
distribution and metabolism to determine the most effective time to administer a drug. 
Links between circadian rhythm, inflammation and disease severity have already been 
studied in the context of rheumatoid arthritis (RA). Studies have demonstrated that 
administration of glucocorticoids to coincide with peak nocturnal rise in IL-6 
significantly reduces joint stiffness and pain compared to when the same dose is taken 
in the morning. It is additionally hypothesised that these rhythmic fluctuations in 
cytokines may also be influencing psychiatric disorders which are comorbid with RA, 
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such as depression (Buttgereit et al., 2015). The study in this thesis is the first to 
demonstrate that the efficacy of a TLR4 antagonist is dependent on time-of-day. Future 
studies are required to determine whether the efficacy of clinically approved drugs to 
treat alcohol dependence depend on the time-of-day. 
 
8.8 The effects of TLR4 on alcohol priming  
The results from chapter 3 highlighted that acute exposure to alcohol increases the 
expression of TLR4 and its immune mediators, and that attenuation of TLR4-TRIF 
pathway reduces reward behaviour. The proceeding chapter sought to determine 
whether the rise in immune mediators persists for several weeks post exposure and if 
they subsequently contribute to reward behaviours later in life. Adolescent mice were 
examined as the effects of alcohol can be particularly detrimental during this 
developmental period. Further, unlike adults, adolescents often have significant 
abstinent periods from alcohol.  
 
Few studies have examined how TLR4 influences the molecular and behavioural 
consequences of alcohol-induced sensitisation during adolescence. The results 
presented in chapter 5 largely contrast those by Montesinos et al., (2016). Their study 
demonstrated adolescent alcohol exposure potentiated the “wanting” component of 
reward and anxiety behaviour but did not alter “liking” later in life as indicated by the 
48 h two bottle choice, elevated plus maze and saccharin intake respectively. 
Importantly, the effects of adolescent alcohol exposure were nullified in TLR4-/- mice. 
In contrast, our study demonstrated that adolescent alcohol exposure potentiated both 
alcohol “wanting” and “liking” but it did not alter anxiety behaviour later in life. Further, 
attenuating TLR4 prevented alterations to the “liking” (inferred by drinking in the dark) 
but not “wanting” component of reward nor did it alter anxiety behaviour. The 
discrepancies between the two studies are likely attributable to the strain of rodents, 
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the behavioural paradigms, genetic vs pharmacological antagonism of TLR4 and 
perhaps most importantly, the adolescent model of alcohol exposure. This highlights 
the need for further studies in this area. The study by Montesinos et al., (2016) used 
high doses of alcohol, and alcohol was administered for twice as long compared to the 
current study. This would likely have engaged the neuroimmune system more and 
could potentially recruit other neurological substrates which are more resilient to lower 
doses of alcohol such as the amygdala. This in turn would sensitise adolescence to 
reward and anxiety behaviours later in life to a greater extent than our study. 
 
By contrast, the model used in this study was designed to more closely resemble what 
occurs in humans. Most adolescents report consuming alcohol infrequently  (NIAAA, 
2017). The infrequent use may serve to limit the neuroimmune response towards 
alcohol thereby reducing the adverse effects associated with adolescent alcohol use – 
an effect mirrored in this study (no anxiety alterations were observed). Further, 
adolescent humans are more resilient towards the effects of alcohol than their rodent 
counterparts (Doremus-Fitzwater et al., 2015; Kane et al., 2013). While on average, 
most rodents who consume high levels of alcohol go on to develop behavioural deficits 
associated with alcohol use later in life, the same cannot be said for humans 
(McCambridge et al., 2011). Most adolescents who binge drink do not develop 
problems associated with alcohol use later in life. This is because neurodevelopment 
and alcohol dependence are multifactorial and are influenced by environmental and 
genetic processes. By contrast, laboratory mice which are genetically homogenous 
and reared in the same environment are likely to exhibit similar developmental and 
alcohol-related outcomes. 
 
In preclinical settings chronic high levels of alcohol are commonly administered 
resulting in profound neurodevelopmental alterations (Ward et al., 2014). This is 
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particularly problematic because this manner of alcohol exposure in rodents can 
exaggerate the behavioural and molecular consequences of alcohol use and thus no 
longer reflect what is occurring in humans. The problem is furthered as neurobiological 
models of human adolescent alcohol use are largely based upon results from rodent 
studies. Therefore, this study aimed to achieve better consilience between rodents and 
human’s alcohol exposure outcomes. 
 
The results from this study suggest that (+)-Naltrexone failed to modify adolescent 
alcohol potentiated “wanting” behaviour later in life despite a reduction in tyrosine 
hydroxylase mRNA. The increased “wanting” for alcohol imparted by adolescent 
alcohol exposure may be attributable to the persistent increases in dopamine receptors 
and the downregulation of GABA receptor mRNA, indicating that the reward pathway 
is sensitised towards dopamine and lacks inhibitory control respectively. By contrast 
TLR4-/- mice are protected against potentiated cocaine-induced CPP and 48 h alcohol 
intake imparted by adolescent alcohol exposure. This raises the possibility that either 
or both the MyD88 and TRIF pathways are required for the sensitization of the 
“wanting” component of alcohol reward. This suggests TLR4-TRIF may not be involved 
in the sensitisation of alcohol “wanting” or is part of a larger system which collectively 
regulates this aspect of reward. It is important to note that, the genes assessed only 
represent a small part of all the processes which are potentially modulated by alcohol. 
Thus, there may be other mechanisms which underlie why the increased “wanting” but 
not “liking” component of alcohol reward remained elevated.  
 
(+)-Naltrexone successfully reduced the adolescent alcohol potentiated “liking” 
component of reward as inferred by a reduction in alcohol intake during the drinking in 
the dark tests. These effects are unlikely due to the downregulation of Th and Gabra2 
mRNA. Rather the reduction in liking is likely related to the decreased expression of 
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Tlr4 or Ifnb (assuming the increases in mRNA translated to increases in protein). The 
mechanism behind how an IFNβ signal modulates the “liking” component of reward 
remains to be fully determined. However, associative evidence suggests IFNβ directly 
interacts with opioid and cannabinoid systems, key molecular mediators of “liking” 
(Downer et al., 2012; Lee et al., 2010; Wang et al., 2006; Jiang et al., 2000).  
 
The persistent upregulation of inflammatory mediators following adolescent alcohol 
exposure likely results from epigenetic remodelling of TLR4-related gene activity. 
Given these mediators remained elevated into neurobiological maturity it reinforces the 
findings that alcohol exposure during adolescence can result in long-lasting 
consequences. However, it is unclear whether, or how much, alcohol is required in 
humans before this type of remodelling (which is typically observed in rodents) occurs 
– a topic for future experiments. 
 
A key advantage of this study was the implementation of a pre- and post-treatment 
paradigm of (+)-Naltrexone. Pretreatment paradigms often have limited applicability in 
humans. However, they often provide insight into specific mechanisms in a preclinical 
setting. Despite this, few studies have evaluated how antagonists or agonists function 
once the pathology has commenced. Results from this study indicated there was no 
difference between the pre- and post-treatment paradigms regarding the behavioural 
or molecular endpoints (effect of order, p > 0.05). This indicates that attenuating TLR4 
signalling post alcohol exposure can still be beneficial to reduce increased alcohol 
“liking” and inflammatory gene transcription later in life: increasing the therapeutic 
relevancy of (+)-Naltrexone. However, 30 minutes is a relatively short time frame post 
exposure. Thus, it is likely that TLR4 signaling events triggered by alcohol are ongoing. 
For example, in vitro studies have shown TLR4-MyD88 interactions are ongoing 30 
min post alcohol exposure (Fernandez-Lizarbe et al., 2009). It would be interesting to 
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determine how far out from the initial exposure (+)-Naltrexone remains effective and 
whether adolescents would take a prophylactic medication given their risk-seeking 
nature. 
 
A key limitation of the studies in chapters 3, 5 and 7 is that sex differences were not 
widely explored or powered intentionally for specific analysis. A brief statistical analysis 
indicated there was no effect of sex on any behavioral or molecular outcomes in 
chapter 5. However, this finding largely contrasts those in both humans and rodents. 
For example, females consume more alcohol at a faster rate, exhibit heightened “liking” 
and “wanting” following alcohol exposure, display greater motor and cognitive 
impairment, have more severe withdrawal symptoms and are more likely to relapse 
sporadically than males (Foster et al., 2015; Schulte et al., 2009; Walter et al., 2005; 
Wilsnack et al., 2000). Further, female adolescent mice appear more sensitive to the 
long-lasting consequences of drugs of abuse with greater risk of consuming alcohol 
later in life (Mateos-García et al., 2015).  
 
Numerous factors have been attributed to sex differences including reproductive 
hormones, GABA, glutamate and endogenous opioid signalling. However, sex 
differences may also be attributable to alterations in TLR4-based neuroimmune 
activity. For example, female mice mount more robust immune responses than males, 
with increases in pro-inflammatory cytokines and glial activation following LPS (Doyle 
& Murphy, 2016). Further, in response to acute alcohol exposure, female mice exhibit 
more pronounced neuroinflammatory responses with greater elevations in glial 
reactivity, TLR4, IL-1β, TNFα, COX-2, iNOS and NFκB p65 expression in brain regions 
associated with reward (prefrontal cortex, VTA and nucleus accumbens) compared to 
males (Baxter-Potter et al., 2017; Pascual et al., 2016; Alfonso-Loeches et al., 2013). 
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However, whether these effects remain following chronic alcohol administration 
remains to be determined. 
 
Few studies have examined the effect of sex on TLR4, alcohol reward and anti-reward 
behaviours. Blednov et al., (2017b) demonstrated female TLR2-/- mice drank less than 
female wildtype mice – an effect absent in male mice. Further MyD88-/- male mice 
drank less than wildtype whereas female MyD88-/- did not. However, these authors did 
not compare male vs female drinking, limiting the findings of their results. Future 
studies are therefore required to fully elucidate the role sex-of-animal plays in TLR4-
induced reward behaviour.  
 
8.9 TLR4 alcohol and chronic reward and anti-reward 
Long-term alcohol use is associated with TLR4-dependent neuroplastic and epigenetic 
events, which assist in desensitising the reward pathway, recruiting the anti-reward 
pathway and from a neuroimmune perspective increase the likelihood of transcribing 
genes pertaining to the TLR4 pathway. The increase in TLR4 and its immune 
mediators further alter and augment reward and anti-reward behaviours respectively 
(in addition to the pre-existing neuronal changes which drive these behaviours). Thus, 
targeting TLR4 may alleviate some of the symptoms of acute withdrawal and lessen 
the rewarding components of alcohol prior to withdrawal.  
 
Given that (+)-Naltrexone reduced the immediate and priming of immune mediators 
and this coincided with a reduction (although not always consistently) in reward-like 
behaviour (conditioned place preference and two-bottle choice), we sought to 
investigate whether (+)-Naltrexone could reduce the rise in immune mediators 
following long-term alcohol exposure and whether this influenced reward and anti-
reward behaviours before and during withdrawal. Consistent with Harris et al., (2017), 
 463 
pharmacologically targeting the TLR4-TRIF pathway failed to reduce the “liking” or 
“wanting” of alcohol as inferred by sucrose and alcohol two-bottle choice tests before 
and during withdrawal. Further, targeting the TLR-TRIF pathway did not modify 
sucrose preference or intake (measures of anhedonia) or elevated plus maze 
performance (measure of anxiety) during withdrawal despite a reduction in immune 
mediators in the amygdala and nucleus accumbens. This highlights that acute 
blockade of TLR4-TRIF cannot overcome existing neuroplastic and epigenetic events 
which confer reduced and enhanced reward and anti-reward behaviours respectively. 
Interestingly, global knockout of TLR4 reduces alcohol drinking, sucrose deficits, 
elevated plus maze and open field test performance (indicators of reward and anti-
reward behaviour) during and before protracted withdrawal (two weeks post alcohol) 
(Pascual et al., 2011) suggesting either the MyD88 or both the MyD88 and TRIF 
pathways are required to modify reward and anti-reward behaviours following long-
term alcohol use. In support of this, TNFα, a cytokine which requires activation of the 
TRIF and MyD88 pathway for transcription, can sensitise mice to alcohol withdrawal 
and blocking TNFα can reduce CRF release in the amygdala, a key contributor of anti-
reward and reward behaviour (following long-term alcohol use) respectively (Knapp et 
al. 2011).  
 
There are many reasons why (+)-Naltrexone failed to modify reward and anti-reward 
behaviour (alcohol and sucrose preference, and elevated plus maze and open field 
test respectively). For example, the limited half-life of (+)-Naltrexone may result in a 
transient short-lived decrease in immune mediators; additional pattern recognition 
receptors, alcohol metabolites and stress hormones (see below) may additionally 
contribute to reward and anti-reward behaviours. Collectively these processes likely 
underscore the continual elevation in immune mediators thus propagating reward and 
anti-reward behaviours.  
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8.9.1 Role of alcohol’s metabolites 
A fundamental tenant of this study is that an alcohol-induced immune response (via 
TLR4) alters neurotransmission, plasticity and in turn reward and anti-reward 
behaviours. However, we are beginning to appreciate the role of ethanol’s metabolites 
in the immunological and neurobiological effects induced by alcohol consumption.  
 
Following acute intake, ethanol is metabolised in the liver to form acetaldehyde, a 
short-lived highly reactive compound, and then to acetate (Zakhari, 2006; Jones, 
1991). Following long-term alcohol intake, ethanol is metabolised in other organs, 
including the brain (Zakhari, 2006). In addition, long-term alcohol use results in non-
oxidative metabolism of alcohol increasing the number of metabolites for example, 
ethyl glucuronide, ethyl sulphate, free fatty acid esters such as ethyl pyruvate and 
phosphatidylethanol (a phospholipid bound to ethanol). Unlike acetaldehyde and 
acetate, these metabolites are long lasting, often persist for days to weeks and can be 
formed within the brain (Maenhout et al., 2013; Calabrese et al., 2001; Lundqvist et al., 
1994). Given these findings, it has been hypothesised that reward and anti-reward 
behaviours are partly attributable to the effects of ethanol’s metabolites. 
 
Interestingly, mice readily self-administer and exhibit conditioned place preference 
towards acetaldehyde (see Deng & Deitrich, 2008; Quertemont & Didone, 2006 for 
review). Further, this compound is a 1000 fold more potent at generating reward-like 
behaviour compared to its parent compound (ethanol) when self-administered into the 
VTA (Rodd-Henricks et al., 2002). Acetaldehyde can also induce aversive responses 
(as measured by conditioned taste aversion), anxiety, memory impairment and loss of 
righting reflex (Quertemont & Didone, 2006). Consequently, acetaldehyde is 
considered a contributor to the development of alcohol dependence and addiction. 
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Further, this metabolite can induce an immune response by increasing the expression 
of cytokines such as TNFα and CCL2; ROS production; and transcription factors 
including NFκB and MAPKs (Ceni et al., 2014; Redmond et al., 2009; Gomez-Quiroz, 
2003). Acetaldehyde is further hypothesised to cause intestinal permeability by 
disrupting tight junctions in the colon (Basuroy et al., 2005; Rao, 1998) and can act 
synergistically with LPS to potentiate immune response (Gutierrez-Ruiz et al., 2001). 
Given acetaldehyde acts in concert with LPS, it highlights a potential role of TLR4 in 
mediating this response. Thus, it raises the possibility that acetaldehyde increases 
TLR4 and neuroimmune activation, propagating ethanol reward and anti-reward 
behaviours.  
 
In addition, the long-lived minor metabolites such as ethyl-glucuronide directly activate 
TLR4 inducing NFκB activation (Lewis et al., 2013). This in turn results in exacerbated 
pain which can be reversed by (+)-Naloxone (Lewis et al., 2013).  Given TLRs pivotal 
involvement in the reward behaviours, it represents another mechanism whereby 
alcohol can cause long-term TLR4 activation. 
 
8.9.2 Role of additional pattern recognition receptors 
The mechanism underlying alcohol-induced TLR4 signalling remains to be determined. 
Early experiments hypothesised alcohol activated TLR4 directly (Blanco et al., 2005). 
However, subsequent studies have largely disproved this notion; instead studies have 
suggested alcohol promotes the release of HMBG1 which subsequently binds to, and 
activates TLR4 expressed on neurons and glia (Crews et al., 2017). However, the 
mechanism underlying the release of HMGB1 remains to be determined (I speculate it 
is likely due to alterations in osmotic stress or production of reactive oxygen species 
induced by local metabolism of ethanol) (Tsung et al., 2007). HMGB1 interacts with 
multiple pattern recognition receptors including TLR2, TLR4, TLR5, TLR9, RAGE and 
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the chemokine receptor, CXCR4 (Das et al., 2016; Yang et al., 2015; Yu et al., 2006) 
with the degree of engagement dependent on the reduced status of HMGB1 (Yu et al. 
2006). Further, HMGB1 release unlikely accounts for the acute effects of alcohol-
induced TLR4 signalling as in vitro studies have shown that HGMB1 is released 24 h 
post alcohol exposure (Lawrimore & Crews, 2017). 
 
Long-term alcohol use additionally increases intestinal permeability. This causes the 
translocation of PAMPs from the colon into the blood and liver, inducing TLR activation 
and the release of inflammatory mediators primarily from macrophages. These 
mediators subsequently cross the blood brain barrier and are hypothesised to induce 
a neuroimmune response (Cui et al., 2014; Mayfield et al., 2013). Consequently, the 
neuroimmune response towards alcohol is complex and is unlikely to be solely 
mediated by TLR4 which may explain why acute attenuation of TLR4 did not alter 
reward or anti-reward behaviour following long-term alcohol use. In support of this 
notion, alcohol increases the expression of multiple parallel neuroimmune pathways. 
For example, alcohol significantly up-regulates the expression of TLR2 on microglia 
and TLR3, RAGE and TLR7 on neurons (Coleman et al., 2017; Lawrimore & Crews, 
2017; Vetreno et al., 2013). Furthermore, the expression of TLR3 and RAGE also 
correlated with lifetime consumption of alcohol in humans (Vetreno et al., 2013). Taken 
together with the increase in expression of TLR4, this further highlights additional TLRs 
as key regulators of alcohol intake (Vetreno et al., 2013). However, few studies have 
considered the behavioural ramifications of the engagement of other TLRs in regards 
to alcohol’s pharmacodynamics. TLR2-/- mice are protected against alcohol-induced 
cytokine and chemokine increases (Pascual et al., 2015) motor impairment and 
sedation (Blednov et al., 2017a; Corrigan et al., 2015). Further, TLR2-/- but not MyD88-
/- or TLR4-/- mice consume significantly less alcohol but more saccharin compared to 
wildtype (C57BL/6J) mice across a range of drinking paradigms (Blednov et al., 2017b) 
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indicating that TLR2 modifies the aversive component or taste alcohol, as the “liking” 
component of reward was increased. Given that TLR2 exclusively signals through 
MyD88 it is unclear why TLR2-/-, but not MyD88-/- mice, do not display altered drinking 
behaviour. If TLR2 is contributing to the reward and anti-reward behaviours following 
long-term alcohol use it, it may provide an additional reason as to why (+)-Naltrexone, 
a TLR4-specific antagonist, failed to modify these behaviours before, and during 
withdrawal. Therefore, future experiments should examine whether and how other 
TLRs contributes to reward and anti-reward behaviours. 
 
8.9.3 Role of stress hormones 
A key driver of anti-reward behaviours (anxiety and anhedonia) are stress hormones 
and neuropeptides such as CRF, ACTH, NPY and dynorphin. These are initially 
upregulated to limit the effects of alcohol on the CNS (opponent B) but remain elevated 
even in the absence of alcohol creating stress-like behaviours including anxiety and 
depression. Importantly, these hormones and neuropeptides interact with TLR4 and 
the neuroimmune system to exacerbate withdrawal symptoms. For example, TNFα 
and CCL2, cytokines produced by alcohol-induced TLR4 activation, sensitise mice to 
alcohol withdrawal and exacerbate symptoms of anxiety and depression (Harper et al., 
2016; 2014; Ming et al., 2013). It is presently unclear whether and how the bidirectional 
relationship between stress and TLR4 augment withdrawal behaviours. Preliminary 
evidence demonstrates CRF augments the release of cytokines following TLR4 
stimulation (Hu et al., 2016), and CRFR1A antagonism reduces alcohol-induced TLR4 
and cytokine expression during withdrawal (Knapp et al., 2016; June et al., 2015; 
Whitman et al., 2013). Collectively these results suggest that in addition to its role in 
stress and anxiety during withdrawal from alcohol, CRF increases the production of 
TLR4-related cytokines and chemokines which further augment withdrawal-like 
behaviours (anxiety and relapse) in mice (Knapp et al., 2016; June et al., 2015).  
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8.10 Translational applicability 
Modelling alcohol dependence and the consequential behavioural and molecular 
alterations in rodents is difficult (Ripley & Stephens, 2012). This problem is further 
confounded as there is no universally accepted theory of addiction nor is there likely 
to be a single theory which can adequately account for such a diverse, complex and 
multifactorial disorder. Further, we are only beginning to appreciate that like depression 
and autism, alcohol dependence is a spectrum disorder with different population 
subtypes more susceptible to specific triggers and treatments. While rodent models 
can model particular aspects of the disorder, the results obtained in these studies are 
subject to interpretation and may be modelling an entirely different phenomena and 
biological process than what is observed in the clinic. This may be a key reason why 
so many drugs have failed in clinical trials. 
 
Preclinical research has demonstrated the importance of TLR4 and the neuroimmune 
system in models of alcohol dependence in rodents. It is unclear whether this system 
plays a role in the pathogenesis of alcohol dependence in humans. Post-mortem 
studies demonstrate increased glial reactivity in the prefrontal cortex, entorhinal cortex 
and hippocampus in alcohol dependent subjects compared to healthy controls (He & 
Crews, 2008). Alcohol dependent subjects exhibit increased expression of TLR2, 3, 4, 
RAGE and HMGB1 in the orbitofrontal cortex compared to controls; an effect which 
correlates with the estimated life-time consumption of alcohol (Vetreno et al., 2013). 
Furthermore, microarray data identified immune genes are differentially expressed in 
the brains of alcohol dependents compared to controls (Ponomarev et al., 2012; 
Lewohl et al., 2011; Jianwen Liu et al., 2005). Importantly, there are commonalities 
between the expression of neuroimmune-related genes in the brains of humans and 
mice suggesting similar pathways are activated between the two species following 
long-term alcohol use (Tabakoff et al., 2008; Mulligan et al., 2006). Of increasing 
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interest are pathways relating to NFκB (Ökvist et al., 2007). Okvist et al., (2007) 
demonstrated the expression of NFκB p65-p50 heterodimer and p50-p50 homodimers 
were increased in the brains of alcohol dependents compared to controls. Further, the 
DNA binding of NFκB was increased and 479 NFκB-dependent genes were 
differentially regulated between alcohol dependents and control individuals highlighting 
the potential importance of this transcription factor in alcohol addiction (Liu et al., 2009; 
Ökvist et al., 2007). However, no study has indicated whether neuroimmune signaling 
occurs within the human brain and whether this can modify reward or anti-reward 
behavior. 
 
Alcohol dependent subjects additionally exhibit increased circulating LPS, a key 
mechanism which is thought to underlie neuroimmune activation. Alcohol renders the 
lumen of the intestines “leaky” enabling the translocation of microbial products such as 
LPS into systemic circulation. Binge drinkers and non-cirrhotic  alcohol dependence 
have increased circulating LPS compared to individuals who drink in moderation 
(Leclercq et al., 2014; 2012; Ward et al., 2014) a finding mirrored in vivo (Mandrekar 
& Szabo, 2009). Furthermore, the immune system of binge drinkers and alcohol 
dependents were sensitized, exhibiting increases in cytokines and MAPKs. The rise in 
immune mediators was transient and resolved three weeks after withdrawal. During 
the withdrawal processes however, the expression of circulating cytokines correlated 
with alcohol consumption and alcohol craving scores (Leclercq et al., 2014; 2012). 
Interestingly, the anti-inflammatory cytokine IL-10 was inversely correlated with 
measures of anxiety, depression and craving three weeks post exposure, indicating a 
potent role of IL-10 in modulating the psychological responses about alcohol – an effect 
reinforced by in vivo observations (Marshall et al., 2016). This reinforces the 
hypothesis that cytokines cross the blood brain barrier and affect brain function 
pertinent to alcohol reward and anti-reward. 
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These caveats have not detracted researchers trialing a glial attenuator to treat alcohol 
dependence. The phase 1 clinical trial of Ibudilast demonstrated that the drug is safe 
and with few adverse effects. Initial experiments determined there was no effect of 
Ibudilast on the levels of craving, stimulation, sedation, positive mood, “liking” and 
“wanting” behaviour. However, Ibudilast decreased aspects of negative mood following 
alcohol exposure and was associated with mood improvements and reduced 
measures of stress and alcohol cue exposure and basal levels of craving. This effect 
was more pronounced in individuals with higher depressive symptoms but not higher 
alcohol use (Ray et al., 2017). Even though this study was not designed to address 
efficacy, Ibudilast attenuated measures mainly associated with relapse but not the 
rewarding properties of alcohol. This suggest that the neuroimmune activation in 
humans plays a much greater role in influencing withdrawal and craving than it does 
in reward. This idea is furthered by examining the efficacy of Ibudilast in opioid 
withdrawal in opioid addicts. Ibudilast reduced the withdrawal symptoms of anxiety, 
perspiration, restlessness and stomach cramps compared to the placebo control group 
(Cooper et al., 2015).   
 
While Ibudilast has shown promise in its ability to mitigate aspects of withdrawal, it is 
unlikely (+)-Naltrexone will be used for alcohol dependence. (+)-Naltrexone was 
unable to modify aspects of reward or anti-reward behavior. Furthermore, given it 
downregulates tyrosine hydroxylase mRNA, it may worsen symptoms of anhedonia 
which are characterised by dopamine deficiency – thus propagating relapse.  
 
8.11 Is TLR4 a good therapeutic target for the treatment of addiction and 
dependence? 
From a pharmacological perspective, TLR4 is an attractive therapeutic target. This is 
due, in large part to the functional redundancies of Toll-like receptors. Each TLR 
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recognises specific molecular epitopes present on bacteria and viruses (Takeuchi & 
Akira, 2010). However, each bacteria and virus has thousands of epitopes each of 
which are recognised by various TLRs and other pattern recognition receptors. 
Consequently, attenuating one TLR may reduce the ability to detect specific parts of 
bacteria, yet additional TLRs can compensate for the loss, thus limiting the 
immunosuppressive effects of TLR antagonists (Bachtell et al., 2015; Akira & Takeda, 
2004). This is particularly pertinent for individuals who consume alcohol, as this drug 
causes immunosuppression and immune dysfunction in the periphery. Unfortunately, 
antagonising TLR4 within the central nervous system is problematic. Traditional high 
affinity and specific TLR4 antagonists such as LPS:RS do not readily cross the blood 
brain barrier (Banks & Robinson, 2010). Consequently, lower affinity TLR4 antagonists 
such as (+)-Naltrexone and T543216 are used. These compounds are further limited 
by their short-half lives and potential off-target side effects thus limiting their efficacy 
(Wang et al., 2016; Chavez et al., 2011). A new longer lasting, high affinity TLR4 
antagonist is therefore required.   
 
(+)-Naltrexone attenuates the “liking” and “wanting” components of reward following 
acute alcohol use but has limited efficacy following long-term alcohol use. Therefore, 
(+)-Naltrexone may prove fruitful for preventing the transition from occasional use to 
dependence, or mitigate some of the detrimental effects of adolescent alcohol use. 
However, given this drug downregulates Th and Gabra2 mRNA, it is unlikely to be 
beneficial following long-term exposure as these processes assist in creating 
anhedonia and compulsivity respectively (Wise, 2004). Future studies should 
determine whether higher doses or a longer duration of (+)-Naltrexone treatment is 
effective at reversing the increase in immune mediators and drinking behaviour 
following long-term alcohol use.  
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However, viewing addiction and dependence as a purely molecular disease is 
restrictive. Addiction and dependence arise from a plethora of reasons including family 
history, genetics, behavioural traits and socio-economic states and psychological 
reasons such as; impulsivity, detrimental learned coping mechanisms, low self-
esteem, depression, stress, resilience and developmental maturity (for example Velez 
et al., 2017; Verdejo-Garcia et al., 2017; Yap et al., 2017; Hägele et al., 2014; Merrill 
& Read, 2010). Further, one’s environment plays a pivotal role in the progression of 
alcohol addiction and dependence. For example, if an individual’s motivator to 
consume alcohol is due to stress from work or home-life using a TLR4 antagonist or 
any molecular antagonist is unlikely to treat the underlying cause. Thus, any 
pharmacological approach should occur in conjunction with psychological counselling.  
 
8.12 Conclusion 
The studies carried out in this thesis aimed to better determine which TLR4 pathway 
was elevated following various alcohol exposure paradigms. Acute and chronic alcohol 
exposure increased all aspects of the TLR4 pathway including co-receptors, the 
MyD88 and TRIF pathway and endogenous agonists. In contrast, acute exposure 
followed by a period of deprivation resulted in a persistent increase in Tlr4, Trif and 
Ifnb suggesting that only the TRIF but not MyD88 pathway remains in a sensitised 
state. 
 
This thesis additionally sought to address whether acutely attenuating the TLR-TRIF 
pathway via (+)-Naltrexone would successfully reduce the “liking” and “wanting” of 
reward generated by acute alcohol intake; the reward-priming effect of adolescent 
alcohol use; and the reward and anti-reward behaviours following long-term alcohol 
use. The results suggest (+)-Naltrexone reduced “liking” and “wanting” components of 
reward following acute use. However, (+)-Naltrexone had limited efficacy reversing the 
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reward sensitising effects of adolescent alcohol use and had no effect on anti-reward 
and the “liking” and “wanting” components of reward following long-term use. 
Consequently, this drug may be beneficial for people at risk of developing alcohol 
dependence by blocking the transition from impulsive to compulsive behaviour, but it 
is unlikely to have any therapeutic benefit for treating alcohol dependence.  
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Appendix: Pharmacological characterisation of the action 
of alcohol and (+)-Naloxone in BV2 cells 
9.1 Introduction 
Neuroimmune activation has recently been implicated as a key mechanism underlying 
drugs of abuse-related behaviours including cognitive dysfunction, pain, anxiety, 
depression and addiction (Crews & Vetreno, 2015; Cui et al., 2014; Hutchinson et al., 
2011). Particular emphasis has been placed on microglia as crucial mediators 
underlying drug-related behaviours (Cadet & Bisagno, 2014; Cui et al., 2014; Kovács, 
2012). Microglia are the primary immune cells within the central nervous system and 
in response to drugs of abuse such as cocaine and opioids, they become activated 
and shift their phenotype to one more in line with an immune response (see Lacagnina 
et al., 2016; Coller & Hutchinson, 2012, for review). This typically manifests as 
elevations in cytokines, reactive oxygen species, proteases and immune-related 
transcription factors (for example, Liao et al., 2016; Wang et al., 2012). Crucially, drug 
of abuse-induced immune responses is lower in magnitude when compared to those 
induced by traditional immunogens such as the bacterial cell wall component, 
lipopolysaccharide (LPS) (Wang et al., 2012). The comparatively reduced immune 
response occurs within discreet brain regions (typically associated with addiction and 
depression) and are therefore thought to function more akin to neurotransmitters than 
their traditional inflammatory role (see Lacagnina et al., 2016 for review). This finding 
is further supported as attenuating cytokines, immune-related transcription factors or 
microglia alter neuronal signalling and in turn adverse behaviours induced by drugs of 
abuse such as addiction (Marshall et al., 2016a; 2016b; Bell et al., 2015; Beardsley et 
al., 2010; Bland et al., 2009; Hutchinson et al., 2009). Consequently, identifying the 
mechanism which underlies drug of abuse-induced microglial activation is of 
importance. 
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Crucially, the mechanism underlying drug-induced microglial activation is beginning to 
be elucidated. Both opioids and cocaine are thought to bind to Toll-like receptor 4 
(TLR4), a pattern recognition receptor, originally characterised as the receptor 
detecting LPS (Northcutt et al., 2015; Hutchinson et al., 2010). TLR4 is broadly 
expressed throughout the central nervous system however, the highest level of 
expression is on microglia (Bsibsi et al., 2002). Binding to this receptor either on 
microglia or other neuroimmune cells results in the activation of two divergent 
signalling pathways; MyD88 and/or TRIF (Akira & Takeda, 2004). Activation of the 
MyD88 pathway leads to the activation of early phase NFκB and the upregulation of 
proinflammatory cytokines such as IL-1β and TNFα. Activation of the TRIF pathway 
leads to late phase NFκB and IRF3 activation, and the upregulation of type one 
interferons and anti-inflammatory cytokines (Akira & Takeda, 2004). While other 
neuroimmune cells additionally express TLR4 it is unclear whether they possess the 
necessary co-receptors and signalling pathways to induce a prototypical immune 
response. Hence the activation of TLR4 on these cells may result in a different 
outcome when compared to a microglial TLR4 response (Okun et al., 2011).  
 
Both opioids and cocaine are thought to bind to TLR4 activating the MyD88 and TRIF 
pathways (Northcutt et al., 2015; El-Hage et al., 2011; Hutchinson et al., 2010). 
However, the TLR4 response towards other drugs of abuse, such as alcohol is 
ambiguous with in vitro, ex vivo and in vivo studies reporting conflicting results. For 
example, studies have shown that alcohol activates both MyD88 and TRIF pathways; 
potentiates but does not initiate a TLR4 signal; or attenuates a TLR4 response 
(Lawrimore & Crews, 2017; Marshall et al., 2013; Goral et al., 2011; Fernandez-Lizarbe 
et al., 2009; Qin et al., 2008; Lee et al., 2004).  
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Consequently, an aim of this study was to determine whether alcohol induces or 
modulates an immune response in vitro with microglia-like cells (BV2 cells). Given 
TLR4’s pivotal role in the immune activating actions of opioids and cocaine, this study 
further sought to examine how attenuating TLR4 may influence the immune response 
elicited by alcohol. To address this aim, both traditional and novel TLR4 antagonists 
were utilised. Although traditional TLR4 antagonists such as LPS:RS are potent TLR4 
modulators, their poor brain penetrance limits their translatable efficacy (Banks & 
Robinson, 2010). By contrast, (+)-Naloxone, an enantiomer of (-)-Naloxone has high 
brain penetrance and therefore represents a more translatable antagonist (Wang et 
al., 2016; Selfridge et al., 2015). Interestingly, recent research has demonstrated that 
(+)-Naloxone is a biased TLR4 antagonist; selectively inhibiting the TLR4-TRIF 
pathway (Wang et al., 2016). Whether LPS:RS exhibits biased antagonism remains to 
be fully determined. 
 
9.2 Methods 
9.2.1 Cell culture 
BV2 microglia-like cells (Blasi et al., 1990) were maintained in Dublecco’s Modified 
Eagle Media (DMEM) (Sigma-Aldrich, NSW, Australia) supplemented with 10 per cent 
(v/v) Fetal Bovine Serum (Life Technologies, CA, USA), 2mM L-glutamine (Sigma-
Aldrich), 50U/mL Penicillin + 50ug/mL Streptomycin (Sigma-Aldrich) and 100ug/mL 
Normocin (Invivogen, CA, USA). Cells were grown in a humidified incubator (5 per cent 
CO2/ 95 per cent air) at 37oC.  
 
BV2 cells were seeded at differing densities reflecting the molecular analysis endpoint. 
For cell viability, immunocytochemistry, protein and mRNA isolation experiments, cells 
were seeded at 1x104cells/well in 96 well plates, 2x104 cells/well in 24 well plates and 




(+)-Naloxone, a pharmacological TLR4 antagonist was synthesised and supplied by 
Dr Kenner Rice (Chemical Biology Research Branch, National Institute on Drug Abuse 
and National Institute of Alcohol Abuse and Alcoholism, MD, USA). Ethanol (99.5%) 
(herein referred to as alcohol) was purchased from Chemsupply (Gliman, SA, 
Australia). Ultrapure Lipopolysaccharide and Lipopolysaccharide from Rhodobacter 
sphaeroides (LPS:RS) were purchased from Invivogen. All drug stocks were made in 
phosphate buffered saline (PBS) and working solutions were diluted in serum free 
media (DMEM + L-glutamine). 
 
9.2.3 Experimental Design 
9.2.3.1 Immunological characterisation of alcohol 
The first series of experiments aimed to determine whether alcohol can induce an 
immune response in BV2 cells. BV2 cells were incubated with 100mM of alcohol for 
0.5, 2, 4 or 24 h reflecting the desired molecular analysis (figure 1a). LPS (100ng/mL), 
a known TLR4 agonist, and volume matched PBS (vehicle) were included as positive 
and negative controls respectively. The concentration of alcohol selected for this study 
was based upon previous findings demonstrating that this concentration successfully 
upregulates proteins and mRNA belonging to the TLR4 pathways (Lawrimore & Crews, 
2017; Fernandez-Lizarbe et al., 2009). Similarly, the duration of alcohol exposure was 
based upon previous studies indicating TLR4-related cytokines and transcription 
factors were upregulated approximately 4 and 24 h post exposure (Lawrimore & 
Crews, 2017; Fernandez-Lizarbe et al., 2009). The concentration of LPS was selected 
based upon a dose response (supplementary figure s1 and s2) demonstrating 
moderate expression of cytokines with comparatively low amounts of cell death.  
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A second series of experiments aimed to determine whether alcohol modulates a TLR4 
response in BV2 cells. BV2 cells received a pretreatment of alcohol (100mM) or vehicle 
(volume-matched PBS) for 0.5 h, after which, LPS (100ng/mL) or vehicle (volume-
matched PBS) was added to the wells. Cells were incubated in the pretreatment + 
treatment (co-treatment) for a further 24 h (figure 1b).  
 
9.2.3.2 Characterisation of (+)-Naloxone’s pharmacology 
To ascertain how (+)-Naloxone modulates TLR4 signalling BV2 cells were pretreated 
with (+)-Naloxone (100 – 800 uM), LPS:RS (200ng/mL) or vehicle (volume-matched 
PBS) for 0.5 h after which LPS (100ng/mL) or vehicle (volume-matched PBS) was 
added to the wells. Cells were incubated in the co-treatment for a further 0.5, 2, 4 or 
24 h depending on the experiment (figure 1c).  
 
9.2.4 Protein isolation and western blotting 
Following completion of the drug treatments, the supernatant was collected and spun 
down (500g for 10min at 4°C) to remove any suspended cells. The supernatant was 
subsequently aliquoted into separate tubes without disturbing the resulting pellet. The 
supernatant was stored at -80°C. 
 
After removal of the supernatant, adherent cells were washed 3 times with ice cold 
PBS. Cells were subsequently incubated with 100uL of RIPA buffer on ice for 10 min. 
Cell lysates were then harvested, placed into 1.5mL tubes, and mixed using a rotatory 
mixer for 1 h at 4°C. Cell lysates were then centrifuged for 10 min at 20,000g (4°C) to 
remove cellular debris. The supernatant was transferred to a new tube and protein 
concentration was quantified. 
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Protein concentration was determined using the Pierceä BCA Protein Assay Kit 
(Thermo Fisher, MA, USA) as per manufacturer instructions. Protein samples were 
normalised to 1.25ug/uL by diluting sample in Laemmli and RIPA buffer. Samples were 
then stored at -80°C.  
 
Twenty-five micrograms of total protein (cell lysates) and 60uL of supernatant were 
resolved onto 4 – 12 or 12 per cent gradient bis-tris gels (Boltä, Thermo Fisher) for 5 
min at 180 V followed for a further 38 min at 200 V. Samples were subsequently 
transferred to a nitrocellulose membrane (BioRad, CA, USA) at 20 V for 1 h. After the 
transfer was complete, the membrane was stained for protein using Ponceau S 
(Sigma), washed and blocked with 5 per cent skim milk in Tris-buffered saline for 2 h 
at room temperature. The membrane was then stained with the following primary 
antibodies overnight at 4°C; Actin (Sigma-Aldrich A2066, 1: 2000), CCL5 (ab10394, 
Abcam, Cambridge, UK, 1:250), IRF3 (ab68481 Abcam, 1:1000), IFNβ (ab85803, 
Abcam, 1:1000) and NFκB p65 subunit (ab16502, Abcam,1:500). The following day, 
the membrane was washed 3 times with Tris-buffered saline + 0.05% Tween20 
(Sigma) and then incubated with donkey anti-rabbit and goat anti-rat antibodies 
containing 700 or 800nm fluorophores (925-68073 and 925-32219, Li-Cor, NE, USA, 
1:10,000) for 1 h at room temperature. The membranes were developed using an 
Odyssey Imaging System (Li-Cor).  
 
9.2.5 Enzyme-linked immunosorbent assay (ELISA) 
The expression of IL-1β and TNFα from cell supernatant and lysates were analysed 
using Mouse IL-1β and Mouse TNFα ELISA MAXä kits (BioLegends San Diego, CA, 
USA) as per manufacturer instructions. Samples were diluted in a ratio of 1:10 
(sample:assay diluent) for the TNFα ELISA. Absorbance was measured at 450nm with 
540nm reference using Synergy MX plate reader (Biotek, VT, USA). 
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9.2.6 mRNA isolation and PCR 
RNA was isolated using Maxwell® 16 LEV simply RNA Tissue Kit (Promega, Madison, 
WI, USA) as per manufacturer instructions. RNA was quantified using 
spectrophotometric analysis, with the quality of RNA verified by the OD260/280 ratio. 
900 ng of RNA was reversed transcribed into cDNA using iScriptTM cDNA reverse 
transcription kit (BioRad, Hercules, CA, USA) as per manufacturer instructions. 
 
Gene expression was assessed using iTaqTM Universal SYBR® Green Supermix (as 
per manufacturer instructions). Real time PCR was performed using the CFX96 
TouchTM Real-Time PCR Detection System (BioRad). All primers were synthesised by 
Integrated DNA Technologies Pte. Ltd. (Baulkham Hills, NSW, Australia) with their 
sequences outlined in the supplementary materials (Table 1).  
 
The relative difference in expression level of each of the genes of interest were 
normalised to the CT of GAPDH for both the test and control sample. The ΔCT of the 
test sample was normalised to the ΔCT a control sample (equal amount of cDNA from 
all samples), and then expressed as a ratio (2-ΔΔCT). This determined the relative fold 
change in expression.  
 
9.2.7 Immunocytochemistry 
9.2.7.1 Immunocytochemistry protocol 
The translocation of NFκB p65 subunit and IRF3 was quantified using 
immunocytochemistry. In brief, BV2 cells were plated onto poly-D-lysine coated cover 
slips. After 24 h, cells underwent their respective treatments and were subsequently 
stained with Wheat Germ Agglutinin 633 (Molecular Probes, OR, USA) for 10 min at 
37°C and fixed using 4 per cent paraformaldehyde + 5 per cent sucrose for 10 min at 
room temperature. Cover slips were washed 3 times with PBS, blocked with 5 per cent 
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skim milk for 10 min and stained for NFκB p65 subunit (ab16502, Abcam,1:500) or 
IRF3 (ab68481, Abcam, 1:200) overnight at 4°C. Secondary antibodies (donkey anti-
rabbit IgG 488, Invivogen, 1:1000) and nuclear stain DAPI (Invivogen 1:10000) were 
then applied to the coverslips for 1 h at room temperature. Coverslips were then 
washed 3 times in PBS and inverted onto microscope slides for imaging.  
 
9.2.7.2 Quantification of translocation and colocalisation 
9.2.7.2.1 Nucleus: total cell ratio 
Using the WGA channel, 10 cells were selected and a line drawn along the longest 
diameter of the cell. Using the RGB profiler plugin in Fiji (Image J) (Schindelin et al., 
2012), the edges of the nucleus and cytoplasm were delineated. The mean grey 
intensity value was then calculated for NFκB p65 or IRF3 channels within the nucleus 
(between the two DAPI peaks) and within the cytoplasm (between the WGA peaks – 
nucleus). To determine the ratio of nucleus to total cell intensity, the nucleus intensity 
was divided by the total mean grey intensity (nucleus + cytoplasmic). This generated 
a ratio where by x > 0.5 indicates the greatest intensity resides in the nucleus; x < 0.5 
indicates the greatest intensity resides in the cytoplasm; and x = 0.5 indicates equal 
intensity in the nucleus and cytoplasm.  
 
9.2.7.2.2 Pearson’s correlation coefficient and Spearman’s Rank Value 
To verify the results obtained using RGB profiler and pixel intensity, Pearson’s 
correlation coefficient and Spearman’s Rank Value were performed as per the coloc2 
plugin in Fiji. In brief, the correlations assess whether pixels from two separate 
channels (for example 405 (DAPI) and 488nm (NFκB p65 subunit and IRF3) channels) 
overlap in the same space relative to a set of randomised pixels. 
 
 504 
9.2.8 Cell viability assays 
9.2.8.1 Neutral red 
The neutral red assay is a quantitative measurement of cell cytotoxicity in vitro and 
was performed as outlined by (Repetto et al., 2008). In brief, cells were incubated in 
neutral red medium (40ug/mL) for 2 h at 37oC (5 per cent CO2/ 95 per cent air), washed 
with PBS and incubated with the neutral red destain solution with gentle agitation. After 
10 min, the plate was measured at 540nm using the Synergy MX plate reader.  
 
The neutral red assay is based on the premise that living cells will retain the neutral 
red solution and therefore will produce higher absorption values at 540nm. By contrast, 
dead/dying cells do not retain the neutral red solution and will therefore exhibit lower 
absorption values. 
 
9.2.8.2 Lactate dehydrogenase 
The lactate dehydrogenase assay measures the cytosolic release of lactate 
dehydrogenase into the supernatant and is used to infer cellular injury (Danpure, 
1984). It was performed as per manufacturer instructions (Piece LDH Cytotoxicty 
Assay Kit, Thermo Scientific). Absorbance was measured at 490 and 680nm using the 
Synergy MX plate reader. LDH activity was determined by subtracting the 680nm from 
the 490nm absorbance value. A low absorption value indicates the concentration of 
lactate dehydrogenase in the supernatant is small suggesting low amounts of cellular 
injury. Higher absorption values indicate greater cellular injury as more lactate 
dehydrogenase is present in the supernatant. 
 
9.2.9 Alcohol concentration assay 
The concentration of alcohol in the supernatant was measured using a commercial kit 
(ADH-NAD Reagent Multiple Test Vial; Sigma-Aldrich) and performed as per the 
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manufacturer instructions. In brief, it estimates alcohol-induced reduction of 
nicotinamide adenine dinucleotide (NAD+) to NADH in the presence of alcohol 
dehydrogenase. The reaction is observed by recording the absorbance of 340 nM from 
the solution. High and low levels of absorption indicate higher and lower amounts of 
alcohol in the supernatant respectively. 
 
9.2.10 Statistical analysis 
Experiments 1 and 2: immunomodulatory effects of alcohol 
ELISA, western blot, immunocytochemistry, neutral red and lactate dehydrogenase 
assays were analysed using a two-way ANOVA with Tukey post-hoc (time x treatment 
or pretreatment x treatment). qPCR was analysed using a two-way ANOVA with 
Bonferroni post-hoc (time x treatment or pretreatment x treatment). 
 
Experiments 3 and 4: characterisation of (+)-Naloxone 
ELISA, western blot, immunocytochemistry, neutral red and lactate dehydrogenase 
assayswere analysed using a two-way ANOVA with Tukey post-hoc (concentration x 
treatment or pretreatment x treatment). qPCR was analysed using a two-way ANOVA 
with Bonferroni post-hoc (pretreatment x treatment). 
 
All summary values presented as mean ± standard error of mean (SEM). p-values ≤ 




ICC; immunocytochemistry; LPS, lipopolysaccharide; mRNA, messenger RNA; S/N 
supernatant. 
 
Figure 1 Experimental timeline. To determine whether alcohol induces an immune 
response which parallels a TLR4 response in BV2 microglia-like cells, cells were 
incubated with alcohol, LPS or vehicle. Cell lysates, mRNA and supernatant were then 
collected for ICC (T0.5 and T2), gene expression analysis (PCR) (T4) and protein 
analysis (ELISA and western blots, T4 and T24) (a). To determine whether alcohol 
modifies a TLR4 response, cells were pretreated with alcohol or vehicle for 0.5 h and 
then stimulated using LPS or vehicle for 4 or 24 h. The treatments of LPS or vehicle 
occurred in the presence of the pretreatments (alcohol or vehicle). Cell lysates, mRNA 
and supernatant were then collected to determine whether the alcohol alters the 
expression of cytokines and transcription factors using ELISAs and western blots (b). 
To characterise the pharmacology of (+)-Naloxone, cells were pretreated with either 
 507 
vehicle, LPS:RS or various concentrations of (+)-Naloxone (100 – 800uM). After 0.5 h 
cells were stimulated with LPS or vehicle in the presence of the pretreatment. Cells 
were collected for ICC, gene expression analysis (PCR) and protein analysis (ELISA 




9.3.1 Experiment 1: Does alcohol induce a TLR4 response in BV2 cells? 
To determine whether alcohol induces an immune response which is similar to (albeit 
lower in magnitude) LPS, a traditional TLR4 agonist, BV2 cells were incubated with 
100mM of alcohol. After 0.5 – 24 h, proteins and genes pertaining to the TLR4 
signalling pathways were assessed. The expression of IL-1β, TNFα, IFNβ and CCL5 
in cell supernatant and lysates were selected as they represent prototypical end-
products of the MyD88 (IL-1β and TNFα) and the TRIF (IFNβ and CCL5) pathways. 
This would allow us to determine whether biased agonism/antagonism was present 
with the compounds being tested. However, the supernatant expression of IFNβ, and 
the supernatant and lysate expression of CCL5 was not detected following any drug 
treatment using western blots.  
 
A two-way ANOVA determined the supernatant expression of TNFα and the lysate 
expression of IL-1β, IFNβ and TNFα were significantly influenced by time (4 h vs 24 h) 
(figure 2) (p < 0.05 for all cytokines, see supplementary material for precise statistical 
information). Post hoc analysis determined the greatest expression of these cytokines 
occurred at 24 h. By contrast the expression of IL-1β in the supernatant was not altered 
by time (effect of time, F(1, 5) = 0.49, p = 0.51) with similar expression at 4 and 24 h.  
 
There was a significant effect of treatment (vehicle vs LPS vs alcohol) on the 
expression of IL-1β and TNFα from cell supernatant and lysates (p < 0.0001 for all 
cytokines, see supplementary material for precise statistical information). Tukey post 
hoc analysis determined LPS significantly potentiated IL-1β and TNFα expression 
compared to vehicle and alcohol at 4 and 24 h. Crucially, there was no post hoc 
difference between alcohol and vehicle at either time point indicating a similar level of 
expression between these treatments. By contrast, the lysate expression of IFNβ was 
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not significantly influenced by treatment (effect of treatment, F(2, 10) = 1.17, p = 0.36). 
No post hoc differences were found between the groups. Collectively, the results 
suggest LPS but not alcohol increases the expression of proteins pertaining to the 
MyD88 but not TRIF pathway following 4 and 24 h of exposure. 
 
To infer whether these drugs modulate the transcription of the assessed proteins, 
qPCR was performed on Il1b, Tnfa, Ifnb and Ccl5 genes (figure 3). Unlike protein 
expression, a two-way ANOVA determined there was no effect of time on the 
expression of Il1b, Tnfa, Ifnb and Ccl5 (p > 0.05, see supplementary material for 
precise statistical information). There was however, a significant effect of treatment for 
the expression of Il1b (effect of treatment, F(2, 6) = 7.86, p = 0.041), Tnfa (effect of 
treatment, F(2, 6) = 10.48, p = 0.026) and Ifnb (effect of treatment, F(2, 6) = 29.94, p = 
0.0039) but not Ccl5 mRNA (effect of treatment, F(2, 6) = 0.19, p = 0.83). Bonferroni 
post hoc analysis determined LPS significantly potentiated the expression of Il1b, Tnfa 
and Ifnb mRNA compared to vehicle and alcohol at 4 h, however, by 24 h the difference 
was mitigated. There was no difference between vehicle and alcohol across any gene 
or time point. Collectively, the results suggest LPS but not alcohol increases the 
expression of mRNA pertaining to the MyD88, and some aspects of the TRIF pathways 
following 4 h of exposure. 
 
To determine whether these compounds alter the expression of transcription factors 
which may underlie the differences in gene expression, western blots were performed 
on NFκB p65 subunit and IRF3 (figure 4). A two-way ANOVA determined time 
significantly influenced the expression of p65 (effect of time, F(1, 4) = 5.04, p = 0.088) 
and IRF3 (effect of time, F(1, 4) = 17.05, p = 0.015). However, only the expression of 
p65 in vehicle treated cells differed between time points (Tukey post hoc). Further, 
there was a significant effect of treatment for p65 (effect of treatment, F(2, 8) = 12.78, p 
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= 0.032) but not IRF3 expression (effect of treatment, F(2, 8) = 1.17, p = 0.36). There 
was a significant increase in p65 expression at 24 h following LPS treatment compared 
to vehicle and alcohol (post hoc). There was no difference in p65 or IRF3 expression 
between vehicle and alcohol across any time point. 
 
To determine whether these compounds alter the potential activity of NFκB p65 and 
IRF3, immunocytochemistry was performed to see if these transcription factors 
translocate to the nucleus after 0.5 and 2h respectively (figure 5). A two-way ANOVA 
evaluating the staining intensity of the nucleus (or cytoplasm) to the total cell 
determined a significant effect of cellular compartment (nucleus vs cytoplasm) on the 
expression of NFκB p65 (effect of compartment, F(1, 4) = 6.38, p = 0.045) and IRF3 
(effect of compartment, F(1, 4) = 54.67, p = 0.0018). Tukey post hoc analysis determined 
there was significantly greater expression of p65 and IRF3 in the cytoplasm in vehicle 
and alcohol treated cells. By contrast, a treatment of LPS caused a greater expression 
of p65 and IRF3 in the nucleus compared to the cytoplasm. There was no significant 
effect of treatment for p65 (effect of treatment, F(2, 8) = 4, p = 0.062) and IRF3 (effect 
of treatment, F(2, 8) = 4.1, p = 0.063). Compared to alcohol and vehicle however, LPS 
significantly increased the nuclear, and decreased the cytoplasmic expression of p65 
and IRF3 (Tukey post hoc). There was no difference between vehicle and alcohol for 
either p65 or IRF3. Importantly, these results were verified using traditional 
colocalisation analysis techniques (supplementary figure s4). 
 
Lastly, to determine whether these compounds induce cytotoxicity or injury, neutral red 
and lactate dehydrogenase assays were performed (figure 6). A two-way ANOVA 
found a significant effect of time for both neutral red (effect of time, F(1, 8) = 68.47, p < 
0.0001) and lactate dehydrogenase assays (effect of time, F(1, 8) = 46.59, p = 0.0064). 
However, there was no post hoc differences between 4 and 24 h for any treatment for 
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either assay. There was a significant effect of treatment in the neutral red (effect of 
treatment, F(2, 6) = 68.26, p < 0.0001) and lactate dehydrogenase assays (effect of 
treatment, F(2, 6) = 89.05, p < 0.0001). Post hoc analysis determined significant 
differences in absorption in the lactate dehydrogenase and neutral red assays between 
the treatments. LPS significantly reduced absorption relative to vehicle in the neutral 
red assay. LPS additionally increased absorption compared to vehicle and alcohol 
suggesting this compound increases the release of lactate dehydrogenase into the 
supernatant thereby inferring an increase in cellular stress/injury. There was no 
difference between vehicle and alcohol in either assay indicating both compounds do 
not induce large amounts of cytotoxicity or cellular injury. 
 
9.3.2 Experiment 2: Does alcohol alter a TLR4 response in BV2 cells? 
Collectively, the results suggest that alcohol is unable to increase the expression or 
release of MyD88 and TRIF mediated cytokines, nor induce the activation of NFκB p65 
or IRF3. This suggests that alcohol is unable to directly induce an inflammatory 
response, a finding which contrasts previous studies (Lawrimore & Crews, 2017; 
Fernandez-Lizarbe et al., 2009; Blanco et al., 2005). However, additional studies have 
suggested alcohol modulates rather than induces an immune response (for example, 
(Goral et al., 2011; Lee et al., 2004). To verify these findings, BV2 cells were incubated 
with alcohol and endogenous TLR4 agonist, HMGB1 (ab18650) to reflect the current 
hypothesis of alcohol-induced neuroimmune activity (Crews et al., 2017). However, 
despite ab18650 being purportedly “active”, initial experiments determined this product 
was unable to induce an IL-1β response from BV2 cells (supplementary figure s5) 
suggesting an “inactive” isoform (Yu et al., 2006). Consequently, cells were pretreated 
for 0.5 h with alcohol and stimulated for 24 h with LPS. It must be kept in mind however, 
that while both LPS and HMGB1 are TLR4 agonists, the mechanism of activation and 
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resulting outcomes may differ between the two. Therefore, caution must be used when 
extrapolating the findings of LPS to alcohol-induced neuroimmune activity. 
 
A two-way ANOVA determined the supernatant and lysate expression of TNFα and IL-
1β were significantly influenced by treatment (LPS vs vehicle (herein termed media)) 
(figure 7) (p < 0.0001 for all cytokines, see supplementary for precise statistical 
information). Tukey post hoc calculated LPS significantly potentiated the expression 
TNFα in both cell supernatant and lysates compared to media across both pretreament 
groups. By contrast, IL-1β expression in the supernatant and lysates differed only in 
vehicle pretreated cells, with LPS inducing a greater expression relative to media. 
There was no main effect of treatment on IFNβ expression (effect of treatment, F(2, 10) 
= 3.18, p = 0.15) nor any post hoc differences. Again, LPS potentiated the expression 
of proteins pertaining to the MyD88 but not TRIF pathway. 
 
A two-way ANOVA determined a significant effect of pretreatment (alcohol vs vehicle) 
on the supernatant and lysate expression of TNFα and IL-1β (p < 0.0001 for all 
cytokines, see supplementary for precise statistical information). An alcohol 
pretreatment significantly reduced LPS-induced increases in supernatant and lysate 
TNFα and IL-1β compared to vehicle (post hoc). However, IFNβ expression was not 
modified by pretreament (effect of pretreatment, F(1, 5) = 4.03, p = 0.12) nor were there 
any post hoc differences between pretreatment groups. Collectively, the results 
suggested pretreating BV2 cells with alcohol significantly reduced LPS-induced 
expression of MyD88-dependent cytokines (IL-1β and TNFα). 
 
To determine whether the immunomodulatory capabilities of alcohol were due to 
alterations in gene transcription, qPCR was performed (figure 8). A two-way ANOVA 
determined there was a significant effect of treatment on the expression of Il1b (effect 
 513 
of treatment, F(1, 3) = 13.71, p = 0.034), Tnfa (effect of treatment, F(1, 3) = 17.38, p = 
0.025) and Ifnb (effect of treatment, F(1, 3) = 8.56, p = 0.041) but not Ccl5 (effect of 
treatment, F(1, 3) = 0.017, p = 0.90). Bonferroni post hoc analysis determined LPS 
significantly increased the expression of Il1b, Tnfa and Ifnb relative to media in vehicle 
pretreated cells. There was no post hoc differences for Ccl5 mRNA. There was an 
additional main effect of pretreatment for Il1b (effect of pretreatment, F(1, 3) = 13.87, p 
= 0.034), Tnfa (effect of pretreatment, F(1, 3) = 22.39, p =0.018), Ifnb (effect of 
pretreatment, F(1, 3) = 73.93, p = 0.033) and Ccl5 mRNA expression (effect of 
pretreatment, F(1, 3) = 29.34, p =0.012). Pretreating the cells with alcohol significantly 
reduced LPS-induced expression of Il1b, Tnfa, Ifnb and Ccl5 mRNA compared to 
vehicle (Bonferroni post hoc). 
 
To determine whether pretreating BV2 cells with alcohol alters the expression of 
transcription factors NFκB p65 and IRF3 western blot were performed (figure 9). A two-
way ANOVA determined the expression of p65 and IRF3 were significantly influenced 
by treatment (effect of treatment, F(2, 10) = 4.73, p = 0.0095 and F(2, 10) = 13.47, p = 
0.035 respectively). However, no post hoc differences were identified. Further, the 
expression of p65 and IRF3 were not influenced by pretreatment (effect of 
pretreatment, F(1, 5) = 0.96, p = 0.38 and F(1, 5) = 2.54, p = 0.21 respectively), with post 
hoc analysis determining there were no significant differences between any of the 
groups.  
 
Neutral red and lactate dehydrogenase assays were performed to determine whether 
pretreating BV2 cells with alcohol reduces cell cytotoxicity and injury (figure 10). Two-
way ANOVAs determined a significant effect of treatment in the neutral red (effect of 
treatment, F(2, 10) = 16.14, p = 0.056) and lactate dehydrogenase assays (effect of 
treatment, F(2, 10) = 415.9, p < 0.0001). Tukey post hoc analysis determined LPS 
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significantly reduced absorbance in the neutral red assay in BV2 cells pretreated with 
vehicle; indicating greater cell cytotoxicity. Similarly, post hoc analysis determined LPS 
increased absorbance in the lactate dehydrogenase assay compared to media across 
both treatment groups (indicating increased cellular injury). Additionally, there was a 
main effect of pretreatment for the lactate dehydrogenase (effect of pretreatment, F(1, 
5) = 21.90, p = 0.0054) but not neutral red assays (effect of pretreatment, F(1, 5) = 0.44, 
p = 0.57). Pretreating cells with alcohol significantly reduced absorbance in the lactate 
dehydrogenase assay compared to vehicle suggesting a reduction in cellular injury.  
 
Collectively, the results suggest pretreating cells with alcohol significantly supressed 
LPS-induced increases in both MyD88 and TRIF-dependent cytokines on a mRNA 
level and MyD88-dependent cytokines on a protein level. Further, alcohol did not alter 
the expression of transcription factors nor cytotoxicity. However, alcohol significantly 
reduced LPS-induced lactate dehydrogenase expression in the supernatant indicating 





Figure 2 IL-1β (a – b), TNFα (c – d) and IFNβ (e) expression following 4 or 24 h of 
vehicle, LPS (100ng/mL) or alcohol (100mM). LPS significantly increased IL-1β and 
TNFα from cell lysates and supernatant. However, neither LPS nor alcohol increased 
IFNβ expression compared to vehicle. All data was analysed using a two-way ANOVA 
with Tukey post-hoc. Summary values represented as mean±SEM; n=6; **p < 0.01, 
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Figure 3 Il1b (a), Ifnb (b), Tnfa (c) and Ccl5 (d) mRNA expression following 4 or 
24 h of vehicle, LPS (100ng/mL) or alcohol (100mM). 4 h of LPS potentiates the 
expression of Il1b, Ifnb and Tnfa mRNA compared to vehicle and alcohol in BV2 cells. 
Neither alcohol or vehicle altered the expression of Il1b, Ifnb, Ccl5 and Tnfa mRNA 
following 24 h of stimulation relative to vehicle. All data was analysed using a two-way 
ANOVA with Bonferroni post-hoc. Summary values represented as mean±SEM; n=3; 


















































































































Figure 4 The expression of NFκB p65 subunit (a) and IRF3 (b) following 4 or 24 
h of vehicle, LPS (100ng/mL) or alcohol (100mM). LPS, alcohol or vehicle had no 
effect on the expression of NFKB p65 or IRF3 following 4 h of stimulation. However, 
24 h of LPS increased the expression of NFκB p65 compared to alcohol and vehicle-
treated cells. Neither drug altered IRF3 expression at 24 h. All data was analysed using 
a two-way ANOVA with Tukey post-hoc. Summary values represented as mean±SEM; 







































































Figure 5 Translocation of NFκB p65 subunit (a) and IRF3 (b) at 0.5 and 2 h 
respectively following stimulation with vehicle, LPS (100ng/mL) or alcohol 



























































































NFκB p65 and IRF3 compared to vehicle and alcohol treated cells. There was no 
difference between alcohol and vehicle treatments. The representative images of a 
and b and the corresponding RGB profile plot and colocalisation output from Fiji are 
shown above. All data was analysed using a two-way ANOVA with Tukey post-hoc. 
Summary values represented as mean±SEM; n=4; ****p < 0.0001 (between 




Figure 6 Estimation of cell cytotoxicity and injury following 24 h of vehicle, LPS 
(100ng/mL) or alcohol (100mM). Neither LPS or alcohol reduced the absorbance in 
the neutral red assay at 4 h indicating similar levels of cellular viability. However, LPS 
significantly reduced the absorbance at 24 h compared to vehicle-treated cells. This 
suggests LPS-induced cytotoxicity. (a). Similarly, LPS, alcohol or vehicle did not differ 
in regards to   lactate dehydrogenase release at 4 h. However, LPS increases the 
release of lactate dehydrogenase into the supernatant following 24 h of stimulation 
compared to vehicle and alcohol treated cells (b). All data was analysed using a two-
way ANOVA with Tukey post-hoc. Summary values represented as mean±SEM; n=4-
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Figure 7 Alcohol pretreatment reduced LPS-induced IL-1β (a, b), TNFα (c, d) but 
not IFNβ (e) expression from BV2 supernatant and lysates. Pretreating with 
100mM of alcohol significantly reduced LPS-induced IL-1β and TNFα expression in 
cell supernatant and lysates compared to vehicle pretreatment. However, neither 
alcohol nor LPS altered IFNβ expression in lysates. All data was analysed using a two-
way ANOVA with Tukey post-hoc. Summary values represented as mean±SEM; n=6; 
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Figure 8 Alcohol reduced LPS-induced mRNA expression of Il1b (a), Ifnb (b), and 
Tnfa (c) but not Ccl5 (d). LPS potentiated the expression of all 4 cytokine genes 
relative to media control. This effect was significantly supressed in cells pretreated with 
alcohol which demonstrated a reduction in LPS-induced Il1b, Ifnb Tnfa, and Ccl5 
mRNA expression. Summary values represented as mean±SEM; n=4; *p < 0.05; **p 
























































































































































Figure 9 Alcohol pretreatment nor LPS altered the total expression NFκB p65 
subunit (a) and IRF3 (b) from BV2 cell lysates. All data was analysed using a two-














































































Figure 10 Alcohol had no effect on LPS-induced cell cytotoxicity (a) but reduced 
cellular injury (b). Incubating cells with alcohol has no effect on absorbance following 
stimulation with LPS compared to vehicle pretreated cells in the neutral red assay (a). 
However, pretreating cells with alcohol significantly reduced absorbance indicating 
decreased lactate dehydrogenases expression in the supernatant  (b). All data was 
analysed using a two-way ANOVA with Tukey post-hoc. Summary values represented 
as mean±SEM; n=6; **p <0.01, ***p < 0.001 (between treatments); # p < 0.05, ###p < 
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9.4 Interim discussion 
Using multiple molecular analysis techniques, the results presented above indicate 
alcohol is unable to elicit an immune response from BV2 cells. Alcohol did not alter the 
expression of prototypical MyD88 and TRIF-dependent cytokines on a protein or 
mRNA level nor did it alter the expression of downstream transcription factors or their 
ability to translocate to the nucleus. These findings contradict existing studies 
(Lawrimore & Crews, 2017; Fernandez-Lizarbe et al., 2013; 2009; Blanco et al., 2005) 
that demonstrate alcohol significantly increases cytokines, immune-related signalling 
pathway proteins and transcription factors – a finding indicative of TLR4 activation. 
However, alcohol modulated a LPS-induced immune response. Pretreating cells with 
alcohol reduced the LPS-induced increases in MyD88 and TRIF cytokines. but did not 
alter the total expression of NFκB p65 or IRF3 suggesting the response may be 
attributable to altered translocation rather than total expression level. Further, 
pretreating cells significantly reduced markers of cellular injury but not overall 
cytotoxicity. Collectively the results suggest alcohol acts as an immunomodulator 
rather than a immunostimulatant. 
 
The differing results observed between Lawrimore & Crews (2017), Fernandez-Lizarbe 
et al., (2009) and the current study are potentially attributable to duration and method 
of alcohol exposure, cell type and time points assessed. The present study used 
microglial-like BV2 cells. This cell line was designed as a substitute for primary 
microglia (Blasi et al., 1990). However, there is conjecture whether BV2 are an 
accurate model and substitute for primary microglia with studies demonstrating that 
the immune response towards LPS differs (Henn et al., 2009). Compared to primary 
microglia, BV2 often exhibit a less pronounced upregulation of genes and proteins 
following stimulation with LPS (Henn et al., 2009; Horvath et al., 2008), and may not 
possess specific transcription factors (for example, IRF5 and STAT1) and epigenetic 
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regulators (for example, NSD3) (Das et al., 2016). Consequently, immune features 
present in primary microglia may not be present in BV2 cells. Therefore, the lack of an 
alcohol-induced immune response in the present study may be due to the different 
cells types used by Fernandez-Lizarbe et al., (2009) (primary microglia) and the 
relative inability of BV2 cells to respond to weak immunogens. 
 
Another important consideration is the time point at which protein and mRNA was 
assessed. The present study evaluated cytokine expression at 4 and 24 h. These time 
points were designed to partly align with those by Lawrimore & Crews, (2017). They 
demonstrated Il1b and Tnfa mRNA was significantly upregulated 24 h after alcohol 
exposure: a finding that contrasts those presented in this study. However, studies have 
additionally demonstrated that the response to alcohol occurs rapidly in primary 
microglia with increases in cytokines and signalling pathways proteins occurring 1 – 3 
h post exposure (Lawrimore & Crews, 2017; Fernandez-Lizarbe et al., 2013; Blanco et 
al., 2005). Importantly, the immune response in BV2 cells not only differs in magnitude 
but also the activation time compared to primary microglia with the onset typically 
earlier and lower in magnitude (Henn et al., 2009). Consequently, the present study 
may be missing the peaks of an alcohol response.  
 
The differing immune response towards alcohol may additionally be due to the method 
of alcohol exposure. The present study added alcohol to serum free DMEM and treated 
cells were placed in a humidified incubator. Alcohol evaporated relatively quickly with 
no detectable alcohol present in the media 12 h post exposure (see supplementary 
figure s3). By contrast, Lawrimore & Crews (2017) used a chamber to maintain alcohol 
saturation - limiting evaporation. Consequently, the concentration of alcohol did not 
differ across time and may therefore represent a more chronic treatment model. This 
is an important experimental consideration as it is hypothesised that chronic alcohol 
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increases cellular stress inducing the release of HMGB1, an endogenous danger 
signal. HMGB1 subsequently acts on TLR4 to induce an immune response from 
microglial cells (Crews et al., 2017; 2004). Given our study did not find an effect of 
alcohol on lactate dehydrogenase expression or supernatant HMGB1 expression (data 
not shown) it is likely the shorter exposure time was insufficient to induce cellular 
stress. By contrast, the chronic saturation model used by Lawrimore & Crews, (2017) 
demonstrated a significant increase in supernatant HMGB1 indicating this model may 
be more suited to explore the immune-inducing potential of alcohol.  
 
This study additionally reinforced the observation regarding the immunosuppressive 
nature of acute alcohol on the immune system (Szabo & Mandrekar, 2009; MacGregor, 
1986). Pretreating BV2 cells for 0.5 h with alcohol significantly reduced LPS-induced 
increases in Il1b, Tnfa, Ifnb and Ccl5 compared to vehicle control. Importantly, the 
expression of NFκB and IRF3 remained unchanged suggesting the immune response 
is likely attributable to reduced translocation or alterations to the TLR4 signalling 
pathway. However, further experiments are required to confirm this.  
 
Importantly, the mechanism underlying the effects of alcohol-induced TLR4 tolerance 
are being increasingly researched. For example, studies have shown acute alcohol 
exposure increases the expression of negative regulators of NFκB; anti-inflammatory 
cytokines; and decreases the expression of kinases and the formation of lipid rafts on 
the cell surface thereby preventing the interaction between TLR4 and its co-receptors 
(Goral et al., 2011; Mandrekar et al., 2009; 2008; 2007; Dai & Pruett, 2006; Dolganiuc 
et al., 2006; Pruett et al., 2004). These studies have focused on the MyD88 pathway. 
Our study is the first to demonstrate the effects of alcohol-induced tolerance also carry 
over to the TRIF pathway. Alcohol significantly reduced the expression Ifnb and Ccl5 
mRNA following LPS exposure suggesting that IRF3, STAT or late phase NFκB may 
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be attenuated. Whether this response is a consequence of the reduced TLR4-co-
receptor interaction which also leads to MyD88 attenuation following acute alcohol, or 
whether there is a specific mechanism inducing TRIF-tolerance remains to be 
determined.  
 
The finding that alcohol can induce tolerance but not elicit an immune response despite 
alcohol rapidly evaporating from the wells is interesting. Previous studies have shown 
that the acute immunosuppressive of alcohol occur quickly and is long-lasting (for 
example, Dolganiuc et al., 2006). Only a short pretreatment is required to elicit a long 
effect thus, the evaporation of alcohol observed above is unlikely to influence this 
response. By contrast, longer exposure times are potentially required to exert stress 
and the release of HMGB1 from BV2 cells. Consequently, this paradigm is more 
sensitive to the effects of evaporation.  
 
Collectively, the results presented in this study demonstrate that acute alcohol 
exposure was unable to induce an immune response which parallels a response to 
prototypical TLR4 agonist, LPS. However, alcohol exhibited potent immunomodulatory 
abilities as it reduced the cytokine response following LPS. Importantly, this study 
demonstrates that alcohol suppresses aspects of both the MyD88 and TRIF-
dependent pathways indicating alcohol severely hampers an ability to mount an 
immune response. However, the duration of suppression and the precise mechanism 
underlying TLR-TRIF based suppression remains to be fully elucidated. 
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9.5 Results  
9.5.1 Pharmacological characterisation of (+)-Naloxone 
Chapters 3, 5 and 7 demonstrated that acute and chronic alcohol exposure significantly 
upregulated cytokines and signalling proteins pertaining to the MyD88 and TRIF 
pathways. Furthermore, attenuating TLR4 mitigated the rise in immune gene 
expression following acute but not chronic alcohol exposure. Collectively, these 
experiments indicated alcohol potentiates TLR4 signalling in vivo. However, the 
preceding in vitro experiments were unable to replicate the immune-inducing ability of 
alcohol. Consequently, (+)-Naltrexone’s mechanism of action in the context of an 
alcohol-induced immune response could not be explored in vitro.  
 
Given alcohol could not elicit an immune response in vitro, the decision was made to 
explore and clarify how TLR4 antagonists function in the context of an immune 
response induced by LPS in BV2 cells. While LPS and alcohol differ in their potencies, 
half-lives and the mechanism underlying TLR4 activation (direct vs indirect), this model 
can still provide us with useful information discerning how TLR4 antagonists modulate 
an inflammatory response in microglia-like cells. 
 
The availability of (+)-Naltrexone was extremely limited throughout my candidature. 
Therefore, the proceeding studies used a chemically similar compound; (+)-Naloxone, 
to antagonise TLR4. (+)-Naloxone is an enantiomer of a µ opioid receptor antagonist 
(-)-Naloxone. Importantly, (+)-Naloxone and (+)-Naltrexone are hypothesised to have 
the same binding site, binding motifs (Hutchinson et al., 2010), and affinity for TLR4 
(Wang et al., 2016). Further, these drugs have almost identical structure and 
stereoisomerism of individual molecules and selectively antagonise the TLR4-TRIF 
pathway in vitro (Wang et al., 2016). While this approach can provide some insight into 
how (+)-isomers function at TLR4, caution must be used when interpreting and 
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inferring the actions of (+)-Naloxone to (+)-Naltrexone as the compounds differ in 
regards to half-life and the presence/absence of specific function groups (C=C bond 
and methyl group). Consequently, this study aimed to characterise the pharmacology 
of (+)-Naloxone in the context of an LPS-induced immune response by microglia-like 
BV2 cells.  
  
The concentrations of (+)-Naloxone used in the following experiments ranged from 100 
– 800uM and were based upon a previous study demonstrating these concentrations 
successfully attenuated a LPS-induced TLR4-TRIF response (Wang et al., 2016).  
 
The first series of experiments were designed to assess (+)-Naloxone influence on 
cytotoxicity and cellular injury. Cells were pretreated with (+)-Naloxone (100 – 800uM) 
or vehicle* (volume-matched PBS, figures 11 – 13 x = 0) for 0.5 h. After which LPS 
(100ng/mL) or vehicle (volume-matched PBS) was added to the wells. Cells incubated 
in the co-treatment for a further 24 h and then underwent the neutral red and lactate 
dehydrogenase assays to determine whether (+)-Naloxone and/or LPS influenced cell 
death or injury. 
 
A two-way ANOVA determined a main effect of treatment (LPS vs vehicle) on 
absorption in the neutral red and lactate dehydrogenase assays (effect of treatment, 
F(1, 11) = 578.3, p < 0.0001 and F(1, 11) = 143.6, p < 0.0001 respectively). Tukey post 
hoc analysis calculated cells treated with LPS exhibited significantly greater 
cytotoxicity (lower absorption) compared to vehicle-treated cells across all 
concentrations of (+)-Naloxone in the neutral red assay. LPS treatment resulted in 
greater cellular injury (higher absorbance) between 0 – 200uM of (+)-Naloxone 
compared to vehicle treated cells in the lactate dehydrogenase assay (post hoc 
analysis).  
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There was an additional main effect of (+)-Naloxone’s concentration on absorption in 
the neutral red and lactate dehydrogenase assays (effect of concentration, F(5, 55) = 
11.33, p < 0.0001 and F(5, 55) = 60.82, p < 0.0001 respectively). 200 – 600uM of (+)-
Naloxone significantly reduced LPS-induced cytotoxicity and injury as inferred by 
increased and decreased absorbance in the neutral red and lactate dehydrogenase 
assays respectively (post hoc analysis). However, higher concentrations of (+)-
Naloxone (600 – 800uM) increased cytotoxicity (decreased absorbance) in vehicle-
treated cells in the neutral red assay. This effect was not observed in the lactate 
dehydrogenase assay. This indicates the highest concentrations of (+)-Naloxone 
induce a small but statistically significant amount of cytotoxicity. Overall, the results 
suggest (+)-Naloxone attenuates LPS-induced cell death and injury. However, higher 
concentrations of (+)-Naloxone additionally cause cell death. 
 
Given that (+)-Naloxone reduced markers of LPS-induced cytotoxicity and injury, the 
next series of experiments were designed to reinforce the observations by Wang et al., 
(2016) who demonstrated the biased antagonistic nature of (+)-Naloxone at TLR4. To 
infer biased antagonism cell supernatant and lysate were collected and the expression 
of IL-1β, TNFα, IFNβ and CCL5 were assessed (figure 12). Again, IFNβ could not be 
detected in the cell supernatant nor could CCL5 in the supernatant or lysate using 
western blots. 
 
A two-way ANOVA determined a significant effect of treatment on the supernatant and 
lysate expression of IL-1β and TNFα and the lysate expression of IFNβ (p < 0.05, see 
supplementary material for precise statistical information). Cells treated with LPS 
exhibited significantly greater expression of IL-1β and TNFα in the cell supernatant and 
lysate across all concentrations of (+)-Naloxone compared to vehicle (post hoc 
analysis). Furthermore, cells treated with LPS exhibited significantly greater IFNβ 
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expression compared to vehicle treated cells. However, this effect was only observed 
in the absence of (+)-Naloxone (x = 0) (Tukey post hoc analysis).  
 
The concentration of (+)-Naloxone additionally influenced the expression of 
supernatant and lysate IL-1β and TNFα (p < 0.05 for all variables, see supplementary 
materials for precise statistical information). Post hoc analysis determined (+)-
Naloxone decreased the LPS-induced expression of IL-1β and TNFα in the 
supernatant and lysate between the 200 and 800uM. By contrast, the concentration of 
(+)-Naloxone did not significantly modify the expression of IFNβ (effect of 
concentration, F(5, 35) = 1.19, p = 0.36). However, post hoc analysis determined a 
significant reduction in LPS-induced IFNβ expression at 200 and 800uM of (+)-
Naloxone compared to vehicle* (absence of (+)-Naloxone (x = 0). Collectively, the 
results suggest (+)-Naloxone reduces the expression of both MyD88 and TRIF 
cytokines. 
 
To explore whether (+)-Naloxone exhibits biased antagonism at the transcription factor 
level, the expression NFκB p65 and IRF3 was assessed (figure 13). IRF3 but not NFκB 
exhibited a significant effect of treatment (effect of treatment, F(1, 7) = 11.62 p = 0.042 
and F(1, 7) = 8.23, p = 0.064 respectively) as inferred by a two-way ANOVA. Post hoc 
analysis determined however, LPS significantly increased the expression of NFκB p65 
and IRF3 in the absence of (+)-Naloxone (x = 0) compared to vehicle treated cells. 
Furthermore, the expression of NFκB p65 and IRF3 were not significantly modified by 
the concentration of (+)-Naloxone (effect of concentration, F(5, 35) = 3.12, p = 0.05 and 
F(5, 35) = 1.73, p = 0.19 respectively). There was no post hoc differences for NFκB p65 
at any concentration of (+)-Naloxone. However, 100 – 200uM of (+)-Naloxone 
significantly attenuated LPS-induced IRF3 expression compared to a vehicle* 
pretreatment (absence of (+)-Naloxone, x = 0).  
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9.5.2 Pharmacological comparison of LPS:RS and (+)-Naloxone 
The preceding results implied (+)-Naloxone attenuated aspects of both MyD88 and 
TRIF pathways. Consequently, we next sought to determine whether (+)-Naloxone 
exhibits similar antagonistic properties at TLR4 compared to LPS:RS. Both LPS:RS 
and (+)-Naloxone are hypothesised to bind to the same pocket in MD2 which prevents 
the activation and recruitment of TLR4 and its downstream signalling pathways 
(Hutchinson et al., 2010). Therefore, these drugs are hypothesised to produce similar 
antagonistic outcomes. The dose of LPS:RS used was based upon previous studies 
performed in this laboratory demonstrating attenuation of TLR4 signalling at 200ng/mL 
(Hutchinson et al., 2010). The dose of (+)-Naloxone used (200uM) represents the 
lowest concentration at which we observed attenuation of LPS-induced cell death, 
injury and the expression of MyD88 and TRIF-dependent cytokines. 
 
The effects of LPS:RS and (+)-Naloxone on cellular cytotoxicity and injury were 
assessed using neutral red and the lactate dehydrogenase assay (figure 14). A two-
way ANOVA determined the absorption values in the neutral red and lactate 
dehydrogenase assays were significantly modified by treatment (LPS vs vehicle 
(herein referred to as media) (effect of treatment, F(1, 30) = 653.9, p < 0.0001 and F(1, 5) 
= 2782, p < 0.0001 respectively). Again, cells treated with LPS exhibited significantly 
greater amounts of cytotoxicity and injury as inferred by higher and lower absorption 
values in the lactate dehydrogenase and neutral red assays respectively (Tukey post 
hoc). Furthermore, the absorption values in the neutral red and lactate dehydrogenase 
assays were significantly affected by pretreatment (LPS:RS vs (+)-Naloxone vs 
vehicle) (effect of pretreatment, F(2, 30) = 12.13, p = 0.0001 and F(2, 10) = 103.7, p < 
0.0001 respectively). Compared to vehicle, both LPS:RS and (+)-Naloxone 
significantly increased absorption in the neutral red (reduced cytotoxicity) with no 
difference observed between the two TLR4 antagonists (post hoc analysis). Similarly, 
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both antagonists reduced absorbance in the lactate dehydrogenase assays compared 
to vehicle (reduced injury). However, there was a significant difference between the 
two antagonists, with (+)-Naloxone reducing absorption to a greater extent than 
LPS:RS. Collectively, both TLR4 antagonists block LPS-induced increases in cell 
death and injury. 
 
The expression of IL-1β, TNFα and IFNβ was again assessed to determine whether 
LPS:RS and (+)-Naloxone attenuate similar aspects of both the MyD88 and TRIF 
pathways (figure 15). A two-way ANOVA determined the supernatant and lysate 
expression of IL-1β and TNFα and the lysate expression of IFNβ was significantly 
influenced by treatment (effect of treatment, p < 0.05, see supplementary material for 
precise statistical information). Cells treated with LPS exhibited significantly greater 
expression of these cytokines compared to media-treated cells (Tukey post hoc 
analysis). In addition, pretreatment significantly modified the expression of supernatant 
IL-1β and TNFα (effect of pretreatment, F(2, 14) = 11.54, p = 0.0011 and F(2, 14) = 16.59, 
p = 0.0002 respectively) and the lysate expression of IL-1β, TNFα and IFNβ (effect of 
pretreatment, F(2, 14) = 4.84, p = 0.033; F(2, 14) = 8.87, p = 0.0061; and F(2, 14) = 19.71, p 
= 0.0023 respectively). Post-hoc analysis determined (+)-Naloxone significantly 
reduced LPS-induced increases in supernatant and lysate IL-1β, TNFα and IFNβ 
compared to vehicle treated cells. By contrast, LPS:RS only reduced the LPS 
increases in supernatant IL-1β and TNFα lysate expression compared to vehicle 
treated cells. LPS:RS did not attenuate IL-1β and IFNβ lysate and TNFα supernatant 
expression compared to vehicle treated cells. At these doses, both LPS:RS and (+)-
Naloxone block proteins pertaining to MyD88 pathway. However, only (+)-Naloxone 
inhibits TRIF-related cytokine expression. 
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To infer whether (+)-Naloxone and LPS:RS attenuate the transcription of cytokines 
pertaining to the MyD88 and TRIF pathways, the expression of Il1b, Tnfa, Ifnb and 
Ccl5 was assessed (figure 16). A significant effect of treatment was observed for Il1b 
(effect of treatment, F(1, 3) = 13.1, p = 0.036) but not Tnfa, Ifnb and Ccl5 expression 
(effect of treatment, F(1, 3) = 8.96, p = 0.058; F(1, 3) = 5.40, p = 0.10; and F(1, 3) = 2.09, p 
= 0.24 respectively) as determined by a two-way ANOVA. Post hoc analysis 
determined LPS potentiated the expression of all cytokine genes relative to media in 
vehicle pretreated cells. Furthermore, only Il1b mRNA exhibited a significant effect of 
pretreatment (F(2, 6) = 6.33, p = 0.033). Tnfa, Ifnb and Ccl5 were unaltered by the 
pretreatment effect (F(2, 6) = 3.49, p = 0.099; F(2, 6) = 1.06, p = 0.40; and F(1, 3) = 2.09, p 
= 0.24 respectively). Post hoc analysis determined LPS:RS significantly reduced the 
LPS-induced increases in Il1b and Ccl5 mRNA compared to vehicle. (+)-Naloxone did 
not modify LPS-induced increases in any MyD88 or TRIF-related gene. 
 
Given that the expression of cytokine protein and mRNA was attenuated by (+)-
Naloxone and LPS:RS we next sought to determine whether these drugs block the 
expression of NFκB p65 and IRF3 (figure 17). A two-way ANOVA determined IRF3 but 
not NFκB p65 expression was significantly influenced by treatment (effect of treatment, 
F(1, 7) = 10.76, p = 0.046 and F(1, 7) = 5.46, p = 0.10 respectively). Post hoc analysis 
determined LPS significantly increased the expression of both transcription factors in 
vehicle pretreated cells. No other treatment related differences were observed. 
Further, NFκB p65 and IRF3 expression was not influenced by pretreatment (effect of 
pretreatment, F(2, 14) = 2.15, p = 0.20 and F(2, 14) = 1.68, p = 0.26 respectively). However, 
post hoc analysis determined both LPS:RS and (+)-Naloxone significantly reduced the 
LPS-induced increases of NFκB p65 and IRF3 compared to vehicle treated cells.  
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To determine whether the reductions in mRNA were attributable to a reduction in NFκB 
p65 and IRF3 activity, the degree of nuclear translocation was assessed (figure 18). 
The translocation of NFκB p65 but not IRF3 was significantly influenced by treatment 
(effect of treatment, F(1, 3) = 23.54, p = 0.016 and F(1, 3) = 4.38, p = 0.13 respectively) 
(two-way ANOVA). Post hoc analysis determined LPS significantly increased 
translocation of NFκB p65 and IRF3 into the nucleus in vehicle pretreated cells. 
Similarly, NFκB p65 but not IRF3 was significantly influenced by pretreatment (effect 
of pretreatment, F(2, 6) = 7.72, p = 0.021 and F(2, 6) = 3.69, p = 0.090 respectively). Post-
hoc analysis determined both LPS:RS and (+)-Naloxone reduced the LPS-induced 
translocation of NFκB p65 and IRF3 into the nucleus compared to vehicle 
pretreatment. There was no post hoc difference between (+)-Naloxone and LPS:RS-
treated cells suggesting both antagonists similarly prevent the actions of transcription 





Figure 11 (+)-Naloxone reduced LPS-induced BV2 cells cytotoxicity and injury 
as inferred by neutral red (a) or lactate dehydrogenase assays (b). Treating cells 
with (+)-Naloxone increases neutral red absorbance following stimulation with LPS 
(decreased cytotoxicity) (a) and reduces lactate dehydrogenases expression in the 
supernatant (decreased injury) (b). However, high doses of (+)-Naloxone additionally 
cause cytotoxicity in vehicle treated cells (a). All data was analysed using a two-way 
ANOVA with Tukey post-hoc. Summary values represented as mean±SEM; n=6-12; 
**p <0.01, ***p < 0.001, ****p < 0.0001 (LPS), ## p <0.01, ###p < 0.001 (vehicle) from 
vehicle* (absence of (+)-Naloxone, x = 0). 
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Figure 12 (+)-Naloxone reduced LPS-induced IL-1β (a, b), TNFα (c, d) and IFNβ 
(e) expression from cell supernatant and lysates. (+)-Naloxone dose-dependently 
reduced LPS-induced IL-1β and TNFα expression from cell lysates and supernatant. 
(+)-Naloxone reduced LPS-induced IFNβ expression at 200uM and 800uM, however, 
there was no main effect of concentration. All data was analysed using a two-way 
ANOVA with Tukey post-hoc. Summary values represented as mean±SEM; n=8; **p 
<0.01, ***p < 0.001, ****p < 0.0001 from vehicle* (absence of (+)-Naloxone, x = 0). 
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Figure 13 (+)-Naloxone did not alter NFκB p65 subunit expression (a) but 
reduced IRF3 expression (b) from cell lysates. (+)-Naloxone did not reduce LPS-
induced increases in NFκB p65 subunit expression (a). However, 100 – 200uM of (+)-
Naloxone reduced LPS-induced IRF3 expression (b). All data was analysed using a 
two-way ANOVA with Tukey post-hoc. Summary values represented as mean±SEM; 
n=6-8; *p <0.05, from vehicle* (absence of (+)-Naloxone, x = 0). 
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Figure 14 TLR4 antagonists LPS:RS and (+)-Naloxone reduced LPS-induced 
cytotoxicity (a) and injury (b). Both LPS:RS and (+)-Naloxone increased absorbance 
in the neutral red assay (a) and reduced absorbance in the lactate dehydrogenase 
assay (b) following LPS treatment (indicating a reduction in cytotoxicity and injury 
respectively). However, (+)-Naloxone further reduced lactate dehydrogenase 
expression compared to LPS:RS. All data was analysed using a two-way ANOVA with 
Tukey post-hoc.  Summary values represented as mean±SEM; n=6-8; ****p < 0.0001 
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Figure 15 TLR4 antagonists LPS:RS and (+)-Naloxone reduced LPS-induced IL-
1β (a, b), TNFα (c, d) and IFNβ (e) expression from BV2 supernatant and lysates. 
LPS:RS and (+)-Naloxone reduced LPS-induced IL-1β expression in cell supernatant 
and TNFα expression from both cell lysate and supernatant. (+)-Naloxone additionally 
reduced LPS-induced IL-1β and IFNβ expression from cell lysates relative to vehicle 
control. All data was analysed using a two-way ANOVA with Tukey post-hoc. Summary 
values represented as mean±SEM; n=6-8; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 































































































































































































































Figure 16 TLR4 antagonists, LPS:RS and (+)-Naloxone reduced LPS-induced Il1b 
(a) mRNA but only LPS:RS reduced Ifnb (b), Tnfa (c) and Ccl5 (d) mRNA 
expression in BV2 cells. Pretreating cells with LPS:RS prevented the LPS-induced 
increases among cytokine mRNA compared to vehicle pretreated cells. (+)-Naloxone 
did not reduce LPS-induced cytokine mRNA compared to vehicle pretreated cells. 
However, the drug prevented LPS-induced increases as inferred by a lack of difference 
between media and LPS in (+)-Naloxone pretreated cells. All data was analysed using 
a two-way ANOVA with Bonferroni post-hoc. Summary values represented as 



































































































































































































Figure 17 TLR4 antagonists, LPS:RS and (+)-Naloxone reduced LPS-induced 
NFκB p65 subunit and IRF3 expression in BV2 cells. LPS:RS and (+)-Naloxone 
reduced the LPS-induced increase in NFκB p65 and IRF3 expression compared to 
vehicle pretreated cells. All data was analysed using a two-way ANOVA with Tukey 
post-hoc. Summary values represented as mean±SEM; n=6-8; *p < 0.05, **p < 0.01 









































































































Figure 18 TLR4 antagonists, LPS:RS and (+)-Naloxone reduced LPS-induced 
NFκB p65 subunit (a) and IRF3 (b) translocation to the nucleus in BV2 cells. 
LPS:RS and (+)-Naloxone reduced the LPS-induced increase in NFκB p65 and IRF3 
translocation as inferred by post hoc analysis. However, there was no main effect of 
pretreatment on translocation. The representative images of a and b and the 
corresponding RGB profile plot and colocalisation output from Fiji are shown above. 
All data was analysed using a two-way ANOVA with Tukey post-hoc. Summary values 
represented as mean±SEM; n=4 *p < 0.05, ***p < 0.001 (between treatments); #p < 












































































































The mechanism and outcomes pertaining to (+)-Naloxone antagonism of TLR4 is 
complex with discrepancies between in vitro and in vivo findings. For example, in vitro 
experiments suggest (+)-Naloxone is a biased TLR4 antagonist exclusively attenuating 
the TRIF pathway (Wang et al., 2016). By contrast, in vivo experiments demonstrate 
(+)-Naloxone attenuates IL-1β expression and increases in reactive gliosis (Northcutt 
et al., 2015; Hutchinson et al., 2010). Consequently, an aim of this study was to further 
characterise (+)-Naloxone’s ability to antagonise a TLR4-induced immune response 
and to compare it to a well-established TLR4 antagonist LPS:RS. The results 
presented in this study demonstrate (+)-Naloxone reduced LPS-induced IL-1β, TNFα, 
IFNβ and IRF3 expression across a range of concentrations with attenuation typically 
occurring between 200 – 800uM. However, there was no main effect of (+)-Naloxone 
concentration on the expression of NFκB p65 subunit. Furthermore, when compared 
to LPS:RS, (+)-Naloxone exhibited a similar antagonistic profile. Both compounds 
reduced cytokines pertaining to the MyD88 and TRIF dependent pathways primarily at 
a protein and not at the mRNA level. Furthermore, both compounds prevented NFκB 
p65 and IRF3 translocation into the nucleus suggesting they are pan rather than biased 
TLR4 antagonists. 
 
The results presented in this study confirm and contrast the existing in vitro and in vivo 
studies assessing the actions of (+)-Naloxone (Wang et al., 2016; Northcutt et al., 
2015). This study showed (+)-Naloxone successfully attenuated LPS-induced 
increases in MyD88 and TRIF pathway products as inferred by a reduction in IL-1β, 
TNFα, IFNβ and IRF3 expression in BV2 cells. These findings contrast those 
presented by Wang et al., (2016). In their study, (+)-Naloxone attenuated TNFα and 
IFNβ but did not attenuate LPS-induced IL-1β expression. They further demonstrated 
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(+)-Naloxone decreased IRF3 but not NFκB p65 expression. This led the authors to 
conclude that (+)-Naloxone exhibited biased antagonism.  
 
The differential results may be due to the concentration of LPS administered to BV2 
cells. Wang et al., (2016) administered 200ng/mL compared to 100ng/mL of LPS used 
in this study. This caveat is important when considering how low affinity antagonists 
such as (+)-Naloxone work. Given that LPS induces a greater MyD88 response 
compared to the TRIF response, it is hypothesised that the large MyD88 mediated by 
200ng/mL of LPS is sufficient to overcome the weak antagonistic abilities of (+)-
Naloxone. Consequently, only the TRIF pathway appears to be attenuated by (+)-
Naloxone. However, at lower doses of LPS, a situation in which the MyD88 pathway 
may not be as engaged, (+)-Naloxone may be able to antagonise both the MyD88 and 
TRIF pathways. This would potentially explain the differential results obtained in this 
study and those by Wang et al., (2016) and why this drug attenuates an in vivo IL-1β 
expression (Northcutt et al., 2015).  
 
Given that (+)-Naloxone attenuated aspects of both the MyD88 and TRIF pathways, it 
was compared to LPS:RS, a well characterised TLR4 antagonist. These two drugs are 
hypothesised to bind to the same pocket in MD2 thereby preventing activation of TLR4 
and its signalling pathways (Hutchinson et al., 2010). While these two drugs exhibit 
different potencies (LPS:RS and (+)-Naloxone require nanomolar and micromolar 
concentrations to antagonise TLR4 respectively) they still bind to the same area in 
MD2. It was therefore thought, that they may function in a similar manner and cause 
comparable outcomes in regard to modifying a TLR4-based immune response. The 
results in this study suggest that (+)-Naloxone and LPS:RS attenuate MyD88-
dependent cytokines IL-1β and TNFα and the upregulation and translocation of NFκB 
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p65 in response to LPS. Similarly, both compounds reduced markers of TRIF-
activation as inferred by a reduction in IRF3 translocation and expression.  
 
However, (+)-Naloxone significantly reduced the TRIF pathway to a greater extent 
compared to LPS:RS, as inferred by post hoc analysis. For example, (+)-Naloxone 
reduced LPS-induced increases in IFNβ protein, ifnb mRNA and IRF3 expression. This 
effect was either absent or not as pronounced in LPS:RS treated cells. This conclusion 
partly supports the results obtained by neutral red and lactate dehydrogenase assays 
which measured cell cytotoxicity and injury respectively. (+)-Naloxone reduced LPS-
induced cytotoxicity and injury more than LPS:RS. LPS-induced apoptosis occurs by 
multiple pathways involving MyD88 and TRIF pathways. However, recent research has 
placed more emphasis on the TRIF pathway as a key mediator underlying apoptosis 
(Jung et al., 2005; Ruckdeschel et al., 2004). This supports the hypothesis that (+)-
Naloxone attenuates the TRIF pathway to a greater extent than LPS:RS as (+)-
Naloxone reduced markers of cell injuy/death to a greater extent than LPS:RS at 
200ng/mL. To confirm this hypothesis however, equal concentrations of LPS:RS and 
(+)-Naloxone should be compared. The concentration of LPS:RS used in this study is 
approximately 10 – 20nM and is therefore significantly less than (+)-Naloxone. 
 
Collectively, these studies provide us with further insight into how (+)-Naloxone 
influences a neuroimmune response in vitro and can be used to potentially infer how it 
is acting in the context of an alcohol-induced neuroimmune response. Overall, the 
results suggest (+)-Naloxone attenuates aspects of both MyD88 and TRIF pathways 
with a potentially greater ability to attenuate the TRIF pathway compared to traditional 
TLR4 antagonists. However, whether this effect is due to the concentration of LPS:RS 
remains to be determined. Therefore, future studies should examine a range of LPS, 
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LPS:RS and (+)-Naloxone concentrations to better understand and compare how 
these agonists and antagonists function at TLR4.  
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9.9 Supplementary material 
Table 1. Primer sequence used in qPCR 
Gene Forward Primer 5’ – 3’ Reverse Primer 5’ – 3’ 
Ccl5 – 
Chemokine (C-
C motif) ligand 
5 
CTTCCCTGTCATTGCTTGCTC CCGAGTGGGAGTAGGGGATT 
















9.9.1 Statistics for in-text figures  
 
Figure 2 IL-1β (a – b), TNFα (c – d) and IFNβ (e) expression following 4 or 24 h of 
stimulation with vehicle, LPS (100ng/mL) or alcohol (100mM). All data was 
analysed using a two-way ANOVA with Tukey post hoc. 
 
(a) Supernatant IL-1β expression 
Time, F(1, 5) = 0.49, p = 0.51 
Treatment, F(2, 10) = 1137, p < 0.0001 
Interaction (time x treatment), F(2, 10) = 0.59, p = 0.57 
 
(b) Lysate IL-1β expression 
Time, F(1, 5) = 96.15, p = 0.002 
Treatment, F(2, 10) = 352.6, p < 0.0001 
Interaction (time x treatment), F(2, 10) = 357.5, p < 0.0001 
 
(c) Supernatant TNFα expression 
Time, F(1, 5) = 370, p < 0.0001 
Treatment, F(2, 10) = 352.6, p < 0.0001 
Interaction (time x treatment), F(2, 10) = 357.5, p < 0.0001 
 
(d) Lysate TNFα expression 
Time, F(1, 5) = 6.36, p = 0.053 
Treatment, F(2, 10) = 6433, p < 0.0001 
Interaction (time x treatment), F(2, 10) = 8.78, p = 0.0065 
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(e) Lysate IFNβ expression 
Time, F(1, 5) = 17.05, p = 0.015 
Treatment, F(2, 10) = 1.17, p = 0.36 
Interaction (time x treatment), F(2, 10) = 0.82, p = 0.48 
 
Figure 3 Il1b (a), Ifnb (b), Tnfa (c) and Ccl5 (d) mRNA expression following 4 or 
24h of stimulation with vehicle, LPS (100ng/mL) or alcohol (100mM). All data was 
analysed using a two-way ANOVA with Tukey post hoc. 
 
(a) Il1b mRNA expression 
Time, F(1, 2) = 0.31, p = 0.64 
Treatment, F(2, 6) = 7.86, p = 0.041 
Interaction (time x treatment), F(2, 6) = 0.37, p = 0.71 
 
(b) Ifnb mRNA expression 
Time, F(1, 2) = 0.011, p = 0.93 
Treatment, F(2, 6) = 29.94, p = 0.0039 
Interaction (time x treatment), F(2, 6) = 9.45, p = 0.031 
 
(c) Tnfa mRNA expression 
Time, F(1, 2) = 3.65, p =0.20 
Treatment, F(2, 6) = 10.48, p = 0.026 
Interaction (time x treatment), F(2, 6) = 0.061, p = 0.94 
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(d) Ccl5 mRNA expression 
Time, F(1, 2) = 10.97, p =0.08 
Treatment, F(2, 6) = 0.19, p = 0.83 
Interaction (time x treatment), F(2, 6) = 2.05, p = 0.24 
 
Figure 4 The expression of NFκB p65 subunit (a) and IRF3 (b) following 4 or 24h 
of stimulation with vehicle, LPS (100ng/mL) or alcohol (100mM). All data was 
analysed using a two-way ANOVA with Tukey post hoc. 
 
(a) NFκB p65 expression 
Time, F(1, 4) = 5.04, p = 0.088 
Treatment, F(2, 8) = 12.78, p = 0.032 
Interaction (time x treatment), F(2, 8) = 8.88, p = 0.0093 
 
(b) IRF3 expression 
Time, F(1, 4) = 17.05, p = 0.015 
Treatment, F(2, 8) = 1.17, p = 0.36 
Interaction (time x treatment), F(2, 8) = 0.822, p = 0.48 
 
Figure 5 Translocation of NFκB p65 subunit (a) and IRF3 (b) at 0.5 and 2 h 
respectively following stimulation with vehicle, LPS (100ng/mL) or alcohol 
(100mM). All data was analysed using a two-way ANOVA with Tukey post hoc. 
 
(a) NFκB p65 expression 
Cellular compartment, F(1, 4) = 6.38, p = 0.065 
Treatment, F(2, 8) = 4, p = 0.062 
Interaction (cellular compartment x treatment), F(2, 8) = 29.3, p = 0.0002 
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(b) IRF3 expression 
Cellular compartment, F(1, 4) = 54.67, p = 0.0018 
Treatment, F(2, 8) = 4.1, p = 0.063 
Interaction (cellular compartment x treatment), F(2, 8) = 172.4, p < 0.001 
 
Figure 6 Estimation of cell cytotoxicity and injury using following or 24h of 
stimulation with vehicle, LPS (100ng/mL) or alcohol (100mM). All data was 
analysed using a two-way ANOVA with Tukey post hoc. 
 
(a) Neutral red assay 
Time, F(1, 8) = 68.47, p < 0.0001 
Treatment, F(2, 6) = 68.26, p < 0.0001 
Interaction (time x treatment), F(2, 6) = 3.05, p = 0.075 
 
(b) Lactate dehydrogenase assay 
Time, F(1, 8) = 46.59, p = 0.0064 
Treatment, F(2, 6) = 89.05, p < 0.0001 
Interaction (time x treatment), F(2, 6) = 292.4, p < 0.0001 
 
Figure 7 Alcohol reduces LPS-induced IL-1β (a, b), TNFα (c, d) but not IFNβ (e) 
expression from BV2 supernatant and lysates. All data was analysed using a two-
way ANOVA with Tukey post hoc. 
 
(a) Supernatant IL-1β expression 
Pretreatment, F(1, 5) = 150.3, p < 0.0001 
Treatment, F(2, 10) = 112.3, p < 0.0001 
Interaction (Treatment x treatment), F(2, 10) = 115.3, p < 0.0001 
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 (b) Lysate IL-1β expression 
Pretreatment, F(1, 5) = 16.84, p = 0.0093 
Treatment, F(2, 10) = 29.05, p < 0.0001 
Interaction (pretreatment x treatment), F(2, 10) = 16.8, p = 0.0006 
 
(c) Supernatant TNFα expression 
Pretreatment, F(1, 5) = 179, p < 0.0001 
Treatment, F(2, 10) = 1085, p < 0.0001 
Interaction (pretreatment x treatment), F(2, 10) = 178.7, p < 0.0001 
 
(d) Lysate TNFα expression 
Pretreatment, F(1, 5) = 352, p < 0.0001 
Treatment, F(2, 10) = 558, p < 0.0001 
Interaction (pretreatment x treatment), F(2, 10) = 401.2, p < 0.0001 
 
(e) Lysate IFNβ expression 
Pretreatment, F(1, 5) = 4.03, p = 0.12 
Treatment, F(2, 10) = 3.18, p = 0.15 
Interaction (pretreatment x treatment), F(2, 10) = 0.052, p = 0.83 
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Figure 8 Alcohol reduces LPS-induced mRNA expression of Il1b (a), Ifnb (b), and 
Tnfa (c) but not Ccl5 (d). All data was analysed using a two-way ANOVA with 
Bonferonni post hoc. 
 
(a) Il1b mRNA expression 
Pretreatment, F(1, 3) = 13.87, p = 0.034 
Treatment, F(1, 3) = 13.71, p = 0.034 
Interaction (time x treatment), F(1, 3) = 13.44, p = 0.035 
 
(b) Ifnb mRNA expression 
Pretreatment, F(1, 3) = 73.93, p = 0.033 
Treatment, F(1, 3) = 8.56, p = 0.061 
Interaction (time x treatment), F(1, 3) = 21.72, p = 0.019 
 
(c) Tnfa mRNA expression 
Pretreatment, F(1, 3) = 22.39, p =0.018 
Treatment, F(1, 3) = 17.38, p = 0.025 
Interaction (time x treatment), F(1, 3) = 21.41, p = 0.019 
 
(d) Ccl5 mRNA expression 
Pretreatment, F(1, 3) = 29.34, p =0.012 
Treatment, F(1, 3) = 0.017, p = 0.90 
Interaction (time x treatment), F(1, 3) = 0.56, p = 0.50 
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Figure 9 Alcohol nor LPS alters the expression NFκB p65 subunit (a) and IRF3 
(b) from BV2 cell lysates. All data was analysed using a two-way ANOVA with Tukey 
post hoc. 
 
(a) NFκB p65 expression 
Pretreatment, F(1, 5) = 0.96, p = 0.38 
Treatment, F(2, 10) = 4.73, p = 0.095 
Interaction (pretreatment x treatment), F(2, 10) = 0.26, p = 0.63 
 
(b) IRF3 expression 
Pretreatment, F(1, 5) = 2.54, p = 0.21 
Treatment, F(2, 10) = 13.47, p = 0.035 
Interaction (pretreatment x treatment), F(2, 10) = 1.77, p = 0.27 
 
Figure 10 Alcohol has no effect on LPS-induced cell cytotoxicity but reduces 
cellular injury as inferred by neutral red (a) Lactate dehydrogenase assays (b) 
respectively. All data was analysed using a two-way ANOVA with Tukey post hoc. 
 
(a) Neutral red assay 
Pretreatment, F(1, 5) = 0.44, p = 0.57 
Treatment, F(2, 10) = 16.14, p = 0.056 
Interaction (pretreatment x treatment), F(2, 10) = 0.00054, p = 0.98 
 
(b) Lactate dehydrogenase assay 
Pretreatment, F(1, 5) = 21.90, p = 0.0054 
Treatment, F(2, 10) = 415.9, p < 0.0001 
Interaction (pretreatment x treatment), F(2, 10) = 97.65, p = 0.0002 
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Figure 11 (+)-Naloxone modulates LPS-induced BV2 cells cytotoxicity and injury 
as inferred by neutral red (a) or Lactate dehydrogenase assays (b). All data was 
analysed using a two-way ANOVA with Tukey post hoc. 
 
(a) Neutral red assay 
Concentration, F(5, 55) = 11.33, p < 0.0001 
Treatment, F(1, 11) = 578.3, p < 0.0001 
Interaction (concentration x treatment), F(5, 55) = 6.45, p < 0.0001 
 
(b) Lactate dehydrogenase assay 
Concentration, F(5, 55) = 60.82, p < 0.0001 
Treatment, F(1, 11) = 143.6, p < 0.0001 
Interaction (concentration x treatment), F(5, 55) = 59.86, p < 0.0001 
 
Figure 12 (+)-Naloxone reduced LPS-induced IL-1β (a, b), TNFα (c, d) and IFNβ 
(e) expression from cell supernatant and lysates. All data was analysed using a 
two-way ANOVA with Tukey post hoc. 
 
(a) Lysate IL-1β expression 
Concentration, F(5, 35) = 10.69, p < 0.0001 
Treatment, F(1, 7) = 70.89, p < 0.0001 
Interaction (concentration x treatment), F(5, 35) = 18.92, p < 0.0001 
 
(b) Supernatant IL-1β expression 
Concentration, F(5, 35) = 7.73, p = 0.002 
Treatment, F(1, 7) = 51.79 p < 0.0001 
Interaction (concentration x treatment), F(5, 35) = 2.24, p = 0.0822 
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(c) Lysate TNFα expression 
Concentration, F(5, 35) = 20.04, p < 0.0001 
Treatment, F(1, 7) = 141.6, p < 0.0001 
Interaction (concentration x treatment), F(5, 35) = 18.92, p < 0.0001 
 
(d) Supernatant TNFα expression 
Concentration, F(5, 35) = 3.87, p = 0.0098 
Treatment, F(1, 7) = 2066, p < 0.0001 
Interaction (concentration x treatment), F(5, 35) = 3.12, p = 0.0253 
 
(e) Lysate IFNβ expression 
Concentration, F(5, 35) = 1.19, p = 0.36 
Treatment, F(1, 7) = 11.25, p = 0.044 
Interaction (concentration x treatment), F(5, 35) = 2.29, p = 0.098 
 
Figure 13 (+)-Naloxone had no effect and reduced the expression NFκB p65 
subunit (a) and IRF3 (b) expression from cell lysates respectively. All data was 
analysed using a two-way ANOVA with Tukey post hoc. 
 
(a) NFκB p65 subunit expression 
Concentration, F(5, 35) = 3.12, p = 0.05 
Treatment, F(1, 7) = 8.23, p = 0.064 
Interaction (concentration x treatment), F(5, 35) = 1.55, p = 0.23 
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(b) IRF3 expression 
Concentration, F(5, 35) = 1.73, p = 0.19 
Treatment, F(1, 7) = 11.62 p = 0.042 
Interaction (concentration x treatment), F(5, 35) = 2.05, p = 0.13 
 
Figure 14 TLR4 antagonists LPS:RS and (+)-Naloxone reduced LPS-induced 
cytotoxicity (a) and injury (b). All data was analysed using a two-way ANOVA with 
Tukey post hoc. 
 
(a) Neutral red assay 
Pretreatment, F(2, 30) = 12.13, p = 0.0001 
Treatment, F(1, 30) = 653.9, p < 0.0001 
Interaction (pretreatment x treatment), F(2, 30) = 6.41, p = 0.0048 
 
(b) Lactate dehydrogenase assay 
Pretreatment, F(2, 10) = 103.7, p < 0.0001 
Treatment, F(1, 5) = 2782, p < 0.0001 
Interaction (pretreatment x treatment), F(2, 10) = 49.35, p < 0.0001 
 
Figure 15 TLR4 antagonists LPS:RS and (+)-Naloxone reduced LPS-induced IL-
1β (a, b), TNFα (c, d) and IFNβ (e) expression from BV2 supernatant and lysates. 
All data was analysed using a two-way ANOVA with Tukey post hoc. 
 
(a) Lysate IL-1β expression 
Pretreatment, F(2, 14) = 4.84, p = 0.033 
Treatment, F(1, 7) = 82.16, p = 0.003 
Interaction (pretreatment x treatment), F(2, 14) = 1.42, p = 0.29 
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(b) Supernatant IL-1β expression 
Pretreatment, F(2, 14) = 11.54, p = 0.0011 
Treatment, F(1, 7) = 17.17, p = 0.0043 
Interaction (pretreatment x treatment), F(2, 14) = 8.23, p = 0.0043 
 
(c) Lysate TNFα expression 
Pretreatment, F(2, 14) = 8.87, p = 0.0061 
Treatment, F(1, 7) = 59.13, p = 0.0006 
Interaction (pretreatment x treatment), F(2, 14) = 9.47, p = 0.0049 
 
(d) Supernatant TNFα expression 
Pretreatment, F(2, 14) = 16.59, p = 0.0002 
Treatment, F(1, 7) = 69.58, p < 0.0001 
Interaction (pretreatment x treatment), F(2, 14) = 17.78, p < 0.0001 
 
(e) Lysate IFNβ expression 
Pretreatment, F(2, 14) = 19.71, p = 0.0023 
Treatment, F(1, 7) = 12.35, p = 0.039 
Interaction (pretreatment x treatment), F(2, 14) = 2.82, p = 0.14 
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Figure 16 TLR4 antagonists, LPS:RS and (+)-Naloxone reduce LPS-induced Il1b 
(a) mRNA but only LPS:RS reduces Ifnb (b), Tnfa (c) and Ccl5 (d) mRNA 
expression in BV2 cells All data was analysed using a two-way ANOVA with 
Bonferonni post hoc. 
 
(a) Il1b mRNA expression 
Pretreatment, F(2, 6) = 6.33, p = 0.033 
Treatment, F(1, 3) = 13.1, p = 0.036 
Interaction (pretreatment x treatment), F(2, 6) = 8.81, p = 0.016 
 
(b) Ifnb mRNA expression 
Pretreatment, F(2, 6) = 1.06, p = 0.40 
Treatment, F(1, 3) = 5.40, p = 0.10 
Interaction (pretreatment x treatment), F(2, 6) = 3.60, p = 0.094 
 
(c) Tnfa mRNA expression 
Pretreatment, F(2, 6) = 3.49, p = 0.099 
Treatment, F(1, 3) = 8.96, p = 0.058 
Interaction (pretreatment x treatment), F(2, 6) = 5.84, p = 0.039 
 
(d) Ccl5 mRNA expression 
Pretreatment, F(2, 6) = 4.84, p = 0.05 
Treatment, F(1, 3) = 2.09, p = 0.24 
Interaction (pretreatment x treatment), F(2, 6) = 4.34, p = 0.068 
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Figure 17 TLR4 antagonists, LPS:RS and (+)-Naloxone reduced LPS-induced 
NFκB p65 subunit expression but had no effect on IRF3 expression in BV2 cells. 
All data was analysed using a two-way ANOVA with Tukey post hoc. 
 
(a) NFκB p65 subunit expression 
Pretreatment, F(2, 14) = 2.15, p = 0.20 
Treatment, F(1, 7) = 5.46, p = 0.10 
Interaction (pretreatment x treatment), F(2, 14) = 8.11, p = 0.02 
 
(b) IRF3 expression 
Pretreatment, F(2, 14) = 1.68, p = 0.26 
Treatment, F(1, 7) = 10.76, p = 0.046 
Interaction (pretreatment x treatment), F(2, 14) = 2.96, p = 0.13 
 
Figure 18 TLR4 antagonists, LPS:RS and (+)-Naloxone reduced LPS-induced 
NFκB p65 subunit (a) and IRF3 (b) translocation to the nucleus in BV2 cells. All 
data was analysed using a two-way ANOVA with Tukey post hoc. 
 
(a) NFκB p65 subunit expression 
Pretreatment, F(2, 6) = 7.72, p = 0.021 
Treatment, F(1, 3) = 23.54, p = 0.016 
Interaction (pretreatment x treatment), F(2, 6) = 24.92, p = 0.0012 
 
(b) IRF3 expression 
Pretreatment, F(2, 6) = 3.69, p = 0.090 
Treatment, F(1, 3) = 4.38, p = 0.13 
Interaction (pretreatment x treatment), F(2, 6) = 8.74, p = 0.016 
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9.9.2 Supplementary figures 
 
Figure s1 LPS dose-dependently increases the lysate and supernatant of IL-1β 
(a, b) and TNFα (c, d) from BV2 cells. All data was analysed using a one-way 
ANOVA.  Summary values represented as mean±SEM; n=12 
*p < 0.0001 compared to LPS concentration = 0ng/mL 
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Figure s2 LPS dose-dependently reduces markers of cell viability (a) and 
increases markers of cell injury (b). Increasing the concentration of LPS significantly 
reduced absorbance in the neutral red assay (indicative of increased cytotoxicity). By 
contrast, increasing the concentration of LPS increased absorbance in the lactate 
dehydrogenase assays indicating increased cellular release of lactate dehydrogenase. 
All data was analysed using a one-way ANOVA.  Summary values represented as 
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Figure s3 The concentration of alcohol (a) and cell viability/cytotoxicity (b) in 
plates that are covered with a plate seal compared to unsealed plates. Alcohol 
evaporates or is metabolised by approximately 12hs following its administration to BV2 
cells. Applying a plate seal to reduce ethanol evaporation does not alter the rate at 
which this occurs (a) however, it does increase cytotoxicity (decrease the absorbance) 
in the neutral red assay. All data was analysed using a two-way ANOVA with Tukey 
post hoc.  Summary values represented as mean±SEM; n=4-8 
a *p < 0.001 from T0 from covered cells; # p <0.001 from T0 uncovered cells 
b *p < 0.05; **p < 0.01; ***p < 0.001; **** p < 0.0001 uncovered compared to covered 
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Figure s4 Validation of nuclear translocation using Pearson’s coefficient and 
Spearman’s Rank Value colocalisation analysis for NFκB p65 subunit (a) and 
IRF3 (b) translocation to the nucleus in BV2 cells. LPS resulted in significant 
colocalisation of the DAPI and NFκB p65 or IRF3 (405nm and 488nm) channels 
compared to alcohol and vehicle treated cells. Alcohol induced significantly greater 
colocalisation between IRF3 and DAPI compared to vehicle. All data was analysed 
using a two-way ANOVA with Tukey post hoc.  Summary values represented as 
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Figure s5 HMGB1(ab18650) failed to induce an IL-1β response from BV2 
supernatant compared to media across multiple time points and concentrations. 
No post hoc differences were identified. All data was analysed using a two-way 
ANOVA with Tukey post hoc.  Summary values represented as mean±SEM; n=3 
 
























Figure s6 Validation of nuclear translocation using Pearson’s coefficient and 
Spearman’s Rank Value colocalisation analysis for NFκB p65 subunit (a, b) and 
IRF3 (c, d) translocation to the nucleus in BV2 cells. LPS treatment resulted in 
significant colocalisation between DAPI and NFκB p65 or IRF3 compared to vehicle 
treated cells. (+)-Naloxone significantly reduced LPS-induced colocalisation between 
NFκB p65 and DAPI compared to vehicle treated cells using the Pearson’s 
colocalisation analysis. Cells pretreated with LPS:RS did not significantly modify 
colocalisation compared to vehicle. All data was analysed using a two-way ANOVA 
with Tukey post hoc.  Summary values represented as mean±SEM; n=4; *p < 0.05 




































Colocalisation analysis of NFκB p65 subunit  






































Colocalisation analysis of IRF3 
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Figure s7 Representative RGB profile plots and colocalisation analysis outputs 
from Fiji of cells pretreated with vehicle, (+)-Naloxone or LPS:RS and treated 




Figure s8 Representative western blots for Figures 2 and 4 
 
 




Figure s10 Representative western blots for Figures 12 and 13 
 
 
Figure s11 Representative western blots for Figures 15 and 17 
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9.9.3 Statistics for supplementary figures 
 
Figure s1 LPS dose-dependently increases the lysate and supernatant of IL-1β 
(a, b) and TNFα (c, d) from BV2 cells. All data was analysed using a one-way 
ANOVA.  
 
(a) IL-1β lysate 
Effect of concentration, F(7, 112)  = 238.2, p < 0.0001 
 
(b) IL-1β supernatant  
Effect of concentration, F(7, 112)  = 36.35, p < 0.0001 
 
(c) TNFα lysate 
Effect of concentration, F(7, 112) = 645.2, p < 0.0001 
 
(d) TNFα supernatant 
Effect of concentration, F(7, 112)  = 1001, p < 0.0001 
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Figure s2 LPS dose-dependently reduces markers of cell viability (a) and 
increases markers of cell injury (b). All data was analysed using a one-way ANOVA.  
 
(a) Neutral red assay 
Effect of concentration, F(7, 120)  = 34.23, p < 0.0001 
 
(b) Lactate dehydrogenase assay  
Effect of concentration, F(7, 24)  = 78.96, p < 0.0001 
 
Figure s3 The concentration of alcohol (a) and cell viability/cytotoxicity (b) in 
plates that are covered with a plate seal compared to unsealed plates. All data 
was analysed using a two-way ANOVA with Tukey post hoc.  
 
 (a) Alcohol concentration assay 
Effect of condition, F(1, 3) = 10.03, p = 0.051 
Effect of time, F(7, 21) = 1108, p < 0.0001 
Interaction (condition x time), F(7, 21) = 46.54, p < 0.001 
 
(b) Neutral red assay 
Effect of condition, F(1, 3) = 1.52, p = 0.34 
Effect of time, F(7, 21) = 1188, p < 0.0001 
Interaction (time x treatment), F(7, 21) = 45.59, p < 0.001 
 
Figure s4 Validation of nuclear translocation using Pearson’s coefficient and 
Spearman’s Rank Value colocalisation analysis for NFκB p65 subunit (a) and 
IRF3 (b) translocation to the nucleus in BV2 cells. All data was analysed using a 
two-way ANOVA with Tukey post hoc.  
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(a) NFκB p65 subunit  
Pearson’s correlation coefficient, F(2, 24) = 18.42, p <0.0001  
Spearman’s rank value, F(2, 26) = 5.72, p = 0.0087 
 
(b) IRF3  
Pearson’s correlation coefficient, F(2, 24) = 19.63, p < 0.0001  
Spearman’s rank value, F(2, 24) = 8.00, p = 0.0022 
 
Figure s5 HMGB1(ab18650) failed to induce an IL-1β response from BV2 
supernatant compared to media across multiple time points and concentrations. 
N All data was analysed using a two-way ANOVA with Tukey post hoc.  
 
IL-1β supernatant 
Effect of concentration, F(6, 12) = 7.32, p = 0.0018 
Effect of time, F(3, 6) = 52.28, p = 0.0001 
Interaction (concentration x time), F(18, 36) = 1.58, p = 0.11 
 
 
Figure s6 Validation of nuclear translocation using Pearson’s coefficient and 
Spearman’s Rank Value colocalisation analysis for NFκB p65 subunit (a, b) and 
IRF3 (c, d) translocation to the nucleus in BV2 cells. All data was analysed using 
a two-way ANOVA with Tukey post hoc.  
 
(a) NFκB p65 subunit Pearson’s coefficient 
Effect of pretreatment, F(2, 6) = 1.46, p = 0.30 
Effect of treatment, F(1, 3) = 5.03, p = 0.11 
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Interaction (pretreatment x treatment), F(2, 6) = 7.82, p = 0.021 
 
(b) NFκB p65 subunit Spearman’s Rank Value 
Effect of pretreatment, F(2, 6) = 7.37, p = 0.024 
Effect of treatment, F(1, 3) = 1.04, p = 0.38 
Interaction (pretreatment x treatment), F(2, 6) = 3.93, p = 0.081 
 
 (c) IRF3 Pearson’s coefficient 
Effect of pretreatment, F(2, 6) = 1.04, p = 0.41 
Effect of treatment, F(1, 3) = 0.15, p = 0.73 
Interaction (pretreatment x treatment), F(2, 6) = 9.34, p = 0.0144 
 
(d) IRF3 Spearman’s Rank Value 
Effect of pretreatment, F(2, 6) = 0.70, p = 0.53 
Effect of treatment, F(1, 3) = 8.77, p = 0.059 
Interaction (pretreatment x treatment), F(2, 6) = 3.35, p = 0.11 
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The aim of this experiment was to determine whether TLR4-/- mice (Balb/c 
background) and wildtype Balb/c mice exhibit differences in the “liking” and “wanting” 




Male (8 – 10-week-old) wildtype mice (Balb/c) from the University of Adelaide 
Laboratory Animal Services (Adelaide, SA, Australia) and male Balb/c mice with 
genetic knockout of TLR4 (TLR4-/-) (originally sourced from Professor Akira (Osaka 
University, Osaka Japan) via Dr. Paul Foster from the University of Newcastle 
(Newcastle, NSW, Australia)) were used for the following experiments. Mice were 
housed in light/dark (12:12 hours) and temperature controlled rooms (23±3°C) with 
food and water available ad libitum. The light cycle began at 7am (ZT0) and concluded 
at 7pm (ZT12). Following seven days of acclimatisation, mice were handled by the 
experimenter for five days prior to experimentation. Mice were weighed daily 
throughout the handling and experimental periods. All animal care and experiments 
complied with the principles of the Australian Code of Practice for the care and use of 
animals for scientific purposes and were approved by the University of Adelaide’s 
Animal Ethics Committee. 
 
10.2.2 Drugs 
Saccharin and quinine were purchased from Sigma Aldrich (St Louis, MO, USA). 
Ethanol (99.5%) (herein referred to as alcohol) was purchased from Chemsupply 
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(Gliman, SA, Australia). Oral gavages of alcohol were dosed at 1.5g/kg (25 per cent 
v/v) for conditioned place preference studies. Saline oral gavages were volume-
matched. The dose of alcohol used in conditioned place preference was based upon 
the effective dose 50 from an unpublished conditioned place preference dose response 
curve.  
 
(+)-Naltrexone, a TLR4-TRIF antagonist was synthesised and kindly supplied by Dr 
Kenner Rice (Chemical Biology Research Branch, National Institute on Drug Abuse 
and National Institute of Alcohol Abuse and Alcoholism, Bethesda, MD, USA). (+)-
Naltrexone was administered via intraperitoneal injections with doses ranging from 1 
to 75 mg/kg (dose volume 10 ml/kg). Saline intraperitoneal injections were volume-
matched. 
 
10.2.3 Alcohol two-bottle choice 
Alcohol drinking and preference was assessed using an 8 h two-bottle choice 
paradigm. Following 14 days of acclimatisation and handling, mice were placed into 
individual cages. After a further week of acclimatisation, mice were presented with two 
bottles containing water 2 h after the beginning of the dark cycle (ZT14) for 8 h. Two 
bottles of water were initially presented to mice in order to control for novelty-induced 
drinking. For the 8 h test, the bottles were removed ZT22, weighed and replaced with 
a single bottle of water randomised to either the left or right side of the cage for the 
remaining 16 h.  
 
Following five days of drinking water from two bottles, mice were offered one bottle 
containing water and the other 3, 6, 9, 12, 15, 18, 21 or 42 per cent alcohol (v/v). The 
concentration and bottle position was randomised daily to prevent the acquisition of 
alcohol drinking and side preferences respectively. After 8 h bottles were removed 
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weighed and replaced by a water bottle randomly allocated to either side of the cage 
lid.  
 
The amount of alcohol consumed was determined by the difference in bottle weights 
before and after drinking sessions. This enabled the calculation of the amount of 
alcohol consumed per kilogram bodyweight (grams/kilogram) and the preference ratio 
(alcohol intake ÷ (total water + alcohol intake)) for each mouse and averaged for each 
group per concentration of alcohol. An empty cage with two bottles was used to 
determine the rate of evaporation. The rate of evaporation was subtracted from the 
final weight of test bottles. 
 
10.2.4 Saccharin and quinine two-bottle choice 
Mice were also tested using the same 8 h paradigm above for saccharin (1, 15, 30, 45 
and 60 mM) and quinine (0.001, 0.01, 0.1, 1 and 5 mM) preference. However, instead 
of the bottle of alcohol, mice received a bottle of saccharin or quinine and a bottle of 
water. 
 
10.2.5 Conditioned place preference 




The conditioning apparatus consisted of two conditioning chambers (10.9 (length) x 
9.3 (width) x 35 (height) cm) separated by a neutral chamber (16.6 x 4.8 x 35 cm). The 
neutral chamber contained black walls with grey flooring. The conditioning chambers 
differed in tactile and visual cues. The flooring of the conditioning chambers were either 
black plexiglass perforated holes (5 mm apart) or black plexiglass grids (5 mm apart). 
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The walls of each chamber were white or black. The combination of wall colour to floor 
texture was randomised for each cohort to prevent any inherent biases mice have for 
a specific texture x colour combination.  
 
During conditioning, a sliding partition restricted access to only one chamber. 
Movement and time spent in each chamber was recorded using Logitech Quickcam 
Pro 5000s and AnyMaze (Stoelting co., Wooddale, IL, USA). 
 
10.2.5.2 Procedure 
Day 1: Pretest. Mice were placed into the neutral chamber and allowed to explore all 
three chambers for 30 min.  
 
Day 2 to 9: Conditioning. Mice received an oral gavage of alcohol (1.5 g/kg) and placed 
within their conditioning chamber for 30 min on days 1, 3, 5 and 7. On days 2, 4, 6 and 
8, mice received an oral gavage of saline and placed within the unconditioned chamber 
for 30 min. Mice received a total of four conditioning sessions with each drug (alcohol 
or saline). 
 
Day 10: Test. Mice received an oral gavage of saline, were placed into the neutral 
chamber and allowed to explore all three chambers for 30 min.  
 
To infer whether the conditioning was successful, the time spent in the conditioned 
chamber during the post-test was subtracted from the time spent in the conditioned 
chamber during the pre-test. 
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10.2.6 Statistical analysis 
Experiment 1: The effect of genotype on the intake and preference for alcohol, 
saccharin and quinine was analysed using a two-way ANOVA with Tukey post hoc 
(figure 1). The effect of genotype on alcohol induced conditioned place preference was 
analysed using a two-way ANOVA with Tukey post hoc (figure 2). 
All summary values presented as mean ± standard error of mean (SEM). p-values ≤ 
0.05 were considered statistically significant.  
 
10.3 Results 
TLR4-/- and wildtype mice underwent saccharin and quinine two-bottle choice tests to 
determine whether they exhibit basal differences in the “liking” component of reward 
and aversion behaviour (figure 1).  
 
A two-way ANOVA determined a significant effect of concentration but not genotype 
on the intake of saccharin (effect of concentration, F(4, 44) = 22.48, p < 0.0001; and 
effect of genotype, F(1, 11) = 0.38, p = 0.55) (a). There was a significant interaction 
between genotype and concentration (F(4, 44) = 4.42, p = 0.043). However, there were 
no post hoc differences. By contrast, concentration and genotype did not alter the 
preference for saccharin (effect of concentration, F(4, 44) = 1.73, p = 0.15; and effect of 
genotype, F(1, 11) = 2.46, p = 0.14) (b). There was no interactive effect (F(4, 44) = 0.17, p 
= 0.95) or post hoc differences. Collectively, both TLR4-/- and wildtype mice exhibit 
similar preference for an innate inducer of the “liking” component of reward suggesting 
these mice do not differ in basal “liking” behaviour. 
A two-way ANOVA determined the intake of quinine was significantly modified by 
concentration (effect of concentration, F(4, 44) = 149.8, p < 0.001) but not genotype 
(effect of genotype, F(1, 11) = 0.19, p = 0.66) nor was there an interactive effect between 
the two variables (F(4, 44) = 0.28, p = 0.90) (c). Again, there were no post hoc 
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differences. Similarly, the preference for quinine was significantly influenced by 
concentration (effect of concentration, F(4, 44) = 3.57, p = 0.013) but not genotype (effect 
of genotype, F(1, 11) = 0.58, p = 0.46) (d). There were no interactive effects (F(4, 44) = 
0.76, p = 0.55) or post hoc differences. This suggests TLR4-/- and wildtype mice exhibit 
similarities in regards to taste and aversion. 
 
To infer whether TLR4 alters the “liking” (and to some extent the “wanting”) component 
of reward TLR4-/- and wildtype mice underwent an alcohol two-bottle choice test. The 
intake of alcohol significantly influenced by concentration (effect of concentration, F(7, 
77) = 106.9, p < 0.0001) but not genotype (effect of genotype, F(1, 11) = 0.27, p = 0.61) 
as inferred by a two-way ANOVA (e). There were no interactive effects (F(7, 77) = 1.03, 
p = 0.41) or post hoc differences between the groups. By contrast, the preference for 
alcohol was modified by both concentration (effect of concentration, F(7, 77) = 10.25, p 
< 0.0001) and genotype (effect of genotype, F(1, 11) = 37.71, p < 0.0001) (f). However, 
no interaction (F(7, 77) = 0.72, p = 0.65) was observed between the two variables. Tukey 
post hoc analysis determined TLR4-/- exhibited reduced alcohol preference at 3, 12 
and 15 per cent alcohol compared to wildtype mice. The reduced preference but not 
intake of alcohol in TLR4-/- mice suggests they consume significantly more water during 
the 8 h test. However, whether this is due to altered taste or reward could not be 
determined.  
 
To determine whether the reduced preference observed in the alcohol-two bottle 
choice test was likely due to alterations in thirst or reward, TLR4-/- and wildtype mice 
underwent conditioned place preference (figure 2). There was a significant effect of 
conditioning drug (F(1, 10) = 6.73, p = 0.027) and genotype (F(1, 10) = 5.53, p = 0.040) on 
the change in chamber time. Further there was a significant interaction between the 
two variables (F(1, 10) = 5.83, p = 0.036). Tukey post hoc analysis determined wildtype 
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mice conditioned with alcohol spent significantly more time in the alcohol conditioned 
chamber compared to TLR4-/-  mice.  
 
Collectively, the results suggest TLR4-/- mice exhibit a reduction in the “wanting” of 
component of alcohol-reward compared to wildtype mice. However, it is unclear 






Figure 1 Genetic knockout of TLR4 reduces alcohol but not saccharin or quinine 
preference. TLR4-/- and wildtype (balb/c) mice exhibited similar levels of intake and 
preference for saccharin (a, b) and quinine (c, d). Interestingly, TLR4-/- mice exhibited 
similar intake of (e), but reduced preference (f) for alcohol compared to wildtype 
(Balb/c) mice. All data was analysed using a two-way ANOVA with Tukey post hoc. 
Summary values represented as mean±SEM; n=12, *p < 0.05; **p < 0.01. 








































































































































































Figure 2 Genetic knockout of TLR4 reduces alcohol-induced conditioned place 
preference. TLR4-/- mice exhibited significantly less change in conditioned chamber 
time post alcohol conditioning compared to wildtype (Balb/c) mice. All data was 
analysed using a two-way ANOVA with Tukey post hoc. Summary values represented 
as mean±SEM; n=10, *p < 0.05. 
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